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Abstract
The studies presented in this thesis demonstrate that foot-and-mouth disease virus 
(FMDV) infection mediated by the integrin avp6 takes place through clathrin- 
dependent endocytosis. Inhibition of clathrin-dependent endocytosis by sucrose 
treatment or transient expression of a dominant-negative version of API 80 inhibited 
virus entr y and infection. Similarly, inhibition of endosomal acidification inhibited an 
early step in infection. Blocking endosomal acidification did not interfere with 
surface expression of avP6, virus binding to the cells, uptake of the virus into 
endosomes, or cytoplasmic virus replication. These observations suggest that the low 
pH within endosomes is required for a post-entiy step of infection, most likely capsid 
uncoating and delivery of viral RNA into the cytosol. FMDV infection occuiTed in 
the absence of caveolae and inhibition of lipid-raft dependent endocytosis did not 
inhibit virus uptake or infection.
Using immunofluorescence confocal microscopy, FMDV colocalised with avp6 at 
the cell surface but not with the B subunit of cholera toxin, a marker for lipid rafts. At 
37°C, virus was rapidly taken up into the cells and colocalised with markers for early 
and recycling endosomes but not with a marker for lysosomes, suggesting that 
infection occurs fi*om within the early or recycling endosomal compartments. This 
conclusion was supported by the observation that FMDV infection is not inhibited by 
nocodazole, a reagent that inhibits vesicular tiafdcking between ear ly and late 
endosomes (and hence trafficking to lysosomes).
Internalisation of avP6 and its accumulation in early and recycling endosomes was 
triggered by virus binding, suggesting that the integr in serves not only as an 
attachment receptor but also to deliver the virus to the acidic endosomes.
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Chapter One: Introduction
The outbreak of foot-and-mouth disease (FMD) in the UK in 2001 graphically 
demonstrated the devastation that an epidemic of the disease in a non-endemic ar ea 
can cause. FMD is one of the most contagious viral diseases known in mammals, and 
affects more than 33 cloven- hoofed speeies, including economically important 
livestock such as sheep, goats, cattle, and pigs. Infected animals typically suffer from 
a short fever, loss of appetite and dullness, followed by the appearance of vesicular 
lesions of the mouth, tongue, and feet, which give the disease its name. Although 
mortality rates in infected adult animals ar e relatively low the disease is economically 
devastating due to its severe impact on the productivity of infected animals. Milk 
yields in cattle and the gi'owth rate of young infected animals, ai e particularly 
severely affected. In countries such as the UK, where the disease is not endemic, the 
slaughter of infected or at risk animals, and resti'iction on livestock movements, is the 
primary economic impact of the disease. The direct cost of the 2001 UK outbreak has 
been estimated to be 2.75 billion pounds (4).
1.1 Picornavims Giassification
Foot-and-mouth disease virus (FMDV) is a member of the family Picornaviridae, 
which includes a wide range of human and animal pathogens e.g. Poliovirus, the 
human, bovine, and equine Rhinovimses, Hepatitis A virus, and FMDV. 
Picomavimses have traditionally been defined in terms of serotypes giouped into 
genera on the basis of shared pathogenic chaiacteristics and biophysical properties 
(300). However, recent sequence data, which reflects genetic relationships and 
evolution of viruses more accm ately tlian previous empirical observations, has been
used to refine the taxonomic scheme. The species concept has now been applied to 
picornavims classification, meaning that genera ai'e divided in to one or more virus 
species (300), which consist of several serotypes.
The cuiTent taxonomic structure of the picornavims family is shown in figure 1.1 
(N. J. Knowles, Personal Communication). There are nine genera: Enterovirus^ 
Rhinovirus, Cardiovirus, Aphthovirus, Hepatovirus, Parechovirus, Erbovirus, 
Kobuvirus, and Teschovirus, There are also a number of viruses that have yet to be 
assigned to a genus. FMDV is the type species of the genus Aphthovirus, which also 
includes Equine Rhinitis A virus (ERAV). Members of the Aphthovirus genus have 
greater than 50% nucleotide identity in the region of the genome which encodes the 
stmctural proteins and greater than 70% identity in the non-structural proteins 2C and 
3CD. There are seven serotypes of FMDV: types O, A, C, Asia-1, SAT 1, 2, and 3, 
each of which contains a number of subtypes (69, 161). Serotypes are antigenically 
but not clinically distinct from one another.
1.2 FMDV Structure
1.2.1 The FMDVVirion
The FMDV virion consists of a single copy of single-stranded positive-sense RNA, 
encased by an icosahedral capsid. The capsid is formed from 60 copies each of four 
stmctural proteins (VP 1-4), and demonstrates icosahedral 5:3:2 symmetry (2). VPl 
VP3 fonn the outer capsid shell whereas VP4 is located (with the vRNA) inside the 
capsid. The mature FMDV particles are 28-30nm in diameter, and appear* spherical 
under the electron microscope.
Genus Species No. of serotypes Serotypes
Euieroviivs
Poliovirus 3 IllllilSJU pDllOVlMI* 1 to  3
Human enterovirus A 12
hiiniuii co \sac lilo v li‘us A 2 , A 3, A 1, AS, AG, A7, A8, 
AID, A I2 , A M , A 16
iiutiittit o iitc ro v lfo s  71
Human enterovirus B 37
bum un  coxsackEcvirus 1)1 to 1)6
bum  on cnxsA tklcvltiix  A9
liMtiiou ec liov lras  1 -7 ,9 , 1 1 .2 1 ,2 4 -2 7 ,2 9 -3 3
htimui) cntct'ovb'uii 69, 73
Human enterovirus C 11 h i i n i D i i  coxsiiïk lcv li’uii A l ,  A l i ,  A13, A IS , A l 7 to  A22, A24
Human enterovirus D 2 h lim on i!flt«rnvlraii GH & 70
Bovine enterovirus 3 Iiovlni! e n te ro v iru s  1 & 2ovine e n te ro v iru s
Porcine enterovirus A 1 p o rc in e  c u tc ro v lru s  &
Porcine enterovirus B 2 p o rc in e  cu terov ii'u s 9 & 10
Uiinssigned simian enteroviruses ? SV 28/ SV 4fSA 4/A -2 p la q u e  v iru s ,  SV 6, N I2S , N203 SV 26/SV 19/SV 35, SV 43, SV 46, SA 5, A 13, S V J7 , SV2, 
SV16, RV18/SV4.I, SV 42, SV 43, SV49
Rhinovirus
Human rhinovirus A 74 liitiuan rh in o v iru s  1, 2 ,7  to  13, IS , 16, IB to 2S, 28 to 3 4 ,3 6 ,3 8  to 41, 43  to 4 7 , 49 to 51 , 53 to  68, 71, 73 to 
78, 80 to  82, 85, 88 to  9 0 ,9 4  to  9 6 , 98 ,1 0 0
Human rhinovirus B 25 liun inu  r lilu o v lriis  3 to 6, 14, 17 ,26 , 27, 3 5 ,3 7 , 42, 48, 52, 69, 7 0 ,7 2 , 79, 83, 84, 8 6 , 91 to 93, 97, 99
ITiiassigncd serotypes 3 bovine rh in o v iru s  1 to  3
Cardiovims
Encephalomyocarditis virus 1 c n c ep b a lo m y o e a rd itls  virus
Theilovirus 2 T h c l le r 's  n iiii'lnc c iiccpbalom yclltls  v iru sV tlyu lsk  b u inao  cuccp b a lo m y e lllls  v iru s
Aphthovirus' Foot-and-mouth disease virus 7
foQ t-aiid.m ntilli d isease  vb us O , A , C , A sia  1, SA T  1, 
SA T  2, SA T 3
Equine rhinitis A virus 1 eq u in e  rh in itis  A v iru s
Ilepatoviras Hepatitis A virus 1
hu m an  h e p a ti tis  A v iru s
fitiiiinn h e p a titis  A v iru s
“Avian cnccphalomycIitis-likc viruses” 1 av ian  eiiecphn ln inyelllls  v iru s
Parechovims Human parechovirus 2 h u m an  p a re e b o v lru s  1 & 2Ljungan virus 14- Lluuisnii v iru s
Erbovirus Equine rhinitis B virus 2 eq u in e  rh in itis  U v irus 1 & 2
Kobuvirus Aichi virus 1 AlchI v iru s
Toschovims Porcine teschovirus 10 p o rc in e  teschov irus 1 to  11
Figure 1.1. The classification and nomenclature of the nine picornavirus genera (N. Knowles, 
Personal Communication)
The asymmetric unit of the mature FMDV capsid (termed a protomer) is made up of 
three proteins (VP 1-3) of unique sequence but similar tertiary structure, and a fourth 
protein VP4, which does not fonn part of the outer surface of the virion. Capsid 
assembly from individual protomers is thought to be a two-stage process. The first 
stage of assembly is the formation of pentameric units, by the association of five 
protomers in a urea-sensitive fashion. The second stage involves assembly of twelve 
pentamers to form an icosahedral shell (the capsid). The mechanism by which the 
viral RNA is incorporated into the capsid remains unclear.
Protomers consist initially of one copy of VPO, VPl and VP3, but on encapsidation 
of the viral RNA, VPO is cleaved to yield VP4 (the N-terminal 85 residues of VPO) 
and VP2 (the remainder of VPO), in a process termed the maturation cleavage. VPO 
cleavage has been shown to be essential for infectivity, since recombinant virions 
carrying mutations that prevent VPO cleavage are non-infectious (160).
1.2.2 Atomic Structure of Mature FMDV Particles
The atomic str ucture of a number of picomaviruses, including poliovirus (128), 
several human rhinovimses (272, 323), mengo vii'us (179) and foot-and-mouth 
disease vims (2, 59, 168, 169) have been determined by x-ray crystallography. The 
structure of type O FMDV is shown in figure 1.2. As dictated by the icosahedral 
arrangement of protomers, the capsid has 5-fold, 3-fold, and 2-fold centres of 
symmetry. There are twelve 5-fold centres of symmetry, one at the centre of each of 
the pentameric units. The VPl proteins are located around the 5-fold symmetry axes, 
one copy being contributed by each of five protomers from a single pentamer. 3-fold 
centres of symmetry are formed at the intersection of three pentamers and are 
surrounded by three copies each of VP2 and VP3, arranged in an alternating pattern.
Biological
protomer
Site 4
FMDV loop
Figure 1.2. The all atom structure of reduced O serotype virus.
VP1 is coloured blue, VP2 green and VP3 red (VP4 is internal and not visible in these views). The 
VP1 GH loop residues 130/160 (GH loop) is shown as a ‘worm’ in cyan with the Arg/Gly/Asp residues 
in orange. Antigenic residues are colour-coded according to their classification into sites: site 1 and 5 
(mid-blue), site 2 (pale yellow), site 3 (light blue), site 4 (magenta). The potential occupancy of the 
VPl GH loop is modelled by a transparent sphere centred at the mid-point between the two ends of 
the loop. The heparin motif which has been visualized in complex with the virus is drawn in yellow 
ball-and-stick. A protomeric subunit (the smallest repeating unit, representing 1/60th of the capsid) is 
outlined and enlarged. The FMDV GH loop is further enlarged with residues that are conserved (or 
virtually conserved) across all strains drawn in full. In this depiction of the loop sequence variability 
between strains is proportional to the thickness of the tube. The residue numbers are shown for the 
conserved residues with the residue type being indicated for the proposed integrin binding RGD motif 
(orange).
Figure adapted from (141)
2-fold cenfres of symmetiy are located at the centre of the interacting surfaces of 
adjacent pentamers, and are also formed from alternating copies of VP2 and VP3.
VPl, 2, and 3 have tertiary sti'uctures that are remarkably similar to one another (2). 
Each protein has a topologically conserved “core”consisting of an eight stranded (3- 
barrel, with vai iable “elaborations” formed by the loops that coimect the individual 13- 
strands. The exterior surfaces of the virus are formed primarily by these variable 
elaborations.
The C-termini of VP 1-3 are located on the outer surface of the virion and make 
limited contacts with each other. The N-termini of VP 1-4 are all located on the inner 
surface of the capsid, and make extensive contacts with each other that help to 
stabilise the formation of pentameric assembly intermediates. Such contacts also help 
to hold the 2-fold related pentamers together. VP4 is covalently modified at its N- 
terminus by a hydrophobic myi'istate fatty acid chain (25, 50). By analogy with other 
picornavirus structures (117) it is likely that the association of myristate groups of 
VP4 at the 5-fold symmetry centre creates a hydrophobic globule which contributes to 
pentamer stability, and partly explains why these associations are urea-sensitive. 
Further stability is provided by a ring of disulphide bonds which link the N-termini of 
VP3 around the 5-fold symmetry axes towards the exterior surface of the virus 
particle. These interactions ensure that pentamer formation is essentially irreversible.
Adjacent pentamers are held together by hydiogen-bonding interactions between 
VP2 and VP3. The FMDV particle is extremely sensitive to acid, dissociating into its 
constituent pentamers, VP4, and genomic RNA at pH values below neutrality (40). 
The extraordinary acid lability of FMDV is in part explained by the participation of a 
large number of histidine residues (pK 6.5-7.0) in inter-pentamer interactions (see 
section 1.6.5.2).
Sequence and sfructural variation at the N- and C-termini and interconnecting loops 
of the major structural proteins VP 1-3 mean that the surface topogiaphy of different 
picomaviruses can vary considerably. Human Rliinoviruses for example contain large 
insertions in V Pl, 2, and 3, which form protrusions on the surface of the virion, 
creating a deep cleft or “canyon” on the virion surface (272). The canyon forms a 
“moat” 25 Â deep and 12-30 Â wide, which separates the bulk of the VPl subunits 
clustered at the 5-fold symmetry axis from the surrounding VP2 and VP3 subunits. A 
similar structure is observed for poliovirus (also termed a canyon) (128) and 
cardioviruses (termed a pit) (179). The canyon is thought to be wide enough to allow 
virus receptors to bind in its base, but not wide enough to allow the binding of 
neutralising antibodies. This is known as the canyon hypothesis (271).
The structural proteins of FMDV (in particular V Pl) are significantly smaller than 
the equivalent proteins found in other picomaviruses. Since the core domains of these 
proteins are well conserved, this is primarily due to reductions in the size of variable 
surface loops. As a result the capsid of FMDV is smoother and thinner than that of 
other picomavimses. The 17 C-terminal residues of VPl form an aim, unique among 
picomaviruses, which occupies and fills the region which would be analogous to the 
canyon or pit. Consequently FMDV lacks a canyon or pit around the five-fold 
symmetry axis (2).
A major structural feature of the surface of FMDV is the long surface-exposed, 
conformationally flexible loop (the GH loop of V Pl) shown in figure 1.2. This loop 
corresponds to residues 141-161 in serotype O viruses (174). In contiast to other 
picomaviruses such as HRV-14, where the GH loop is hidden fr om immune 
surveillance at the base of the canyon (271, 272), the VPl GH loop of FMDV forms a 
highly antigenic surface protrusion (2). Synthetic peptides con esponding in sequence
to this loop induce high levels of protective antibodies (35), indicating that this site is 
highly immunogenic. In all serotypes of FMDV studied the VPl GH loop is 
structurally disordered and so is virtually invisible in the crystal stinctures of 
unperturbed virus particles. However, analysis of the crystal structures of both native 
particles and neutralising antibody escape mutants, suggested that the GH loop could 
adopt two predominant conformations (2, 239). These conformations were termed 
“down” and “up” according to the orientation of the loop relative to the surface of the 
particle. It is thought that conformational restiictions are imposed by the tethering of 
one end of the loop by a disulphide bond which links cysl34 of VPl to cysl30 of 
VP2 in FMDV sti'ain OIBFS. This disulphide bond drives the loop towards the less 
intrinsically stable up conformation (239). Consistent with this theory the GH loop of 
VPl was visualised in a well ordered down conformation by determination of the 
structure of OIBFS virus following chemical reduction using DTT (174). In this 
sti'ucture the loop lies in a small depression on the surface of the particle and forms a 
(3-strand adjacent to strand C of VP2, which is followed by the integi’in binding RGD 
motif (see section 1.6.1) presented in an extended conformation prior to a 3io helix. 
This loop structure was conserved in a complex of an FMDV loop peptide (serotype 
C) with the Fab fragment of two different neutialising antibodies (325, 326). This 
indicates that the internal structure of the loop observed in the reduced type O virus is 
conserved and therefore most likely biologically relevant. Direct evidence for the up 
conformation of the loop was obtained by analysis of the cryostructure of a type C 
virus complexed with the Fab fragment from a neutralising antibody, since this loop 
confonnation best explained the observed location of the Fab fragment (124). Taken 
together this evidence supports a model whereby the VPl GH loop exists as a self- 
contained unit which acts as a domain hinged relative to the surface of the particle
(239), that can adopt at least two radically different positions relative to the particle 
surface. Under reducing conditions, such as those found in the cytoplasm, the loop 
takes on the more ordered “down” conformation (174). The down conformation may 
allow the vims to be more efficiently released fi*om infected cells. However under 
oxidising conditions, such as those found outside the cell, the loop adopts the more 
disordered up conformation. The mobility of the GH loop relative to the particle 
surface in the up conformation is likely to aid virus binding to its integrin receptor 
(144, 192) (see section 1.6,1).
1.3 FMDV Genome Organisation
The organisation and main features of the genome of FMDV are shown in figure 
1.3. The genome consists of a single molecule of single-stranded, positive-sense 
RNA, which is over 8300 nucleotides in length. This RNA molecule contains a single 
long open reading frame which encodes the viral proteins. The open reading frame is 
flanked by a long 5’ untianslated region (5’ UTR) of over 1300 nucleotides, and a 
relatively short 3’ untranslated region (3’ UTR) of 100 nucleotides excluding the poly 
(A) tail (191). A small virally encoded peptide termed VPg (also known as 3B) is 
covalently linked to to the 5’ end of the genome (83, 104).
The single open reading fr ame has two alternative initiation sites, and encodes a 
single viral polyprotein which is processed by viral proteases to give a total of fifteen 
mature polypeptide products and a variety of paitial cleavage intermediates (106). As 
shown in figure 1.3 the polyprotein is divided in to four regions. These are from 5’ to 
3’: L (the leader protease), PI (the stiuctural proteins lA-lD , also known as 
VP4,VP2, VP3 and VPl), P2 (non-structural proteins 2A-2C), and P3 (non-stmctural
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Figure 1.3. Schematic diagram of the FMDV genome showing the position of the genetic elements.
(A) Overview: open boxes indicate protein-encoding regions, lines indicate RNA structures. Thick 
lines below the genome diagram indicate prominent partial cleavage products.
(B) Expanded view of the 5’Untranslated region; S-f rag ment, short fragment of the genome, poly(C), 
poly cytosine tract, PK, pseudoknot, ere , cis replicatiion element (showing the conserved AAACA' 
sequence), 1RES, internal ribosome entry site.
Figure adapted from (188).
proteins 3A-3D). The non-sti'uctural proteins are involved in the replication of the 
FMDV genome (see section 1.4.4) and processing of the viral polyprotein (see section 
1.4.3). The poly(A) tail of FMDV differs from those of cellular messenger RNA’s in 
that it is genome encoded rather than added as a post-translational modification.
1.3.1 The 5’ UTR
The structures present in the 5 ’ UTR of the FMDV genome are shown in figure 
1.3b). The 5’ UTR includes a number of elements involved in RNA translation and 
replication, including the S-ffagment, poly C tract, pseudoknots, and cis replication 
element (ere) and internal ribosome entry site (1RES).
1.3.1.1 The S Fragment
The S-ffagment is approximately 360 nucleotides long and is predicted to form a large 
hairpin structure in silico (52, 81). Little data exists about the role of the S-fr agment 
in the life cycle of FMDV or any proteins which interact with it; however, deletion of 
the S-fi*agment renders FMDV non-viable. The equivalent structure found in 
poliovirus is the “cloverleaf’. This structure is only around 80 nucleotides in length 
and has been shown to interact with the cellular protein poly(rC) binding protein 2 
(PCBP2) and the poliovinrs 3CD protein (via sequences located within 3C) to form a 
ternary complex (10, 120, 219, 240). The binding of PCBP 2 to the cloverleaf is 
required to maintain the stability of poliovirus RNA (219), whereas the binding of 
3 CD is required for the initiation of synthesis of negative strand copies of the 
poliovirus genome and also helps to stabilise the viral RNA (15). A ternary complex 
is formed by the 5’ cloverleaf, PCBP2, and 3CD. This complex interacts with poly A 
binding protein (PABP) bound to the 3 ’ poly(A) tail resulting in the circularisation of
the poliovirus genome, an event thought to be required for the initation of negative 
strand RNA synthesis (15, 120, 180, 309)
1.3.1.2 Poly(C) Tract and PseudoJcnots
On the 3’ side of the S-ftagment of FMDV RNA lies an RNase-Tl resistant tract 
containing approximately 90% C-residues, which is known as the poly(C) tiact (41).
A poly(C) tract is also found in the genomes of most cardioviruses but is absent from 
other piconiavimses such as Theiler’s murine encephalitis vims. The poly(C) tiact 
varies in length between strains of FMDV, fr om around 80 to 420 nucleotides. Field 
strains of FMDV contain a poly(C) tract of around 200 nucleotides on average, 
whereas shorter poly(C) tracts are generally found in tissue culture adapted strains. 
These observations indicate that there is sti ong selection pressure to maintain the 
poly(C) tract within FMDV RNA. The poly(C) tract may play a role in replication of 
the FMDV genome as the predicted binding of PCBP to the poly(C) tract could 
mediate the circularisation of the FMDV genome via an interaction with PABP bound 
to the 3’ UTR.
The FMDV poly(C) tr act is followed by a stretch of some 250 nucleotides in length 
that is thought to contain between 2 and 4 pseudoknots, depending on the virus strain 
in question (52, 80). The role of the pseudoknots found within FMDV RNA is as yet 
undefined, but it may be that these structures are involved in a joint function with the 
poly(C) tract. Cardiovirus RNA’s are also predicted to contain multiple pseudoknots, 
but these structures are located on the 5’ side of the poly(C) tract rather than the 3’ 
side (73, 185). The pseudoknots found in EMCV have been suggested to play an 
undefined role in genome replication, since in vitr o translation of viral RNA 
containing pseudoknot deletions occur s normally, whereas accumulation of viral RNA 
upon infection of Hela cells is impaired (185). .
1.3.1.3 Cis Replication Element (ere)
Following the RNA pseudoknots found in the FMDV genome is a predicted hairpin 
loop, known as the cis replication element (ere), which is required for replication of 
the viral RNA. The first such element identified in Picornaviruses was a stem loop, 
located within the coding region for VPl (ID) of HRV-14 RNA, that was required for 
RNA replication (200). This structure was termed a “ere”, and subsequently similar 
structures were identified in the VP2 (IB) region of two cardioviruses (173), the 2C 
region of poliovirus (97), and the 2 A region of HRV-2 (92). The role of this element 
in viral RNA replication is independent of its location within the genome (97) and is 
disscussed further in see section 1.4.4.2.
1.3.1.4 Internal Ribosome Entry Site (1RES)
The 1RES is a highly structured RNA element which mediates internal, non cap- 
dependent, initiation of translation of the FMDV genome. The role of this element in 
viral replication will be discussed in see section 1.4.2.
1.3.2 The 3’ UTR
The 3 ’ unti anslated region of FMDV consists of two components, a region of about 
100 nucleotides of heterogenous sequence and the poly(A) tail. Little is known about 
the role of the 3’ UTR in infection, but deletion of the heterogenous sequence within 
this region blocks infection (282). It has also recently been shown that the FMDV 3’ 
UTR can stimulate the activity of the FMDV 1RES (178).
The poly(A) binding protein (PABP) binds to the poly(A) tail of the FMDV 
genome, but can also bind simultaneously to the tianslation initiation factor eIF4G 
(which binds the FMDV 1RES) and PCBP (which binds to the FMDV 1RES (301) and
10
presumably the poly(C) tract). Interaction of PABP with either eIF4G or PCBP could 
serve to circularise the FMDV genome, an event proposed to be required for RNA 
replication in poliovirus (see above) (120).
1.4 The FMDV Replication Cycie
Figure 1.4 shows the replication cycle of a picomavirus from cell attachment to 
particle assembly and release. The stages of the replication cycle are discussed 
below.
1.4.1 Attachment and entry
FMDV replication takes place within the cellular cytoplasm, therefore the viral 
RNA genome must be delivered to the cytosol across a cellular membrane. To 
achieve this the virion first attaches to the host cell via an integiin receptor at the cell 
surface (figure 1.4 step 1 -  see section 1.6.1). Subsequently the virion is internalised, 
uncoated, and the viral RNA translocated to the cell cytoplasm by an as yet undefined 
mechanism (figure 1.4 step 2 -  see sections 1.6.4.2 and 1.6.5.2).
1.4.2 Translation
An important feature of the FMDV RNA genome (shared with other picornaviruses) 
is that it is infectious, meaning that the viral RNA does not require any viral proteins 
to initiate the infection cycle. Once the viral RNA has been delivered to the cytosol 
of the host cell it is tianslated in order to produce the viral proteins required for 
replication (figure 1.4 step 3). Inside the cell the genome linked peptide VPg is 
removed by cellular factors and the viral RNA associates with ribosomes. The viral
11
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Figure 1.4. Overview of the Life Cycle of a Picomavirus.
Virus binds to its receptor at the cell surface (1), and following particle uncoating the viral genomic 
RNA is delivered to the host cell cytoplasm (2). VPg is removed from the viral RNA, which is then 
translated (3). The polyprotein is cleaved nascently to produce individual viral proteins (4). RNA 
synthesis occurs on membrane vesicles (not drawn to scale). Viral positive (+) strand RNA is copied 
by the viral RNA-dependent RNA polymerase to form full length negative (-) strand RNAs (5), which 
are then copied to produce additional positive strand RNA (6). Early in infection newly synthesised 
positive strand RNA is translated to produce additional viral proteins (7), but later in infection the 
positive strands associate with structural protein to form new virus particles (8). Newly synthesised 
virus particles are released from the cell by lysis (9).
Figure adapted from (261)
RNA genome is positive sense and so is translated directly by the host cell’s 
translation machinery. The polyprotein synthesised is processed co-translationally by 
virus-encoded proteases via a number of stable intermediates to give 15 mature 
polypeptides (see section 1.4.3).
All eukaryotic messenger RNA (inRNA) molecules have a cap stmcture at the 5’ 
end which plays an essential role in the initiation of translation. The cap is recognised 
by the tianslation initiation factor eIF4F (95). eIF4F is a heterotrimeric complex of 
the translation initiation factors eIF4E, eIF4A, and eIF4G. eIF4E binds directly to the 
5’ cap structure, eIF4A is an RNA helicase, and eIF4G binds to both eIF4A and 
eIF4E and acts as a bridge between the two. Since the genomic RNA of FMDV lacks 
a 5’ cap structure, and the translation initiation start site is located some 800 
nucleotides downsti eam of the 5 ’ end of the genome, translation must be initiated by a 
different mechanism to cellular mRNA. Translation of FMDV RNA is initiated at a 
structure known as the internal ribosome entry site (1RES). The 1RES is a highly 
structured RNA element of approximately 450 nucleotides in length and is located 
immediately upsti eam of the translation start sites and downstream of the ere structure 
(see figure 1.3 b) (26, 164). The 1RES facilitates translation by direct recruitment of 
the translational apparatus (including eIF4A, eIF4B, eIF4G, eIF2, and eIF3) to a site 
very close to the site of translation initiation
Within 1-2 hours of the initiation of infection of the host cell by FMDV, the 
synthesis of host cell proteins declines to almost zero, due to the “shutoff ’ of cap- 
dependent protein synthesis. Shutoff of cap-dependent protein synthesis is due to the 
cleavage of the ti anslation initiation factors eIF4GI and eIF4GII by the virus encoded 
L protease (65, 100, 176, 201). However, 1RES mediated tianslation of FMDV RNA 
is not affected by eIF4G cleavage, since the C-terminal fragment of eIF4G binds
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directly to the 1RES and is sufficient to mediate 1RES dependent initation of 
translation (177)
1.4.3 Polyprotein Processing
The full length polyprotein is never detected in infected cells or in vitro translation 
reactions since primary proteolytic processing of the nascent polypeptide begins co- 
translationally (figure 1.4 Step 4). The processing of the FMDV polyprotein is 
depicted in figure 1.5. The FMDV polyprotein undergoes three primary cleavage 
events. The first is mediated by the L protease which cleaves the junction between its 
own C-terminus and the N-terminus of VPO (lAB) (303). The second “cleavage” 
occurs at the junction between the C-terminus of the short 2A peptide and the N- 
terminus of the 2B region, and is mediated by the 2A sequence together with the first 
amino acid of 2B (280). It has been proposed that this event is not in fact a 
proteolytic cleavage of an existing peptide bond, but instead results from a 
modification of ti anslation such that the bond is never formed but translation of the 
downstream sequence still continues (71). The properties of the 2 A oligopeptide 
together with the first residue of 2B (a proline) can also mediate cleavage in artificial 
polyprotein systems (70, 279). The third cleavage event occurs at the 2C/3 A 
boundary and is mediated by the virus encoded 3C protease. The four products of 
primary cleavage of the FMDV polyprotein are therefore as follows: The L protease, 
the capsid protein precui’sor P1-2A, and the 2BC and P3 replicative protein 
precursors.
The P I-2A, 2BC and P3 precursors undergo further “secondary” cleavages, which 
are also mediated by the 3C protease (12, 322). Although the 3C protease efficiently 
cleaves the sites mentioned above, processing of the capsid protein precursor (PI-2 A)
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Figure 1.5. Proteolytic processing map for Foot-and-mouth disease virus
The FMDV polyprotein is shown as an open box. The positions of the virus-encoded proteases and 
their claeavage sites are indicated. The 2A “cleavage” site is marked by an open arrow, 30 
cleavages by thin closed arrows, and the L protease cleavage site by a wide closed arrow. Figure 
adapted from (23)
occurs more efficiently with 3CD, indicating that this precursor also possesses 
protease activity (278). Processing of the P3 and 2BC precursors is thought to occur 
both in cis and ti*ans, with the cis reaction presumably predominating during the early 
stages of infection when the concenti ation of fi'ee 3C protease is at its lowest. 
Processing of the P I-2A capsid precursor can only occur in trans since it is released 
from the ribosome before the 3C or 3CD proteases have been synthesised.
As shown in figure 1.5, full processing of the FMDV polyprotein results in the 
production of 15 mature polypeptides. A variety of cleavage intermediates are also 
observed, some of which have distinct biological roles. The 3CD precursor for 
example is relatively stable (278) and is required for the in vitro uridylylation of 
FMDV VPg in addition to the free 3D polymerase (221), as well as for maximally 
efficient cleavage of the P I-2 A precursor (12). The 3AB precursor is very stable in 
vitro (278) and is thought to be the form in which the VPg peptide primer is delivered 
and anchored to the membranes on which viral RNA replication occurs (see section 
1.4.4.3). The 3 A protein itself may help to detenuine the host range of FMDV sti'ains 
(238).
The 2BC precursor of FMDV (but not the mature 2B, 2C, or 3 A proteins) has 
recently been shown to inhibit protein secretion in BHK cells (207). In poliovirus, the 
2B, 2BC and 3A proteins can all perform this function (67), and the 3A protein has 
been shown to reduce the release of antiviral interferon by preventing its secretion 
(66). FMDV 2BC also causes remodelling of the ER into large vesicular structures 
close to the nucleus (207). This suggests that 2BC plays a role in the formation of 
replication vesicles required for RNA replication during vims infection. Consistent 
with this theory, co-expression of the poliovirus 2BC and 3 A proteins has been shown 
to induce the formation of vesicles identical to those observed during poliovirus
14
infection (306). Within poliovirus infected cells both the 2B and 2C proteins are 
found within membrane associated viral replication complexes, suggesting they play a 
role in RNA replication (31, 33). The FMDV 2C protein is the target for guanidine 
hydr ochloride, an antiviral compound which inhibits replication of FMDV RNA (263, 
285, 286). These observations provide direct evidence that the FMDV 2C protein 
plays a role in RNA replication.
1.4.4 Viral RNA Replication
1.4.4.1 The Switch from Translation to Replication
After the FMDV genome has passed in to the cytoplasm of the host cell, it is first 
tianslated to yield the proteins required for RNA replication, and then used as a 
template for negative strand RNA synthesis. It is thought that translation of the viral 
RNA must be terminated prior to negative-stiand synthesis since translating 
ribosomes inhibit viral RNA replication by the 3D polymerase (14, 90). The 
mechanism of the switch from RNA tianslation to negative stiand synthesis is unclear 
although a model for this process has been proposed. The poliovirus genome is 
thought to become circularised due to the interaction between the ternary complex of 
the 5’ cloverleaf, PCBP2, and 3 CD at one end of the genome with PABP bound to the 
3’ poly(A) tail at the other (15, 120, 180, 309). The formation of this structure has 
been proposed to inhibit the binding of translation initiation factors and ribosomes to 
the 5' terminal 1RES, meaning that the viral RNA would be naturally cleared of 
ti'anslating ribosomes over time, and hence would then be free to act as a template for 
negative strand RNA synthesis (15). Genome circularisation could therefore be the 
event which mediates the switch fr om ti anslation to replication of viral RNA. A
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similar mechanism is also possible in FMDV, since it has been proposed that the 
FMDV genome could become circularised via the interaction of PCBP bound to the 
poly(C) tract in the 5’ UTR, with PABP bound to the 3’ poly(A) tail (191).
1.4.4.2 Initiation o f  Positive and Negative Strand RNA Synthesis
Replication of the FMDV RNA genome follows ti anslation and occurs via a two-step 
process common to all lytic vimses with a single stranded positive-sense genome.
The viral genomic RNA is tianscribed to form a full-length negative-sense copy of the 
genome (figure 1.4 Step 5), which is used as a template for the production of new 
positive-sense genomes (figure 1.4 Step 6) (258).
Synthesis of both negative- and positive-sti ands is catalysed by the virus-encoded 
3B primer and RNA dependent RNA polymerase, but several other virus non­
structural proteins, and possibly host proteins, also participate in this process. RNA 
replication is asymmetric since many more positive strand than negative stiand 
genome copies accumulate in infected cells. The viral peptide VPg (3B) acts as the 
primer for the synthesis of both negative and positive sense RNA. Unlike other 
picornaviruses, FMDV encodes three tandem similar but distinguishable copies of 
VPg all of which have been shown to be linked to FMDV genomic RNA (155).
In both poliovirus and FMDV infected cells a pool of uridylylated forms of VPg 
(VPgpU and VPgpUpU) can be detected. Formation of VPgpU and VPgpUpU is 
known as uridylylation, and is also caiTied out by the virus-encoded 3D polymerase. 
Uridylylation of VPg is dependent on a conserved stem loop known as the cis 
replication element (ere) (221). In vitro, uridylylation of FMDV VPg requires UTP, 
divalent cations, RNA containing the ere stem loop, the 3D polymerase and its 3CD 
precursor (221). All three copies of VPg encoded by the FMDV genome can be 
uridylylated in vitr o, although the reaction is most efficient when the third of the
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tandemly encoded copies is utilised. The efficiency of uridylylation is also 
significantly enhanced when the entire 5’ UTR (including the ere) is included in the 
reaction rather than the ere alone (221). The requirements indentified for cre- 
dependent in viti'o uridylylation of FMDV VPg are similai* to those previously 
identified for poliovirus (244, 245). Uridylylation of FMDV, poliovirus, and human 
rhinovims VPg is dependent upon a conserved AAACA motif found in the non-base 
paired loop region of the ere stem loop (221, 244, 339). Mutation of each of the first 
three A residues of this motif drastically reduces VPg uridylylation in vitro as well as 
replication of an FMDV replicon in BHK cells, although mutation of the first A 
residue has the greatest effect (190,221). These observations are consistent with 
studies in poliovirus which lead to the proposal of a “slide back” mechanism of 
uridylylation. In this model the first A residue of the ere AAACA motif is used as the 
template for the addition of both the fii'st and second U residues to VPg (247). It 
should be noted that it is not clear- whether the species uridylylated is VPg (3B) itself 
or a precursor which contains VPg, such as 3AB.
Based on studies can-ied out using poliovirus, negative strand synthesis has been 
proposed to occur following ti anslocation of VPgpUpU formed on the ere structure to 
the 3’ poly (A) tail of the infectious positive sense genome (245). VPgpUpU may 
become anchored to the poly (A) tail by Watson-crick base pairing, and the negative 
strand copy of the positive sense genome is then synthesised by the 3D polymerase 
using the positive strand as a template, and VPgpUpU as a primer (245). Priming of 
negative strand synthesis is thought to occur at an internal site since an authentic 3’ 
end of the genome is not required for maximal efficiency negative strand synthesis 
(119).
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More recent studies on poliovirus however indicate that negative stiand synthesis is 
not dependent upon the ere structure in vitio, since mutations which disrupt cre- 
dependent uridylylation of VPg do not inhibit negative sti and synthesis (99, 212, 
218). This suggests that negative-strand synthesis by the 3D polymerase is not 
primed by VPgpUpU, but by the unmodified form of VPg (212, 217). By this model, 
the poly (A) tail would act as a template for uridylylation of VPg by the 3D 
polymerase to give VPg poly (U), which would subsequently be extended to give the 
full-length negative-strand genome copy. This is consistent with a previous study 
which showed that reactions containing 3D, VPg, UTP, Mg2+, and poly(A), result in 
the formation of VPg-poly(U) (246).
The above studies also showed that synthesis of positive-sense infectious poliovims 
RNA fi*om the negative sense template is dependent on the ere element, since 
mutations which prevent cre-dependent uridylylation of VPg also prevent positive 
sti'and synthesis (although not negative strand synthesis) in viti'o (99, 212, 217). In 
addition, it has been shown that, unlike the initiation of negative strand synthesis, the 
initiation of positive strand synthesis occurs at the 3’ terminus of the template RNA, 
since an authentic 5’ end to the poliovirus genome is required for efficient positive 
stiand synthesis (119). Following uridylylation, the elongation phase of both positive 
and negative strand synthesis is carried out by the virus encoded 3D polymerase
1.4.4.3 The Site o f  RNA Synthesis
Infection of tissue culture cells by FMDV and other picornaviruses causes dramatic 
intracellular membrane rearrangements, resulting in the proliferation of vesicular 
structures within the host cell cytoplasm (208). This process has been most 
extensively studied in poliovirus infected cells, in which double-membraned vesicles
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of between 200-400nm in diameter are seen to accumulate in tight clusters (60, 287). 
Virus RNA synthesis has been shown to be associated with these membranous 
structures (32, 44, 45), and is thought to take place on the outer cytoplasmic surface 
(31). Formation of vesicles with similar biochemical and moiphological 
characteristics to those seen in poliovirus infected cells can be induced by co­
expression of the poliovims 2BC and 3 A proteins in tissue culture cells (306). 
Poliovirus-induced vesicles share a number of features with cellular structures called 
autophagosomes, including their double membranes, and the presence of cytoplasmic 
material within the vesicles. Autophagic vacuoles are double membraned structures 
which envelop cytoplasmic proteins and organelles, and become degiadative upon 
maturation and fiision with lysosomes (171). The vesicles induced by poliovirus (and 
those of human rhinovims-2 and -14 also) are thought to be derived from the ER by a 
process which subverts the cellular autophagosomal machineiy, since the two 
stiuctures share a number of characteristics (148, 306).
Vesicular- structures induced by FMDV infection differ slightly from those induced 
by poliovims infection. The majority of induced vesicles appear to be bounded by a 
single membrane rather than a double membrane, are relatively few in number, and 
are less tightly clustered than those induced by poliovirus (208). Secondly it has been 
observed that in cells infected with FMDV virtually all cytoplasmic organelles 
collapse in to a region located on one side of the nucleus which also contains the 
vesicles on which RNA replication is thought to take place (208). This accumulation 
of organelles was not observed when the same cell line was infected with bovine 
enterovirus (208) and has not been observed in previous work carried out on 
poliovirus infected cells (e.g. (31)). The significance of this difference is as yet 
unclear. It should also be noted that FMDV and poliovirus differ in their sensitivity to
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Brefeldin A (BfA). BfA inhibits membrane transport between the ER and the Golgi 
apparatus by preventing the formation of COPI-dependent secretory transport vesicles 
(274). Replication of poliovirus is extremely sensitive to the action of BfA (139), 
whereas FMDV replication is unaffected by this agent (210, 233), suggesting that the 
mechanism of formation and/or the source of the vesicles on which replication occurs 
may differ between the two viruses.
The precise role played by membranous structures in the replication of picomavirus 
RNA is still unknown. One possible role for the vesicles induced by picornaviruses is 
to act as a scaffold on which the virus-encoded proteins and template RNA required 
for genome replication can be assembled in the correct context. In poliovirus 
infection all non-stiuctural proteins (including the 3 CD precursor) except the viral 
proteases 2A and 3C have been detected on the surface of replication vesicles (77, 
287, 306, 310). The 2C and 2B proteins of enteroviruses have been shown to bind 
membranes peripherally via amphipathic helices (243), whereas poliovirus 3 A and its 
3AB precursor are integial membrane proteins which interact with membranes via a 
hydrophobic region of 3 A (314). The hydrophobic domain of 3 A, in the form of the 
3AB precursor, is thought to serve to deliver and anchor the VPg peptide primer of 
negative and positive strand synthesis to the membrane vesicles on which RNA 
replication occurs. The 3D polymerase and its 3CD precursor have been shown to be 
associated with replication vesicles in poliovirus infected cells and are required for 
RNA replication, yet have not been shown to interact with membranes. The 
membrane binding precursor 3AB binds to 3D and 3CD, and stimulates the 
polymerase activity of the former (257). 3AB may therefore serve to recruit and 
anchor 3D and 3CD to the virus induced vesicles on which viral RNA replication 
takes place.
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1.4.5 Particle Assembly, Maturation, and Release
The first step in assembly (figure 1.4 step 8) is the formation of the 12S 
intermediate termed a “pentamer”. Pentamers are formed by the iiTeversible 
association of five protomers in a ui ea-sensitive fashion. The second stage in 
assembly sees the association of 12 pentamers in an acid-sensitive fashion to yield the 
final capsid stiucture. The stage at which RNA encapsidation occurs is unclear. 
Mutations which prevent the myristoylation of VPO prevent the assembly of FMDV 
empty capsids, indicating that this lipid modification is required for particle assembly
(1). The final stage o f assembly is the maturation cleavage of VPO (see below).
A number of intermediate particles have been indentified in picomavirus infected 
cells, including a particle containing RNA but uncleaved VPO (the provirion) (111), 
and a particle with uncleaved VPO which lacks RNA (empty capsid) (105). The role 
of these particles, together with the signals necessary for encapsidation, remains 
unclear. In one model of assembly the genomic RNA is inserted in to preformed 
empty capsids to yield the provirion. In the second model the provirion is formed by 
the assembly of 12 pentamers around a single copy of viral positive sense RNA. 
Evidence for the first model includes the ability to chase a radioactive label fiom 
FMDV structural proteins found in protomers, to pentamers, empty capsids, and 
ultimately virions (336). In addition the capsid proteins of both FMDV (1) and 
poliovirus can self-assemble into empty capsids in the absence of viral RNA.
However more recent work using the poliovims cell-fiee replication system supports 
the second model, since only pentamers can interact with viral RNA to form virions in 
this system (327). This indicates that empty capsids may be a by-product of the 
assembly reaction. Picomavimses package only newly synthesised, VPg linked,
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positive strand RNA (229, 230), suggesting there is a link between active RNA 
replication and encapsidation, perhaps mediated by a cis-acting packaging signal 
Any packaging signal may lie in the PI region of the genome, since, in contrast to 
replicons based on poliovirus (259), FMDV replicons lacking virtually all of this 
region are inefficiently packaged when capsid proteins are provided in ti ans (199), 
Recently a cis-acting encapsidation element has been identified within a stem loop 
located at the 5 ’ end of the Aichi virus genome, which is the first report of such an 
element in a picomavirus (283).
Once the viral RNA has been packaged the final stage in virion assembly is the 
cleavage of VPO to yield VP4 and VP2, an event termed the maturation cleavage.
The degree of VPO cleavage is higher in infectious virus particles than either naturally 
or artificially produced empty particles, indicating that the viral RNA plays a role in 
this process (56, 58, 275). VPO cleavage is thought to be autocatalytic, and has been 
proposed to result fi om the activation of local water molecules by a conserved 
histidine residue (His 195 of poliovirus VP2 or His 145 of the FMDV protein), 
leading to a nucleophilic attack on the scissile bond and cleavage (16, 58, 125). 
Consistent with this model, mutation of histidine 195 of poliovirus results in the 
formation of unstable particles containing poliovirus RNA and uncleaved VPO (125). 
The increased stability of mature particles over empty capsids results from increased 
ordering of the network of structural protein N-termini due to both the physical 
presence of RNA, and the increased degree of VPO cleavage (58).
Recombinant FMDV particles in which the maturation cleavage is prevented firom 
occurring by site-directed mutagenesis are non-infectious (160). The introduced 
mutations did not prevent normal RNA replication, protein expression, assembly, cell 
binding, or acid-mediated particle uncoating, but the acid breakdown products of the
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particles were considerably more hydr ophobic than wild type, presumably due to a 
failure to release myristoylated VP4 (160). These data appear to indicate that the 
maturation cleavage is required in order that the viral RNA is translocated in to the 
cytoplasm, a process known as RNA escape.
The final step in the FMDV replication cycle is the release of the newly foimed 
mature virus particles from the host cell (figure 1.4 Step 9). Infection of a cell 
monolayer by FMDV results in cell lysis and plaque formation, hence it is believed 
that progeny virions ar e primarily released upon lysis of the infected host cell (24). 
The mechanism by which lysis is triggered is unclear, although in the case of 
poliovirus the virus 3 A protein has been implicated in this process (165). Wlien 
poliovirus replicates in polarised epithelial cells resembling those that line the 
gastrointestinal tiact (a natural site of infection), progeny virions are released at the 
apical surface of the cells by a non-destructive mechanism (320). It is likely that 
FMDV can also be released by non-lytic as well as lytic mechanisms.
1.5 Endocytosis Pathways
Mammalian cells take up extracellular material by a variety of different mechanisms 
that are collectively termed endocytosis. Endocytic mechanisms serve many 
important cellular functions including the uptake of extracellular* nutrients, regulation 
of cell-surface receptor expression, and the maintenance of cell polarity. Endocytosis 
pathways are also exploited by viruses in order to gain entry to and infect cells. The 
endocytic pathways exploited by viruses, and the distinguishing features used to 
classify them, are depicted in figure 1.6. Each pathway is discussed individually 
below.
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Figure 1.6. Different endocytosis pathways used by cells to internalise ligands.
The endocytosis pathways shown are classified according to four criteria: the dependence on clathrin, 
caveolae, dynamin and lipid rafts. The best-characterised pathways are (a) the clathrin-mediated 
pathway and (b) the caveolar pathway. The lipid-raft-mediated uptake pathways can be dynamin- 
dependent (c), or dynamin-independent (d). In addition, there are pathways that do not seem  to 
depend on any of these factors (e). The intracellular routing for each of the pathways is also shown, 
but for all except the clathrin-mediated pathway they are poorly defined (indicated by thin arrows). 
Figure adapted from (245).
1.5.1 Clathrin-dependent Endocytosis
The most well known and intensively studied endocytosis mechanism is the clathrin- 
dependent endocytosis pathway. This pathway is characterised by the formation of 
shallow coated-pits at the plasma membrane, which become deeply invaginated and 
then pinch off from the plasma membrane to form coated vesicles within the cell 
cytoplasm. The coat found on the cytoplasmic surface of coated pits and vesicles is a 
honeycomb-like lattice composed of both hexagonal and pentagonal faces (295), and 
is formed by the oligomerisation of clathrin triskelions. The clathrin triskelions which 
make up the clathrin coat are thi*ee legged structures composed of three copies of the 
190kDa clathrin heavy chain (CHC) and three copies of the smaller (~15kDa) clathrin 
light chain (156, 321).
Clathrin coated pit formation, invagination, and membrane fission require an array 
of accessory proteins in addition to clathrin. A wide variety of proteins have been 
identified as components of coated pits including the AP-2 adaptor complex, API 80, 
Epsin, Eps 15, Dab2, Hipl, and Numb-1. In addition, proteins that are not 
components of the coated pit, but are involved in later stages of clathrin-dependent 
vesicle formation include dynamin, amphiphysin and endophilin. Dynamin is a large 
GTPase that self-assembles into a helical collar around the neck of invaginated coated 
pits. It is unclear however whether dynamin ti'iggers vesicle fission directly, or 
regulates the activity of other factors that mediate the fission reaction.
Many of the above proteins can act as dominant negative inhibitors of clathrin- 
dependent endocytosis when full length or truncated fonns are overexpressed in tissue 
culture cells. One of the most widely utilised specific dominant negative inhibitors of 
clathrin-dependent uptake is API 80, A PI80 binds directly to the ear domain of AP-2 
a  subunit (113, 206, 316), and in doing so forms a complex which co-operatively
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recruits clathrin (113). Over-expression of a full length version of API 80, or a C- 
terminal fragment containing only the clathrin-binding domain, potently inhibits 
clathrin-dependent endocytosis by mislocalizing clathrin and preventing its 
incorporation into nascent coated pits (82, 342).
Membrane proteins that are internalised in clathrin coated vesicles generally contain 
one or more signal sequences in their cytoplasmic domain that direct the protein to 
clathrin coated pits. Three such sorting signals have been indentified in single 
membrane spanning receptors thus far: 1) Tyrosine based signals of the form NPxY or 
YXX0 (0  = a bulky hydrophobic residue, x = any residue), 2) Dileucine (LL) based 
motifs and 3) motifs involving serine phosphorylation and the ubiquitination 
machinery. Receptors bearing tyi'osine or dileucine based endocytosis motifs within 
their cytoplasmic domains interact with the AP-2 adaptor complex, which itself binds 
directly to clathrin (via the p2 ear and hinge regions). It is unclear whether receptors 
carrying such motifs recruit AP2, resulting in clathrin coated pit formation, or rather 
the receptors are recruited to coated pits via interaction of their cytoplasmic domain 
with AP-2. The interactions mediated by serine based internalisation motifs are 
unclear.
Once a ligand or receptor has been delivered to a clathrin coated vesicle, the vesicle 
uncoats. The uncoated vesicle is then able to fuse with an eaiiy endosome (also 
known as sorting endosomes) in a Rah5 GTPase dependent fashion, and its contents 
are delivered to the endosomal lumen. Early endosomes are tubulo-vesicular 
sti'uctures bounded by a single membrane, whose lumen is mildly acidic (pH -6.0). 
Many are located at the cell periphery close to the plasma membrane. The limiting 
membrane of early endosomes contains a peripheral membrane protein called early
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endosomal antigen-1 (EEA-1), and this protein is used as a specific marker for this 
compartment (215).
Material delivered to eai’ly endosomes can either be delivered to late endosomes and 
lysosomes for degradation or recycled back to the cell surface. The relationship 
between early and late endosomes is unclear. An intermediate compartment with 
distinct properties (the endosomal earner vesicle) has been defined (107), but it has 
proved difficult to distinguish whether early endosomes are formed de novo and 
mature into late endosomes (via EC V s) or whether material is transported between 
stable early and late endosomes by EC V s  . Late endosomes are more acidic (pH 
-5.5), more spherical, and tend to adopt a more juxtanuclear distribution than early 
endosomes. The cation independent mannose-6-phosphate receptor is concentrated 
within late endosomes and is a characteristic marker of this compar tment (102). Late 
endosomes also contain a number of internal vesicles, thought to play a role in the 
degradation of a number of membrane proteins by enzymes delivered to this 
compartment following fusion with lysosomes (256).
Receptors and ligands that are not passed to late endosomes and lysosomes for 
degradation, can be recycled back to the cell surface for reuse. This process has been 
most intensively studied using transfenin and the transferrin receptor. After leaving 
early endosomes recycling receptors are found in tubular recycling endosomes, fiom 
which they are delivered back to the cell surface. These compai*tments are less acidic 
than early endosomes and are located close to the centiioles in some cell types (88, 
337). Marker proteins for this compar tment include recycling receptors such as the 
transferrin receptor, and the Rabl 1 GTPase (51). Kinetic studies have indentified 
both a slow and a fast recycling pathway (112), leading to the suggestion that
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recycling receptors may be able to ti’affic back to the cell surface directly from early 
endosomes as well as via recycling endosomes.
1.5.2 Lipid Raft-dependent Endocytosis
Lipid rafts are sphingolipid and cholesterol rich microdomains found at the cell 
surface and can be envisaged as islands of highly ordered saturated lipids that are 
laterally mobile in a more disordered and fluid bilayer of unsaturated lipids. They are 
defined biochemically by their insolubility in the non-ionic detergent Triton X-100 at 
4°C and their sedimentation with low density fr actions following centrifiugation 
through sucrose giadients. A subset of endocytosis pathways operating in tissue 
culture cells (highlighted in gi*een in figure 1.6) are dependent on the presence of 
intact lipid rafts at the cell surface, and are outlined briefly below.
1.5.2.1 Caveolae-dependent Endocytosis
Caveolae are a specialised form of lipid raft and typically appear as flask shaped 
invaginations of the plasma membrane of between 50-80nm in diameter by electron 
microscopy (249). Caveolae at the cell surface are characterised by the presence of 
the integral membrane protein caveolin-1 (or caveolin-3 in muscle cells) (273). 
Formation of caveolae appears to be dependent on caveolin since cell lines which do 
not express this protein do not possess any morphological caveolae at their cell 
surface.
The best characterised example of caveolae-dependent endocytosis of a ligand is the 
internalisation of Simian Virus 40 (SV40) by tissue culture cells (see figure 1.6
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pathway b). Unlike clathrin-dependent endocytosis, this uptake pathway is not 
thought to be constitutive but instead is ti'iggered. SV40 binds to the cell surface via 
MHC class I molecules and then moves laterally within the plasma membrane until 
trapped in caveolae (8, 251). The caveola and associated virus aie then internalised, 
an event which is dependent on GMl ganglioside (319), the actin cytoskeleton and the 
recruitment of dynamin (252). The internalised caveolar vesicles (cavicles) 
subsequently deliver internalised virus to a membrane-bound cytoplasmic organelle, 
termed the caveosome (251). This organelle is devoid of markers of classical 
endocytosis pathways, has a neutral pH, and possesses multiple flask-shaped caveolar 
domains enriched in caveolin-1. After a few hours, virus filled tubules devoid of 
caveolin-1 are released ftom the caveosome and traffic to the ER in a microtubule 
and COPI dependent manner (251, 268), and it is from this compartment that SV40 
infection is initiated.
Other ligands known to be taken up by caveolae-dependent endocytosis include 
murine polyoniavirus (a close relative of SV40) (182) and echovirus-1 (183, 254), 
both of which are thought to be delivered to caveosomes. Recent work utilising 
cholera toxin suggests that internalised caveolar vesicles can also deliver internalised 
ligands to early endosomes (248). Upon docking with early endosomes caveolar 
membrane domains do not disassemble but instead remain as distinct and stable 
membrane domains. The low pH within the early endosome allows cholera toxin to 
diffuse out of the caveolar domain to the sunounding membrane, and it is then 
delivered to the ER via the golgi apparatus.
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1.5.2.2 Other Lipid-raft Dependent Endocytosis Pathways
A number of ligands which have been reported to utilise caveolae-dependent 
endocytosis pathways are also internalised normally by cells which do not express 
caveolin-1 in a lipid raft dependent fashion. This suggests that cells can internalise 
material via caveolae and clathrin independent but lipid raft dependent endocytosis 
pathways (see figure 1.6 pathways d and e). A good example is the virus SV40 which 
has been shown to be taken up by a caveolae-dependent uptake pathway (see above) 
yet will readily infect cells lacking caveolin-1 expression (62). The endocytosis 
pathway utilised by SV40 in cells lacking caveolae was rapid, dependent on lipid rafts 
and tyi'osine kinase activity, but was independent of clathrin, and dynamin (62). The 
virus is internalised in small tight fitting vesicles and was delivered to pH neutral 
organelles with similar properties to caveosomes bai" the absence of caveolin-1 and 
caveolin-2. A pathway with similar properties has been shown to mediate the 
internalisation of the cholera toxin B-subunit (CTB) in caveolin-1 knockout mouse 
embryonic fibroblasts, albeit that this molecule is delivered to the golgi rather than the 
ER (158). The lipid raft dependent but caveolar independent uptake of both CTB and 
SV40 were both also shown to occur in cells expressing caveolin-1, indicating that 
this pathway coexists with the caveolae dependent uptake pathway (62, 158).
In addition to the dynamin independent pathways described above, internalisation 
of other ligands has been shown to be mediated by caveolae-independent but lipid 
raft- and dynamin-dependent pathways. Examples of ligands taken up by this 
mechanism include interleukin-2 in cells lacking caveolae or following reduction of 
caveolin-1 expression by RNAi (166, 227), and autocrine motility factor (AMF) in 
ti'ansformed NIH-3T3 cells which express little caveolin-1 (167).
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A recent review has suggested that caveolae-dependent endocytosis and the lipid 
raft dependent endocytosis mechanisms described above constitute a common 
endocytosis system in which caveolin-1 acts as a negative regulator of the 
internalisation of caveolae/raft domains at the cell surface (220). This hypothesis is 
consistent with the observation that decreased expression of caveolin-1 in ras- and 
abl- transformed NIH-3T3 cells is associated with an increased rate of delivery of 
AMF to the ER, and that the réintroduction of caveolin-1 results in a reduction in the 
rate of AMF internalisation (167). Similarly the rate of uptake of the DNA virus 
SV40 is much greater in caveolin-1 knockout mouse embiyonic fibroblasts than the 
wild type cell line (62). Tire available evidence suggests that lipid rafts are 
constitutively internalised in the absence of caveolin-1, but are only internalised 
following the induction of cellular signalling events in cells which do express 
caveolin-1 (220).
1.5.3 Other Endocytosis Pathways
The final category of endocytosis pathway observed in cells (figure 1.6 pathway e) 
covers those internalisation mechanisms that are independent of clathrin, caveolin, 
and lipid rafts, about which relatively little is known. One such pathway is 
macropinocytosis, a triggered pathway used by cells to internalise lai'ge amounts of 
fluid and membrane (307). This internalisation pathway is strictly dependent upon 
actin polymerisation but is dynamin independent, and is exploited by vaccinia virus 
which is too large to enter via clathrin coated pits.
Other clathrin and lipid raft independent internalisation pathways are less well 
defined. Mmine polyoma virus has been reported to utilise such a pathway in cells 
lacking caveolin-1 expression (94). Recent work has shown that around one third of 
influenza virus particles are also taken up by a clathrin and lipid raft independent
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endocytosis mechanism, and the remainder by clathrin-dependent endocytosis (277, 
294). These studies show that influenza virus uses this alternative pathway not only 
when clathrin-dependent endocytosis is blocked, but also in parallel under normal 
conditions (277).
1.6 Picornavirus Cell Entry
In order to initiate the infection cycle all that is required is the delivery of the viral 
RNA genome to the host cell cytoplasm across a host lipid membrane. First the virus 
particle must attach to the host cell via a specific cell surface receptor. The vims 
particle is then delivered to tlie membrane across which the viral RNA will pass in to 
the cellular cytoplasm. This process is mediated either by the initial primary 
attachment receptor or by secondary cell surface receptors. Once the viral genome 
has reached the cytoplasm, it is translated and replicated, and progeny virus particles 
are assembled and released. The process by which the FMDV genome is delivered to 
the cytoplasm of the host cell is discussed in detail below.
1.6.1 FMDV Receptors
1.6.1.1 Background
The viral structural protein VPl contains the major antigenic site on the surface of the 
FMDV capsid, which also encompasses the major receptor attachment site on the 
virion surface (47, 331). Early sequencing studies revealed that VPl contains a 
conserved Arginine-Glycine-Aspartic Acid (RGD motif) within its GH loop (84, 93).
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This motif is conseiwed across all natural isolates of FMDV (141), and is located at 
the apex of the GH loop (2). Proteolytic cleavage of the GH loop of VPl abolishes 
cell attachment and synthetic RGD-containing peptides have been shown to inhibit 
binding of FMDV to BHK cells (19, 84) indicating that the RGD motif may be 
important for receptor binding . The role of the RGD in cell attachment was 
confirmed by the creation of mutant viruses lacking this motif using an infectious 
clone, which were uninfectious and were unable to bind susceptible cell lines (192).
A subset of the integrin family of cell-adhesion molecules are known to interact 
with an RGD-motif within their ligand, which lead to the proposal that the receptor 
for FMDV may be an integidn.
1.6.1.2 Integrin Attachment Receptors
Integrins are a family of cell surface, a - p  heterodimeric glycoproteins composed of 
at least 1 8 a  and 8 P subunits which associate to form over 24 different a -p  
combinations (135). Integrins contribute to a variety of processes, including adhesion 
between cells, and between cells and the extr acellular matrix, and induction of signal 
transduction pathways that modulate various processes, including cell proliferation, 
morphology, migration, and apoptosis. O f the possible heterodimer combinations, 
a v p l, avp3, allbp3, ocvP5, avp6, avp8, o5p l and a8p l have been shown to interact 
with their ligands in an RGD-dependent fashion (136, 228, 288, 299). O f the RGD- 
dependent integrins, av p l (145), avp3 (29, 222-224), avp6 (141, 204), and avp8 
(142) have been shown to act as attachment receptors for FMDV. The integrins avP5 
and a5 p l however do not act as receptors for FMDV infection, despite the fact that
32
virus binds to purified a5p l in an in vitro ELISA assay (141). The ability of aSpi to 
act as a receptor for FMDV has not been tested.
The first integi'in reported to act as a receptor for FMDV was avp3 (29). Berinstein 
et a l showed that FMDV shares a common receptor binding site with 
Coxsackievirus A9 (previously reported to utilise ocvp3 as a receptor), when utilising 
cells permissive to both viruses (29). In addition, binding and infection of LLC-MK2 
cells by FMDV was shown to be partially inhibited by a polyclonal serum directed 
against otvp3. The virus has also been shown to bind avidly to purified avp3 in vitio, 
a process which is inhibited by RGD-, but not RGE-, containing peptides (146).
Subsequently a number of non-FMDV permissive cell lines such as K562 (224), 
CHO (224) and COS (222, 223) cells have been shown to become permissive upon 
transfection with the human av and p3 integrin subunits, indicating that one or both 
of these subunits are required for the infection process. In the latter system, 
tr ansfection with bovine av  and p3 lead to more efficient infection than transfection 
with the equivalent human subunits, a property that can be localised to the C-terminal 
one-third of the bovine p3 subunit (223). Since the p3 subunit is limited to pairing 
with the av chain in this system it follows that avp3 must play an active role 
infection. This conclusion is supported by the observation that the infection of COS-1 
cells transfected with the bovine av and P3 subunits is inhibited by a function 
blocking monoclonal antibody directed against the avp3 heterodimer (222).
More recently, three other RGD-dependent integrins have been reported to act as 
receptors for FMDV: av p i (145), avp6 (142, 145, 147, 204), and avp8 (142). These 
experiments utilised two cell lines, a human colon carcinoma cell line (SW480 cells) 
and CHOB2 cells, both of which are normally non-peimissive for FMDV infection. 
SW480 cells and wild type CHO cells normally express only the avp5 and a5p l
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integrins as their RGD-binding integrins, but the CHOB2 variant cell line lacks 
endogenous cx5 production and so expresses only avp5. SW480 cells become 
susceptible to infection by FMDV upon tiansfection with either the p6 or p8 integrin 
subunits and the consequent expression of the integrins avP6 or avp8 at the cell 
surface respectively (142, 147, 204). In addition, CHOB2 cells become susceptible to 
infection by FMDV upon transfection with either the P6 or av integrin subunits and 
the consequent expression of the integiins avp6 or avp i at the cell surface 
respectively (145). The av p l, avp6, and avp8 integrins were shown to serve as 
receptors for FMDV attachment to the host cell as this process was inhibited by RGD- 
containing peptides and also by function blocking antibodies specific for the 
transfected integrin (142, 145, 147). The same function blocking antibodies which 
blocked attachment of FMDV to the above integrins also blocked infection, 
confuming the role of av p l, avp6 and ocvP8 in infection (142, 145, 147). It should 
however be noted that the level of virus binding and infection mediated by avp 1 is 
relatively low unless this integrin is activated using manganese ions or an activating 
antibody (145).
The relative efficiency with which FMDV utilises different integrin receptors may 
vary from serotype to serotype. For example. Type A viruses have been reported to 
use avP6 and avp3 with equal efficiency and avp 1 to a lesser extent, whereas type O 
viruses have been reported to utilise both avP6 and avp l more efficiently than avp3 
(74). The basis for this difference is unclear since a type A virus carrying a type O 
GH loop showed virtually the same receptor utilisation pattern as the parent type A 
virus. However, experiments using soluble integrins showed that both type A and 
type O viruses are neutralised much more effectively by soluble avp6 than soluble
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avp3 (75). This may suggest that the interaction between FMDV and avp6 is of 
much higher affinity than that between FMDV and avP3.
1.6.1.3 The Role o f  Integrins in Post-Attachment Events
As described above, four RGD-dependent integiins have been shown to act as 
attachment receptors for FMDV on cells. However, the role of integiin receptors in 
post-attachment events is not clear from these studies. In the case of avP6, mutant 
receptors containing certain deletions within the p6 cytoplasmic domain (the T1 and 
T5 deletion mutants -  see section 7.1) aie still able to bind FMDV but are no longer 
competent to mediate infection (204). This suggests that sequences within the 
cytoplasmic domain of the P6 subunit are required to mediate post-attachment steps of 
infection. More recently it has been shown that a chimeric avp6 receptor (avp6/8), 
in which the p6 cytoplasmic domain has been replaced by the equivalent region fr om 
the p8 integrin subunit, also binds FMDV but fails to mediate infection (142). Certain 
epitopes recognized by antibodies against the avp6 heterodimer are absent from the 
chimeric receptor, indicating that the p6 cytoplasmic domain is required for normal 
heterodimer assembly. Although the chimeric receptor binds FMDV, it is a less 
effective receptor for virus attachment and has altered specificity for RGD peptides 
compared to the wild type integrin. Interestingly a chimeric avp8 receptor, in which 
the p8 cytoplasmic domain is replaced by that from p6, is able to mediate both virus 
binding and infection similar to wild type av p 8 (142). Following these observations it 
was shown that the same epitopes are lost from cells expressing avP6 with truncations 
in the p6 cytodomain (The T1 and T5 deletion mutants). There are three possible 
explanations for the above data.
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(1) The P6 cytoplasmic domain is required to maintain the ectodomain of avP6 in a 
conformation that is necessary for both high-affmity binding of FMDV and 
subsequent infection. Such high affinity binding may be required to mediate cross- 
linking of the integrin receptor and/or internalisation of the integiin:virus complex by 
endocytosis.
(2) The cytoplasmic domain of the p6 integrin subunit is required for membrane 
penetration by FMDV, a role proposed previously for the cytodomain of the p5 chain 
in (xvp5-mediated infection by adenovirus (328). This activity is thought to be 
mediated by the three C-terminal residues of the p5 subunit. However these residues 
are different in the P6 subunit chain, and their deletion does not inhibit avp6- 
mediated infection by FMDV (204). Therefore, it would appear that, if the p6 
cytodomain is needed for virus penetration into the cell, it works by a mechanism 
distinct from that used by ocvp5.
(3) The P6 cytoplasmic domain contains endocytosis motifs required for 
internalisation of the integrin :virus complex. Consistent with this notion both the T1 
and T5 deletion mutants, and the avp6/8 chimeric receptor, lack a conserved NPXY 
motif known to mediate clathrin-dependent endocytosis. However, the integiin avp8 
is able to mediate binding and infection of the same cell line (SW480 cells) by 
FMDV, despite the fact that the sequence of the P8 cytoplasmic domain is divergent 
from other p cytoplasmic domains and lacks the NPXY putative endocytosis motif. It 
is possible that internalisation of avp8 is mediated by a novel, as yet unidentified 
endocytosis motif.
As outlined above the cytoplasmic domain of the p6 integi in subunit is required for 
post-attachment events in avp6-mediated infection of tissue culture cells by FMDV,
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although the precise role played by this domain is imclear. By contrast, removal of 
both the av  and P3 cytoplasmic domains (including the conserved NPXY moti:^ 
appears to have no effect on av p 3-mediated infection by FMDV (222). This would 
suggest that either ocvP3 mediates only binding but not internalisation of FMDV, or 
that this integrin can be internalised in the absence of the av and P3 cytoplasmic 
domains. Further work is required to clarify the role of integrin receptors of FMDV 
in post-attachment events.
1.6.1.4 Other Receptors
Heparan sulphates are randomly sulphated (and hence negatively charged) 
polysaccharides formed from an L-iduronic acid D-glucosamine disaccharide repeat. 
They form the carbohydrate component of proteins called heparan sulphate 
proteoglycans which are expressed on virtually all cell types as integial membrane 
proteins or as part of the extracellular matrix.
Heparan sulphate was originally identified as a potential co-receptor or enhancer of 
the entry of certain strains of type O FMDV into tissue culture cells (143). At this 
time it was thought that heparan sulphate acts as the first point of contact of the virus 
en route to the integrin receptor. It was subsequently shown however that field strains 
do not bind heparan sulphate with high affinity, and that this phenotype is acquired 
rapidly upon adaptation to tissue culture (224, 281). Such viruses do not require 
integrin receptors at all since their replication is not inhibited by mutation of the RGD 
integrin binding motif (13, 186, 224). In addition, stiains that acquire the ability to 
bind heparan sulphate are attenuated in cattle, and infection of cattle with such sti ains 
yields revertant viruses which lack the ability to bind heparan sulphate (281).
37
The available data described above suggests that whilst high efficiency interaction of 
FMDV with heparan sulphate confers a clear advantage for growth in tissue culture 
cells, this phenotype is disadvantageous in the natural host animal. In subtype O- 
strains passage in tissue culture causes a single amino acid change (VP3-residue 56 
fi'om arginine to histidine), which causes a dramatic increase in the affinity of virus 
for heparan sulphate (281). It is not known whether a switch from integrin to heparan 
sulphate receptors late in infection, or a low affinity interaction of FMDV with 
heparan sulphate, play any role in infection.
FMDV has also been shown to be able to utilise artificial receptors in tissue culture. 
For example, FMDV is unable to infect CH0-B2 cells ti’ansfected with the Fc 
receptor, unless first coated with antibody (192). By contiast antibody coated 
poliovirus could not infect this cell line. The Fc receptor at the cell surface mediates 
the attachment of FMDV by binding the constant region of the antibodies coating the 
virion, and in doing so mediates infection of the host cell (192). Another artificial 
receptor that can be utilised by FMDV is a genetically engineered receptor consisting 
of ICAM-1 fused to a virus-binding single chain antibody (269). CHO cells are 
normally not susceptible to non-hepaiin binding strains of FMDV, but become 
susceptible upon tiansfection with this chimeric receptor (269). Both artificial 
receptors can mediate infection by RGD-deleted viruses. It has also been reported 
that a highly tissue culture adapted virus has been identified which does not use 
heparan sulphate or integrins as receptors but an unidentified third class of receptor 
(341). The plasticity of receptor use by FMDV suggests that unlike poliovirus and 
major group rhinoviruses, the FMDV receptor simply binds the virion rather than 
catalysing conformational changes required for uncoating.
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1.6.2 Attachment to the host cell by other PIcornavlruses
Picornaviruses have evolved to utilise a wide variety of cell surface proteins as 
receptors. The receptors utilised include members of the immunoglobulin 
superfamily such as the poliovirus receptor (PVR), complement-inactivating proteins 
such as decay acceleration factor (DAF), lipoprotein receptors, and integrins.
A number of picornaviruses have been shown to utilise RGD-dependent integi ins as 
receptors, including: Human parechovirus 1 (parechovirus) (151), echovirus 9 (225, 
264) and coxsackievirus A9 (both enterovirus) (332), and of course foot-and-mouth 
disease virus (aphthoviriis). In the case of FMDV, the RGD motif is located in the 
prominent GH loop of V Pl, whereas in the other viruses it is located close to the VPl 
C-terminus (117). Both FMDV and Coxsackievirus A9 have been shown to utilise 
the integrin avp6 as a receptor, and interestingly the sequence context of the RGD 
motif found in the two viruses is very similar to each other, and also to that of other 
ligands of avp6 such as latency associated protein-1 (LAP-1) (141, 147). This 
suggests that the residues sun ounding the RGD motif may influence integrin 
specificity. Other viruses also shown to utilise RGD-dependent integrins as receptors 
include hantaanvirus, and certain adenoviruses.
The poliovirus receptor (CD 155) is a member of the immunoglobulin superfamily 
of receptors, and its ectodomain consists of three immunoglobulin-like domains (202), 
of which only domain 1 (the largest domain nearest the N-terminus of the protein) is 
required for virus binding (162, 213). Stinctures of all three poliovirus serotypes 
bound to soluble derivatives of the poliovirus receptor have been determined by 
cryoelectron microscopy (23, 116). Domain 1 of the poliovirus receptor penetiates 
the canyon at a glancing angle and makes contacts with both the south and north 
walls, contacts which involve all three surface exposed capsid proteins. This confirms
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previous genetic data which indicated that the primary contact points between virus 
and receptor were located within the canyon.
The rhinovimses can be divided in to two groups based on receptor usage. The 
major receptor group rhinoviruses include human rhinovirus-3,-14, and -16 (HRV-3,- 
14,-16). These viruses utilise intercellular adhesion molecule-1 (ICAM-1) as their 
receptor (101). ICAM-1 is a member of the immunoglobulin supergene family which 
mediates the attachment of leukocytes to a number of cell types by binding to the 
integrin aLp2 (76). The ectodomain of ICAM-1 contains five immunoglobulin-like 
domains, of which only domain 1 (the domain nearest the N-terminus of the protein) 
is thought to be directly involved in the binding of vims (197, 267) and the integrin 
aLp2 (197). Cryostmctures of ICAM-1 bound to HRV-16 (163, 236) and HRV-14 
(163) have been deteiinined and show that, like the poliovirus receptor, the major 
group rhinovirus receptor binds in the canyon surrounding the 5-fold symmetry axis, 
and makes more extensive contacts with the south rim of the canyon than the north 
rim. In conhast to the poliovirus receptor, ICAM-1 is oriented perpendicular to the 
surface of the vims particle.
The minor receptor group rhinoviruses include human rhinovirus-2 (HRV-2) and 
utilise members of the low density lipoprotein receptor family to attach to the host cell 
(126, 184). The LDL receptor family are a group of molecules which mediate the 
clathrin-dependent uptake and lysosomal targeting of a diverse range of ligands 
including lipoproteins, proteinases and hormones (11). All members of this family 
identified to date contain at least one clathrin-dependent endocytosis motif 
(FXNPXY) within their cytoplasmic domain. The very low density lipoprotein 
receptor (VLDL receptor) contains eight imperfect ligand binding repeats (each of 40 
amino acids) in its ectodomain. A truncated version of the VLDLR, consisting of the
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three ligand binding repeats closest to the N-terminus of the receptor, has been 
visualised in complex with HRV-2 by cryoelection microscopy (123). This work 
revealed that this receptor does not bind in the canyon which encircles the 5-fold 
symmetry axis, as is the case for ICAM-1 binding to major gioup rhinoviruses, but 
instead the ligand binding repeats interact with the star shape dome on the icosahedral 
5-fold axis. Further cryo-electi on microscopy structures have revealed that virus 
binding is mediated by ligand binding repeats 2 and 3 (226), and a crystal structure of 
these domains bound to HRV-2 has been determined (324).
As described above, the receptors of poliovirus and the major group rhinoviruses 
bind to sites within the canyon surrounding the 5-fold symmetiy axis. It was 
originally proposed that the reason receptors bound to a depression on the viiion 
surface was to protect epitopes required for receptor binding from neutralisation by 
antibodies (“the canyon hypothesis”) (271). However, this hypothesis is not 
consistent with the finding that the minor group rhinovirus receptor binds not within 
the canyon but to the highly exposed star shaped dome at the 5-fold axis itself. In 
addition the surface of FMDV possesses few significant surface depressions, and its 
integrin receptors bind to the exposed GH loop of V P l. The different receptor 
binding sites may reflect differences in the uncoating mechanisms of the respective 
viruses. Uncoating of major group rhinoviruses and polioviruses are at least partially 
receptor dependent, whereas uncoating of minor group rhinoviruses (and also FMDV) 
is dependent on exposure to acidic pH alone (see section 1.6.5). It has therefore been 
proposed that binding of the receptor within the canyon on the surface of poliovirus 
and major gioup rhinoviruses helps to destabilise the viral particle and facilitates the 
structural changes required for uncoating (127) (see section 1.6.3), changes which are 
triggered solely by exposure to acidic pH in minor gioup rhinoviruses.
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Other receptors utilised by picornaviruses include vascular cell adhesion molecule-1 
(VCAM-1), a member of the immunoglobulin superfamily utilised by EMCV (134), 
and hepatitis A virus cellular receptor 1 (HAVcrl) (153), a mucin like molecule 
which carries an immunoglobulin-like domain at its N-terminus. The attachment of a 
number of enteroviruses to the host cell has been shown to be mediated by decay 
acceleration factor (DAF), the coxsackieadenovirus receptor (CAR), or a combination 
of the two. Examples include echovirus 11 which utilises DAF alone (304), and 
coxsackievirus B3 which utilises both DAF and CAR (although DAF cannot mediate 
infection in the absence of CAR), or CAR alone (292).
1.6.3 A-Particle Formation
Upon binding to its receptor at physiological temperatures, poliovims undergoes an 
iiTeversible stiuctural change resulting in the formation of a particle which sediments 
at 135S (rather than 160S for the native virion), termed the A-particle. A-particle 
formation results in a decreased affinity for the PVR, the externalisation of VP4 and 
the relocation of the N-terminus of VPl fiom the inner to the outer surface of the 
capsid (86). The structure of the 135 S A-particle of poliovims has recently been 
solved to lOA and this s tincture revealed that the externalised N-termini of VPl lie 
around the 3-fold symmetiy axis, rather than the 5-fold axis as previously thought 
(42). A-particle formation is thought to be a prerequisite for the release of the viral 
genomic RNA. It has been a matter for debate in recent years as to whether or not A- 
particles are an intermediate in poliovirus cell entry, but a number of lines of evidence 
suggest that this is the case (see section 1.6.5).
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Decay acceleration factor (DAF) serves as an attachment receptor for a number of 
enteroviruses, including coxsackievirus A21, some isolates of coxsackie B3 (CB3) 
and several echoviruses. However, the above DAF-binding viruses all fail to infect 
normally non-permissive cells tiansfected with DAF, indicating that binding to DAF 
is insufficient to trigger postattachment events required for infection (27, 28, 291, 
292). Coxsackievirus B3 is also able to bind to the Coxsackievirus and Adenovirus 
receptor (CAR) and, can attach to and infect non-permissive rodent cells tiansfected 
with this receptor (187). Interaction of CB3 with CAR, both in solution and at the cell 
surface, induces the formation of A-particles, whereas interaction with soluble or cell 
surface DAF does not (98, 205). This would explain why attachment to cell surface 
CAR, but not DAF, leads to infection of the host cell, since A-particle formation is 
thought to be required for genome release. It is likely that the same is true for the 
other viruses which bind but do not infect DAF-transfected cells. Echovirus 7 for 
example has been shown to form A-particles upon binding susceptible cells 
transfected with DAF, but not soluble DAF. This is consistent with A-particle 
formation being mediated by a second receptor (260). Interaction with DAF is not a 
dead end pathway for CB3 however, since non-permissive CHO cells tiansfected with 
CAR and DAF are more susceptible to infection than those transfected with DAF 
alone (205). This indicates that the vims may be concentrated at the cell surface by 
an initial attachment to DAF, before passing to a second receptor (CAR), which 
initiates cell entry and the conformational changes required for infection.
The human rhinovimses can be divided into two gi'oups based upon receptor usage. 
Major gi'oup rhinovimses (e.g. HRV-14, HRV-3) utilise ICAM-1, whereas minor 
group rhinovimses (e.g. HRV-2) utilise receptors of the low density lipoprotein 
receptor family. All rhinovimses are thought to form A-particles prior to uncoating
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and release of the viral RNA genome into the cytoplasm. For the minor gionp 
rhinoviruses, A-particle formation does not appear to be receptor-dependent, but 
instead is ti'iggered on exposure to low pH (37). The conditions required for A- 
particle formation amongst the major gioup rhinoviruses varies from serotype to 
serotype (130). Human rhinovirus 14 for example will readily foiin A-particles at 
neutral pH when incubated with soluble ICAM-1, whereas complexes of human 
rhinovirus 16 and soluble ICAM-1 are relatively stable at pH 7 (130). It should be 
noted however that in all major gioup serotypes optimal A-particle formation and 
uncoating requires a mildly acidic pH in addition to receptor binding (231).
As described above, rhinoviruses and poliovirus form A-particles upon binding their 
cell surface receptor, upon exposure to low pH, or both. There is no evidence 
however for A-particle formation by FMDV, and indeed such a conformational 
change is unlikely to be required by FMDV, given that the virion dissociates into 
pentamers, VP4 and viral RNA at pH values just below neutrality. Unlike rhino- and 
polio-viruses, FMDV has been shown to be capable of using a range of receptors 
including an artificial receptor consisting of a single chain antibody fused to ICAM-1, 
and when pre-coated with antibody, the Fc receptor. It is therefore clear that 
uncoating of FMDV is not receptor dependent, but instead is triggered at a post­
attachment stage.
1.6.4 Particle Uptake
All picornaviruses must deliver their genomic RNA across a cellular membrane to the 
cytosol of the host cell. The membrane across which the viral RNA passes may be 
either the plasma membrane or an internal organelle membrane, and differs between 
picornaviruses. Following attachment to the host cell, picornavirus virions must be
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delivered to a compartment in the host cell in which the prevailing conditions are 
suitable to trigger A-particle formation, particle uncoating and delivery of the viral 
RNA to the cytoplasm. The endocytosis pathways exploited by viruses to achieve this 
are described in section 1.5
1.6.4.1 Uptake o f  Picornaviruses
Infection of the host cell by the minor group of human rhinoviruses (e.g. HRV-2) is 
mediated by the low density lipoprotein receptor (LDLR) and certain other members 
of the LDLR family (126, 184). This family of receptors are delivered to early and 
late endosomes by clathrin-dependent endocytosis, a process mediated by a conserved 
NPXY internalisation motif within the receptor cytoplasmic domain (49). The low 
pH within intracellular endosomes (pH <6) causes the release of the natural ligand 
from the receptor, the ligand being directed to lysosomes for degiadation (276), and 
the receptor being recycled back to the cell surface. HRV-2 is also thought to be 
taken up by clathrin dependent endocytosis, since virus internalisation is inhibited by 
overexpression of dominant negative versions of API 80 and amphiphysin (296), both 
of which block internalisation of ligands by clathrin-dependent endocytosis. In 
addition, HRV-2 has been shown to colocalise with clathrin at the cell surface by 
immunofluorescence, consistent with uptake via clathrin-coated pits (296).
Formation of A-particles, and subsequent uncoating and RNA delivery, by minor 
group rhinoviruses is not dependent on receptor binding but is instead triggered by pH 
values below 5.6 (37). Consistent with this, infection by this virus is blocked by 
agents which dissipate the prevailing acidic pH within endosomes, such as 
bafilomycin A1 (21, 181,231, 261), ammonium chloride (181), and the ionophore 
monensin (181). Human rhinovirus-2 is released fr om its receptor at mildly acidic pH
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in early endosomes (37), before being delivered to late endosomes via endosomal 
caiTier vesicles where the more acidic pH triggers uncoating (21, 261).
Another picornavirus thought to enter cells via clathrin-dependent endocytosis is 
human parechovirus-1 (151), Infection of susceptible cells by this virus is inhibited 
by chlorproniazine, a dmg which inhibits clathrin-dependent endocytosis. Also, viral 
protein was shown to colocalize first with mar kers of early endosomes, and 
subsequently with markers of late endosomes, two compartments associated with the 
clathrin-dependent endocytosis pathway. However, in contrast to HRV-2, it is likely 
that infection occurs from within early endosomes, since infection is not inhibited by 
nocodazole, a drug which inhibits transport fiom eaiiy to late endosomes.
Infection of the host cell by major gi oup rhinoviruses (e.g. HRV-3, -14, and -16) is 
mediated by intiacellular adhesion molecule 1 (ICAM-1) (101). HRV-14 has been 
detected within endosomes inside cells (290), and infection by this virus has been 
reported to be dependent on both dynamin (64) and a low pH step (231, 253). Since 
dynamin is required for both clathrin and caveolae-dependent endocytosis, this 
implies that uncoating of this virus (and subsequent RNA delivery) does not occur at 
the cell surface, but instead requires delivery to an acidic endosomal compartment. 
However, unlike the minor group rhinovirus receptors, ICAM-1 does not contain any 
known endocytosis motifs within its cytoplasmic domain. In addition, neither the 
cytoplasmic domain nor the transmembrane domain of ICAM-1 are required for 
infection of Hela cells by HRV-14, since a genetically engineered receptor, consisting 
of the ectodomain of ICAM-1 fused to a GPI anchor, is just as effective at mediating 
infection as the wild type receptor (302). This would either imply that infection 
occurs from the plasma membrane, or that internalisation of the receptor:vims 
complex is triggered by receptor clustering or natural membrane turnover. Some
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investigators report that HRV-14 infection can still occur in the presence of 
bafilomycin, indicating that low pH is not essential for infection by minor gioup 
rhinoviruses (20, 290) but instead merely reduces yield and delays host cell protein 
shutoff, consistent with the ability of this virus to uncoat upon binding soluble ICAM- 
1 at neutral pH (130). However, this could be explained by the observation that 
although uncoating of some minor gioup serotypes does occur at neutral pH, the 
maximum efficiency of uncoating requires both receptor binding and exposure to 
mildly acidic pH (231). The available data indicates that HRV-14 may infect cells by 
more than one route, namely direct penetration through the plasma membrane, and 
following uptake into acidic endosomes.
The entiy pathway utilised by poliovirus is not well defined. Infectious intact virus 
particles have been detected within clathrin-coated vesicles within 10 minutes of 
adsorption to HeLa cells, and can be recovered from endosomal stinctures up to 30 
minutes after adsoiption (333). This data would suggest that infection of Hela cells 
by poliovirus is dependent on the clathrin-dependent delivery to acidic endosomes. 
However, later studies showed that clathrin-dependent endocytosis (and also 
caveolae-dependent endocytosis) may not be essential for infection of this cell line by 
poliovirus, since expression of dominant-negative dynamin does not abolish infection 
(64). This would suggest that poliovirus can deliver its genomic RNA across the 
plasma membrane to the host cell cytoplasm, meaning that only the genomic RNA 
enters the host cell. It should be noted however that expression of dominant negative 
dynamin can lead to the upregulation of other (non-dynamin dependent) endocytosis 
pathways (61). In addition, both A-particle formation and infection of cells by
poliovirus do not appear to require a low pH step since these processes are not
I
inhibited by agents which raise endosomal pH (96, 103, 253). This would also
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suggest tliat (in HeLa cells at least) delivery to acidic endosomes is not required for 
poliovirus infection, or at least that acidic pH witliin this compartment is not the 
trigger for uncoating.
More recent studies using tiansgenic mice expressing the poliovirus receptor, have 
shown that intact poliovims can be incorporated into intracellular vesicles at 
neuromuscular junctions following intramuscular' inoculation, a process dependent on 
the poliovims receptor (234), Vesicles containing polioviins and the poliovirus 
receptor have also been detected within neuronal tissue culture cells, and are 
tr ansported in a retrograde direction along axons in a microtubule dependent manner, 
due to interactions between the cytoplasmic domain of the poliovirus receptor and 
dynein (234). Replication of poliovii'us then occurs in the neural cell body. These 
observations suggest that infection of neuronal cells by poliovirus is dependent on 
delivery o f intact virions to intracellular' endosomes by clathrin-dependent 
endocytosis. There is also evidence for direct delivery of poliovirus RNA across the 
limiting membranes of neurones in vivo, since naked poliovirus replicon RNA has 
been shown to be delivered from neuromuscular-junctions to the neural cell body 
(140). It seems likely that poliovirus can infect tissue culture and neuronal cells by 
multiple mechanisms, including direct delivery of the genomic RNA across the 
plasma membrane, or following clathrin-dependent delivery to endosomes.
The viruses described above either infect cells by direct penetr ation of the plasma 
membrane, or following clathrin-dependent delivery to intracellular endosomes. 
Infection by several other picor-navir-uses requires lipid raft dependent endocytosis 
pathways, the best studied of which is the caveolae-dependent pathway (see section 
1.5.2.1). Echovirus-1 and its receptor, the integrin a2 p l, have been localised to 
caveolae and infection is inhibited by rnethyl-P-cyclodextrin (MpCD) and a
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dominant-negative version of caveolin, both of which inhibit caveolae formation and 
hence caveolae-dependent endocytosis (183). Echovirus-11 and its receptor DAF are 
found in lipid rafts, and infection and virus internalisation are inhibited by pre- 
treatment of the cells with the raft dismpting reagent, nystatin, indicating that 
infection by this virus requires uptake via a lipid raft dependent endocytosis pathway 
(304). Similarly, infection by two other picornaviruses, coxsackievirus B4 and 
coxsackievirus A9 have been reported to require intact lipid rafts for infection (317, 
318).
L6.4.2 Uptake o f  FMD V
The pathways utilised by FMDV to enter tissue culture cells are not well defined, 
but the available evidence would suggest that FMDV is delivered to endosomes by 
receptor-mediated endocytosis. A number of factors would suggest this. One is tlie 
extreme acid-lability of the viral particle. The proteinaceous capsid dissociates into 
its constituent pentamers, releasing VP4 and viral RNA, at pH values below neutrality 
(43, 56). This suggests that viral uncoating would readily be triggered following 
uptake into mildly acidic early endosomes via receptor mediated endocytosis. A 
structural model which helps to explain how acid-induced disassembly of viral 
capsids occurs has been developed, and is based on the protonation of histidine 
residues found at inter-pentamer boundaries, (see section 1.6.5.2). Delivery to 
endosomes may be mediated by the virus’ integrin receptor, since the cytoplasmic 
domain of the p6 integrin subunit is required for postattachment events in the avp6- 
mediated infection of cells by FMDV (142, 204).
Further evidence for virus entry thi'ough endosomes comes fiom the use of chemical 
compounds that raise endosomal pH. Both the ionophore monensin (which raises pH 
by exchanging protons for Na"^ ), and concanamycin A (a specific inhibitor of the
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vacuolar ATPase), inhibit infection but not binding of FMDV to cells. These 
experiments imply that endosomal acidification is required for post attachment steps 
in infection of cells by FMDV. However, these experiments were carried out using a 
high multiplicity of infecting virus per cell which can cause infection to proceed via 
endocytic pathways that are not normally used by the virus (304). In addition, these 
studies did not clearly establish whether the inhibitory effect of these reagents on 
infection resulted directly from raising the endosomal pH or non-specific effects of 
these reagents.
1.6.5 Particle Uncoating and RNA delivery
1.6.5.1 Uncoating o f  Picornaviruses
Poliovirus undergoes a major structural rearrangement upon binding its receptor, to 
form the 135S A-particle, a transition that is thought to be an essential precursor to 
virus uncoating. This conformational change does not appeal' to be dependent upon 
exposure to low pH. A substantial portion of A-particles formed are eluted from the 
cell surface upon incubation at 37°C, however this particle is also the major form of 
the virus within infected cells at early times of infection and can be chased into the 
80S empty capsid. The available evidence suggests that A-particles are an important 
intermediate in cell entry, and are converted to 80S empty capsids upon delivery of 
the viral RNA to the cytoplasm. However, the precise role of A-particles has 
remained an area of great debate.
Poliovirus A-particles differ fiom the native virion due to the externalisation of 
VP4, and the N-terminus of VPl (86), and no longer bind to any form of the 
poliovirus receptor (175). In addition, unlike native virions, poliovims A-particles
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possess the ability to bind directly to lipid membranes, a property ascribed to the N- 
terminus of VPl, which is thought to form an amphipathic a-helix (86). A-particles 
have been shown to be able to infect tissue culture cells in a receptor-independent 
fashion (57, 133). Although the level of infectivity is low in comparison to that of 
native poliovirus virions, infectivity can be improved by 2-3 logs if A-particles are 
concentrated at the surface of cells expressing the Fc receptor by coating the altered 
virus particles with a monoclonal antibody (133). This indicates that A-particles 
display low infectivity because they do not interact with the poliovirus receptor and so 
do not become concentiated at the cell membrane, since infectivity is enhanced when 
they are artificially concentrated at the cell surface.
Addition of both native 160S poliovirus virions, and 135S A-particles to an artificial 
lipid bilayer results in the formation of cation specific, pH independent ion channels, 
albeit that the two types of particle form ion channels with differing properties (312). 
However, in artificial membranes containing the poliovirus receptor, addition of 
native virions, but not A-particles, resulted in the formation of ion channels, 
presumably since A-particles do not bind to the poliovirus receptor (313). The 
properties of the ion channels formed in lipid bilayers containing the poliovims 
receptor differ from those formed in the absence of the poliovirus receptor, and are 
consistent with the binding to the membrane of a complex of the poliovirus and its 
receptor (313). The biggest difference is that the conductance of the channels is 
temperature dependent in the presence of the poliovirus receptor. Raising the 
temperature from 21°C to 3 1°C results in a large increase in the conductance of the 
ion channels, and the activation energy for this change is in the same order of 
magnitude as that calculated for the formation of 135S paiticles from 160S native 
virions (313). It has therefore been suggested that the conformational change
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observed represents the transition fi'om a complex in which only binding of virus 
occurs (a complex of 160 S poliovirus, its receptor and the membrane) to one at which 
infection can start (a complex of 135S poliovirus, its receptor and the membrane) 
(313). Given that the formation of A-particles from native virions is receptor 
dependent, this theory is consistent with the observation that 135S particles are 
infectious in a receptor-independent fashion, whereas native poliovirus virions are 
not.
It is thought that the ion channels formed by poliovirus are formed by sequences 
from the N-terminus of VPl and also VP4. The N-terminus of VPl has been 
proposed to be involved in channel formation since these regions are thought to 
mediate the attachment of A-particles to membranes and can also be modelled as 
membrane interacting amphipathic helices (86). VP4 is thought to be directly 
involved in channel formation, and remains present in the plasma membrane 
following elution of A-particles from the surface of the cell (63). Mutants of 
threonine 28 of VP4 have been shown either to abolish ion channel formation or to 
result in the formation of ion channels with altered electrical characteristics, 
suggesting that VP4 is a key player in channel formation (63).
The ion channels foimed by poliovirus upon membrane binding are thought to serve 
to bring about the delivery of the viral genomic RNA to the host cell cytoplasm. 
Viruses in which threonine-28 is replaced by glycine assemble correctly and form A- 
particles, but do not form ion channels in artificial membranes, and are also imable to 
ti'ansfer their genomic RNA to the host cell cytoplasm (63). It is therefore likely that 
the defect in cell entry previously identified for this mutant virus (214) lies at the 
stage of uncoating and/or RNA delivery. Mutations within the N-terminus of VPl
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have also been shown to slow RNA delivery (157), providing further evidence for the 
role of poliovirus-induced channels in this process.
The precise role of the ion channels induced by poliovirus in RNA delivery is 
unclear but two models for how this could occur have been proposed (22, 266): 1)
The viral RNA is extruded from the viral capsid to the host cell cytoplasm via the 
channel, or 2) The virion is taken up in to endosomes and channel formation changes 
the ionic permeability of the endosomal membrane resulting in endosome lysis. 
Further work is required to elucidate which of these models is correct.
In contiast to poliovirus, the mechanism by which the minor receptor group 
rhinovims HRV-2 releases its genome into the cytoplasm has begun to be revealed.
As outlined in sections 1.6.3 and 1.6.4.1, HRV-2 is taken up by clathrin-dependent 
endocytosis and delivered to early endosomes. In early endosomes HRV-2 is released 
from its receptor and delivered to late endosomes, where the acidic pH (<5.6) triggers 
A-particle formation. When virus internalisation is carried out for 2hours at 20°C 
(conditions where virus particles accumulate in late endosomes) the particles found in 
purified endosomes were either C-antigenic (A particles lacking VP4; 40%) or B 
particles (virions lacking VP4 and RNA; 60%) (261). In the presence of bafilomycin 
the particles isolated were exclusively native virions, indicating that uncoating was 
pH dependent. The above data suggests that HRV-2 undergoes low pH mediated 
conformational changes within late endosomes leading to particle uncoating and the 
delivery of the genomic viral RNA (but not its protein coat) to the cytosol across the 
endosomal membrane, via a virally induced membrane pore. This model is supported 
by work which has shown using in vitro (262) and in vivo (38) experimental systems, 
that uptake of HRV-2 into endosomes causes the release of co-intemalised lOkDa 
dextran, but not co-internalised TOkDa dextran, from this compartment. This process
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is dependent on the low pH within endosomes (38), and suggests that the virus fonns 
a size restricted pore in the endosomal membrane which permits the release of 
molecules of sufficiently small size (including the viral RNA in extended form) from 
the endosomal lumen. The virus does not induce endosomal lysis since this would 
result in the release of both lOkDa and 70 kDa dextran, as obseiwed with adenovirus 
(a virus known to induce endosomal lysis).
The nature and composition of the pore formed by HRV-2 is unclear. Uncoating of 
HRV-2 results in the externalisation of the N-terminus of VPl at the 3-fold symmetry 
axis, the loss of VP4 fr om the capsid interior, and the formation of a channel of 
around 10Â by an iris like movement of the 5 copies of VPl at the 5-fold symmetry 
axis (122). The channel at the 5-fold symmetry axis is large enough to accommodate 
an extended molecule of single stranded RNA and so the viral RNA is presumed to 
exit the particle by this route. It is not known whether the pore fonned by HRV-2 
within the endosomal membrane is contiguous with the viral capsid or is formed by 
VP4 alone following its release fr om the virion after A-paiticle formation. It is worth 
noting that the major group rhinovirus HRV-14 is thought to escape from endosomes 
by lysis of the endosomal membrane radier than by pore formation. This is because 
HRV-14 particles accumulate in endosomes under conditions which prevent 
uncoating, but not under conditions under which uncoating can occur (290). In 
addition infection with HRV-14, unlike infection with HRV-2, causes a reduction in 
the number of dextran labelled endosomes (290).
L6,5,2 Uncoating o f  FMD V
Unlike other picomaviruses, there is no evidence for A-particle formation by 
FMDV. Instead, FMDV uncoats when exposed to pH values below neutrality, 
resulting in the dissociation of the proteinaceous capsid into its constituent pentamers
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and the release of VP4 and the viral RNA (43, 56). Given the extieme acid lability of 
the FMDV capsid, it is thought that uncoating is likely to be üiggered by the mildly 
acidic pH found within early endosomes.
A sti'uctural model which helps to explain how acid-induced disassembly of viral 
capsids occurs has been developed (2, 56, 78). The 2-fold interfaces between 
pentamers contain a high proportion of histidine residues, which have a pKa of 6.8 in 
solution, which is the pH at which the FMDV particle disassembles. It was thus 
postulated that at pH values below neutrality, the imidazole side chains become 
protonated, and the resultant repulsion leads to uncoating (2). It is now believed that 
His-142 of VP3 is particularly important for this process, since it lies at the end of the 
positive pole of an a-helical dipole formed by residues 89-98 of VP2 (56). Each two­
fold symmetry axis contains two such interfaces. When protonated, the histidine 
residue would repel the a-helix, resulting in disassembly. This model is supported by 
mutational data, which shows that if this residue (His-142) is mutated to aspartate 
(which is negatively charged), acid sensitivity of the capsid is markedly reduced, 
whereas mutation to arginine (positively charged) leads to a great reduction in capsid 
assembly (78).
Following uncoating of the FMDV virion, the viral RNA must be tiansferred to the 
cytoplasm of the host cell. The maturation cleavage of VPO is reported to be essential 
for this process, since mutant virions in which VPO cleavage does not occur bind cells 
normally, have normal acid sensitivity, but are non-infectious (160). These particles 
only differ from the wild type vims in that the acid breakdown products are 
considerably more hydrophobic than wild type, presumably due to the failure to 
release myiistoylated VP4. It remains unclear' however as to whether VP4 itself 
actually plays a role in RNA release into the cytoplasm, or whether its release allows
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the capsid pentamers to facilitate this process. It is also unclear whether the viral 
RNA is transferr ed to the cytoplasm via a virus-induced pore in the endosomal 
membrane, as is the case for HRV-2 (38, 262), following vims induced lysis of the 
endosomal membrane, as reported for HRV-14 (290), or by another undefined 
mechanism.
1.7 Research Aims
The major objectives of the work presented in this thesis are to gain a better- 
understanding of the entry pathways utilised by FMDV to enter and infect cells, and 
the role of the vir*us’ integr in receptor in post-attachrnent events. Entry of FMDV was 
studied using immunofluorescence microscopy and inhibitors of specific endocytosis 
pathways (or steps within those pathways) were utilised.
The virus used to carry out these studies is FMDV strain 01Kcad2. Unlike some 
tissue culture adapted strains this virus does not bind heparin sulphate and is reliant on 
RGD-dependent integrins as its sole receptor family.
The cell lines used to study FMDV entry and infection in these studies are SW480 
and Chinese hamster ovary-B2 (CHO-B2) cells transfected with the human (36 
integrin subunit (SW480-(36 and CHO-(36 cells respectively). SW480 cells are a 
human colon carcinoma cell line which normally expresses av|35 and a5|31 as its only 
RGD-dependent integrins. The only RGD-dependent integrin expressed by CHO-B2 
cells is (xv|35. Untransfected SW480 and CHO-B2 cells are non-perrnissive fbr 
infection by field strains of FMDV, but this is not as a result of a defect in 
intracellular virus replication since both cell lines are efficiently infected by the tissue 
culture adapted virus OIBFS, which uses heparan sulphate as its receptor. Both
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CHO-B2 and SW480 cells become susceptible to infection by field str ains of FMDV 
upon transfection with the human integr in (36 subrmit and the consequent expression 
of the integrin av(36 at the cell surface. The integr in av|36 has been shown to act as 
the primary attachment receptor for field strains of FMDV on both SW480-(36 and 
CH0-P6 cells (145, 147).
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Chapter Two: Materials and Methods 
2.1 Cell Culture
The human colon carcinoma cell line SW480 transfected with full-length human p6 
integrin subunit cDNA (SW480-(36) or a mutant form of the p6 subunit containing 
two mutations within the cytoplasmic domain (SW480-APLA) was grown in 
Dulbecco’s modified Eagle’s medium (DMEM-Sigma) supplemented with 10% foetal 
calf serum (FCS-Sigma), 20mM glutamine, penicillin (100 SI units/ml), and 
streptomycin (100|Lig/ml). The transfected cells were grown in the presence of 
Geneticin (1 mg/ml. Life Technologies) to maintain p6 expression. CHO cells 
transfected with the human p6 integrin subunit (CHO-p6) were cultivated using the 
same medium. Mock- and p6-transfected mouse embryonic fibroblasts (MEF’s) were 
gr own in DMEM supplemented with 10% PCS, 20rnM glutamine, penicillin (100 SI 
units/ml), streptomycin (lOOjag/ml), and Puromycin (4p,g/ml).
Baby hamster kidney (BHK) cells were grown in DMEM supplemented with 10% 
FCS, 20mM glutamine, streptomycin (100|Xg/ml), and penicillin (100 SI units/ml). 
Primary bovine thyroid cells (BTY’s) were grown in glasgows modified eagle’s 
medium (GMEM) supplemented with 10% adult bovine serum, streptomycin 
(100)Lig/ml), and penicillin (100 SI units/ml).
2.1.1 Cell Passage
Confluent cell monolayers were washed twice with 0.25% trypsin-versene, and 
incubated at 37°C in the presence of trypsin-versene for 5-10 minutes. Cells in 
suspension were pelleted by centr ifugation in a Sorvall Legend RT centrifrige for 3
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minutes at lOOOipm. Cell pellets were resuspended in culture medium and seeded at 
an appropriate dilution in a fresh tissue culture flask.
2.2 Virus
Virus stocks were stored at -80°C. All experiments utilise the non-heparin binding 
FMDV strain O lKcad2. Seed and working stocks were prepared using primary 
bovine thyroid cells (BTY’s). Virus utilised for inimunfluorescence and FACS 
studies was purified on sucrose gr adients as described previously (56).
2.2.1 Preparation of viral working stocks
Monolayers of primary bovine thyroid cells (prepared in 175cm^ tissue culture flasks) 
were washed with PBS, and infected with an aliquot of seed stock diluted in PBS at 
37°C in a humidified 5% CO2 incubator. After 15 minutes, ~20 ml of prewarmed 
viral growth medium (cell culture media containing 1% FCS) was added, and the 
flask incubated at 37°C, until full cytopathic effect was observed. The flask was then 
fieeze-thawed to increase virus yield, and cell debris removed by centrifugation at 
lOOOipm for 3 minutes. The supernatant was aliquoted into screw capped 1.5ml 
eppendorf tubes and stored at -80°C.
2.2.2 Virus titration by plaque assay
Working stocks of virus prepared as above were titiated on BHK cells. In order to 
show that the virus stocks still utilised integrin receptors rather than heperan sulphate 
proteoglycans, they were also titiated on CHO cells. FMDV does not normally infect 
wild type CHO cells unless it has become adapted to use heperan sulphate as a
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receptor. Duplicate BHK cell monolayers on 60mm tissue culture dishes were 
incubated with 10-fold dilutions of virus working stock in PBS for 15 minutes at 37°C 
in a humidified 5% CO2 incubator. The cells were then overlaid with 4ml of Eagle’s 
overlay (Eagle’s medium supplemented with 0.6% indubiose, 5% tryptone phosphate 
broth, 1% foetal calf serum, 100 SI Units of penicillin/ml, and lOOpg of 
streptomycin/ml) prewarmed to 42°C. After the overlay had set, the dishes were 
incubated for 48 hours at 37°C. Plaques were visualised by fixing and staining the 
cell monolayer with a solution of methylene blue and 4% pai-aformaldehyde in PBS, 
for at least 4 hours.
2.3 Antibodies, peptides, and other reagents.
The RGD peptide with its sequence derived fi'om the GH loop of VP 1 of type O 
FMDV (VPNLRGDLQVLAQKVAR) and the control RGB peptide were synthesized 
at the peptide synthesis facility at the Institute for Animal Health, Compton, United 
Kingdom
The anti-FMDV monoclonal antibodies B2 (mouse IgGl) and D9 (mouse IgG2A), 
which recognize antigenic site 1 of type O FMDV (196) were purified using protein A 
(Pierce) according to the manufacturer’s instructions. The anti-integrin antibodies 
used in these studies were 10D5 (mouse IgG2a; anti-avp6), E7P6 (mouse IgGl; anti- 
avP6) and P1F6 (anti-avP5) ftoin Chemicon, 6.3G6 and 6.8G9 (both mouse IgGl; 
anti avP6) ft om Biogen, and a rabbit monoclonal antibody, 4B5 (anti-P6) (131), 
obtained ft om Dean Sheppard (University of California).
In the course of these studies a number of antibodies directed against markers of 
cellular compartments were utilised. Early endosomes were detected using a 
monoclonal antibody (clone 14) which recognises early endosomal antigen-1 (mouse
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IgGl; BD Transduction Laboratories). The transferrin receptor was detected using 
the monoclonal antibody H68.4 (mouse IgGl; Zymed Laboratories). Human LAMP- 
2 was detected using monoclonal antibody H4B4 whereas the hamster version was 
detected using the monoclonal antibody UH3 (both mouse IgGl; both obtained from 
the Developmental Studies Hybridoma Bank). Caveolin-1 was detected using a rabbit 
polyclonal antisemm (N-20) directed against the cytoplasmic domain of the human 
protein (Santa Cruz Biotech). All Alexa-fluor conjugated secondary antibodies were 
also obtained from Molecular Probes. Alexa fluor-488 and -568 conjugated 
transfeiTin, Alexa fluor-488 conjugated cholera toxin B (CTB), and acridine orange 
were also obtained from Molecular Probes.
Filipin (stock 5mg/ml in DMSO), nystatin (stock lOOmg/ml in DMSO), 
cytochalasin D (stock 20niM in DMSO), nocodazole (stock 40mM in DMSO), 
wortmannin (stock 2mM in DMSO) and methyl-p-cyclodexti'in (stock lOOmM in 
DMEM) were all obtained from Sigma. Concanamycin A (stock lOmg/ml in DMSO) 
was obtained from Fluka.
2.4 Flow Cytometric Analysis
Virus binding and avp6 expression on SW480-p6 cells and MEF cell lines were 
determined by flow cytometry. Cells were harvested using a non-enzymatic cell 
dissociation solution (Sigma), and resuspended at 5 x 10  ^cells/ml in FACS buffer 
(20mM Tris, ImM CaCL, 0.5mM MgCl 2, 1% Normal Goat Serum, 2% Bovine 
Serum Albumin, in 150 mM NaCl). 3 0 |li1  of cells were placed in to a number of round 
bottomed wells of a 96-well plate. Cells were incubated sequentially with FMDV 
01kcad2 (10|ig/ml) where appropriate, primary antibodies (10|Lig/ml), and R- 
phycoerythrin conjugated anti-mouse isotype specific secondary antibodies (Southern
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Biotechnology Associates) for 30 minutes on ice. Between each step cells were 
washed once with FACS buffer. Virus was detected with MAh B2 (lOfXg/ml), and 
avp6 with MAh 10D5 (10p,g/ml). Finally, the cells were washed twice with FACS 
buffer and resuspended in PBS (pH 7.5)-2mM CaCl2- ImM MgCU, containing 1% 
paraformaldehyde. The samples were then analysed by flow cytometiy using a 
FACSCalibur (Becton Dickinson) instrument, with 6000 cells being counted per 
sample. Backgi'ound fluorescence was measured by omitting the primary antibody or, 
in the case of virus binding, the virus itself.
2.5 Virus Infectivity Assays
FMDV infection was quantified using either an infectious centre assay, an elispot 
assay, or using immunofluorescence microscopy. Each assay is outlined below.
2.5.1 Infectious Centre Assay
Mouse Embryonic Fibroblasts transfected to express avp6 were harvested using 
trypsin versene, collected by centiifugation (lOOOipm 3mins), resuspended in cell 
culture medium, and incubated for 1 hour at 37°C with continuous rotation. One 
million cells were infected with FMDV type 01Kcad2 (m.o.i = 0.25) in a 200|xl 
volume for 1 hour at 37°C with continuous rotation. Virus which had not been 
internalised was inactivated by the addition of 1.3 ml of IM citiic acid buffer (pH5.2) 
for 2 mins. The cells were neutralised by washing with PBS (pH 7.5) containing 
2mM CaCl 2 and ImM MgCh, and resuspended in 300|Li1 of this buffer supplemented 
with 0.5% FCS. 10-fold dilutions of infected cells were made using the same buffer. 
100|il of each dilution was mixed with 1ml of molten Eagle’s overlay and layered
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over subconfluent BHK cells in 60mm dishes. Following solidification of the 
medium a further 3ml of overlay was laid over the top. Following incubation for 48 
hours at 37°C and 5% CO 2, infectious centres were visualised as plaques by staining 
with a solution of methylene blue and 4% paraformaldehyde in PBS, for at least 4 
hours. To verify the inactivation of cell surface virus by the acid wash step, control 
samples were incubated with virus in parallel at 4°C (to prevent virus internalisation). 
The number of infectious centres obtained for this control was <10 per million cells.
2.5.2 Elispot Infection Assay
2.5.2J Standard Assay
Cells were prepared in 96-well tissue culture plates and giown overnight at 37°C until 
approximately 70-80% confluent. The cells were washed once with DMEM and 
incubated with FMDV strain 01Kcad2 (m.o.i. "-0.3 pfu/cell) for either 0.5 or Ih at 
37°C (see figure legends for details). The monolayers were washed once with 
DMEM and incubated with DMEM at 37°C for 4-4.5 hours before being fixed with 
4% paraformaldehyde in PBS for 1 hour. The cells were washed five times with PBS 
after this and each subsequent step, and then permeabilised with 0.1% Triton X-100 in 
PBS for 15mins. After an incubation for 0,5 hours in blocking buffer (lOmM Tris- 
HCl pH 7.5; 140mM NaCl; ImM CaCh; 0.5mM MgCh; 10% normal goat serum; 1% 
fish gelatin), the cells were incubated with MAb 2C2 (Mouse IgG2a) diluted in block 
buffer (1/1000) for Ih at room temperature (RT). The cells were then incubated 
sequentially with a biotinylated, goat anti-mouse IgG secondary antibody (1/500- 
Southern Biotechnologies) and streptavidin-conjugated alkaline phosphatase (1/1000- 
Caltag Laboratories) prepared in block buffer, for Ih each at RT. 200|il of the alkaline 
phosphatase substiate (BIO-RAD) was added to each well and colour development
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monitored using a light microscope. The cells were then washed four times with 
distilled water and allowed to air dry. The infected cells appear dark-blue and were 
counted using an ELIspot plate reader (Zeiss). Non-specific labelling was determined 
by either omitting Mab 2C2 or performing the assay on mock-infected cells. The 
extent of non-specific labelling was similar for either condition. Where appropriate 
(see chapter 3), cells were tr eated with chemical inhibitors of endocytosis before, 
during, and after incubation with virus (see below).
2.5.2.2 Hypertonic Sucrose Treatment
The effect of hypertonic sucrose on infection of cells by FMDV was assayed as 
follows. Cells in triplicate wells were washed once with DMEM, before being treated 
with 0.1-0.4M sucrose (or mock treated with DMEM alone) for 15 or 30 minutes at 
37°C. Following sucrose pre-treatment, cells were incubated with FMDV 01Kcad2 
in DMEM (m.o.i ~ 0.3) for 30 or 60 minutes at 37°C in the presence or absence of 
sucrose (see chapter 3). Cells were then incubated with DMEM in the absence of 
sucrose for 4.5 or 4 hours, and fixed and infection quantified using the elispot assay as 
described in section 2.5.2.1. In the replication controls (marked RC in the relevant 
figures) cells were incubated with sucrose after the removal of the virus inoculum.
2.5.2.3 Nocodazole, Wortmannin, Filipin and Nystatin Treatment
The effect of nocodazole, wortmannin, filipin, and nystatin on infection of cells by 
FMDV was assayed as follows. Cells in triplicate wells were washed once with 
DMEM, before being incubated with nocodazole, wortmannin, filipin, or nystatin for 
30 minutes at 37°C (see chapter 3). Since the stock solutions of each of these drugs 
were made up using DMSO, mock treated samples were tr eated with an equivalent
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dilution of DMSO. Following drug tr eatment, cells were incubated with FMDV 
01Kcad2 in DMEM (m.o.i ~ 0.3) for 60 minutes at 37°C in the presence of drug.
Cells were then washed once with DMEM, and incubated with DMEM in the 
presence of dr ug for a firrther 4 hours at 37°C, before being fixed and infection 
quantified using the elispot assay as described in section 2.5.2.1. In the replication 
contr ols cells were not pre-tr eated with dr ug. Instead the drug was added to the cells 
after the removal of the virus innoculurn.
2.5.2.4 Methyl-p-Cyclodextrin Treatment
The effect of rnethyl-p-cyclodextrin on infection of cells by FMDV was assayed as 
follows. Cells in tr iplicate wells were washed once with DMEM, and incubated with 
rnethyl-p-cyclodextrin in DMEM for 30 minutes. Mock treated samples were treated 
with DMEM alone. The cells were then incubated with FMDV 01Kcad2 (m.o.i ~ 
0.3) for 60 minutes at 37°C in the presence or absence (mock-treated samples)of drug. 
Cells were then washed once with DMEM, incubated with DMEM in the absence of 
drug for a further 4 hours at 37°C, before being fixed and processed as described in 
section 2.5.2.1.
2.5.2.5 Concanamycin A Treatment
The effect of Concanamycin A on infection of cells by FMDV was assayed as 
follows. Cells in triplicate wells were washed once with DMEM, before being 
incubated with Concanamycin A for 30 minutes at 37°C. Since the stock solution of 
concanamycin A was prepared using DMSO, mock tr eated samples were treated with 
equivalent dilutions of DMSO. Following pre-tr eatment with concanamycin A, cells 
were incubated with FMDV 01Kcad2 in DMEM (m.o.i ~ 0.3) for 60 minutes at 37°C
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in the presence of drug. Cells were then washed once with DMEM, incubated with 
DMEM in the absence of dmg for a further 4 hours at 37°C, before being fixed and 
processed as described in section 2.5.2.1. In the replication controls, diug was added 
after the removal of the virus innoculurn.
2.5.3 Immunofluorescence Infection Assay
2.5.3.1 Standard Assay
Cells grown on 13mm glass coverslips were washed twice with DMEM and then 
infected at an m.o.i o f-0.5 with FMDV O lKCad2 for five hours at 37°C. Cells were 
then fixed using 4% paraformaldehyde in PBS for 1 hour. Infected cells were 
identified with a rabbit polyclonal serum to FMDV and an Alexa-568 conjugated goat 
anti-rabbit IgG secondary antibody, by immunofluorescence microscopy (see section 
2 .6)
2.5.3.2 Dominant Negative A P I80
SW480-P6 cells were prepared on glass coverslips and transiently tiansfected using 
lipofectamine 2000 (Invitiogen) with a plasmid containing the coding sequence for 
the C-terminal ft agment (residues 530-915) of API 80 (AP180C) fused to a c-myc tag. 
The protocol for transfection is as described in section 2.7.11. At 7.5 hours post- 
tiansfection, the cells were infected at an m.o.i -0.5 with FMDV 01Kcad2 for 5 hours 
at 37°C (chapter 3). The cells were fixed and processed for the confocal microscope 
as described in section 2.6.1. Cells transfected with AP180C were detected using the 
anti-c-myc tag antibody (9E10) and Alexa-488 conjugated goat anti-mouse IgG 
secondary antibody. Infected cells were identified with a rabbit polyclonal serum to
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FMDV and an Alexa-568 conjugated goat anti-rabbit IgG. The proportion of non­
transfected and infected cells that were also infected was then calculated.
2.6 Immunofluorescence Microscopy
2.6.1 Detection of intracellular antigen
Cells were grown on 13mm glass coverslips (BDH) to 40-60% confluency. The cells 
were washed twice in PBS, and the cells fixed for 40 minutes using 4% 
paraformaldehyde in PBS. Following two washes with Tris-buffered saline (TBS), 
cells were permeabilised for 15 minutes using 0.1% Triton X-100 or 0.5% saponin in 
block buffer (TBS, ImM CaCl2, 0.5mM MgCl2, 0.1% Sodium Azide, 1% Fish 
gelatin (Sigma), and 10% noimal Goat Serum (Sigma)). Following permeablisation, 
cells were washed using TBS and non-specific binding sites were blocked for a 
further 30 minutes using block buffer. The cells were incubated with primary 
antibodies diluted as appropriate in block buffer for 60 minutes, with unbound , 
antibody being removed at the end of this period by three five minute TBS washes. 
When saponin was used to peimeabilise the cells, 0.1% saponin was included in this 
and all of the subsequent steps. Alexa fluor 488nm (green labelling) or 568nm (red 
labelling) conjugated secondary antibodies (Molecular Probes) were diluted 1:200 in 
block buffer, and incubated with the cells for a further 45 minutes, before being 
washed with TBS as before. Finally the coverslips were washed with distilled water 
and mounted in Vectastain mounting medium containing DAP I to label the nucleus, 
and sealed in place using nail varnish. For double labelling experiments the 
specificity of the secondary conjugated-antibodies was confirmed by showing a lack
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of cross-reactivity of the anti-mouse-IgGl secondary antibody for mouse IgG2a and 
vice versa.
2.6.2 Detection of surface antigen
To detect antigen present at the cell surface, the above procedure was modified.
Cells, prepared on coverslips as above, were cooled on ice, and non-specific binding 
sites blocked by incubation with ice cold block buffer for 30 minutes on ice. Where 
appropriate ligands (e.g. virus, cholera toxin b subunit) were bound to cells on ice for 
the times indicated (see results chapters). The cells were then incubated sequentially 
with primaiy and secondary antibodies diluted in cold block buffer on ice for 60 and 
45 minutes respectively. The cells were then fixed with cold 4% paraformaldehyde 
for 40 minutes on ice, and washed, mounted and sealed as above.
2.6.2.1 Lipid raft labelling using Cholera Toxin B
Cholera Toxin B binds GMl ganglioside which is enriched in lipid rafts. Cells grown 
on coverslips were incubated with Alexa-488 conjugated cholera toxin B (0.2jLig/ml) 
in cold DMEM for 45 minutes at 4°C. Excess unbound CTB was removed by three 
washes of five minutes each with cold DMEM. Surface bound CTB was cross-linked 
by incubation for 60 minutes at 4°C with a rabbit anti-cholera toxin antiserum 
(Sigma-diluted 1 in 125 in DMEM). Unbound antibody was removed by washing 
with cold DMEM as before. Coverslips were washed and mounted as described in 
section 2.6.1.
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2.6.3 Ligand intemaiîsatîon
2.6.3.1 Virus binding and internalisation
Cells were incubated with FMDV (5jig/ml) at 4°C in DMEM for 45mins. Excess 
unbound virus was removed by three washes of five minutes each with cold DMEM. 
For co-localization experiments with surface antigens, the cells were processed as 
described in section 2.6.2 above. Where virus internalisation was required, cells were 
washed twice with prewaimed DMEM and incubated at 37°C for the times indicated 
on the figures. Internalisation was halted by fixation with cold 4% paraformaldehyde 
for 40 minutes on ice. Coverslips were then processed as described in section 2.6.1. 
Virus was detected using Mab D9 (5|Lig/ml) and a goat anti-mouse IgG2a Alexa- 
conjugated antibody. In the experiment shown in fig 3.3, the pre-binding step at 4°C 
was omitted and the virus was added directly to the cells at 37°C.
2.6.3.2 Transferrin binding and internalisation
Cells were washed four times with serum-free DMEM, and incubated for 45 minutes 
at 37°C. This incubation in the absence of serum serves to deplete the cells of iron 
thus enhancing subsequent ti’ansferrin uptake. Alexa-488 or -568 conjugated 
transferrin (Molecular Probes-10p,g/ml) in cold DMEM was bound to the cells for 
45min at 4°C. Excess unbound transferrin was removed by thr ee washes of five 
minutes each with cold DMEM. In order to initiate internalisation of bound 
transferrin, cells were washed twice with prewarmed DMEM and incubated at 37°C 
for the times indicated on the figures. After this time internalisation was halted by 
fixation with a cold 4% paraformaldehyde/0.2% glutaraldehyde solution for 40 
minutes on ice. Coverslips were then processed as described in section 2.6.1. Where 
transferrin uptake was used as a control for the effect of inhibitors of endocytosis on
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the clathrin-dependent pathway, the pre-binding step was omitted and Alexa- 
conjugated transferrin was added directly to the cells at 37°C.
2 .6 .33  Cholera Toxin B binding and internalisation
Cells were incubated with alexa-488 conjugated cholera toxin B subunit (Molecular 
Probes — 0.2|xg/ml) at 4°C in DMEM for 45miiis. Excess unbound CTB was removed 
by three washes of five minutes each with cold DMEM. For co-localization 
experiments with surface antigens, the cells were processed as described in section
2.6.2 above. Where ligand internalisation was required, cells were washed twice with 
prewarmed DMEM and incubated at 2>TC for the times indicated on the figures. 
Internalisation was halted by fixation with cold 4% paraformaldehyde for 40 minutes 
on ice. Coverslips were then processed as described in section 2.6.1. Where CTB 
uptake was used as a control for the effect of inhibitors of endocytosis on lipid raft 
dependent endocytosis pathways, the pre-binding step was omitted and Alexa-488 
conjugated CTB was added directly to the cells at 37°C.
2.6.4 Acridine orange iabeliing of acidic vesicies
Cells on coverslips were tieated with concanamycin-A (lOOnM) in DMEM for 0.5 
hours at 37®C. Mock-cells were tieated with an equivalent dilution of DMSO. The 
cells were then incubated with acridine orange (0.5 j-tg/ml in DMEM) in the presence 
or absence (Mock) of the drug for a further 15 min. The cells were washed in the cold 
with PBS and mounted and sealed as described in section 2.6.1 except that PBS was 
used in place of Vectashield. The cells were visualized immediately on the confocal
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microscope (k ex = 488) collecting fluorescent emission in the green (490-550) and 
red (590-640) regions of the spectroim.
2.6.5 Image collection
All immunofluorescence images were collected using the 63x objective lens of a 
Leica SP2 confocal microscope. Each image represents a single confocal section 
through the middle of the cell(s) in question. In order to remove crosstalk between 
detection channels, data were collected sequentially. Images were processed using 
Adobe Photoshop software.
2.7 DNA Techniques
2.7.1 Restriction Endonuciease Digests
Digests were carried out in a total volume of 20|O.l according to the insti'uctions 
supplied with each enzyme. All enzymes were supplied by Promega, except SunI 
which was from New England Biolabs.
2.7.2 Polymerase Chain Reaction
PCR was performed in a volume of 50|xl. The reaction was constituted as follows: 
Template DNA
200 pmoles Primer 1 and Primer 2 (MWG or Sigma) 
dNTP mix (Promega - Final concentiation = 800 |LiM) 
lOx enzyme buffer
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sterile filtered deionised water to 50)li1
5 units Taq or Pfli polymerase (Roche and Promega respectively)
The template DNA utilised was either plasmid DNA, or in the case of overlap PCR, 
two overlapping PCR products. The reaction was overlaid with sterile mineral oil and
incubated in a thermal cycler according to the following protocol:
Step 1 94°C 2 min
Step 2 94°C 1 min
Step 3 50"C or 60'C 1 min
Step 4 72°C 1 min
Step 5 cycle to step 4 30 Times
Step 6 72°C 10 min
PCR products were purified by agarose gel electr ophoresis before use in ligation 
reactions or further rounds of PCR. Pfu polymerase was used when the PCR products 
were to be used as templates for further PCR, and Taq polymerase was used when the 
PCR product needed to be cloned into a vector. PCR products amplified using Taq 
polymerase were ligated without further modification in to pGEMT Easy (Promega).
2.7.3 Agarose Electrophoresis of DNA
DNA was subjected to electrophoresis using gels of between 0.8 and 1.5% agarose 
dissolved in TAB buffer (0.04M Tris-Acetate, 0.00IM EDTA). Ethidium bromide 
(Promega) was added to the gel mix before it set at a concentration of 0.5[Xg/ml. Gels 
were normally run at a constant voltage of 1OOV.
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2.7.4 Purification of DNA Fragments
The desired ethidium bromide stained DNA bands were excised from agarose gels 
using a scalpel, having been visualised on a UV lightbox (Biorad). The DNA was 
purified using the QIAEXII kit from QIAGEN, as per the manufacturers instructions. 
The agarose was first solubilised in buffer QXl, and the DNA bound to QXII beads. 
The beads were then washed using an ethanol containing buffer, and the bound DNA 
eluted firom the beads in 20|Lil tris buffer (lOmM Tris-Cl pH8.5).
2.7.5 Shrimp Alkaline Phospahatase Treatment
Vector DNA was dephosphorylated using shrimp alkaline phoshatase (Roche). This 
tr eatment improves the efficiency of ligation by preventing vector resealing. The 
reaction was constituted as follows:
7|il Linearised and gel extracted vector
0.9pl lOx reaction buffer
Ipl Shrimp Alkaline Phosphatase
This reaction was incubated for 30 minutes at 37°C. The phosphatase enzyme was 
then heat inactivated by treatment at 65°C for 15 minutes
2.7.6 Ligations
Ligation Reactions were performed using T4 DNA Ligase (Promega) and the supplied 
1 Ox buffer according to the manufacturers instructions. All ligations were performed
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using a vector:insert ratio of 1:3 in a total volume of lOjul. Ligation mixes were 
incubated overnight at 4°C, and were transformed into E.coli DH5a or JM109 cells.
2.7.7 Preparation of Competent Cells
Competent E.coli DH5a and JM109 cells were prepared in bulk and frozen at -70°C 
as lOOp.1 aliquots. The method used to prepare the cells is outlined below:
1. Single colonies of either E.coli strain were grown overnight at 37°C in 5ml of LB 
broth supplemented with 20mM MgS0 4  (LB-Mg).
2. 1ml of the overnight culture was added to 10ml of LB-Mg
3. 10ml cultures were gi'own until an ODeoo of 0.2 to 0.8 was reached.
4. The above 10ml cultures were transferred to a 1 litr e flask, containing 50ml of 
LB-Mg, and the cultures incubated at 37°C until an ODeoo of 0.5 to 0.9 was reached.
5. At this point 200ml of LB-MG were added, and the culture was incubated at 37 °C 
until an ODeoo of 0.6 was reached.
6. The cells were cooled on ice, before being centrifuged at 4200 ipm for 15 minutes 
at4®C.
7. The pellet was resuspended in 50ml Fresh TFBl (30mM Potassium Acetate, 
50mM MnCh, lOOmM KCl, lOmM CaCL, and 15% Glycerol) and incubated on ice 
for 5 minutes.
8. The cells were recentrifiiged at 4200 rpm for 15 minutes at 4“C.
9. The pellet was resuspended in 10ml ice cold TFB2 (lOmM MOPS, 75mM CaCh, 
lOmM KCl, and 15% Glycerol).
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10. Cells were divided into lOOpl aliquots, snap frozen on diy-ice and stored at -  
10°C until required.
2.7.8 Transformation of Competent Ceils
Frozen competent cells were thawed for 5 minutes on ice. An aliquot of DNA (e.g. 
5ul of a ligation reaction) was added to 50pl o f competent cells. The mixture was 
incubated on ice for 30 minutes. The samples were heat shocked for 50 seconds at 
42°C, and incubated for 2 minutes on ice. 1ml of LB was added and the culture 
incubated for 60 minutes at 37°C. Die cultures were then centrifuged at 1000 rpm for 
1 minute, and resuspended in 150jil of LB. The tr ansformed bacteria were then plated 
onto LB/agar- plates containing a suitable antibiotic (e.g. Ampicillin (lOOpg/ml)). 
Where the vector used was suitable for blue-white screening the LB/agar plates were 
also supplemented with O.lmM IPTG, X-Gal (40pg/ml) and Ampicillin (lOOpg/ml). 
The plates were incubated overnight at 37°C.
2.7.9 Isolation of Plasmid DNA
2.7.9.1 Small scale plasm id purification (mini-preps)
5 ml of LB broth was inoculated with a single bacterial colony with a sterile toothpick 
and incubated overnight at 37°C with shaking. 1.5ml of the culture was transferred to 
a fr esh eppendorf tube and centrifuged at 14000rpm for 1 minute. The supernatant 
was removed and the DNA extr acted using the Qiagen miniprep system as per the 
manufacturers instructions. DNA was routinely analysed on a 1% agarose gel.
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2.7.9.2 Large scale plasm id purification (Maxi-preps)
5ml of LB broth was inoculated with a single bacterial colony and gr own up as if for a 
miniprep as described above. 200jJil of this culture was diluted in to 100ml of LB, and 
gr own up overnight. The DNA was extracted using the Qiagen maxiprep system as 
per the manufacturers instructions, and analysed on a 1 % agarose gel.
2.7.10 Spectrophotometric Determination of DNA Concentration
For quantitation of the concentration of DNA in a given sample, optical density 
readings were taken at 260 and 280nm using an Ultr*ospec 2100 pro UV/visible 
spectrophotometer (Amersham Biosciences). Typically maxi-prep DNA was diluted 
1/100 in distilled water before these readings were taken using 1ml capacity quartz 
cuvettes with a 1cm path length. Distilled water was used as a reference.
an OD260 of 1 = A double stranded DNA concentration of SOpg/rnl (50ng/pl)
The OD260/OD280 ratio gives an estimate of the purity of the DNA sample. A pure 
DNA preparation has an OD260/OD280 ration of approximately 1.8.
2.7.11 Transient Transfection of Mammalian Cells with plasmid DNA
The cells to be transfected (SW480-p6 cells) were grown overnight on glass 
coverslips in the absence of Geneticin and Penicillin/S ti eptomycin. 1.5|ig of the 
plasmid DNA to be transfected and 8jil of the transfection reagent lipofectamine 2000 
(Inviti'ogen) were made up to 400pl with OPTI-MEM (Gibco). This solution was
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mixed by vortexing for 1 second and incubated for 45 minutes at room temperature. 
After 45 minutes the ti'ansfection mixture was made up to a volume of 2ml using 
OPTI-MEM. The coverslips were washed twice with OPTI-MEM, and the 
ti'ansfection mixture was divided equally between 2 coverslips (0.75|ig of DNA per 
coverslip). The coverslips were then incubated with the transfection medium for 4 
hours at 37°C. After this time the coverslips were washed twice with cell culture 
medium lacking Geneticin, and incubated at 37°C for sufficient time for the protein 
encoded by the plasmid DNA to be expressed to an appropriate level (see results 
chapters). After this time period (typically 8 hours), the cells were fixed with 4% 
paraformaldehyde for 40 minutes and processed for immunofluorescence microscopy. 
Where appropriate cells were infected with FMDV for 5 hours prior to 
paraformaldehyde fixation (chapter 3).
2.7.12 DNA Clean Up
The DNA to be treated was made up to 250[il with Tris buffer (lOmM Tris-Cl pH8.5). 
An equal volume (250jxl) of Phenyl:Chloroform;Isoamyl alcohol (Life Technologies) 
was added to the DNA, and mixed by shaking. The organic and aqueous phases were 
separated by centrifugation for 2 minutes at 11000 ipm. The majority of the upper 
aqueous phase (~220p,l) was removed and placed in a fi*esh tube, an equal volume of 
chloroform was added, and the contents mixed by shaking. The phases were 
separated by centriftigation as above, and the upper aqueous layer removed and 
placed in a fiesh tube.
In order to precipitate the DNA, 2.5 volumes of 100% ethanol and 0.1 volumes of 
3M sodium acetate (Sigma; pH 5.2) were added, and the mixture incubated at -20°C
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for 3 hours. The precipitated DNA was pelleted by centrifugation at 13000 ipm for 
10 minutes. The supernatant was removed and the pellet washed using 70% ethanol, 
and the mixture recentiifliged as above. The pellet was allowed to air dry and 
resuspended in RNase free water.
2.7.13 DNA Sequencing
Sequencing was performed using the CEQ2000 capillary sequencing system 
(Beckman-Coulter). Sequencing reactions were performed using the CEQ2000 dye 
terminator cycle sequencing quick start kit, as outlined in the manufacturers’ 
instructions. This system utilises four colour dideoxy-temiinator cycle sequencing, 
using an unlabelled sequencing primer. The sequencing reactions were ethanol 
precipitated, resuspended in 40pl of sample loading solution, and loaded on to the 96- 
well sequencing plate. Samples were then run overnight. Sequence data was 
tiansfened to the UNIX GCG software package for manipulation.
2.8 RNA Techniques
2.8.1 In Vitro Transcription
Full length RNA genome copies were transcribed fr om both wild-type and 
recombinant versions of the infectious copy plasmid pT7S3 using the megascript kit 
(AMBION). Template DNA for this reaction was first phenohchloroform extiacted, 
and ethanol precipitated, before being linearised using the restriction endonuclease 
Hpal. Following proteinase K treatment, the linearised templates were run on a 1% 
agarose gel, and gel extracted. Each reaction was constructed as follows:
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2pi ATP Solution
2pl CTP Solution
2pi GTP Solution
2pl GTP Solution
2pl 1 Ox Reaction Buffer
Ipg Template DNA
2pl T7 Polymerase Enzyme Mix
Make up to 20pl Nuclease free water
The reactions were constiucted at room temperature, and then incubated for 4 hours at 
37°C. Ipl DNasel was then added, and the reaction mixture incubated for a further 15 
minutes at 37°C.
2.8.2 RNA Purification
In vitro transcribed RNA was purified using the Megaclear kit (AMBION) as per the 
manufacturers instructions. This kit uses a column based system to separate the RNA 
fr om the components of the in vitro transcription reaction.
2.8.3 RNA Transfection by Electroporation
BHK cells were grown to 90% confluency in a 175cm^ tissue culture flask. The cells 
were removed using trypsin-versene, and pelleted by centrifrugation (lOOOrpm for 3 
minutes at 4°C) and resuspended in ice cold electroporation buffer (21mM Hepes 
pH7, 137niM NaCl, 5mM KCl, 0.7mM Na2HP0 4 , and 6mM Glucose, in RNase free 
water). The cells were then counted using a haemocytometer and resuspended at 2
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million cells per ml in ice cold electroporation buffer. 0,8ml of this cell suspension 
was transferred to a pre-chilled electroporation cuvette (BioRad) with a 0.4cm gap 
length and stored on ice. Viral RNA or RNA transcripts derived from the infectious 
copy plasmid (chapter 8) were added to the cells in the cuvette, mixed gently, and 
immediately electroporated at 750V with a capacitance of 25pFD. Each sample was 
pulsed twice, and a time constant of between 0.6 and 0.7 was typically recorded. All 
electroporations were carried out using a BioRad gene puiser. Following 
electroporation, the cuvette was allowed to stand at room temperature for 10 minutes, 
and the cells were then added to 6ml cell culture medium in a 25 cm^ tissue cultur e 
flask and incubated at 37°C and 5% CO2 .
2.8.4 Total RNA Extraction
CHO cells and SW480-P6 cells were grown to 100% confluency in 35mm tissue 
culture dishes. Total RNA was extracted using the trizol reagent (Life Technologies) 
according to the manufacturers protocol. The final RNA pellet was dissolved in 2Oui 
of RNase fr ee water in an RNase fi’ee tube (AMBION) and stored at -80°C.
2.8.5 Reverse transcription of total cellular RNA
5pi of total RNA isolated fr om CHO or SW480-p6 cells, 2pl of random 
hexanucleotide primers (Promega-5 Opg/pl) and 3 pi of RNase-free water were added 
to an RNase-fr ee tube and incubated at 70°C for 5 minutes in order to melt secondary 
structure and allow primer annealing. The tube was then cooled by incubation at 
room temperature for 10 minutes. To each reaction the following were added:
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4pl first strand synthesis buffer
2pl Acetylated BSA (Promega-Final Cone O.lrag/ml)
2pi DTT (Promega-Final Cone 1 OmM)
Ipl dNTP Mix (Promega)
Ipl Moloney Murine Leukemia Virus reverse transcriptase (Promega)
This reaction mixture was incubated for 5 minutes at room temperature, and then the 
first shand synthesis reaction was allowed to proceed for 60 minutes at 37°C. Finally 
the reverse tianscriptase enzyme was denatured by incubation at 70°C for 15 minutes.
The cDNA produced from CHO and SW480-p6 cells was used as a template for the 
amplification of Caveolin-1, and as a contiol, p-Actin. Amplification was carried out 
using Taq polymerase in conjunction with the primers shown below.
Caveolinl Amplification:
Cavlfor = 5’-atg tct ggg ggc aaa tac gta ga-3’
Cavlrevl = 5’- gta aat gcc cca gat gag tgc ca-3’
Actin Amplification
Actinfor = 5’-gag aag ctg tgc tac gtc gc-3’
Actinrev = 5’-cca gac age act gtg ttg gc-3’
The PCR method used was as described in section 2.7.2.
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Chapter Three: The Effect of Pharmacalogical 
Inhibitors of Endocytosis on FMDV Uptake and 
Infection
3.1 Introduction
The route by which foot-and-mouth disease virus (FMDV) enters and infects tissue 
culture cells remains poorly defined. Material, such as virus particles, can be taken up 
into cells via a variety of different endocytic uptake pathways, such as clathrin- 
dependent endocytosis and caveolae-dependent endocytosis (see section 1.5). There 
are a number of pharmacological inhibitors and cell ti eatments capable of inhibiting 
specific endocytic uptake pathways, and indeed specific steps in those pathways. The 
aim of the work presented in this chapter is to look at the effects of the inhibition of 
specific pathways by these tr eatments on avP6-mediated infection of SW480-P6 
cells. This has enabled us to gain a better insight in to the endocytic uptake pathways 
required for avP6-mediated infection of cells by FMDV.
A number of viruses have been shown to utilise the clatlirin-dependent endocytosis 
pathway to enter and infect cells. Examples include: influenza virus (194), hantaan 
virus (150), semliki forest virus (72), human rhinovirus 2 (296), human parechovirus 
1 (151), and vesicular stomatitis virus (195). There are a number of methods by 
which clathrin-mediated endocytosis can be inhibited. One such method is the 
tieatment of cells with hypertonic media (121). Following incubation in hypertonic 
medium the geodesic lattices of clathrin present under each coated pit are replaced by 
accumulations of small empty clathrin “microcages” and cell surface receptors, such 
as the LDL receptors, lose their normal clustered distribution at the cell surface (121). 
Upon return of cells to isotonic medium normal clathrin lattices begin to reappear
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within 2 minutes and recover to normal levels within 10-15 minutes. This method has 
been found to inhibit clathrin-dependent endocytosis in virtually all cell types studied.
A second method used to inhibit this pathway is to express dominant negative 
versions of proteins involved in clathrin-coated pit formation and internalisation in the 
target cells. The cellular protein, A PI80 was first purified and characterised fiom 
coated vesicles taken from bovine brain tissue (3). It was found to bind clathrin 
triskelia in vitro and to promote the formation of an*ays of clathrin similar to the 
surface coat of coated vesicles (3). Subsequently it was also found to bind directly to 
the ccc-appendage domain of the adaptor protein AP-2 (113, 206, 316) to form a 
complex that co-operatively recruits clathrin (113). A PI80 is thought to be tethered 
to the plasma membrane via a phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) 
binding site located in the N-terminal region of the molecule (82). Overexpression of 
either full length or a C-terminal fiagment of API 80 inhibits clathrin-dependent 
endocytosis by mislocalizing clathrin and preventing its incoiporation into nascent 
coated pits (82, 342). Hence clathrin-mediated endocytosis can be inhibited by 
transient transfection of cells with the C-terminal portion (residues 530 -915) of 
AP180(AP180-C).
Both of the above techniques (treatment of cells with hypertonic sucrose and 
transient ti*ansfection with AP180-C) are utilised in experiments described in section
3.2.1 to look at the role of clathrin-dependent endocytosis in the entry and infection of 
SW480-P6 cells by FMDV.
Recently a number of viruses have been reported to utilise lipid raft dependent 
uptake mechanisms to enter and infect cells. Reported examples include echovimses 
1 (254) and 11 (304), coxsackievirus B4 (317) and SV40 (9, 251, 252). Lipid rafts 
are envisaged as highly ordered “islands” of saturated lipids and cholesterol. The
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non-raft portions of the membrane consist primarily of a bilayer of unsaturated lipids, 
which is disordered and fluid, allowing lipid rafts to move laterally in the plane of the 
bilayer (242). The straight acyl chains of the saturated lipids present in lipid rafts 
allow close packing with cholesterol, creating ordered microdomains. The acyl 
chains of the unsaturated phospholipids are crooked and as a result cannot pack 
together so tightly, resulting in a more disorganised and fluid nature. Cholesterol is 
therefore essential to maintaining the integrity of lipid rafts.
A number of agents can be used to deplete the cell membrane of cholesterol, 
including Nystatin, Filipin, and Methyl-P-cyclodextrin (MpCD). The sensitivity of 
raft-dependent endocytic pathways to nonacute cholesterol depletion by such agents 
distinguishes them from the clathrin dependent and constitutive pinocytic uptake 
pathways. Methyl-P-cyclodextiin is a water soluble heptasaccharide, consisting of (ot 
-l,4)-linked a-D-glucopyranose units. The molecule has a hydrophilic outer surface 
and a lipophilic central cavity, in which cholesterol molecules bind. Methyl-p- 
cyclodextrin is utilised in experiments described below, in order to establish the role 
(if any) of lipid raft dependent uptake pathways in avP6-dependent infection of 
SW480 cells.
Foot-and-mouth disease virions are thought to be locked in to the metastable state 
(For a review see (127)) by the cleavage of VPO to give VP2 and VP4 (the so called 
maturation cleavage). Virtually all known viruses are released from the metastable 
state by interaction with the virus (co)receptor, exposure to low pH, or a combination 
of both. This is thought to expose hydrophobic residues which can interact with 
biological membranes, facilitating the tiansfer of the viral genome to the appropriate 
compartment of the cell (the cytoplasm in the case of FMDV). Other Picornaviruses, 
such as Poliovirus, undergo a stiuctural change upon interaction with their receptor, to
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form the so-called “Altered-” or A-particle (see section 1,6.3). FMDV has never been 
shown to form A-particles, or indeed to undergo any sti'uctural changes upon 
interaction with its integrin receptors. Interaction with its receptor is therefore 
unlikely to be the tiigger for release of FMDV virions from the metastable state.
FMDV capsids are however extremely acid labile dissociating into their constituent 
pentamers and viral RNA at pH values just below neutrality. A structur al model has 
been developed for the acid-induced disruption of the FMDV capsid, involving the 
protonation of histidine residues (pKa « 6.5) at inter-pentamer interfaces (56, 78)(see 
section 1.6.5.2). This sensitivity to acid lead to speculation that infection of cells by 
FMDV requires a low pH step, in order to release the virus from the metastable state, 
and that entry proceeds through endosomes. The low pH within endosomes is 
maintained by the vacuolar H^-ATPase, by means of ATP-dependent proton 
translocation (a process termed “Active Endosomal Acidification”). Concanamycin A 
blocks the action of this enzyme, and in doing so dissipates the acidic pH within 
endosomal compartments.
Concanamycin A, and the related compound Bafilomycin A l, have been used to 
study the role of low pH in infection by a number of viruses. Examples include 
enveloped viruses such as semliki forest virus (138), influenza virus (108-110), and 
non-enveloped viruses such as human rhinoviruses-2 (21) and -14 (253) (HRV-2 and 
HRV-14), poliovirus (253), and encephalomyocarditis virus (253). If the entry of 
FMDV does require a low pH step this compound would be expected to inhibit 
infection of susceptible cells by this virus. Concanamycin A is used as a tool to 
investigate whether cell entry by FMDV requires a low pH step in the experiments 
described below.
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In non-polarized cells, internalized receptors and their ligands generally take one of 
two paths following uptake in to early endosomes. Firstly membrane receptors and/or 
their ligands can be delivered to late endosomes and ultimately lysosomes, resulting 
in their degradation. Alternatively, the membrane rich tubular portions of the early 
endosome deliver material to the pericentriolai* recycling endosome compartments, 
and thence back to the cell surface. In certain cell types, a pathway capable of 
delivering some receptors/ligands (e.g. the transferrin receptor/ti'ansfeii'in) directly 
back to the surface from early endosomes, without passage through pericentriolar 
recycling endosomes, has also been identified. The above pathways are affected 
differently by pharmacological reagents such as nocodazole and wortmannin, 
allowing the role (if any) of these pathways in entry of FMDV into susceptible cells to 
be investigated.
Transport of material from early to late endosomes has been reported to be 
dependent on microtubules in unpolarized BHK cells (107) and polarized MDCK 
cells (36) since transport between these two compartments is inhibited by the 
microtubule depolymerising drug Nocodazole, Recycling of receptors or their ligands 
back to the cell surface however is thought to be microtubule independent, since these 
pathways are not inhibited by treatment with Nocodazole(198, 308).
Depolymerisation of microtubules also interferes with caveolae-dependent 
endocytosis since tieatment with Nocodazole causes the accumulation of Caveolin-1 
and invaginated caveolae at the siuface of CHO cells(216), indicating that 
internalisation of these structures is dependent on the microtubule network. However 
this remains controversial since delivery of SV40 to caveosomes via caveolae in CV-1 
cells was not affected by the action of Nocodazole(251)
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The phosphatidylinositol-3“kinase (PI3kinase) inhibitor wortmannin has been 
widely used to look at the role of these enzymes in vesicular tiafficking. The initial 
stages of fluid phase uptake have been reported to be sensitive to wortmannin (284). 
In contrast, the available data suggests that wortmannin has only minimal effects on 
clathrin-dependent delivery of ligands, such as transferrin, to early endosomes (172, 
188, 284, 298). However, the transport of proteins such as internalized platelet 
derived growth factor receptors and Semliki Forest Virus beyond early endosomes to 
late endosomes and ultimately lysosomes has been reported to be wortmannin 
sensitive (152, 188). Wortmannin also inhibits the recycling of transferrin fr om early 
endosomes back to the cell surface (188, 293, 298), and is thought to achieve this by 
reducing both the rate of influx and efflux from pericentriolar recycling endosomes.
It is worth noting however that some studies report that wortmannin has no impact on 
transferrin recycling (284), so this effect may be cell type dependent. To summarise 
the available data, wortmannin has no effect on clathrin-dependent delivery to eai'ly 
endosomes, but does interfere with transport beyond early endosomes, to either late 
endosomes/lysosomes or to recycling endosomes. Nocodazole and Wortmannin ar e 
useful tools to study the role of transport beyond early endosomes in infection, 
whether that be via late endosomes or recycling endosomes.
It is known that the cytoskeleton, including the microtubule network and actin 
filaments, plays a role in endocytic uptake pathways at distinct stages. The role of the 
microtubule network is discussed briefly above. The actin cytoskeleton has been 
shown to be required for caveolae-dependent uptake of ligands, including SV40 (252) 
and clustered alkaline phosphatase (241). Lipid raft dependent uptake in caveolin-1 
deficient cells has very similar properties to that seen in caveolin-1 expressing cells 
(79, 114), and so is also dependent on the actin cytoskeleton. Macropinocytic uptake
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pathways are also dependent on rearrangements of the actin cytoskeleton in a number 
of cell types. The precise role of actin in clathrin-dependent endocytosis is less clear 
since the sensitivity of clathrin-dependent endocytosis to microfilament disrupting 
dings seems to vary according to cell type and whether the cells are grown in 
suspension culture or on a solid substrate (87). This indicates that actin plays a 
variable and non-obligatory role in clathrin-dependent endocytosis in mammalian 
cells. The fimgal metabolite Cytochalasin D has been shown to disrupt the actin 
cytoskeleton by binding to the barbed gi owing end of microfilaments at which net 
polymerisation occurs, thereby preventing the addition of actin monomers (39, 55). 
This agent is thus a useful tool for examining the role of the actin cytoskeleton in 
entry and infection of cells by FMDV.
Described above are a number of pharmacological reagents and cell treatments 
which inhibit different endocytic pathways at distinct stages. The work described 
below is an investigation of the effects these reagents and treatments have on avP6 
mediated entry and infection of SW480-P6 cells. In the majority of cases infection is 
quantified using the ELIspot assay (see methods section 2.5.2). In this assay SW480- 
p6 cells in a 96-well plate are incubated with FMDV (01Kcad2; m.o.i -0.3) for up to 
1 hour at 37°C. The cells are then washed and incubated in culture medium for a 
further 4 hours, fixed with 4% paraformaldehyde and permeabilised with 0.1% 
Triton-X-100. The infected cells are incubated sequentially with Mab 2C2 (which 
recognises the viral protein 3 A, a marker for virus replication), a biotinylated goat 
anti-mouse IgG secondaiy antibody and streptavidin-conjugated alkaline phosphatase. 
Following incubation with enzyme substrate the infected cells appear dark-blue in 
colour and can be counted using an ELIspot plate reader. Examples of a mock 
infected cell monolayer (panel A) and an infected cell monolayer (panel B) subjected
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to this assay are shown in figure 3.1. Infection is assayed at a low m.o.i (-0.3), as it 
has been hypothesised that vast excesses of virus may cause virions to be taken up by 
pathways which would not be utilised under normal physiological conditions (304).
89
Mock Infected Control Infected (m.o.i. -  0.3)
F ig u re  3.1. Q uantification o f infection using the ELIspot a s sa y .
SW 480-av(36 c e lls  in a  96-w ell plate w ere  incubated with FMDV (01 K ca d 2 ;m .o .i -0 .3 )  for 1h at 37°C . The ce lls  w ere  w a sh ed  
and incubated in culture m edium  for a further 4h . fixed with 4% paraform aldehyde and perm eabilised  with 0.1%  Triton-X-100. 
T he in fected  c e lls  w ere  incubated seq uentia lly  using Mab 2 0 2  (which re c o g n ise s  the viral protein 3A, a marker for virus 
replication), a biotinylated g oa t an ti-m ou se IgG seco n d a ry  antitxjdy and streptavidin-conjugated alkaline p h o sp h a ta se . In the  
p r e se n c e  o f en zy m e  substrate  the in fected  c e lls  ap p ear  dark-blue and w ere  counted  using an ELIspot plate reader. P a n e l  
(A) s h o w s  the background labelling o f a m ock infected  cell m onolayer. O m ission  o f the primary antibody from the a s s a y  
(rather than virus) produced a similar level o f background labelling. P a n e l (B) sh o w s  an infected  cell m onolayer.
3.2 Effect of Pharmacalogical Inhibitors of 
Endocytosis on FMDV Entry and infection
3.2.1 inhibitors of Ciathrin-Dependent Endocytosis
3.2.1.1 Hypertonic Sucrose Treatment
Treatment of cells with hypertonic concentrations of sucrose has been shown to 
inhibit clathrin-dependent endocytosis (121, 129). We therefore decided to 
investigate the effect of this treatment on infection of SW480-p6 cells by FMDV 
strain 01Kcad2. Unlike tissue culture adapted stiains 01Kcad2 utilises the integrin 
avp6 as its receptor on this cell line and not heparan sulphate proteoglycans (147). 
Figure 3.2 shows the effect on infection of sucrose tieatment. Infection was assessed 
using the elispot infection assay (see above). Cells were pretreated with a range of 
concentrations of sucrose (0.1-0.4M) for 30 minutes, prior to incubation with virus in 
the presence of sucrose for 1 hour. Virus and sucrose were then washed away and the 
assay completed. Pre-treatment with O.IM and 0.2M sucrose had no effect on 
infection. In contrast, pre-treatment with hypertonic concentrations of sucrose (0.3M 
and 0.4M) virtually abolished infection, leading to gieater than 95% inhibition. In 
order to determine the effect of these treatments on intracellulai' virus replication, 
sucrose was added for 1.5 hours following removal of the virus inoculum, rather than 
prior to the addition of virus. At this time it would be expected that virus had ali eady 
entered the cell and intracellular virus replication initiated. On figure 3.2 this data is 
marked RC followed by the relevant concentration of sucrose. These data show the 
same pattern as for pre-tieatment, i.e. infection is abolished by 0.3 and 0.4M, but not 
by 0.1 and 0.2M sucrose (Fig 3.2). From this experiment it is not clear at which stage
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infection is being inhibited. The possibilities are: a) uptake of virus is blocked so any 
impact of sucrose on replication is irrelevant, b) sucrose ti eatment is blocking 
infection at the stage of intracellular virus replication. It should be noted however 
that the replication contiols aie not exactly analogous to the data shown when cells 
are pretieated with sucrose. In the samples pretreated with sucrose, no sucrose is 
present during the “replication stage” of the assay, that is after the virus innoculum 
has been removed, and virus has entered the cells and is undergoing cytoplasmic 
replication. For the replication conti ols sucrose is present for 1.5 hours of the 4 hour 
“replication stage” of the assay. Since cells rapidly recover from tieatment with 
hypertonic sucrose (within 30 minutes), it is by no means clear that replication is 
being inhibited at all in the pre-treated samples in the manner implied by the 
replication contiols.
In order to establish the stage at which hypertonic sucrose tieatment inhibits 
infection of SW480-p6 cells by FMDV, the effect of this treatment on uptake of 
Alexa-fluor labelled Transferrin (a ligand taken up exclusively by clathrin mediated 
endocytosis) and virus was investigated by confocal microscopy. Cells were either 
mock treated or pretieated with 0.4M sucrose for 30 minutes, prior to incubation with 
ligand (either transferrin or purified FMDV) for 20 minutes at 37®C in the presence of 
sucrose where appropriate. Cells were then fixed, and where appropriate vims was 
labelled using the monoclonal antibody D9 and an Alexa-568 labelled goat anti­
mouse IgG2a secondary antibody. Figure 3.3 shows the results of these experiments. 
Panels A and B show the uptake of Transferrin in both mock treated (panel A) and 
sucrose tieated cells (panel B). It is clearly evident that hypertonic sucrose has 
blocked the uptake of Transferrin, confirming that this ti eatment does indeed block 
clathrin-dependent endocytosis. Transferrin is not seen at the cell surface in panel B
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since the extensive washing steps performed in this assay result in the removal of 
ti'ansferrin remaining at the cell surface. Panels C and D show the uptake of virus in 
mock treated (panel C) and sucrose treated cells (Panel D). In mock tieated cells 
virus was seen in vesicular structures in the cell cytoplasm, whereas in sucrose treated 
cells the vast majority of vims remained at the cell surface. This shows that sucrose 
treatment blocks the uptake of virus as well as ti*ansferrin, suggesting that virus is 
taken up by clathrin-dependent endocytosis. This also clarifies the data shown in 
figure 3.2 panel A. The block in infection shown here must be at the stage of virus 
entry, since pre-tieatment with 0.4M sucrose prevents virus from entering the cell, 
making any impact on cytoplasmic replication less important.
The above evidence sti ongly suggests that pre-ti eatment of cells with hypertonic 
sucrose tieatment inhibits infection by FMDV by preventing clathrin-dependent 
uptake of virus particles. We were interested to see however if the use of milder 
conditions for sucrose treatment could separate the effects on entiy and cytoplasmic 
replication of FMDV. Figure 3.4 shows the effect on infection of two concentrations 
of sucrose (0.3M and 0.4M), using two different ti eatment protocols for each. The 
treatment protocols were as follows 1)15 minutes pre-treatment with sucrose 
followed by a 30 minute incubation with virus in the absence of sucrose and 2) 15 
minutes pre-tieatment with sucrose followed by a 30 minute incubation with virus in 
the presence of sucrose. In both assays, virus and sucrose were then washed away 
and the assay completed. In order to look at the effect of these treatments on 
intiacellular replication, sucrose (either 0.3 or 0.4M) was added for a period of 15 
minutes (the contiol for treatment 1) or 45 minutes (the control for tieatment 2) 
following the removal of the virus inoculum. On Fig 3.4 this data is marked RC 
followed by the concentration of sucrose used, with the assay conditions indicated
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below. Fig 3.4 shows that tieatment of the cells with 0.4M sucrose for 15 minutes 
(treatment 1) inhibited infection by ~80% when sucrose was added prior to infection 
but only by ~30% when added after infection had been initiated (RC treatment 1). A 
flirther two experiments were then earned with 0.4M sucrose using treatment 1. The 
results of these experiments are shown in figure 3.5 panel A, and as an average of the 
three experiments in figure 3.5 panel B. These experiments confirm that 0.4M 
sucrose (using treatment 1) inhibits infection between 68-80% (mean = 74%), whereas 
the equivalent replication conti ol showed an inhibition of between 5 and 29% (mean 
= 16%). These data show that it is possible to separate the impact of sucrose on entry 
and replication, using milder conditions than those used in figure 3.2, albeit that the 
inhibition of infection is less dramatic.
Pre-tieatment with hypertonic sucrose inhibits infection of SW480-|36 cells by 
FMDV, which indicates that enti*y of FMDV is clathrin-dependent. The fact that the 
same ti eatment regime inhibits uptake of ti'ansferrin (a marker for clathrin-dependent 
endocytosis) and virus by these cells, strongly supports this conclusion. When 
sucrose is added after the addition of virus rather than before (the replication 
contiols), inhibition of infection is also seen. This indicates that sucrose ti eatment 
can inhibit intracellular replication of FMDV as well as entry of the vims. However, 
when milder treatment conditions are used inhibition of infection is much greater 
when sucrose is added prior to the virus inoculum rather than after it, suggesting that 
under these conditions the major inhibitory effect of sucrose is on the enti'y stage of 
infection. Taken together this evidence suggests that hypertonic sucrose tieatment 
inhibits clathrin-dependent endocytosis, and in so doing prevents uptake of virus from 
the cell surface and hence infection of the target cells.
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F igu re  3 .2 . Hypertonic S u cro se  Inhibits infection by FMDV
S W 4 8 0 -a v p 6  c e lls  w ere treated with su c ro se  for 0 .5h  prior to incubation (m .o.i - 0 .3 )  with FMDV for 1 h at 37°C  in the  
p r e se n c e  o f su cro se . Mock c e lls  w ere  treated with DMEM. D ata poin ts marked RC ( Replication Control") rep resen t 
s a m p le s  that w ere  not pre-treated with su c ro se  but in stead  w ere  treated with the indicated concen tration  o f  su c r o se  for 
1 .5h following rem oval o f the virus inoculum . Following rem oval o f virus, sa m p le s  w ere incubated for a further 4  h at 37°C , 
and then  fixed with 4% paraform aldehyde. Infection w a s  quantified a s  descr ib ed  in figure 3 .1 .
The num ber of infected  c e lls  in the su cro se -trea ted  s a m p le s  w a s  e x p r esse d  a s  a p ercen ta g e  o f the num ber of infected ce lls  
in m ock-treated sa m p le s . T he m ean  and ±SD  o f three ob serv a tio n s  is show n.
Mock Treated Sucrose Treated
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(/>3
F ig u re  3 .3 . S u cr o se  inhibits uptake o f both FMDV and transferrin.
S W 4 8 0 -a v p 6  ce lls  w ere  treated with 0  4M su c ro se  (p a n e ls  B and D) or Mock T reated (p an els  A and C) for 0 .5h . T he c e lls  w ere then  
incubated with A lex a -4 8 8  conju gated  transferrin (green  - P a n e ls  A and B) or FMDV (red -  P a n e ls  C and D) for 20m in at 37"C in the  
p r e se n c e  (P a n e ls  B and D) or a b s e n c e  (P a n e ls  A and C) o f su c ro se . DAP I sta in ed  nuclei are show n in blue. Bars = 5pm
S u cr o se  treatm ent inhibited uptake o f both transferrin (com p are pan el B with A) and FMDV (com p are pan el D with C).
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F ig u re  3.4. Hypertonic S u cr o se  Inhibits infection by FMDV
S W 4 8 0 -a v p 6  c e lls  w ere  treated with su c ro se  for 15 m in utes prior to incubation (m .o.i - 0 .3 )  with FMDV for 0 .5h  at 37  °C in 
th e a b s e n c e  (T reatm ent 1) or p r e se n c e  (T reatm ent 2) o f su c ro se  a s  indicated. Mock ce lls  w ere  treated with DMEM. Data  
points m arked RC (“R eplication Control”) rep resen t s a m p le s  treated  with the indicated concentration  o f su c ro se  for 15 
(Treatm ent 1) or 4 5  m inutes (Treatm ent 2) following rem oval o f the virus inoculum .
Following rem oval o f virus, s a m p le s  w ere  incubated for a  further 4 .5 h  at 37°C , and then fixed with 4% paraform aldehyde. 
Infection w a s  quantified a s  d escr ib ed  in figure 3 .1 . T he num ber o f in fected  c e lls  in the su crose -trea ted  sa m p le s  w a s  
e x p r e s s e d  a s  a p ercen ta g e  o f th e num ber o f in fected  c e lls  in m ock-treated  sa m p les . T he m ean  and ±SD  o f three  
ob serv a tio n s  is show n.
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F igu re  3 .5 . Hypertonic S u cr o se  Inhibits infection by FMDV
SW 480-otvp6 c e lls  w ere  treated with su c ro se  for 15 m in utes prior to incubation (m .o.i - 0 .3 )  with FMDV for 0 .5h  in th e  
a b s e n c e  o f su c ro se . Mock c e lls  w ere  treated with DMEM. D ata poin ts m arked RC (“Replication Control") rep resen t sa m p le s  
treated with the indicated concentration  o f su c ro se  for 15 m inutes following rem oval o f the virus inoculum . Following  
rem oval o f virus, s a m p le s  w ere  incubated for a further 4 .5 h  at 37°C , and then fixed with 4% paraform aldehyde. T he  
num ber o f in fected  c e lls  in the su crose -trea ted  s a m p le s  w a s  e x p r e s s e d  a s  a  p ercen ta g e  o f the num ber o f infected  c e lls  in 
m ock-treated sa m p le s .
P a n e l A . S h ow n  are the resu lts  o f three in d ep en d en t exp erim en ts. E xperim ent 1 is rep resen ted  by unfilled bars, 
experim ent 2 by grey bars and experim ent 3 by black bars. T he m ean  and  ±SD  of three ob serv a tio n s is sh ow n . 
P a n e l B. S h ow n  is the m ean  and ±SD  o f th e data sh ow n  in panel A.
3.2.1.2 Dominant Negative A P I80C
In order to confirm the role of clathrin-dependent endocytosis in infection of SW480- 
p6 cells by FMDV, a more specific method of inhibiting this pathway was employed, 
namely transient transfection of dominant negative AP180C. Overexpression of 
either full length or a C-terminal fragment of A PI80 inhibits clathrin-dependent 
endocytosis by mislocalizing clathrin and preventing its incorporation into nascent 
coated pits (82, 342).
SW480-p6 cells, prepared on coverslips, were tiansiently transfected with a constiuct 
containing the C-terminal portion (residues 530 -915) of API 80 (AP180-C). At 12.5 
hours post-ti'ansfection, the transfected cells were infected with FMDV sfrain 
01Kcad2. Infection was allowed to proceed for 5 hours, before die cells were fixed 
and processed for immunofluorescence microscopy. The AP180C expressed in the 
cells was c-myc tagged and so was detected under the confocal microscope using the 
anti-c-myc antibody 9E10. Infected cells were identified using a rabbit polyclonal 
serum that recognises FMDV capsid proteins. Input vims was not detected since cells 
infected in the presence of guanidine hydrochloride (a reagent that inhibits FMDV 
replication) showed little or no fluorescent labelling (not shown). Figure 3.6 shows 
the results of these experiments. Panels A and B show representative regions where 
cells had been transfected with AP180C (shown as green) and subsequently infected 
with FMDV (shown as red), as viewed down the confocal microscope. None of the 
tr ansfected cells shown were infected, and none of the infected cells are also 
transfected to express AP180C. On each coverslip the proportion of non-transfected 
cells which were infected, and the proportion of transfected cells infected was 
calculated by sampling a number of fields of view down the confocal microscope.
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These data are shown in panel C. Approximately 19% of non-transfected cells were 
infected with FMDV (n-901), whereas only 1.6% of transfected cells were also 
infected. This means that expression of dominant negative API 80 C, which 
specifically inhibits clathrin-dependent endocytosis, inhibited infection by 
approximately 91%. This data, taken together with the sucrose data outlined in 
section 3.2.1.1, shows that clathrin-dependent endocytosis is required for entry and 
infection of SW480-|36 cells by FMDV.
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Red = Virus Green = AP180C
Untransfected
Cells
API 800 
Transfected 
Cells
Number of 
Infected Cells 171 4
Total Number of 
Cells Counted 901 244
% of cells 
infected 19.0 1.6
F ig u re  3 .6 . E xpression  o f A P 180C  inhibits infection by FMDV.
P a n e ls  A  a n d  B. S W 4 8 0 -a v p 6  c e lls  w ere  transfected  to e x p r e s s  c-m yc ta g g ed  A P 180C  and su b seq u en tly  infected  with FMDV for 5 
hours. Infected and/or transfected  c e lls  w ere  d e tec ted  by indirect im m u n oflu orescen ce  using th e con foca l m icroscop e . T ran sfected  
ce lls  (green ) w ere d e tec ted  using an anti-c-m yc m on oclon al antibody (9E 7) and infected c e lls  (red) with a rabbit polyclonal serum  to 
FMDV. N uclei w ere  sta in ed  with DAPI and are sh ow n  a s  blue A s sh ow n  in th e s e  im ages , in general, tran sfected  cells  w ere not found  
to b e  infected , and infected  c e lls  w ere  not found to b e  transfected . B ars = 10pm
P a n e l C  P ictures of random  fields o f view  w ere  taken using th e  6 3x  objective lens. In the fields o f view  sa m p ed , the total num ber of 
transfected  ce lls  and th e num ber of transfected  and infected  c e lls  w ere  counted , and u sed  to work out th e p ercen ta g e  o f transfected  
ce lls  that w ere a lso  infected. Similarly, th e total num ber of un transfected  ce lls  and th e num ber o f un transfected  and infected ce lls  
w ere  cou n ted , and u sed  to work out the proportion of un transfected  ce lls  that w ere infected. This data is p resen ted  in th e  tab le show n  
in panel C.
E xpression  of A PI 80C  inhibited infection a s  th e proportion o f transfected  ce lls  that w ere infected w a s  greatly reduced com pared  to the  
equ ivalen t figure for untransfected  cells.
3.2.2 Effect of Inhibition of Lipid Raft-dependent Endocytosis on 
FMDV infection
3.2.2.1 Cholesterol Depletion by Methyl-P-Cyclodextrin.
As described in section 3.1, plasma membrane lipid rafts are rich in cholesterol and 
are disrupted by agents that deplete the membrane of cholesterol or sequester 
cholesterol within the membrane. Consequently, lipid raft-dependent endocytic 
pathways (including the caveolae dependent uptake pathway) are also sensitive to 
such agents. We therefore decided to use methyl-p-cyclodextrin, filipin, and nystatin, 
all of which are agents that bind plasma membrane cholesterol and inhibit lipid-raff 
dependent endocytosis, to investigate the role (if any) of lipid raft dependent uptake 
pathways in infection of SW480-p6 cells.
Figure 3.7 shows the effect of methyl-p-cyclodextrin on infection of SW480-P6 
cells by FMDV. Infection was measured using the elispot infection assay (see figure 
3.1). Cells were pretreated with methyl-P-cyclodextrin for 30 minutes prior to 
incubation with virus (m.o.i~0.3) for 30 minutes in the presence of drug. Both the 
virus and dmg were then washed away, and the assay completed. The drug was not 
present throughout the assay because it proved toxic to the cells if present for this 
length of time. The concentrations of drug utilised (5 and 7.5mM) did not inhibit 
infection by FMDV, indicating that infection was not reliant on lipid raft dependent 
endocytic pathways.
Further experiments were carried out to confirm that methyl-p-cyclodexti'in 
tr eatment disrupts lipid rafts and lipid raft dependent endocytosis at the concentrations 
utilised in figure 3.7. Lipid rafts were visualised at the cell surface using the cholera 
toxin B subunit (CTB). CTB binds the ganglioside GMl which is located
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predominantly within lipid rafts. Fluorescently conjugated CTB can therefore be used 
as a marker for lipid rafts at the cell surface. Raft resident molecules (including 
GMl) adopt a diffuse distribution at the cell surface rather than a punctate pattern 
when visualised by immunofluorescence methods (255). This is thought to be 
because of extensive coverage of the plasma membrane surface by lipid rafts and the 
fact that the diameter of lipid rafts is below the resolution limit of the light 
microscope, resulting in an apparently even distribution of raft localized proteins. 
Therefore, to aid raft identification the rafts were visualised as puncta by antibody 
cross-linking alexa-conjugated CTB at the cell surface. Janes et. al. have utilised this 
method of lipid raft visualisation previously and showed that CTB labelled membrane 
patches display characteristics consistent with biochemically isolated lipid rafts(149).
SW480-p6 cells were either treated with methyl-P-cyclodextrin or mock treated, 
and subsequently CTB was allowed to bind the cells for 45 minutes at 4°C and then 
crosslinked with a rabbit anti cholera toxin polyclonal semm. The resulting data is 
shown in figure 3.8. Panel A shows that lipid rafts visualised by crosslinked CTB 
have a punctate distribution at the surface of mock treated SW480-p6 cells. In 
contrast, panel B shows that a diffuse labelling pattern is observed at the surface of 
SW480-P6 cells pre-treated with 7.5 raM methyl-p-cyclodextrin. This indicates that 
treatment with methyl-p-cyclodextrin results in the disruption of lipid rafts, since the 
punctate structures corresponding to lipid rafts on the surface of mock treated cells are 
not observed in dmg treated cells.
The impact of methyl-p-cyclodextrin treatment on lipid-raft dependent endocytosis 
pathways was investigated by examining the effect of the drug on the uptake of alexa- 
fluor labelled CTB by SW480-p6 cells using confocal microscopy. Since the cell 
surface receptor for CTB, GMl ganglioside, is highly enriched in lipid rafts, CTB
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predominantly enters cells by lipid raft dependent endocytosis in a number of 
different cell types (115, 211, 289, 311,315). Methyl-p-cyclodextrin has also been 
reported to inhibit clathrin-dependent endocytosis under certain conditions (270, 305). 
In order to investigate this possibility, the effect of methyl-p-cyclodextrin on the 
uptake of Alexa-fluor labelled tmnsferrin (a marker for clathrin-dependent 
endocytosis) was also examined. Figure 3.9 shows the results of these experiments. 
Panels A and C show that Alexa-labelled CTB (green) and Alexa-labelled transferrin 
(red) are both taken up by mock-ti*eated SW480-p6 cells following a 20 minute 
incubation at 37°C. Panel B shows that pre-treatment with 7.5mM methyl-P- 
cyclodexti'in inhibits uptake of CTB, since the majority of ligand remained at the cell 
surface, indicating that lipid-raft dependent endocytosis had been inhibited. Panel D 
shows that methyl-p-cyclodextrin does not inhibit clathrin-dependent endocytosis 
since pre-treatment with this drug did not prevent the uptake of ti*ansfeiTin. In 
summary, treatment with methyl-P-cyclodextrin inhibits uptake of CTB (a marker of 
lipid raft-dependent endocytosis), but not transferrin (a marker of clathrin-dependent 
endocytosis). Since the same treatment did not inhibit infection of SW480-p6 cells by 
FMDV (see figure 3.6), this indicates that FMDV does not enter cells by lipid-raft 
dependent endocytosis.
In order to reinforce the data shown above, we also investigated the effect of 
nystatin and filipin on FMDV infection of SW480-P6 cells. Like methyl-p- 
cyclodextrin these agents bind cholesterol and inhibit lipid raft-dependent 
endocytosis, but they act via a different mechanism. Methyl-p-cyclodextrin 
selectively extracts cholesterol fioin cells but does not become incor'porated in to the 
plasma membrane (137, 235, 338). This results in depletion of cholesterol fiom the 
lipid bilayer. Nystatin and Filipin however become incorporated into lipid
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membranes where they chelate cholesterol (91, 203, 237). This means that the 
cholesterol is still present in the membrane but is sequestered by the drug molecules 
such that it cannot form part of the structure of lipid rafts, resulting in the inhibition of 
lipid raft-dependent uptake mechanisms. Unlike methyl-p-cyclodextrin, these agents 
have not been reported to inliibit the clathrin-dependent endocytosis pathway (270).
Figure 3.10 shows two independent experiments investigating the effect of nystatin 
on infection of SW480-p6 cells by FMDV. The cells were pretreated with a range of 
nystatin concentrations (5.25-lOOp.g/ml), and infection was assessed using the elispot 
infection assay. Samples were pretieated with Nystatin for 1 hour and the drug 
remained present throughout the assay. Nystatin heatment did not inhibit infection in 
comparison to mock treated samples at any of the concentrations tested. In 
comparison, infection by SV40 is inhibited by ~60% at 25{ig/ml (9) and infection by 
Echovirus 11 is inhibited by -60% at 23.2p.g/ml (304). Both of these viruses utilise 
lipid raft dependent endocytic uptake mechanisms.
Figure 3.11 shows the effect of filipin on infection of SW480-p6 cells. The cells 
were pretreated with a range of concenti ations of filipin (1.25-lOp.g/ml), and infection 
assessed by the elispot assay using the same experimental design as for Nystatin. 
Filipin treatment did not inhibit infection in comparison to mock treated samples at 
any of the concentrations tested. Together tire experiments with nystatin and filipin 
support the methyl-p-cyclodexti'in data and show that virus entry and infection of 
SW480-p6 cells by FMDV is not dependent on lipid raft dependent endocytic 
pathways.
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F ig u re  3 .7 . MpCD d o e s  not inhibit FMDV infection.
S W 4 8 0 -a v p 6  c e lls  w ere  treated  with MpCD in DMEM for 0 .5h  and infected  with FMDV (m .o.i - 0 .3 )  for 0 .5 h  in the p r e se n c e  o f the 
drug and infection quantified a s  d escr ib ed  in figure 3 .1 . T he m ock c e lls  w ere  treated with DMEM. Following rem oval o f virus, 
s a m p le s  w ere Incubated for a further 4 .5 h  (P a n e l B) at 37°C , and th en  fixed with 4% paraform aldehyde. Infection w a s  quantified  
a s  d escr ib ed  in figure 3 .1 . T he num ber o f infected  c e lls  In the M pCD-treated sa m p le s  w a s  e x p r essed  a s  a  p ercen ta g e  o f the  
num ber o f infected  ce lls  in m ock-treated sa m p le s . Two in d ep en d en t exp erim en ts are sh ow n , and e a c h  data point rep resen ts  the  
m ean and ±SD  o f  three ob servation s.
Mock
Treated
7.5mM
MpCD
F ig u re  3 .8  . MpCD disrupts p lasm a m em b ran e lipid rafts.
S W 480-P 6  ce lls  w ere  pretreated with 7.5m M  MpCD (P a n e l B) or m ock treated with DMEM (P a n e l A ) for 0 .5h . A lexa -488  conju gated  
CTB (green ) w a s  allow ed to bind to th e cell su rface  for 4 5  m ins on ice, and crosslinked using an anti cholera  toxin polyclonal antibody  
for 1h on ice. T he ce lls  w ere  fixed using paraform aldehyde and v iew ed  under the confocal m icroscop e . N uclei are sta in ed  with DAPI 
and are sh ow n  a s  blue
Mock Treatment 7.5mM Methyl-p-Cyclodextrin
F ig u re  3 .9  . MpCD blocks uptake o f cholera  toxin B (CTB) but not Transferrin.
S W 4 8 0 -a v p 6  ce lls  w ere treated with 7.5m M  MpCD (p a n e ls  B and D) or M ock T reated (p an els  A and C) for 0 .5h . T he c e lls  w ere then  
incubated  with A lex a -4 8 8  conju gated  CTB (green  - P a n e ls  A and B) or A lexa -568  transferrin (red -  P a n e ls  C and D) for 20m in at 37*C  
in th e p r e se n c e  (P a n e ls  B and D) or a b s e n c e  (P a n e ls  A and C) o f MpCD. DAPI sta ined  nuclei are show n in blue. Bars = 10pm
MpCD treatm ent inhibited uptake o f CTB (com p are pan el B with A) but not Transferrin (com p are pan el D with C).
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F igu re  3 .1 0 . Nystatin d o e s  not inhibit FMDV infection.
SW 480-otvp6 c e lls  w ere  treated with Nystatin for 1h and in fected  with FMDV (m .o.i - 0 .3 )  for 1h in the p r e se n c e  o f th e drug. T he 
m ock c e lls  w ere  treated with DM SO. Follow ing rem oval o f virus, sa m p le s  w ere Incubated for a further 4h  at 37°C  in th e  p r e se n c e  
o f drug, and then fixed with 4%  paraform aldehyde. Data poin ts m arked RC rep resen t sa m p le s  treated  with lOOpg/ml Nystatin for 
4h following rem oval o f th e virus inoculum . Infection w a s  quantified a s  d escr ib ed  in figure 3 .1 . T he num ber o f infected  c e lls  in the 
N ystatin-treated s a m p le s  w a s  e x p r es s ed  a s  a p ercen ta g e  o f the num ber of infected  ce lls  in m ock-treated  sa m p le s . Two  
ind ep en dent exp erim en ts are sh o w n , and e a c h  data point rep resen ts  th e m ean  and ±SD  of three ob serva tion s.
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F igu re 3 .1 1 . Filipin d o e s  not inhibit FMDV infection.
S W 4 8 0 -a v p 6  c e lls  w ere  treated with Filipin for 1h and in fected  with FMDV (m .o.i - 0 .3 )  for 1h in the p r e se n c e  o f the drug. The 
m ock c e lls  w ere  treated with DMSO. Following rem oval o f virus, s a m p le s  w ere  incubated for a further 4h  at 37®C in th e p r e se n c e  
o f drug, and then fixed with 4% paraform aldehyde. Data points m arked RC rep resen t sa m p le s  treated  with IGpg/ml Filipin for 4h  
following rem oval o f the virus inoculum . Infection w a s  quantified a s  descr ib ed  in figure 3.1 . The num ber o f infected  ce lls  in the  
Filipin-treated sa m p le s  w a s  e x p r e ssed  a s  a p ercen ta g e  o f th e num ber o f infected  c e lls  in m ock-treated sa m p le s . T he m ean  and  
±SD  o f  three ob serv a tio n s is show n
3.2.3 Inhibition of Endosomal Acidification
The experiments described above strongly suggest that FMDV utilises the clathrin- 
dependent endocytosis pathway but not lipid-raft dependent endocytosis pathways to 
enter and infect cells. Having been taken up by clathrin-dependent endocytosis, 
ligands such as tiansferrin are delivered to early endosomes (sometimes termed 
“sorting” endosomes pH~6.0). We next sought to establish whether FMDV requires 
the low pH within endosomes in order to successfully infect SW480-p6 cells. As 
described in the intioduction (section 3.1), because of the extreme acid lability of the 
FMDV capsid it has long been thought that FMDV may require such a low pH step 
during entiy in order to infect cells successfully. This theory has been in part tested 
previously using the ionophore monensin (18) and the macrolide antibiotic 
Concanamycin A (204). Concanamycin A is a potent and highly specific inhibitor of 
the vacuolar H+-ATPase, and hence raises the pH within endosomal compartments, 
including early endosomes. However, the previous experiments (18, 204) were 
carried out at a high m.o.i, which can cause infection to proceed via endocytic 
pathways not usually utilised by the virus (304). In addition, these studies did not 
establish whether the inhibitory effects of these reagents could be attributed to a rise 
in the pH within these compartments, or to non-specific effects of the reagents. We 
therefore decided to investigate the effect of concanamycin A on FMDV infection 
more rigorously.
To investigate whether FMDV infection requires the low pH within endosomes, we 
investigated the effect of Concanamycin A on infection of SW480-p6 cells by FMDV 
sti'ain 01Kcad2. Cells were pre-treated with Concanamycin A for 0.5h prior to the 
Ih incubation with virus in the presence of drug (see methods). Infection was
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determined using the ELIspot infection assay at low m.o.i (-0.3). Figure 3.12 shows 
the results of three independent experiments. FMDV infection was inhibited by 
Concanamycin A in a dose-dependent manner in all experiments. At Ipm and lOOnM 
Concanamycin A drastically reduced infection in all three experiments. At these 
concentrations, infection was inhibited by between 83 and 97% relative to mock 
tieated cells. The effect of lOnM concanamycin A was variable between experiments 
ranging from a 5-75% inhibition. This suggests that a concentration of lOnM may be 
close to the Ki for the drug under the conditions used in the assay, which would mean 
that slight variations in the conditions due to experimental error could make a large 
differenced to the level of inhibition observed. When IjxM Concanamycin A (the 
highest concenti'ation of drug used) was added for a period of 1.5h following the 
removal of the virus innoculum (RC in figure 3.12), no inhibition of infection was 
observed. This indicates that the drug is inhibiting an early stage in infection of cells 
by (i.e. cell entry) rather than intracellular virus replication. The data in figure 3,12 
show that at a low multiplicity of infection, successful infection SW480-P6 cells by 
FMDV requires the low pH within an endosomal compartment.
In order to verify that Concanamycin A raised the pH within the acidic endosomal 
compartments of SW480-P6 cells, experiments were performed using the vital 
fluorescent dye Acridine Orange. Acridine orange is a membrane peniieant weak 
base whose spectial properties vary according to its local concentration. At relatively 
low concentrations, the dye emits fluorescence in the gi'een region of the spectrum 
upon excitation at 488nm. The dye becomes tiapped within the acidic endosomal 
compartments of live cells due to protonation, leading to an increase in the local 
concentration of dye within these compartments. At these elevated concentrations 
fluorescence emission is observed in the red region of the spectium as well as the
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green region. Hence acridine orange has frequently been used to stain acidic 
endosomes within live cells (6, 7, 340), since these compartments show up as 
red/orange coloured vesicular stmctures in fluorescence images.
SW480-P6 cells were either tieated with lOOnM Concanamycin A or with an 
equivalent concentration of DMSO (mock treatment), and stained with Acridine 
Orange. Figure 3.13 panel A shows SW480-p6 cells which have undergone mock- 
tieatment. The acidic endosomal compartments show up as the orange/red vesicular 
structures seen in this image. Panel B shows cells which have undergone treatment 
with lOOnM Concanamycin A prior to Acridine Orange staining. This concentiation 
of concanamycin A was used since it is the lowest concentration which inhibited virus 
infection by >95% (see figure 3,12). As is clearly evident, there are no orange/red 
labelled acidic vesicles to be seen following tieatment with Concanamycin A, 
indicating that at this concentration this reagent has raised endosomal pH.
One possible consequence of raising the pH within endosomes is to inhibit the 
recycling of internalised cell surface receptors back to the plasma membrane, since a 
low pH step is often required to trigger separation of a receptor and its cargo. If this 
were the case, the inhibitory effect of Concanamycin A on FMDV infection could 
result from depletion of the viral receptor, avp6, from the cell surface rather than as a 
direct consequence of the inhibition of endosomal acidification. In order to eliminate 
this possibility, we used FACS to investigate the level of avp6 expression and virus 
binding at the cell surface following treatment of cells with lOOnM Concanamycin A 
or an equivalent concentration of DMSO (mock tieatment). Figure 3.14 shows the 
results of two such experiments. Panel A shows that treatment with Concanamycin A 
does not result in a reduction in the level of avp6 expressed at the cell surface. Panel 
B depicts representative histograms taken fr om experiment 2. The level of surface
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avp6 expression on concanamycin A treated cells is represented by the black 
histogram, the equivalent data for mock treated cells by the white histogiam, and the 
level of background fluorescence (measured by omission of the primary antibody) by 
the gi*ey histogram. In agreement with this, panel C shows that the level of virus 
binding in both experiments at the cell surface is not altered by ti eatment with 
Concanamycin A. Panel D depicts representative histograms from experiment 2. The 
level of virus binding at surface of concanamycin A treated cells is represented by the 
black histogram, the equivalent data for mock tieated cells by the white histogiam, 
and the level ofbackgi ound fluorescence (measured in the absence of virus) by the 
grey histogram. Since avp6 expression and virus binding at the cell surface are not 
altered by Concanamycin A tieatment, the notion that the inhibition of FMDV 
infection by this agent is due to depletion of its receptor from the cell surface can be 
discounted.
The experiments described in this section show that Concanamycin A (i) raises 
endosomal pH, (ii) potently inhibits FMDV infection of SW480-P6 cells (iii) does not 
inhibit intracellular virus replication, and (iv) does not reduce virus binding or avp6 
expression at the cell surface. Taken together, these data show that FMDV infection 
requires exposure to the low pH within endosomes for successful infection. The 
block to infection following treatment with Concanamycin A lies after binding of 
virus to the cell surface, but prior to translation and replication of the viral RNA. 
Given the acid lability of the vims capsid, it is likely that the acid pH within 
endosomes is required for uncoating and/or fransfer of the viral genome in to the 
cytosol. However, it is also possible that Concanamycin A blocks infection by 
altering inti acellular ti affrcking of virus particles following virus binding. This issue 
is addressed in section 4.3.
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F igu re  3 .1 2 . C oncanam ycin  A inhibits FMDV infection.
SW 480-ocvp6 ce lls  w ere  treated with C oncanam ycin  A for 0 .5h  and infected  with FMDV (m .o.i -0 .3 )  for Ih  in the p r e se n c e  o f the  
drug. T he m ock c e lls  w ere  treated with DM SO. Following rem oval o f virus, s a m p le s  w ere  incubated for a  further 4h  at 37°C , and  
then  fixed with 4% paraform aldehyde. D ata poin ts m arked RC rep resen t sa m p le s  treated with Ipg/m l C oncanam ycin  A for 4h  
following rem oval o f th e virus inoculum . Infection w a s  quantified a s  descr ib ed  in figure 3 .1 . T he num ber o f infected  c e lls  in the  
drug-treated sa m p le s  w a s  e x p r essed  a s  a p ercen ta g e  o f the num ber o f infected  c e lls  in m ock-treated sa m p les . T hree ind ep en dent 
exp erim en ts are sh ow n , and  ea ch  data point rep resen ts  th e  m ean  and ±SD  o f three ob servation s.
Mock (DMSO) 
Treated
lOOnM
Concanamycin A
F ig u re  3 .1 3 . C oncanam ycin -A  ra ises  th e intra-en dosom al pH. S W 4 8 0 -a v p 6  cells, prepared on coverslip s  w ere treated with 
either concanam ycin-A  (lOOnM) or DM SO (m ock-treated) for 0 .5h  at 37°C . T he ce lls  w ere then incub ated  with acridine 
oran ge  and visualized  on th e con foca l m icroscop e . F lu o resc en ce  em issio n  w a s  co llected  for green  and red reg ions o f the  
spectrum . T he figure s h o w s  an overlay o f th e green  and red flu o rescen ce . P an el A) sh o w s  th e intracellular acid ic  v e s ic le s  
(orange labelling) in the m ock-treated ce lls . This staining w a s  com p letely  ab olish ed  in the con can am ycin -A  treated cells  
(p anel B) show ing that intra-endosom al pH had b een  raised. B ars = 10pm
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F igu re  3 .1 4 . C oncanam ycin  A treatm ent d o e s  not red u ce  ctvpo ex p r ess io n  or virus binding at th e su r fa ce  o f SW 480-P 6  cells.
S W 480-P 6  c e lls  w ere  pre-treated with DM SO (M ock) or 100 nM C oncanam ycin  A for 0 .5h  and then prepared for flow cytom etry. 
S u rface  Integrin ex p ress io n  w a s  d e tec ted  using Mab 10D 5 and cell-bou nd virus with Mab B2, follow ed by R-phycoerythrin  
conju gated  seco n d a ry  antibod ies. B ackground f lu o re scen ce  w a s  determ ined by omitting the primary antitxidy (ctvps exp ress ion )  
or virus (virus binding).
P a n e ls  A  a n d  C. S h ow n  are the level o f a v p s  ex p ress io n  (P an el A) and virus binding (P anel C) on  th e su rfa ce  o f mock (DM SO) 
treated and C oncanam ycin  A treated cells . D ata are e x p r es s ed  a s  a p ercen ta g e  o f the MFI (m ean  f lu o rescen ce  intensity) v a lu es  
obtained for m ock treated cells . S h ow n  are th e m ean  ±SD  o f three ob serv a tio n s for two ind ep en dent experim ents; E xperim ent 1 
(op en  bars) and E xperim ent 2 (sh a d ed  bars).
P a n e ls  B  a n d  D. Sh ow n  are rep resen tative h istogram s for su rface  ex p ress io n  of avpS (P anel B) and virus binding (P anel D) on  
S W 480-P 6  cells; Virus binding or integrin ex p ress io n  on  th e  Mock T reated C ells is show n a s  an o p e n  h istogram s. Virus binding or 
integrin ex p ress io n  C oncanam ycin  A treated ce lls  is show n a s  a black histogram . B ackground F lu o resc en ce  is sh ow n  a s  a grey  
histogram s.
3.2.4 Inhibition of PI 3-kinases
PI 3-kinases are a gi'oup of enzymes that phosphorylate the membrane lipid 
phosphatidyl inositol and its phosphorylated derivatives at the 3-position of the 
inositol head group. Wortmannin is a specific inhibitor of human class I, II |3 and y, 
and III PI 3-kinases at nanomolar concentrations (50-200nM). However, Class II 
C2c( PI 3-kinases are less sensitive to Wortmannin, since complete inhibition is only 
achieved at a concentration of lOmM (Ic50 = 420 nM) compared to a value of lOOnM 
for the type l a  enzyme (68). At such high concentiations wortmannin is no longer a 
specific inhibitor since the PI 4-kinases, PI-4Ka and PI-4Kp are inhibited by 
Wortmannin concentiations of 150 nM and above(68).
Figure 3.15 shows the effects of Wortmannin on infection of SW480-P6 cells by 
FMDV 01Kcad2. The drug concentrations used were specific for PI 3-kinases (25- 
lOOnM) and do not inhibit PI 4-kinases. Infection by FMDV was not inhibited at any 
of these concentiations suggesting that the activities of PI 3-kinases (except Class 
C2a which is less sensitive to wortmannin) are not essential for entry to and infection 
of SW480-p6 cells. As described in section 3.1, clathrin dependent delivery to early 
endosomes is not wortmannin sensitive, whereas ti'affic from early endosomes to 
either late- or recycling-endosomes is wortmannin sensitive for most cell types. The 
inability of wortmannin to inhibit infection implies that ti'affic of virus beyond early 
endosomes to late- or recycling-endosomes is not required for successful infection of 
SW480-P6 cells.
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F igu re 3 .1 5 . W ortmannin d o e s  not inhibit FMDV infection.
SW 480-ocvp6 c e lls  w ere treated with W ortmannin for 0 .5h  and infected  with FMDV (m .o.i - 0 .3 )  for Ih  in the p re se n c e  o f the drug. 
T he m ock c e lls  w ere  treated with DM SO. Following rem oval o f virus, s a m p le s  w ere incubated for a further 4h at 37°C  in the  
p rese n c e  o f drug, and then fixed with 4% paraform aldehyde. D ata poin ts marked RC rep resen t sa m p le s  treated with 2 0 0  nM 
W ortmannin for 4h following rem oval o f the virus inoculum . Infection w a s  quantified a s  descr ib ed  in figure 3 .1 . The num ber o f  
in fected  c e lls  in the W ortm annin-treated s a m p le s  w a s  e x p r e s s e d  a s  a p ercen ta g e  o f the num ber o f infected  c e lls  in m ock-treated  
sa m p le s . T he m ean  and ±SD  o f three ob serv a tio n s is sh ow n
3.2.5 Disruption of the Cytoskeieton
3.2.5.1 Microtubule Disruption by Nocodazole
As described in section 3.1, nocodazole causes the complete disassembly of the 
microtubule network. This does not inhibit clathrin-dependent delivery of receptors 
and ligands to early endosomes, or their recycling back to the cell surface, but does 
inhibit ti'affic fi'om early endosomes to late endosomes.
To investigate whether FMDV infection requires an intact microtubule network, we 
investigated the effect of nocodazole on infection of SW480-p6 cells by FMDV strain 
01Kcad2. The cells were pre-treated for 0.5h with Nocodazole, or an equivalent 
concenti ation of DMSO (mock treatment), prior to the addition of vims. Infection 
was measured using the elispot infection assay. The drug, or DMSO, was present 
throughout the remainder of the assay up until paraformaldehyde fixation. The results 
of two identical experiments are shown in figure 3.16. It is clear that neither 20|xM 
nor 40p.M nocodazole has any inhibitory effect on infection of SW480-P6 cells by 
FMDV. In order to verify that the treatments used in these experiments had disrupted 
the microtubule network, cells on coverslips were tr eated with 40mM Nocodazole or 
DMSO (mock tieatment) for 30 minutes, before being fixed with parafonnaldehyde. 
Microtubules were then fluorescently labelled using a monoclonal antibody directed 
against p-tubulin, and an Alexa-488 conjugated goat anti mouse IgGl antibody. The 
results of these experiments are shown in figure 3.17. A gi'oup of mock tieated cells 
is shown in panel A, and a group of nocodazole treated cells in panel B, p-tubulin is 
shown in gieen. The mock treated cells contain thin filamentous structures which 
represent intact microtubules. The nocodazole treated cells show only a diffuse gi*een 
fluorescence throughout the cytoplasm which represents depolymerised tubulin
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subunits. This shows that tr eatment of SW480-p6 cells witlr 40p.M nocodazole does 
cause disassembly of the microtubule network.
At a concentration of 40|xM nocodazole causes disassembly of the microtubule 
network as observed by immunofluorescence, but does not inliibit infection as 
measured using the elispot infection assay. Since nocodazole was present at all stages 
of the infection assay, this indicates that an intact microtubule network is not essential 
for any step of the infection cycle, be that enti y of virus particles, translation and 
replication of the viral RNA, or particle assembly.
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F igu re  3 .1 6 . N o co d a zo le  d o e s  not inhibit FMDV infection.
S W 4 8 0 -a v p 6  c e lls  w ere treated  with N o co d a zo le  for 0 .5 h  and in fected  with FMDV (m .o.i - 0 .3 )  for Ih  in the p r e se n c e  o f the drug. 
T he m ock c e lls  w ere treated with DM SO. Following rem oval o f virus, sa m p le s  w ere incubated for a further 4h  at 37°C  in the  
p r e se n c e  o f drug, and th en  fixed with 4% paraform aldehyde. Infection w a s  quantified a s  d escr ib ed  in figure 3 .1 . T he num ber o f 
in fected  c e lls  in th e N ocod azo le-trea ted  s a m p le s  w a s  e x p r es s ed  a s  a p ercen tage  o f  the num ber o f infected  ce lls  in m ock-treated  
sa m p le s . Two in d ep en d en t exp erim en ts are sh ow n , and e a c h  data point rep resen ts  the m ean  and ±S D  o f three ob serva tion s.
Mock Treated 40pm Nocadazole
F ig u re  3 .1 7 . N o co d a z o le  disrupts th e m icrotubule network
S W 4 8 0 -a v p 6  c e lls  w ere  treated with 40pM  N o co d a zo le  for 0 .5h  (P an el B) or m ock treated with an equ iva len t concentration of 
DM SO (P an el A). T he cells  w ere  then fixed with 4% paraform aldehyde. T he m icrotubule network (green ) w a s  labelled by 
im m u n oflu orescen ce  m icroscopy using a m on oclon al antibody raised  a ga in st a-tubulin (c lon e  DM1 a; S igm a) and an A lexa -488  
conju gated  g o a t an ti-m ou se  seco n d a ry  antibody. N uclei w ere sta in ed  with DAPI and are sh ow n  a s  blue. Bars = 10pm . In 
n o co d a zo le  treated  c e lls  (P anel B) tubulin labelling is diffuse, indicating that th e filam entous m icrotubules v isible in m ock treated  
ce lls  (P an el A) h ave  b een  disrupted by th e  drug treatm ent.
3.2,5.2 Actin Disruption by Cytochalasin D
Actin has been shown to play a role in the uptake of ligands by a number of 
endocytic pathways including lipid raft and caveolae dependent endocytosis (241, 
249), and macropinocytosis. However, the actin cytoskeieton is not thought to play 
an obligatory role in uptake of ligands via clathrin-dependent endocytosis in all cell 
types(87). The fungal metabolite Cytochalasin D has been shown to disrupt the actin 
cytoskeieton by binding the growing barbed end of microfilaments at which net 
polymerisation occurs, thus preventing the addition of actin monomers(39, 55). This 
agent is therefore a usefiil tool to study the role of the actin cytoskeieton in cellular 
processes.
Given the involvement of the actin cytoskeieton in certain endocytic uptake 
pathways, we sought to investigate the effect o f the disruption of microfilaments by 
Cytochalasain D on infection of SW480-P6 cells by FMDV. Cells were either mock 
treated or pre-treated with Cytochalasin D or for Ih prior to the addition of virus at an 
m.o.i~0.3. The drug remained present throughout and infection was measured using 
the elispot infection assay. Figure 3.18 shows the results of two independent 
experiments investigating the effect of Cytochalasin D on infection of SW480-p6 
cells by FMDV. Taken together, these two experiments show that infection is 
enhanced by Cytochalasin D concentrations ranging fiom 2.5 to 40jiM. The extent of 
this enhancement is variable, ranging fiom 1.5 to 3-fold. Infection of cells heated 
with drug after the addition of virus was also enhanced, although less so compared 
with when the diug was added prior to infection. In experiment 2, virus particles left 
at the cell surface following removal of the virus inoculum were neutralised using an 
acid cell wash step. This treatment appeared to make no difference to the results
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obtained (compare experiments 1 and 2). This obseiwation suggests that the 
enhancement in infection observed in the replication controls cannot simply be 
ascribed to enhancement of the uptake of vims remaining at the cell surface following 
removal of the vims inoculum. This indicates that Cytochalasin D may enhance both 
the enti'y and replication stages of infection of SW480-P6 cells by FMDV.
The enhancement of infection by Cytochalasin D is not consistent with uptake of 
FMDV via lipid rafts, caveolae, or macropinocytosis, since uptake of ligands via these 
pathways is thought to be dependent on the actin cytoskeieton. Clathrin-dependent 
endocytosis however is not inhibited by Cytochalasin D in all cell types, meaning that 
this data does not preclude against uptake of virus by this pathway.
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F igu re  3.18. C ytochalasin  D e n h a n c e s  FMDV infection.
S W 4 8 0 -a v p 6  c e lls  w ere  treated with C ytochalasin  D for 1 h and in fected  with FMDV (m .o.i - 0 .3 )  for Ih in th e p r e se n c e  o f the drug. 
The m ock c e lls  w ere  treated with DM SO. S a m p le s  in experim ent 2  (but not experim ent 1) w ere  treated for 2 m inutes with acid  cell 
w a sh  to d estroy  any  virus particles left at th e cell su rface. Follow ing rem oval o f virus, sa m p le s  w ere  incubated  for a further 4h  at 
37°C  in the p r e se n c e  o f drug, and then fixed with 4% paraform aldehyde. Data poin ts m arked RC rep resen t sa m p le s  treated with 
the indicated concentration  o f C ytochalasin  D for 4h  following rem oval o f th e  virus inoculum . Infection w a s  quantified a s  d escr ib ed  
in figure 3 .1 . The num ber of in fected  c e lls  in th e C ytochalasin  D -treated sa m p le s  w a s  e x p r e s s e d  a s  a p e rcen ta g e  o f  the num ber o f 
in fected  ce lls  in m ock-treated sa m p les . Two in d ep en d en t exp erim en ts  are sh ow n , and ea ch  data point r ep resen ts  th e m ean  and  
±SD  of three ob serva tion s.
3.3 Summary and Discussion
In this chapter experiments were caiTied out using inhibitors of specific endocytosis 
pathways in order to determine the cellular uptake route of FMDV. The experiments 
described in section 3.2.1 stiongly suggest that infection of SW480-(36 cells by 
FMDV strain 01Kcad2 requires clathrin-dependent endocytosis. Infection was 
blocked by pre-treatment of SW480-p6 cells with hypertonic concentiations of 
sucrose, a tieatment that is known to block clathrin-dependent endocytosis in a 
number of cell lines(121). Using SW480-p6 cells this ti eatment was shown to block 
the uptake of fluorescently labelled transferrin as observed by confocal microscopy, 
confirming that clathrin-dependent endocytosis had been inhibited. The observed 
block to infection was confirmed to be at the level of virus enti y since pre-treatment 
with hypertonic sucrose also blocked virus uptake. The role of clathrin-dependent 
endocytosis in infection was confirmed by showing that overexpression of the C- 
terminal fiagment of API 80 (AP180C), which acts as a specific dominant negative 
inhibitor of clathrin-dependent endocytosis(82, 342), inhibited FMDV infection.
Following uptake by clathrin-mediated endocytosis, receptors and their ligands are 
delivered to the acidic early endosome. The experiments outlined in section 3.2.3 
investigate whether the early stages of infection of SW480-p6 cells by FMDV 
requires the prevailing low pH within these compartments. Treatment with 
concanamycin A, an agent that raises endosomal pH by blocking the activity of the 
vacuolar H^-ATPase, inhibited infection by up to 95%, indicating that infection 
requires a low pH step. The inhibitory effect of the drug was exerted at an early stage 
of infection since addition of dr ug immediately following removal of the vims 
inoculum had virtually no effect on infection, indicating that intracellular virus
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replication was not altered. The ability of concanamycin A to raise the pH within 
acidic endosomal compar tments was confirmed using Acridine Orange, a dye which 
accumulates in low pH compartments and alters its spectral properties as a result.
Raising endosomal pH can inhibit receptor recycling, resulting in the depletion of 
these molecules at the cell surface. It is therefore possible that the inhibitory effect of 
concanamycin A could have resulted from reduced virus binding to the cell as a 
consequence of depletion of the 0tvp6 integiin receptor fr om the cell surface. This 
possibility was ruled out however since treatment with concanamycin A did not 
reduce either virus binding or the level of avp6 expression at the cell surface, as 
measured by flow cytometiy.
Bafilomycin A1 (a compound related to concanamycin A that also inhibits the 
vacuolar H+-ATPase) has been shown to interfere with vesicular fransport and to 
prevent the tiansport of HRV-2 from early to late endosomes (21). It is therefore 
possible that the inhibition of FMDV infection by concanamycin A is a result of the 
inhibition of intiacellular trafficking events rather than the elevation of endosomal 
pH. This issue was investigated by immunofluorescence microscopy in section 4.3.1. 
These experiments showed that delivery of FMDV to compartments positive for 
markers of early and recycling endosomes was not inhibited in concanamycin A 
freated cells. It is therefore unlikely that the inhibition of FMDV infection by 
concanamycin A is due to the inhibition of virus tiaffrcking. To summarise, 
concanamycin A raises endosomal pH and inhibits infection, but does not alter 
expression of the integiin avP6, virus binding, delivery of virus to early and recycling 
endosomes or intracellular replication of the virus. The low pH within endosomes is 
therefore required for a step prior to the initiation of intracellular' virus replication but 
post attachment of the virus to the cell surface.
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Clathrin-dependent endocytosis is one of a number of distinct endocytic pathways 
that are exploited by viruses in order to gain entry to cells (see section 1.5.1). A 
number of viruses have been shown to be taken up by endocytic pathways that depend 
on cholesterol rich lipid rafts (see section 1.5.2). Lipid-raft dependent endocytosis 
pathways are sensitive to the action of dmgs which bind cholesterol. The experiments 
shown in section 3.2.2 strongly suggest that FMDV does not require lipid raft 
dependent endocytosis pathways in order to infect SW480-p6 cells. Infection was not 
inhibited by three reagents (Methyl-P-Cyclodextrin, Filipin, Nystatin) which inhibit 
lipid raft dependent endocytic uptake pathways. Methyl-p-cyclodextrin treatment was 
shown to block uptake of Cholera Toxin B (a mar ker for lipid raft dependent uptake) 
but not transferrin (a marker for clathrin-dependent uptake), confirming the specificity 
of the treatment for raft-dependent endocytosis.
Nocodazole and wortmannin have been used to investigate trafficking of ligands 
fi'om early endosomes to late- and recycling-endosomes. Nocodazole depolymerises 
microtubules and blocks transport from early to late endosomes in BHK(I07) and 
MDCK (36) cells. Nocodazole treatment of SW480-p6 cells resulted in the 
depolymerisation of microtubules, as judged by immunofluorescence microscopy, but 
did not block infection by FMDV. These observations indicate that FMDV does not 
require a functional microtubule network and implies that transport from early to late 
endosomes is not needed for FMDV infection of SW480-P6 cells. The PI-3 kinase 
inhibitor wortmannin does not block clathrin dependent delivery of ligands such as 
transferrin to early endosomes(172, 188, 293, 298), but does interfere with transport 
beyond early endosomes to late- and recycling-endosomal compartments (152, 188, 
293, 298). Like nocodazole treatment, wortmannin did not inhibit infection of
111
SW480-p6 cells by FMDV, indicating that tiansport beyond early endosomes to late 
or recycling endosomes is not essential for infection.
As described above, experiments using nocodazole indicate that the microtubule 
network is not required for infection of SW480-p6 cells by FMDV at any stage. The 
role of the actin cytoskeleton was also investigated using the drug Cytochalasin D 
which dismpts the actin cytoskeleton by binding the barbed growing end of 
microfilaments (39, 55). The experiments outlined in section 3.2.5.2 show that 
disruption of the actin cytoskeleton using cytochalasin D enhances infection. The 
actin cytoskeleton has been shown to play a role in caveolae dependent endocytic 
uptake (241, 252), and the equivalent pathway in cells which do not express caveolin- 
1 (114). Macropinocytosis is also dependent on the actin cytoskeleton. The 
enhancement of infection by Cytochalasin D is therefore inconsistent with uptake of 
virus by these pathways. Clathiin-dependent endocytosis however is not inhibited by 
Cytochalasin D in all cell types (87), meaning that this data does not preclude uptake 
of virus by this pathway.
There ar e a number of possible explanations for the enhancement in infection seen 
following treatment with Cytochalasin D. The plasma membrane of cells is linked 
directly to an underlying actin-rich cytoskeleton (the cell cortex), so the actin 
cytoskeleton may act to regulate endocytic events. The virus receptor avP6 has been 
shown to localize to focal contacts in SW480-p6 cells when plated on Fibronectin(54, 
132) and associates with the actin cytoskeleton upon ligand binding. Association of 
the cytoplasmic domain of avp6 with the actin cytoskeleton may constrain the lateral 
mobility of the integiin in the cell membrane, thereby regulating it’s entry into 
endocytic vesicles. Disruption of the actin cytoskeleton by Cytochalasin D would 
remove this constraint, allowing avp6 and its ligand (the virus) to more readily
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migrate to sites of clathrin-coated pit formation, thereby possibly enhancing virus 
uptake and hence infection. Alternatively, actin may act as a molecular “fence”, 
acting as a barrier to the formation of endocytic vesicles. Examination of the plasma 
membrane by quick-freeze deep-etch techniques reveals that few of the actin 
filaments lying in the plane of the membrane are observed in the immediate vicinity 
of clathrin-coated pits(87). Dismption of cortical actin filaments by Cytochalasin D 
may clear aieas of the plasma membrane of this “molecular fence” allowing endocytic 
vesicles to form more readily at the cell surface. This would increase the rate of 
uptake of FMDV and hence enhance infection as a result. However, Cytochalasin D 
also appeared to have a small stimulatory effect on the cytoplasmic replication of 
FMDV. Infection of BHK cells by FMDV has been shown to cause accumulation of 
cytoplasmic organelles and viral proteins in a region to one side of the cell 
nucleus(208). It is possible that dismption of the actin cytoskeleton by Cytochalasin 
D aids the reaiTangements of the cell interior observed in FMDV infected cells, thus 
enhancing infection.
In suramaiy, the data presented in this chapter show that infection of SW480-P6 
cells by FMDV requires clathrin-dependent delivery to early endosomes, and the low 
pH within this compartment, but not lipid rafts or lipid raft dependent endocytosis 
pathways. The data presented suggest that tiansport beyond early endosomes to late 
or recycling endosomes is not essential for infection.
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Chapter Four: Investigation of the Entry Pathways 
Utilised by FMDV by Immunofluorescence
4.1 Introduction
In the previous chapter, the effect of inhibitors of endocytosis on infection of SW480- 
p6 cells by FMDV (01Kcad2) was investigated. These studies have shown that 
avp6-mediated infection of SW80-p6 cells is dependent on clathrin-dependent 
endocytosis and active endosomal acidification, but not on intact lipid rafts and 
suggest that FMDV most likely infects its host cell following virus uptake into early- 
or recycling-endosomes. These experiments were can'ied out using a low multiplicity 
of infecting virus per cell to limit the possibility of virus uptake (and hence infection) 
proceeding via endocytic pathways that are not normally used by FMDV.
To verify that on entiy, FMDV is taken up in to endosomes, the intracellular 
trafficking of vims in SW480-p6 cells at early times post-entry was investigated using 
indirect immunofluorescence confocal microscopy (Chapter 4). The vims used for 
these studies was FMDV 01Kcad2. Virus was purified by sucrose gradient 
sedimentation. To visualise the virus during entry the amount of virus used in the 
experiments described in this chapter was necessarily high. Virus, and/or 
fluorescently labelled ligands were allowed to bind to the cell siuface at 4°C, (a 
temperature which does not allow endocytosis to occur), excess unbound vims (or 
ligand) was removed by washing, and virus internalisation initiated by a shift to 37®C 
for a defined period of time. The cells were then fixed with paraformaldehyde and 
perrneabilised. Virus, and/or markers of particular cellular compartments were 
labelled using specific monoclonal or polyclonal primary antibodies, followed by 
Alexa Fluor conjugated secondary antibodies (see section 2.6 for details). The
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monoclonal antibody D9 was used to label vims. This antibody recognises a linear 
epitope within the GH loop of VPl and so would be expected to recognise dissociated 
pentamers as well as intact virus particles (196).
4.2 Uptake of Virus by SW480-P6 cells
4.2.1 Time Course of Virus Uptake
Figure 4.1 shows a time course of virus uptake by SW480-p6 cells. The times 
indicated on the figure are the time elapsed following the initiation of internalisation 
by the shift to 37°C, following a virus pre-binding step at 4°C. The virus adopts a 
punctate pattern at the cell surface, presumably reflecting the disti ibution of its 
receptor avp6. At 37°C virus is rapidly taken up into the cell. After 5 minutes (Panel 
A) virus has already begun to enter the cell and was observed in relatively small 
puncta deep of the cell membrane. By 10 and 15 minutes (Panels B and C) the 
majority of virus has entered the cell and is located in peripheral vesicle-like 
stinctures. After 30 minutes (Panel D), viral proteins have accumulated in larger 
structures in the perinuclear region. In the experiments described below, vims was 
allowed to enter the cell for defined periods of time as above, but the cells were dual 
labelled for virus and markers of particular cellular compartments.
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A) 5 minutes B) 10 minutes
C) 15 minutes C) 30 minutes
F ig u re  4 .1 . FMDV entry into S W 480-P 6  cells . S W 4 8 0 -p 6  cells, prepared on coverslip s  w ere  incubated  with FMDV strain 
0 1 K c a d 2  (5pg/m l) at 4°C  for 4 5  m ins, w a sh ed  to rem ove e x c e s s  unbound virus and shifted to 37°C . After incubation at 
37°C  for (A) 5, (B) 10, (C) 15, and (D) 30m in, internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Virus 
that had en tered  th e c e lls  w a s  d e tec ted  using th e con foca l m icroscop e . Following perm eabilisation with 0.1%  Triton, virus 
w a s  d e tec ted  using the m on oclon al antibody D 9 (m o u se  lgG 2A -5pg/m l), followed by an A lexa fluor conju gated  isotype  
sp ec ific  goat-anti m o u se  seco n d a ry  antibody. S h ow n  is iabelling o f FMDV (red). DAPI sta ined  nuclei are show n a s  blue.
4.2.2 Early Endosomal Antigen-1
Early Endosomal Antigen-1 (EEA-1) is a marker for early endosomes (215), Figures 
4,2-4.5 show colocalisation of FMDV (labelled gi een) and EEA-1 (labelled red). On 
the figure, colocalisation of virus with EEA-1 does not always result in bright yellow 
labelling since the green and red signals can be of variable intensity. At 5 minutes 
(figure 4.2), intracellular virus can be seen to colocalise with peripheral EEA-1 
positive early endosomes, although most virus remains on the cell surface. At 10 
minutes (figure 4.3) a greater amount of virus has entered the cells and the extent of 
virus colocalisation with EEA-1 is gieater than seen at 5 minutes. At 15 minutes 
(figure 4.4) virus and EEA-1 were also colocalised with one another indicating that 
virus is present in early endosomes up to 15 minutes post internalisation. By 30 
minutes (figure 4.5), the labelling for virus and EEA-1 appeared close by one another, 
but extensive colocalisation was not observed. This indicates that the virus has either 
been delivered to a different compartment at this time, or has excluded marker 
proteins. These data are consistent with the rapid delivery of vims to early 
endosomes The detection of virus in EEA-1 positive early endosomes is consistent 
with the inhibition of infection by treatments that inhibit clathrin-dependent 
endocytosis and endosomal acidification (see sections 3.2.1 and 3.2.2 respectively)
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A) EEA-1 D) EEA-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 . Dual labelling o f S W 480-P 6  c e lls  for early e n d o s o m e s  (EEA-1) and FMDV at 5  m in utes after initiation o f virus 
internalisation. S W 480-P 6  cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1  K cad2 (Spg/m l) for 4 5  m inutes  
at 4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 5 m in utes incubation at 3 7 ”C 
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, EEA- 
1 and virus w ere  d e tec te d  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and D9 (m o u se  lgG 2A -5pg/m l) 
resp ectively , follow ed by A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  seco n d a ry  antibod ies. P a n e ls  A  a n d  D  
sh o w  EEA-1 labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  sh o w s  an overlay o f p a n e ls  A and B, P a n e l F  
s h o w s  an overlay  o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) EEA-1 D) EEA-1
B) Virus E) Virus
C).Overlay A+B F) Overlay D+E
F ig u re  4 .3 . Dual labelling o f S W 480-p 6  ce lls  for early e n d o s o m e s  (EEA-1) and FMDV at 10 m inutes after initiation o f virus 
internalisation. S W 480-P 6  cells, prepared on coverslip s  w ere incubated  with FMDV strain 0 1 K c a d 2  (Spg/m l) for 4 5  m in utes  
at 4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 3 7 ”C. Following 10  m in utes incubation at 3 7 X  
internalisation w a s  halted by fixation on ice using 4% paraform aldehyde. Following perm eabilisation with 0.1%  Triton, EEA- 
1 and virus w ere  d e tec ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and D9 (m o u se  lgG 2A -5pg/m l) 
respectively , followed by A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  seco n d a ry  antibod ies. P a n e ls  A  a n d  D 
sh o w  EEA-1 labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  sh o w s  an overlay o f p a n e ls  A and B, P a n e l F  
sh o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) EEA-1 D EEA-1
B) Virus E) Virus
C) Overlay A+B
F ig u re  4 .4 . Dual labelling o f SW 480-P 6  c e lls  for early e n d o s o m e s  (EEA-1 ) and FMDV at 15 m in utes after initiation o f virus 
internalisation. S W 480-p 6  cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in utes  
at 4°C . Virus internalisation w a s  initiated by shifting th e  tem perature to 3 7 “C. Following 15 m in utes incubation at 37°C  
internalisation w a s  halted by fixation on  ice  using 4%  paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, EEA- 
1 and virus w ere  d e tec ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  lgG 2A -5pg/m l)  
respectively , follow ed by A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  seco n d a ry  antibod ies. P a n e ls  A  a n d  D 
sh o w  EEA-1 labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  sh o w s  an overlay o f p a n e ls  A and B, P a n e l F  
sh o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A EEA-1 D EEA-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .5 . Dual labelling o f S W 480-p 6  ce lls  for early e n d o s o m e s  (EEA-1) and FMDV at 30  m in utes after initiation o f virus 
internalisation. S W 480-P 6  cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes  
at 4 “C. Virus internalisation w a s  initiated by shifting th e  tem perature to 37°C . Following 30  m in utes incubation at 37"C  
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, EEA- 
1 and virus w ere  d e te c ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and D9 (m o u se  lgG 2A -5pg/m l) 
respectively , follow ed by A lexa fluor conju gated  iso typ e  sp ec if ic  goat-anti m o u se  seco n d a ry  an tib od ies. P a n e ls  A  a n d  D 
sh o w  EEA-1 labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  
s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
4.2.3 Lysosomal Associated Membrane Protein-2
Following ti’ansit through early endosomes one possible destination for viral protein is 
late endosomes and lysosomes. A marker protein used for lysosomes (and to a lesser 
extent late endosomes) is Lysosomal Associated Membrane Protein-2 (LAMP-2) (48). 
A time course of virus uptake was undertaken as above, and cells labelled for virus 
(green) and LAMP-2 (red). The results of these experiments are shown in figures 4.6- 
4.9. Little or no colocalisation could be detected at 5 (figure 4.6), 10 (figure 4.7), 15 
(figure 4.8), or 30 (figure 4.9) minutes following the initiation of virus internalisation. 
This indicates that within the first 30 minutes of infection viral protein is not 
trafficked to lysosomes, and that the intracellular virus which was not colocalised 
with EEA-1 at 30 minutes (see Figure 4.5) is not present in lysosomes. These data are 
consistent with the lack of inhibition of infection of SW480-p6 cells by nocodazole 
and wortmannin (see sections 3.2.4 and 3.2.5.1), both of which are reported to inhibit 
tiansport from early- to late-endosomes and hence delivery to lysosomes. However, 
although virus was not detected in lysosomes, it is possible that the epitope recognised 
by the anti-virus monoclonal antibody is rapidly destroyed upon entry to lysosomes, 
hence resulting in no colocalisation being observed. However the antibody epitope 
recognised by mab D9 is linear (159, 335) making this less likely, and neither the 
intensity of virus labelling or the number of virus positive vesicles appeared to decline 
with time, indicating that lai'ge amounts of the epitope recognised by D9 are still 
present inside the cells at 30 minutes.
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A) LAMP-2 D LAMP-2
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .6 . Dual labelling o f S W 480-P 6  c e lls  for late e n d o s o m e s / ly s o s o m e s  (LAMP-2) and FMDV at 5  m in utes after 
initiation o f virus internalisation. SW 480-P 6  ce lls , prepared on coverslip s  w ere incubated with FMDV strain 0 1 K c a d 2  
(5pg/m l) for 4 5  m in utes at 4 “C. Virus internalisation w a s  initiated by shifting the tem perature to 37°C . Following 5  m inutes  
incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 
0.1%  Triton, LAMP-2 and virus w ere  d e tec te d  using m on oclon al an tib od ies H4B4 (m o u se  IgG I- 0 .25p g /m l) and D9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  seco n d a ry  antibodies. 
P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  s h o w s  an overlay o f p a n els  
A and B, P a n e l F  sh o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue.
A) LAMP-2 D LAMP-2
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .7 . Dual labelling o f S W 480-P 6  c e lls  for late e n d o s o m e s / ly s o s o m e s  (LAMP-2) and FMDV at 10 m in utes after 
initiation o f virus internalisation. S W 480-P 6  ce lls , prepared on coverslip s  w ere incubated with FMDV strain 0 1 K c a d 2  
(5pg/m l) for 4 5  m in utes at 4 “C. Virus internalisation w a s  initiated by shifting th e tem perature to 37"C. Following 10 m in utes  
incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation  with 
0.1%  Triton, LAMP-2 and virus w ere  d e tec ted  using m on oclon al an tib od ies H4B4 (m o u se  IgG I- 0 .25p g /m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor con ju gated  iso type sp ec ific  goat-anti m o u se  seco n d a ry  an tib od ies  
P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  s h o w s  an overlay o f p a n els  
A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A LAMP-2 D) LAMP-2
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .8 . Dual labelling o f S W 480-P 6  c e lls  for late e n d o s o m e s / ly so s o m e s  (LAMP-2) and FMDV at 15 m in utes after 
initiation o f virus internalisation SW 480-P 6  ce lls , prepared on coverslip s  w ere incubated with FMDV strain 0 1 K ca d 2  
(5pg/m l) for 4 5  m in utes at 4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 15 m inutes  
incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 
0.1%  Triton, LAMP-2 and virus w ere  d e te c ted  using m on oclon al an tib od ies H 4B 4 (m o u se  IgGI - 0 .25p g /m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  antibod ies. 
P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green). P a n e l C  s h o w s  an overlay o f p a n els  
A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue.
A) LAMP-2 D) LAMP-2
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .9 . Dual labelling o f S W 480-P 6  c e lls  for late e n d o s o m e s / ly s o s o m e s  (LAMP-2) and FMDV at 30  m in utes after 
initiation o f virus internalisation. SW 480-P 6  ce lls , prepared on coverslip s  w ere incubated with FMDV strain 0 1 K c a d 2  
(5pg/m l) for 4 5  m in utes at 4 “C. Virus internalisation w a s  initiated by shifting the tem perature to 37"C. Following 3 0  m in utes  
incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation  with 
0.1%  Triton, LAMP-2 and virus w ere  d e tec te d  using m on oclon al an tib od ies H4B4 (m o u se  IgG I- 0 .25p g /m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  seco n d a ry  antibod ies. 
P a n e ls  A  a n d  D sh o w  LAMP-2 labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  s h o w s  an overlay o f p a n els  
A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue.
4.2.4 Transferrin Receptor
Upon leaving early endosomes, another possible fate of internalised ligands and 
receptors is to pass to recycling endosomes which are usually located in the 
perinuclear region of the cell. Transferrin and the transferrin receptor are both 
delivered to early endosomes via clathrin-dependent endocytosis. Subsequently, both 
receptor and ligand are delivered back to the cell surface via recycling endosomes. 
The Transferrin receptor is therefore used as a marker for early- and recycling- 
endosomes. A timecourse of vims uptake was undertaken, with cells labelled for 
virus (green) and Transferrin Receptor (red). The results of these experiments are 
shown in figures 4.10-4.13. Virus was seen to partially colocalises with the 
ti'ansfeiTin receptor at 5 and 10 minutes post internalisation (figures 4.10 and 4.11 
respectively). More extensive colocalisation was observed at 15 minutes (figure 4.12). 
This is consistent with the traffic of vims from the cell surface to early- and then 
recycling-endosomes. By 30 minutes however (figure 4.13), the level of 
colocalisation of vims with the transferrin receptor is reduced compared to that seen 
at 15 minutes. This indicates that virus passes fiom early- and recycling- endosomes 
to an unidentified compartment by 30 minutes, or has caused the exclusion of marker 
proteins from the recycling endosomes.
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A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 0 . Dual labelling o f S W 480-P 6  c e lls  for th e transferrin receptor and FMDV at 5 m in utes after initiation o f virus 
internalisation. S W 480-P 6  cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m inutes  
at 4°C . Virus internalisation w a s  initiated by shifting th e tem p eratu re to 3 7 ”C. Following 5 m in utes incubation at 37"C  
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, the  
transferrin receptor and virus w ere  d e tec ted  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  seco n d a ry  antibod ies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  s h o w s  an overlay  
of p a n e ls  A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 1 . Dual labelling o f S W 4 8 0 -p 6  c e lls  for th e transferrin receptor and FMDV at 10 m in utes after initiation o f virus 
intem alisation. S W 480-P 6  cells, prepared on  coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m inutes  
at 4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 37°C  Following 10 m in utes incubation at 3 7 “C 
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, the  
transferrin receptor and virus w ere  d e te c ted  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5 |ig /m l) respectively , followed by A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  secon d ary  antibodies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (red) and p a n e ls  B  a n d  E  sh ow  virus (green). P a n e l C  sh o w s  an overlay  
of p a n els  A and B, P a n e l F  sh o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 2 . Dual labelling of S W 480-P 6  c e lls  for th e transferrin receptor and FMDV at 15 m in utes after initiation o f virus 
internalisation. S W 4 8 0 -p 6  cells, prepared on coverslip s  w ere  incub ated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m inutes  
at 4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 3 7 “C. Following 15  m in utes incubation at 37°C  
in tem alisation  w a s  halted by fixation on  ice  using 4%  paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, the  
transferrin receptor and virus w ere  d e tec ted  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5 |ig /m l) respectively , follow ed by A lexa fluor con ju gated  iso typ e  sp ec if ic  goat-anti m o u se  seco n d a ry  antibod ies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (red) and p a n e ls  B  a n d  E  sh o w  virus (green ). P a n e l C  sh o w s  an overlay  
of p a n e ls  A and B, P a n e l F  sh o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 3 . Dual labelling o f S W 480-P 6  c e lls  for th e transferrin receptor and FMDV at 30  m in utes after initiation o f virus 
internalisation. S W 480-P 6  cells, prepared on  coverslip s  w ere incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m inutes  
at 4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 37"C. Following 3 0  m in utes incubation at 3 7 'C  
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, the  
transferrin receptor and virus w ere  d e tec te d  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , followed by A lexa fluor conju gated  iso typ e  sp ecific  goat-anti m o u se  seco n d a ry  antibod ies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (red) and p a n e ls  B  a n d  E  sh ow  virus (green ). P a n e l C  s h o w s  an overlay  
of p a n els  A and B, P a n e l F  sh o w s  an overlay o f p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
4.2.5 Alexa Fluor Conjugated Transferrin
As described above, transferrin and the tiansfenin receptor are delivered to early 
endosomes by clathrin-dependent endocytosis, before being delivered back to the cell 
surface via recycling endosomes. Therefore ti'ansferrin is also commonly used as a 
marker for clathrin dependent endocytosis. Virus and Alexa-fluor conjugated 
transferrin were allowed to bind to the surface of SW480-p6 cells at 4°C, before being 
co-intemalised by shifting the temperature to 37°C. At 5 minutes (figure 4.14), virus 
and transferrin can be seen to colocalise in vesicular structures close to the cell 
surface. At 10 minutes (figure 4.15), virus and ti'ansferrin appeared to have 
accumulated in the same compartment and colocalise extensively. At 15 minutes 
(figure 4.16), virus and ti'ansferrin are still colocalised but in vesicles in the 
perinuclear region. No data was obtained at 30 minutes because a tiansfenin signal 
was not obsei'ved at this time point, presumably because the ti'ansfeii'in had recycled 
out of the cells by this time. Virus and transferrin colocalise at all time points at 
which ti'ansferrin can be observed, indicating that the two ligands are trafficked by the 
same route, i.e. clathrin-dependent delivery to early- and recycling-endosomes. 
Colocalisation appeared lower at 5 minutes than other time points, but this could be 
due to the two receptors (transferrin receptor and av|36) recycling at different rates.
In order to observe the eai liest stages of ti'ansferrin and virus endocytosis, uptake 
was slowed by allowing intemalisation to occur at 19°C rather than 37°C. As shown 
in figure 4.17, at this early stage, virus and transferrin can be seen to colocalise just 
below the plasma membrane, indicating that virus and ti'ansferrin are delivered to 
early endosomes by the same, rather than different, routes.
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A) Transferrin D) Transferrin
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 4 . C o-in ternalised transferrin and FMDV at 5  m in utes after initiation o f internalisation in S W 480-P 6  cells. 
S W 480-P 6  cells, prepared on coverslip s  w ere incubated  with A lexa Fluor-488 conju gated  transferrin (lO pg/m l) and FMDV 
strain 0 1  K cad2 (5pg/m l) for 4 5  m inutes at 4 “C. Internalisation of virus and transférrin w a s  initiated by shifting the  
tem perature to 37°C . Following 5  m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  
paraform ald eh yde/ 0.2%  glutaraldehyde. Following perm eabilisation  with 0.1%  Triton, virus w a s  d e tec ted  using the  
m on oclon al antibody D 9 (m o u se  lgG 2A -5pg/m l), follow ed by an A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  
s eco n d a ry  antibody. P a n e ls  A  a n d  D sh o w  flu orescently  labelled transferrin (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). 
P a n e l C  sh o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are show n  
a s  blue.
A) Transferrin D) Transferrin
B) Virus E) Virus
C) Overlay A+B
F ig u re  4 .1 5 . C o-in ternalised transferrin and FMDV at 10 m in utes after initiation o f internalisation in SW 480-|36  ceils. 
S W 480-P 6  cells, prepared on  coverslip s  w ere incub ated  with A lexa Fluor-488 conju gated  transferrin (lO pg/m l) and FMDV 
strain 0 1  K cad2 (5pg/m l) for 4 5  m inutes at 4 ‘ C. Internalisation o f virus and transferrin w a s  initiated by shifting the  
tem perature to 37°C  Following 10 m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  
paraform ald eh yde/ 0.2%  glutaraldehyde. Following perm eabilisation  with 0.1%  Triton, virus w a s  d e tec ted  using the  
m on oclon al antibody 0 9  (m o u se  lgG 2A -5pg/m l), follow ed by an A lexa fiuor conju gated  iso type sp ecific  goat-anti m o u se  
seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  flu orescen tly  labelled transferrin (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). 
P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAP I sta ined  nuclei are show n  
a s  blue.
A) Transferrin D) Transferrin
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 6 . C o-internalised transferrin and FMDV at 15 m in utes after initiation o f internalisation in SW 480-|36  cells. 
S W 480-P 6  cells , prepared on c overslip s  w ere  incubated  with A lexa Fluor-488 conju gated  transferrin (lO pg/m l) and FMDV 
strain 0 1  K cad2 (5pg/m l) for 4 5  m inutes at 4°C . internalisation of virus and transferrin w a s  initiated by shifting the  
tem perature to 37°C . Following 15 m in utes incubation at 37*C internalisation w a s  halted by fixation on  ice  using 4%  
paraform aldehyde/ 0.2%  glutaraldehyde. Following perm eabilisation  with 0.1%  Triton, virus w a s  d e tec ted  using the  
m on oclon al antibody D9 (m o u se  lgG 2A -5pg/m l), follow ed by an A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  
seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  flu orescently  labelled transferrin (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). 
P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAP I sta in ed  nuclei are sh ow n  
a s  blue.
A) Transferrin D) Transferrin
B) Virus E) Virus
•
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 7 . C o-in ternalised  transferrin and FMDV in SW 480-P 6  ce lls  after 30  m in utes incubation at 19  °C. S W 480-p 6  
cells, prepared on coverslip s  w ere  incubated with A lexa  Fluor-488 conju gated  transferrin (1 Opg/ml) and FMDV strain 
0 1 K c a d 2  (5p g/m l) for 4 5  m in utes at 4°C . Internalisation of virus and transferrin w a s  initiated by shifting th e tem perature to  
19°C . Following 3 0  m in utes incubation at 19°C  internalisation w a s  halted at an early s ta g e  by fixation on ice  using 4%  
paraform ald eh yde/0  2% glutaraldehyde. Following perm eabilisation  with 0.1%  Triton, virus w a s  d e te c te d  using th e  
m on oclon al antibody D9 (m o u se  lgG 2A -5pg/m l), follow ed by an A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  
seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  flu orescently  labelled  transferrin (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). 
P a n e l C  sh o w s  an overlay o f p a n e ls  A and B, P a n e l F  sh o w s  an overlay  o f p a n els  D and E. DAPI sta ined  nuclei are show n  
a s  blue.
4.2.6 Alexa Fluor Conjugated Cholera Toxin B
Cholera Toxin B (CTB) has been reported to be taken up into cells by lipid raft 
dependent endocytosis, and in particular the caveolae-dependent endocytic pathway 
(118, 211, 289, 311,315). CTB is therefore often used as a mai'ker for lipid raft 
dependent endocytosis. Therefore, the intracellular transport of FMDV and 
fluorescently labelled CTB were compaied. Virus and Alexa-Buor conjugated CTB, 
were allowed to bind to the surface of SW480-p6 cells at 4°C, before being co­
internalised by shifting the temperature to 3TC.  At 5 minutes (figure 4.18), a 
relatively small amount of virus and CTB has been internalised, but there is a degree 
of colocalisation between the two. By 10 and 15 minutes (figures 4.19 and 4.20), 
slightly greater colocalisation between vims and the CTB was observed. At 30 
minutes (figure 4.21), CTB has accumulated in perinuclear regions but was also- 
present in vesicular-like structures. At this time point, colocalisation of CTB with 
vims was observed in the small vesicular-like CTB positive structures, rather than the 
larger perinuclear accumulations. These observations were unexpected given that 
reagents (methyl-p-cyclodextrin, nystatin and filipin) that inhibit lipid-raft dependent 
endocytosis failed to inhibit infection of SW480-p6 cells by FMDV (see figures 3.6, 
3.8, and 3.9 respectively). However, CTB has been shown recently to be taken up by 
a number of different endocytic pathways, and is no longer considered a specific 
marker for lipid raft- or caveolae-dependent endocytosis. For example, it has been 
shown that in certain cell types, CTB can be taken up by clathrin-dependent 
endocytosis (311), or by a dynamin- and caveolae-independent pathways (311). It has 
also been shown that cholera toxin that has been internalised via caveolae can be 
delivered to early endosomes in Hela cells (248). Therefore, it is possible that the
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observed colocalisation of FMDV with CTB inside the cell results from CTB (or at 
least a fr action of it) being delivered to early and/or recycling endosomes, rather than 
a result of virus being taken up by lipid raft-dependent endocytic mechanisms (See 
section 4.2.7).
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A) Cholera Toxin B D) Cholera Toxin B
B) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 8 . C o-internalised cholera toxin B subunit (CTB) and FMDV at 5 m inutes after initiation o f internalisation in 
S W 480-P 6  cells. S W 480-P 6  cells, prepared on coverslip s  w ere  incubated with A lexa Fluor-488 conju gated  CTB (0 .2pg/m l) 
and FMDV strain 0 1  K cad2 (Spg/m l) for 4 5  m in utes at 4°C . Internalisation o f virus and CTB w a s  initiated by shifting the  
tem perature to 37°C . Following 5 m inutes incubation at 37°C  internalisation w a s  halted by fixation on  ice  using 4%  
parafom rialdehyde/ 0.2%  glutaraldehyde. Following perm eabilisation  with 0.1%  Triton, virus w a s  d e tec ted  using the  
m on oclon al antibody D9 (m o u se  lgG 2A -5pg/m l), follow ed by an A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  
seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  flu orescently  labelled CTB (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l  
C  s h o w s  an overlay of p a n els  A and B, P a n e l F  sh o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are show n a s  
blue.
A) Cholera Toxin B D) Cholera Toxin B
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .1 9 . C o-internalised cholera toxin B subunit (CTB) and FMDV at 10 m inutes after initiation o f internalisation in 
S W 480-P 6  cells. S W 480-P 6  cells, prepared on c overslip s  w ere  incubated with A lexa Fluor-488 conju gated  CTB (0 .2pg/m l) 
and FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in utes at 4°C . Internalisation of virus and CTB w a s  initiated by shifting the  
tem perature to 37°C . Following 10 m in utes incubation at 3 7 “C internalisation w a s  halted by fixation on  ice  using 4%  
paraform aldehyde/ 0.2%  glutaraldehyde. Following perm eabilisation  with 0.1%  Triton, virus w a s  d e tec te d  using the  
m on oclon al antibody D9 (m o u se  lgG 2A -5pg/m l), follow ed by an A lexa fluor conju gated  isotype sp ecific  goat-anti m o u se  
seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  flu orescently  labelled CTB (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l  
C  s h o w s  an overlay of p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  
blue.
A) Cholera Toxin B D) Cholera Toxin B
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 0 . C o-internalised cholera toxin B subunit (CTB) and FMDV at 15 m inutes after initiation o f internalisation in 
S W 480-P 6  cells . S W 480-P 6  cells, prepared on c o v erslip s  w ere  incubated with A lexa Fluor-488 conju gated  CTB (0 .2pg/m l) 
and FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in u tes at 4°C . Internalisation of virus and CTB w a s  initiated by shifting the  
tem perature to 37°C . Following 15 m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  
paraform ald eh yde/ 0.2%  glutaraldehyde. Following perm eabilisation  with 0.1%  Triton, virus w a s  d e tec ted  using the  
m on oclon al antibody D9 (m o u se  lgG 2A -5pg/m l), follow ed by an A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  
seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  flu orescen tly  labelled CTB (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l  
C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  
blue.
A) Cholera Toxin B D) Cholera Toxin B
B) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 1 . C o-in ternalised cholera toxin B subunit (CTB) and FMDV at 30  m in utes after initiation o f internalisation in 
SW 480-P 6  ce lls  S W 480-P 6  cells, prepared on co v erslip s  w ere  incubated  with A lexa Fluor-488 conju gated  CTB (0 .2pg/m l) 
and FMDV strain 0 1  K cad2 (Spg/m l) for 4 5  m in utes at 4°C . Internalisation o f virus and CTB w a s  initiated by shifting the  
tem perature to 37°C . Following 3 0  m in utes incubation at 37°C  internalisation w a s  halted by fixation on  ice  using 4%  
paraform ald eh yde/ 0.2%  glutaraldehyde. Following perm eabilisation  with 0.1%  Triton, virus w a s  d e tec ted  using th e  
m on oclon al antibody D 9 (m o u se  lgG 2A -5pg/m l), follow ed by an A lexa  fluor conju gated  iso type sp ec ific  goat-anti m o u se  
seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  flu orescently  labelled CTB (green ) and p a n e ls  B a n d  E  sh o w  virus (red). P a n e l  
C  sh o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are show n a s  
blue.
4.2.7 Endocytosis of Cholera Toxin B in SW480-P6 Ceils
To determine whether CTB is delivered to eaiiy- and recycling-endosomes following 
uptake by SW480-p6 cells, the colocaliastion of CTB with EEA-1 was investigated. 
The results of these experiments are shown in figures 4.22^.25. At 5 minutes (figure 
4.22), a proportion of the CTB which had been internalised was colocalised with 
EEA-1. At 10 minutes (figure 4.23), CTB can again be found in vesicular stmctures 
which also label for EEA-1. At 15 minutes (figure 4.24), the level of colocalisation 
between CTB and EEA-1 appears to be slightly reduced compared with the earlier 
time points and CTB had begun to accumulate in the perinuclear region. By 30 
minutes (figure 4.25), the majority of CTB was found in the perinuclear region and 
was not colocalised with EEA-1. These data suggests that a proportion of internalised 
CTB is delivered fiom the cell surface to eaiiy endosomes. The CTB found in the 
perinuclear region presumably represents CTB present in the golgi apparatus since 
CTB has been shown to be delivered to this compartment at later times (17).
Next, colocalisation of CTB with a marker of early- and recycling-endosomes, the 
Transferrin Receptor was investigated. These data are shown in figures 4.26-4.29. 
Internalised CTB can be seen to colocalise with the transferrin receptor at 5, 10 and 
15 minutes (see figures 4.26, 4.27, and 4.28 respectively) following initiation of 
internalisation. There is also some colocalisation at 30 minutes (figure 4.29), but this 
is mostly restiicted to more punctate structures, rather than the stiuctures where CTB 
accumulates in the perinuclear region. Consistent wiüi these observations, co 
internalised fluorescent Transferrin and CTB show colocalisation after 5 minutes and 
15 minutes (see figures 4,30 and 4.31 respectively). This is again consistent with a 
proportion of the internalised CTB being delivered to early- and recycling endosomes.
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Finally, colocalisations of CTB with a marker of lysosomes (Lamp-2) was 
investigated. These data are shown in figures 4.32-4,35. Little colocalisation was 
observed at 5, 10, 15, or 30 minutes. This indicates that CTB is not delivered to 
lysosomes within this time fiame.
CTB (or at least a proportion of it) appears to be delivered from the cell surface to 
early/recycling endosomes. Colocalisation of CTB and FMDV particles is therefore 
consistent with the model of clathrin-dependent delivery of virus to acidic early and 
recycling endosomes (Chapter 3). It is likely that the majority of CTB that is 
delivered to early endosomes is delivered via a non-clathrin dependent pathway since 
methyl-(3-cyclodextrin blocks uptake of CTB but not tiunsfen in by SW480-p6 cells 
(see figure 3.7)
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D) EEA-1A EEA-1
B) Choiera Toxin B E) Choiera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 2 . Labelling o f S W 4 8 0 -p 6  c e lls  for EEA-1 at 5 m in utes after initiation o f A lexa -488  conju gated  C holera Toxin B 
subunit (CTB) internalisation. S W 480-P 6  ce lls , prepared on coverslip s  w ere incubated with A lex a -4 8 8  conju gated  CTB  
(0 .2 |ig /m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting th e tem perature to 37"C. Following 5 m in utes  
incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 
0.1%  Triton, EEA-1 w a s  d ete c ted  using th e m on oclon al antibody 14 (m o u se  lgG 1-5pg/m l), follow ed by an A lexa fluor 
conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  EEA-1 labelling (red) and p a n e ls  B  
a n d  E  sh o w  A lex a -4 8 8  conju gated  CTB (green ). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay of 
p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A EEA-1 D) EEA-1
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 3 . Labelling o f S W 4 8 0 -p 6  ce lls  for EEA-1 at 10 m in utes after initiation o f A lexa -488  conju gated  C holera Toxin B 
subunit (CTB) internalisation. S W 480-p 6  cells , prepared on coverslip s  w ere incubated with A lex a -4 8 8  conju gated  CTB  
(0 .2pg/m l) for 4 5  m inutes at 4°C . CTB internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 10  
m in utes incubation at 3 7 ”C internalisation w a s  halted by fixation on  ice  using 4%  paraform aldehyde. Following  
perm eabilisation with 0.1%  Triton, EEA-1 w a s  d e tec ted  using th e  m on oclon al antibody 14 (m o u se  lgG 1-5pg/m l), follow ed by 
an A lexa fluor conju gated  iso typ e  sp ecific  goat-anti m o u se  seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  EEA-1 labelling (red) 
and p a n e ls  B  a n d  E  sh o w  A lex a -4 8 8  conju gated  CTB (green ). P a n e l C  s h o w s  an overlay of p a n e ls  A and B, P a n e l F  sh o w s  
an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) EEA-1 D) EEA-1
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 4 . Labelling o f SW 480-P 6  ce lls  for EEA-1 at 15 m in utes after initiation o f A lexa -488  conju gated  C holera Toxin B 
subunit (CTB) internalisation. S W 480-p 6  cells , prepared on coverslip s  w ere incubated with A lex a -4 8 8  conju gated  CTB  
(0 .2pg/m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting the tem perature to 37°C . Following 15  
m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following  
perm eabilisation  with 0.1%  Triton, EEA-1 w a s  d e te c ted  using th e  m on oclon al antibody 14 (m o u se  lgG 1-5^g/m l), follow ed by 
an A lexa fluor conju gated  iso typ e  sp ecific  goat-anti m o u se  seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  EEA-1 labelling (red) 
and p a n e ls  B  a n d  E  sh o w  A lex a -4 8 8  conju gated  CTB (green ). P a n e l C  sh o w s  an overlay o f p a n els  A and B, P a n e l F  sh o w s  
an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A EEA-1 D EEA-1
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 5 . Labelling o f SW 480-P 6  ce lls  for EEA-1 at 3 0  m in utes after initiation o f A lexa -488  conju gated  C holera Toxin B 
subunit (CTB) internalisation. S W 480-P 6  cells, prepared on coverslip s  w ere incubated with A lex a -4 8 8  conju gated  CTB 
(0 .2p g /m l) for 4 5  m inutes at 4°C . CTB internalisation w a s  initiated by shifting the tem perature to 37°C . Following 30  
m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following 
pen n eab ilisa tion  with 0.1%  Triton, EEA-1 w a s  d e tec ted  using th e  m on oclon al antibody 14 (m o u se  lgG 1-5pg/m l), follow ed by 
an A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  seco n d a ry  antibody. P a n e ls  A  a n d  D sh o w  EEA-1 labelling (red) 
and p a n e ls  B  a n d  E  sh o w  A lex a -4 8 8  conju gated  CTB (green ). P a n e l C  sh o w s  an overlay o f p a n els  A and B, P a n e l F  sh o w s  
an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 6 . Labelling o f SW 480-P 6  c e lls  for th e transferrin receptor at 5  m inutes after initiation o f A lex a -4 8 8  conju gated  
C holera Toxin B subunit (CTB) internalisation. S W 4 8 0 -p 6  cells, prepared on coverslip s w ere incubated with A lexa -488  
conju gated  CTB (0 .2pg/m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting th e tem perature to 37°C . 
Following 5  m in utes incubation at 3 7 'C  internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following  
perm eabilisation with 0.1%  Triton, th e transferrin receptor w a s  d e tec ted  using the m on oclon al antibody H 68 .4  (m o u se  IgG I- 
5pg/m l), follow ed by an A lexa fluor conju gated  iso typ e  sp ec if ic  goat-anti m o u se  secon d ary  antibody. P a n e ls  A  a n d  D  sh o w  
transferrin receptor labelling (red) and p a n e ls  B  a n d  E  sh o w  A lex a -4 8 8  conju gated  CTB (green ). P a n e l C  sh o w s  an overlay  
of p a n els  A and B, P a n e l F  sh o w s  an overlay of p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue
A) Transferrin Receptor D) Transferrin Receptor
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 7 . Labelling o f S W 4 8 0 -p 6  c e lls  for th e transferrin receptor at 10 m inutes after initiation o f A lexa -488  conju gated  
C holera Toxin B subunit (CTB) internalisation. S W 480-P 6  cells, prepared on coverslip s w ere incubated with A lexa -488  
conju gated  CTB (0 .2pg/m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting th e tem perature to 3 7 ”C. 
Following 10 m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following  
perm eabilisation  with 0.1%  Triton, th e transferrin receptor w a s  d e tec ted  using th e m on oclon al antibody H 68.4  (m o u se  IgG I- 
5pg/m l), follow ed by an A lexa fluor conju gated  iso typ e  sp ec if ic  goat-anti m o u se  seco n d a ry  antibody. P a n e ls  A  a n d  D  sh ow  
transferrin receptor labelling (red) and p a n e ls  B  a n d  E  sh o w  A lex a -4 8 8  conju gated  CTB (green ). P a n e l C  sh o w s  an overlay  
of p a n els  A and B, P a n e l F  sh o w s  an overlay o f p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 8 . Labelling o f SW 480-P 6  ce lls  for th e transferrin receptor at 15 m inutes after initiation o f A lexa -488  conjugated  
C holera Toxin B subunit (CTB) internalisation. SW 480-P 6  cells, prepared on coverslip s w ere incubated  with A lexa -488  
conju gated  CTB (0 .2ng/m l) for 4 5  m in utes at 4 ”C. CTB internalisation w a s  initiated by shifting the tem perature to 3 7 “C. 
Following 15 m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following  
perm eabilisation  with 0.1%  Triton, the transferrin receptor w a s  d etec ted  using th e m on oclon al antibody H 68.4  (m o u se  IgG I- 
5pg/m l), follow ed by an A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  secon d ary  antibody. P a n e ls  A  a n d  D  sh ow  
transferrin receptor labelling (red) and p a n e ls  B  a n d  E  sh o w  A lex a -4 8 8  conju gated  CTB (green ). P a n e l C  s h o w s  an overlay  
of p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .2 9 . Labelling o f SW 480-P 6  c e lls  for th e transferrin receptor at 30  m inutes after initiation o f A lex a -4 8 8  conju gated  
C holera Toxin B subunit (CTB) internalisation. S W 480-P 6  cells, prepared on coverslip s w ere  incubated  with A lexa -488  
conju gated  CTB (0.2(ig/m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting the tem perature to 37°C . 
Following 30  m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following  
perm eabilisation  with 0.1%  Triton, th e transferrin receptor w a s  d e tec te d  using the m on oclon al antibody H 68.4  (m o u se  IgG I- 
5/ig/m l), follow ed by an A lexa fluor conju gated  iso type sp ec if ic  goat-anti m o u se  secon d ary  antibody. P a n e ls  A  a n d  D  sh ow  
transferrin receptor labelling (red) and p a n e ls  B  a n d  E  sh o w  A lex a -4 8 8  conju gated  CTB (green ). P a n e l C  s h o w s  an overlay  
of p a n els  A and B, P a n e l F  sh o w s  an overlay o f p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
D) TransferrinA) Transferrin
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 0 . C o-internalised transferrin and C hoiera Toxin B subunit (CTB) at 5 m inutes after initiation o f internalisation in 
S W 480-P 6  cells. S W 480-P 6  cells, prepared on coverslip s  w ere  incubated with A lexa Fluor-568 conju gated  transferrin 
(1 Opg/ml) and A lexa -488  conju gated  CTB (0 .2pg /m l) for 4 5  m in utes at 4°C . Internalisation of CTB and transferrin w a s  
initiated by shifting th e  tem perature to 37"C. Following 5  m in utes incubation at 37°C  internalisation w a s  halted by fixation 
on ice  using 4%  paraform aldehyde/ 0.2%  glutaraldehyde. P a n e ls  A  a n d  D  sh o w  flu orescently  labelled  transferrin (red) and  
p a n e ls  B a n d  E  sh o w  flu orescently  labelled  CTB (green ). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an  
overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) Transferrin D) Transferrin
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 1 . C o-internalised transferrin and C holera Toxin B subunit (CTB) at 15 m inutes after initiation of internalisation in 
SW 480-P 6  cells. S W 480-P 6  cells, prepared on coverslip s  w ere incubated with A lexa Fluor-568 conju gated  transferrin 
(1 Opg/ml) and A lexa -488  conju gated  CTB (0 .2pg/m l) for 4 5  m in utes at 4°C . Internalisation o f CTB and transferrin w a s  
initiated by shifting th e tem perature to 3 7 ”C. Following 15  m in utes incubation at 37°C  internalisation w a s  halted by fixation  
on ice  using 4%  paraform aldehyde/ 0.2%  glutaraldehyde. P a n e ls  A  a n d  D  sh o w  fluorescently  labelled transferrin (red) and  
p a n e ls  B a n d  E  sh o w  flu orescently  labelled CTB (green ). P a n e l C  sh o w s  an overlay o f p a n els  A and B, P a n e l F  sh o w s  an  
overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) LAMP-2 D) LAMP-2
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 2 . Labelling o f S W 480-P 6  c e lls  for late e n d o s o m e s / ly s o s o m e s  (LAMP-2) at 5  m inutes after initiation o f A lexa- 
4 8 8  con ju gated  C holera Toxin B subunit (CTB) internalisation. S W 480-p 6  cells, prepared on coverslip s  w ere  incubated with 
A lexa-fluor 4 8 8  conju gated  CTB (0 .2pg/m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting th e  
tem perature to 37°C . Following 5 m in utes incubation at 37°C  internalisation w a s  halted by fixation on  ice  using 4%  
paraform aldehyde Following perm eabilisation  with 0.1%  Triton, LAMP-2 w a s  d e tec ted  using th e m on oclon al antibody  
H 4B 4 (m o u se  lgG 1-0 .5p g/m l) follow ed by an A lexa  fluor con ju gated  iso typ e  sp ecific  goat-anti m o u se  seco n d a ry  antibody. 
P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling (red) and p a n e ls  B a n d  E  sh o w  CTB (green ). P a n e l C  s h o w s  an overlay o f p a n els  
A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) LAMP-2 D) LAMP-2
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 3 . Labelling o f SW 480-P 6  ce lls  for late e n d o s o m e s / ly s o s o m e s  (LAMP-2) at 10 m in utes after initiation o f A lexa- 
4 8 8  conju gated  C holera Toxin B subunit (CTB) internalisation. S W 480-p 6  cells, prepared on coverslip s  w ere  incubated with 
Alexa-fluor 4 8 8  conju gated  CTB (0 .2pg/m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting the  
tem perature to 37°C . Following 10 m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  
paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, LAMP-2 w a s  d etec ted  using th e m on oclon al antibody  
H 4B4 (m o u se  lgG 1-0 .5pg/m l) follow ed by an A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  seco n d a ry  antibody. 
P a n e ls  A  a n d  D sh o w  LAMP-2 labelling (red) and p a n e ls  B  a n d  E  sh o w  CTB (green). P a n e l C  sh o w s  an overlay o f p a n els  
A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue.
A) LAMP-2 D) LAMP-2
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 4 . Labelling o f S W 480-P 6  ce lls  for late e n d o s o m e s / ly s o s o m e s  (LAMP-2) and 15 m in utes after initiation o f A lexa- 
4 8 8  conju gated  C holera Toxin B subunit (CTB) internalisation. S W 480-P 6  cells, prepared on coverslip s  w ere incubated with 
A lexa-fluor 4 8 8  conju gated  CTB (0 .2pg/m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting the  
tem perature to 37°C . Following 15 m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  
paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, LAMP-2 w a s  d etec ted  using th e  m on oclon al antibody  
H 4B4 (m o u se  lgG 1-0 .5pg/m l) followed by an A lexa  fluor conju gated  isotype sp ecific  goat-anti m o u se  seco n d a ry  antibody. 
P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling (red) and p a n e ls  B a n d  E  sh ow  CTB (green). P a n e l C  s h o w s  an overlay o f p an els  
A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) LAMP-2 D) LAMP-2
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 5 . Labelling o f S W 4 8 0 -p 6  ce lls  for late e n d o s o m e s / ly s o s o m e s  (LAMP-2) at 30  m in utes after initiation o f A lexa- 
4 8 8  con ju gated  C holera Toxin B subunit (CTB) internalisation. S W 480-P 6  cells, prepared on coverslip s  w ere  incubated  with 
A lexa-fluor 4 8 8  conju gated  CTB (0 .2pg/m l) for 4 5  m in utes at 4°C . CTB internalisation w a s  initiated by shifting the  
tem perature to 37°C . Following 3 0  m in utes incubation at 37°C  internalisation w a s  halted by fixation on ice  using 4%  
paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, LAMP-2 w a s  d etec ted  using th e  m on oclon al antibody  
H 4B 4 (m o u se  lgG 1-0.5pg/m l) follow ed by an A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  seco n d a ry  antibody. 
P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling (red) and p a n e ls  B  a n d  E  sh o w  CTB (green ). P a n e l C  s h o w s  an overlay o f p a n els  
A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue.
4.2.8 Caveolîn-1
Caveolin-1 is a marker for caveolae-dependent endocytosis (section 1.5.2.1).
Caveolae are defined morphologically by electron microscopy as smooth surfaced 
invaginations of the plasma membrane of around 55-65 nm in diameter, and caveolin- 
1 forms a major protein constituent of caveolae (273). Caveolin-1 is also a major 
component of internalised caveolai* vesicles (or cavicles) (216), and a neutral pH 
endocytic compartment called the caveosome, (251) to which the virus SV40 is 
delivered upon caveolae-dependent endocytic uptake. Therefore colocalisation of 
FMDV with caveolin-1 was investigated. However four different antibodies directed 
against human caveolin-1 failed to produce any caveolin-1 labelling under the 
confocal microscope.
The above observations prompted investigations of caveolin-1 expression in 
SW480-p6 cells by PGR. PCR primers complementary to conseiwed regions of human 
caveolin-1 were synthesized. Total RNA was extracted fi'om both SW480-P6 and 
CHO cells; a cell line known to express caveolin-1 and possess caveolae. This RNA 
was then reverse transcribed and conventional PCR carried out using primers 
complementary to caveolin-1, and p-actin (a positive control). The resulting gel is 
shown in figure 4.36. A band of ~275bp corresponding to P-actin is present in lanes 2 
and 4, indicating that P-actin is expressed in both SW480-p6 and CHO cells as 
expected. This confirms that the RNA extinction, reverse transcription and PCR 
processes have been successful. However a band of —350 bp representing caveolin-1 
is present in lane 3 (CHO cells) but not lane 1 (SW480-p6 cells) confirming that 
SW480-p6 cells express little or no caveolin-1 and therefore would be expected to 
lack caveolae. However, it is thought that the endocytic pathways associated with
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caveolin-1 in cells that express this molecule have functional equivalents in cells 
lacking caveolin-1 expression and surface caveolae (see reviews (220, 242)). For 
example in cells lacking caveolin-1, SV40 is taken up in to a neutral pH endocytic 
compartment in a lipid-raft dependent fashion, just as observed in cells expressing 
caveolin-1 (62). The only apparent difference is that this compartment lacks caveolin- 
1 on its surface. It is unlikely therefore that a lack of caveolin-1 expression has a 
major impact on the route utilised by FMDV to enter SW480-p6 cells.
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S W 480-qvP6 
1 2
CHO
500 bp
250  bp
F igu re  4 .3 6 . S W 480-P 6  ce lls  do not e x p r e s s  ca v eo lln -1 . An R T-PCR w a s  carried out for th e p r e se n c e  o f actin or caveolin-1  
m RNA in CHO and S W 480-P 6  cells. A PC R  product (~ 275b p ) w a s  d e tec ted  for actin in both cell lin es (la n es  2 and 4 ). In 
contrast a PCR product (~ 350b p ) for caveolin-1  w a s  d e tec ted  for CHO (lan e 3) but not for S W 480-P 6  c e lls  (lan e 1). M = s ize  
markers.
4.3 Effect of Pharmacalogical Inhibitors of 
Endocytosis on the uptake of Virus by SW480-P6 
ceiis.
4.3.1 Concanamycin A
The experiments shown in chapter 3 established that concanamycin A inhibits 
infection of SW480-|36 cells by FMDV. It has been reported that agents that raise the 
pH within endosomes can also inhibit intracellulai* trafficking events. Therefore, the 
effect on FMDV tiafficking and virus delivery to early- and recycling-endosomes was 
investigated in concanamycin A treated cells.
SW480-(36 cells were either pre-treated for 30 minutes with 100 nM concanamycin 
A or mock treated with an equivalent concentration of DMSO. Virus was then bound 
to the cell surface at 4°C, and allowed to enter cells for 15 minutes at 37°C. the cells 
were then fixed with paraformaldehyde with the dmg being present throughout the 
period prior to fixation. Figures 4.37 to 4.42 show the results of these experiments. 
Virus appeared to colocalises with EEA-1 at 15 minutes to the same extent in both 
mock-treated (figure 4.37) and concanamycin A ti'eated (figure 4.38) cells. Similarly, 
extensive colocalisation between virus and the tiansferrin receptor at 15 minutes was 
observed in both mock treated (figure 4.39) and concanamycin A ti*eated (figure 4.40) 
cells. FMDV did not colocalise with LAMP-2 after 15 minutes in mock tieated 
(figure 4.41) or concanamycin A (figure 4.42) treated cells. These data show that 
virus is still delivered to compartments positive for markers of early endosomes 
(EEA-1 and Transferrin Receptor) and recycling endosomes (Transferrin Recptor)
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when treated with concanamycin A. These data (in conjunction with that shown in 
section 3.2.3) shows tliat concanamycin A raises endosomal pH and inhibits infection 
by FMDV, but does not inhibit surface integiin expression, virus binding to the cells, 
delivery of FMDV to early- and recycling-endosomes, or intracellular virus 
replication. Hence it appears that raising endosomal pH using Concanamyin A blocks 
FMDV infection of SW480-|36 cells by preventing virus uncoating and/or delivery of 
viral RNA across the endosomal membrane.
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A EEA-1 D EEA-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 7 . Dual labelling o f DM SO treated S W 4 8 0 -p 6  c e lls  for early e n d o s o m e s  (EEA-1) and FMDV at 15 m in utes after 
initiation o f virus internalisation. SW 480-P 6  cells , prepared on coverslip s  w ere  pre-treated with 0 .001%  DM SO  for 30  
m in utes at 37  °C, and then incubated with FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in utes at 4"C. Virus internalisation w a s  
initiated by shifting th e tem perature to 3 7 “C. Following 15  m in utes incubation at 3 7 “C in th e  p r e se n c e  o f DM SO, 
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, EEA- 
1 and virus w ere  d e tec te d  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and D9 (m o u se  lgG 2A -5pg/m l) 
respectively , follow ed by A lexa fluor conju gated  iso typ e  sp ecific  goat-anti m o u se  seco n d a ry  an tib od ies P a n e ls  A  a n d  D 
sh o w  EEA-1 labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  
s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue
A EEA-1 D EEA-1
B) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 8 . Dual labelling o f C oncanam ycin  A treated S W 480-P 6  c e lls  for early e n d o s o m e s  (EEA-1) and FMDV at 15  
m in utes after initiation o f virus internalisation. SW 480-P 6  cells , prepared on coverslip s  w ere  pre-treated with lOOnM 
C oncanam ycin  A for 3 0  m in utes at 37  °C, and th en  incub ated  with FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in utes at 4"C. 
Virus internalisation w a s  initiated by shifting the tem perature to 37°C . Following 15 m in utes incubation at 37°C  in th e  
p r e se n c e  o f C on can am ycin  A, internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following  
perm eabilisation  with 0.1%  Triton, EEA-1 and virus w ere  d e te c te d  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) 
and D 9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  
antibodies. P a n e ls  A  a n d  D  sh o w  EEA-1 labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay  
of p a n els  A and B. P a n e l F  sh o w s  an overlay of p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .3 9 . Dual labelling o f DM SO treated S W 480-P 6  ce lls  for th e transferrin receptor and FMDV at 15 m in utes after 
initiation o f virus internalisation. SW 480-P 6  ce lls , prepared on coverslip s w ere pre-treated with 0 .001%  DM SO for 30  
m in utes at 37  ”0 ,  and then incubated with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 4°C . Virus internalisation w a s  
initiated by shifting the tem perature to 37°C . Following 15  m in utes incubation at 37°C  in th e  p r e se n c e  of DM SO, 
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, the  
transferrin receptor and virus w ere  d e tec te d  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  antibodies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (green ) and p a n e ls  B  a n d  E  sh ow  virus (red). P a n e l C  sh o w s  an overlay  
of p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .4 0 . Dual labelling o f C oncanam ycin  A treated S W 480-P 6  ce lls  for the transferrin receptor and FMDV at 15 m inutes  
after initiation o f virus internalisation. S W 480-P 6  ce lls , prepared on  coverslip s w ere pre-treated with lOOnM C oncanam ycin  
A for 3 0  m in utes at 37  °C, and then incubated with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m inutes at 4°C . Virus 
internalisation w a s  initiated by shifting th e  tem perature to 37°C . Following 15  m in utes incubation at 37°C  in th e p r e se n c e  of 
C oncanam ycin  A internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following perm eabilisation with 
0.1%  Triton, transferrin receptor and virus w ere  d e tec ted  using m on oclon al antibod ies H 68.4  (m o u se  lgG 1-5pg/m l) and D9  
(m o u se  lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  
antibod ies. P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  
sh o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue.
A) LAMP-2 D) LAMP-2
B) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .4 1 . Dual labelling o f DM SO treated  S W 480-P 6  c e lls  for late en d o so m esM y so so m es  (LAM P-2) and FMDV at 15  
m in utes after initiation o f virus internalisation. S W 4 8 0 -p 6  cells , prepared on coverslip s  w ere  pre-treated with 0 .001%  DM SO  
for 3 0  m in utes at 3 7  °C, and then incubated with FMDV strain 0 1  Kcad2 (5pg/m l) for 4 5  m in utes at 4°C . Virus internalisation  
w a s  initiated by shifting th e tem perature to 37°C . Following 15 m in utes incubation at 37°C  in th e p r e se n c e  o f DM SO, 
internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following perm eabilisation with 0.1%  Triton, 
LAMP-2 and virus w ere d e te c ted  using m on oclon al an tib od ies H 4B 4 (m o u se  lgG 1-0 .25pg/m l) and D 9 (m o u se  lgG 2A - 
5 |ig /m l) respectively , followed by A lexa fluor conju gated  iso typ e  sp ec ific  goat-anti m o u se  seco n d a ry  antibod ies. P a n e ls  A  
a n d  D  sh o w  LAMP-2 labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, 
P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei are show n a s  blue.
D) LAMP-2A) LAMP-2
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  4 .4 2 . Dual labelling of C oncanam ycin  A treated  S W 4 8 0 -p 6  c e lls  for late en d o so m esM y so so m es  (LAMP-2) and  
FMDV at 15 m in utes after initiation o f virus internalisation. S W 4 8 0 -p 6  cells , prepared on coverslip s  w ere  pre-treated with 
lOOnM C oncanam ycin  A for 30  m inutes at 3 7  °C, and th en  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 
4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 3 7 ”C. Following 15 m in utes incubation at 3 7 ’ C in the  
p r e se n c e  o f C oncanam ycin  A internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following  
perm eabilisation with 0.1%  Triton, LAMP-2 and virus w ere  d e te c ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) 
and D 9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  secon d ary  
antibod ies. P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling (green ) and p a n e ls  B  a n d  E  sh ow  virus (red). P a n e l C  sh o w s  an 
overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay of p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
4.4 Summary and Discussion
The data presented in chapter 3 showed that avp6-mediated infection of SW80-p6 
cells is dependent on clathrin-dependent endocytosis and active endosomal 
acidification, but not on intact lipid rafts and suggest that FMDV most likely infects 
its host cell following viius uptake into early- or recycling-endosomes. To confirm 
these observations the intracellular tiafficking of FMDV was determined using 
immunofluorescence confocal microscopy.
Virus (and fluorescently conjugated ligands where appropriate) was bound to the 
cell surface at 4°C and then allowed to enter SW480-P6 cells for 5, 10, 15 or 30 
minutes at 37°C. The cells were fixed and permeabilised, and labelled for virus alone 
or both virus and markers of specific cellular compartments. At 5 minutes after the 
initiation of internalisation the majority of virus remained at or near the cell surface, 
but some virus could already be observed within punctate intracellular vesicles. By 
10 to 15 minutes the majority of virus has been internalised and is present in 
inti'acellular vesicle-like structures. By 30 minutes after internalisation virus appeared 
to accumulate in larger vesicle-like structures located closer to the nucleus. The 
compartment markers used in this study were EEA-1 (a marker of early endosomes), 
the tiansferrin receptor (a marker of early and recycling endosomes), fluorescently 
labelled transferrin (a mai'ker for die recycling endocytic pathway), LAMP-2 (a 
lysosomal marker), and fluorescently labelled cholera toxin B (previously reported as 
a ligand which is internalised predominantly via caveolae-dependent endocytosis).
At 5 minutes post internalisation there was significant colocalisation between 
internalised virus and EEA-1, as well as with co-internalised transferrin, and to a
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lesser extent the ti'ansfeiTin receptor. Little or no colocalisation was observed 
between virus and LAMP-2. At 10 minutes there is extensive colocalisation of vims 
with EEA-1 and the ti’ansfenin receptor, and with co-internalised transferrin. Again, 
at this time point, little or no colocalisation with LAMP-2 was seen. At 15 minutes 
virus colocalises extensively with cointemalised transfemn, and colocalisation can 
still be seen between virus and EEA-1. Colocalisation between the tiansfenin 
receptor and vims is extensive and maximal at this time point. Very little 
colocalisation can be seen between vims and LAMP-2. By 30 minutes little 
colocalisation can be observed between virus and EEA-1, the tiansferrin receptor or 
LAMP-2. Fluorescently labelled tiansferrin has recycled out of the cells by this time 
point and so no signal can be observed.
The above data aie consistent with the rapid delivery of FMDV to early endosomes 
and its trafficking to recycling endosomes as vims colocalises with EEA-1 and 
ti'ansfeiTin at early time points post uptake. The level of colocalisation of vims with 
the transferrin receptor (a recycling endosome marker) reaches a maximum at 15 
minutes, suggesting that a proportion of virus is also delivered from early- to 
recycling-endosomes. The observation that virus colocalises with co-intemalised 
tiansferrin (a ligand which is delivered to early- and subsequently recycling- 
endosomes) at 5, 10, and 15 minutes supports these data. The results of this study are 
consistent with the inhibition of virus infection by concanamycin A (see section 
3.2.3). In chapter 3, this drug was shown to raise endosomal pH and inhibit infection 
by FMDV, but not inhibit surface integrin expression, virus binding, delivery of 
FMDV or intracellular virus replication. The data presented in section 4.3 show that 
concanamycin A does not prevent delivery of FMDV to acidic early- and recycling- 
endosomes. Dissipation of the acidic pH within these compartments using
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concanamycin A therefore most likely blocks FMDV infection of SW480-p6 cells by 
preventing virus uncoating and/or delivery of viral RNA across the endosomal 
membrane. The lack of colocalisation of vims with LAMP-2 at any time point 
suggests that virus is not delivered to late endosomes or lyosomes. This is consistent 
with the insensitivity of infection of SW480-p6 by FMDV to agents such as 
wortmannin and nocodazole which inhibit transport between early and late endosomes 
(see sections 3.24 and 3.2.5.1).
At 30 minutes, little colocalisation was observed between virus and EEA-1, the 
ti'ansfeiTin receptor or LAMP-2. This data suggests that after delivery to early- and 
recycling-endosomes virus (or virus protein at least) is tiansported from these 
compartments to an unidentified compartment, or alternatively that virus causes 
exclusion of markers of these compartments. However, it is unlikely that virus 
transport beyond early- or recycling-endosomes is significant for infection. The 
FMDV capsid is extremely acid labile, and virus uncoating and the subsequent 
tianslocation of the viral RNA to the cytoplasm would be triggered by the mildly 
acidic pH within early- and recycling-endosomes. Once viral RNA has reached the 
cytoplasm the subsequent fate of viral protein is therefore most likely to be irrelevant 
to infection.
Cholera toxin and in particular its B subunit, have been favoured as markers of 
caveolae-dependent endocytosis following early studies showing labelling of caveolae 
using Cholera toxin conjugated to gold (211). Therefore CTB was used as a marker 
for caveolae-dependent endocytosis to investigate entry of FMDV into caveolae. 
Immunofluorescence experiments revealed partial colocalisation between FMDV and 
CTB at the 10 and 15 minute timepoints. These observations were unexpected as they 
appear to suggest that FMDV is taken up by a caveolae-dependent mechanism and
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would conti'adict the observations made in chapter 3, that infection of SW480-p6 cells 
is insensitive to cholesterol binding agents (filipin, nystatin, and methyl-p- 
cyclodextrin), which inhibit lipid raft dependent endocytosis pathways, including 
caveolae-dependent endocytosis.
A possible explanation for the apparently contradictory nature of the above data is 
the observation that CTB can efficiently enter cells via early endosomes when the cell 
does not express caveolin-1 and lack caveolae (193, 227, 311). The data presented in 
section 4.2,8 shows that SW480-p6 cells lack caveolin-1, and therefore would not be 
expected to possess caveolae. In cells lacking caveolin-1, it has also been shown that 
CTB can be taken up via a non-clathrin and non-caveolae dependent endocytosis 
pathway (158). This pathway is dependent on lipid rafts, and displays similai* 
properties to the non-caveolae and non-clathrin dependent pathway utilised by SV40 
in cells lacking caveolae (62). Additionally CTB has been shown to be able to enter a 
number of different cell types in a clathrin-dependent manner (193, 227, 311), 
resulting in its delivery to early endosomes. CTB can also be delivered to early 
endosomes via caveola-dependent endocytosis, since a recent study has shown that 
internalised caveolae ai*e delivered to early endosomes as well as caveosomes, and 
that delivery of CTB to the golgi is dependent on contact with the low pH within 
endosomes in the system used (248). It is likely that a similar pathway exists in cells 
lacking caveolin-1, since toxin internalisation and delivery to the golgi occurs 
normally in cells lacking caveolin-1. In summary, these studies have shown that CTB 
internalisation is a complex process and that CTB can be delivered to early 
endosomes via either clathrin-dependent or lipid raft dependent mechanisms. 
Consistent with this, the data shown in section 4.2.7 shows that in SW480-p6 cells, 
internalised CTB colocalises with EEA-1 (an early endosome marker) and the
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transferrin receptor (a marker of early/recycling endosomes), indicating that CTB is 
internalised via early endosomes in this cell type. On SW480-P6 cells, delivery to 
early endosomes is likely to be via a lipid raft dependent mechanism rather than a 
clathrin-dependent mechanism since uptake of CTB was inhibited by methyl-p- 
cyclodextrin under conditions whereby clathrin-dependent endocytosis (as assayed by 
tiansferrin uptake) was not blocked (see section 3.2.2). The observations that both 
CTB and viras are delivered to early- and recycling-endosomes explains why they 
show colocalisation inside the cell.
In summary, the data presented here show that FMDV is rapidly taken up in to 
compartments positive for mar kers of early- and recycling-endosomes, and 
colocalises with co-internalised CTB and transferrin, both of which are known to be 
delivered to these compartments. When internalisation was slowed by incubation at 
19°C rather than 37°C, enabling an early stage of internalisation to be captured, 
internalised virus and transferrin remained colocalised, suggesting that the two 
ligands are delivered to early endosomes by the same mechanism (i.e. clathrin 
dependent endocytosis). Caveola-dependent endocytosis is not required for infection 
of SW48ÔD6 cells since this cell line does not express caveolin-1. Taken together the 
data presented here is consistent with the inhibitor studies presented in chapter 3, and 
suggests that the entry pathway used by virus to infect SW480-P6 cells is clathrin- 
dependent delivery ofvhus from the cell surface to early and recycling endosomes.
132
Chapter Five: Investigation of the Entry Pathways
Utilised by FMDV by immunofluorescence -  CHO ^6 
cells 
5.1 Introduction
Chapter four investigated the entry of FMDV strain 01Kcad2 into SW480-p6 cells by 
immunofluorescence confocal microscopy. However, as outlined in section 4.2.8, this 
cell line does not appear to express Caveolin-1, since four antibodies against this 
protein failed to produce any immunofluorescence signal, and the cells were negative 
for Caveolin-1 mRNA by PCR. Cells lacking caveolin-1 expression possess little or 
no caveolae at their cell surface, and réintroduction of Caveolin-1 into such cells 
induces the formation of caveolae at the plasma membrane (85). It is possible 
therefore that the virus can utilise different endocytosis pathways in cell lines which 
do express caveolin-1. In order to explore this possibility FMDV endocytosis and 
infection was investigated using a cell line which does express caveolin-1, and 
therefore possesses caveolae, namely CHO-P6 cells. These cells are CHO cells 
tiansfected to permanently express the P6 integrin subunit, and consequently express 
the integrin avp6 at the cell surface. The integrin avP6 has been shown to act as the 
major receptor for virus attachment and infection on this cell line (145). This cell line 
is therefore a useflil tool to investigate the entry pathways utilised by FMDV to infect 
cells which possess caveolae.
5.2 Low pH Dependence of Infection of CHO-|36 Cells
Infection of SW480-p6 cells was shown to be dependent on the acid pH within 
endosomes at an early stage of infection in section 3.2.3. Therefore it was decided to
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establish whether this was also true for CHO-p6 cells using Concanamycin A. CHO- 
p6 cells were pre-tieated with concanamycin A for 0.5h prior to the Ih incubation 
with virus in the presence of di'ug. Infection was detennined by using the ELIspot 
infection assay at an m.o.i of 0.3. Figure 5.1 shows the results of these experiments. 
Each data point represents the mean of three independent experiments, each of which 
was carried out in triplicate. As shown in the figure, infection was inhibited by pre 
treatment with 10p,M (93% inhibition), IjiiM (75% inhibition) and lOOnM (74% 
inhibiton) concentiations of Concanamycin A. This is consistent with the data 
obtained for SW480-p6 cells, albeit that the level of inhibition observed at 
concentrations of l|iM  and lOOnM are slightly lower. The effect of concanamycin A 
on later stages of infection (i.e. intiacellular vims replication) is shown on figure 5.1 
by the data points marked RC, These samples were treated with the indicated 
concentiation of Concanamycin A for 4h following removal of the virus inoculum, 
i.e. when the entiy stage of the replication cycle is over. These data show that lOp-M 
and IjiM Concanamycin A appear to inhibit infection when added after cell entry has 
finished, indicating that these high concentrations of drug inhibit intracellular virus 
replication. However, lOOiiM Concanamycin A has a minimal effect on infection 
when added at this time, indicating that this concentration of drug does not inhibit the 
intracellular replication of FMDV. To summarise, lOOnM Concanamycin A inhibits 
infection of CHO-P6 cells by an average of 74% when cells are pretreated with the 
drug, but has a minimal impact on infection when added immediately following the 
removal of the virus innoculum. These observations show that raising endosomal pH 
using lOOnM Concanamycin A inhibits infection of CH0-p6 cells at an early stage in 
the infection cycle, most likely at the stage of virus entry/uncoating rather than 
inti acellular replication. Higher concentrations of Concanamycin A appear to inhibit
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virus replication as well as cell entry, perhaps due to inhibition of replication complex 
formation. The data presented here show that infection of CHO-p6 cells by FMDV 
requires a low pH step at an early stage, just as is the case for SW480-P6 cells.
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F ig u re  5.1. C oncanam ycin  A inhibits FMDV infection.
C H O -pe c e lls  w ere  treated with C oncanam ycin  A for 0 .5h  and infected  with FMDV (m .o.i - 0 .3 )  for Ih  in the p r e se n c e  o f 
the drug. T he m ock ce lls  w ere treated with DM SO. Following rem oval of virus, sa m p le s  w ere  incubated  for a further 4h  
at 37°C , and then fixed with 4% paraform aldehyde. D ata poin ts m arked RC rep resen t s a m p le s  treated  with the 
indicated concentration (nM) of C oncanam ycin  A (in nM) for 4h following rem oval o f the virus inoculum . Infection w a s  
quantified a s  descr ib ed  in figure 3 .1 . T he num ber of infected  ce lls  in the C oncanam ycin  A -treated s a m p le s  w a s  
e x p r essed  a s  a p ercen ta g e  o f the num ber o f infected  c e lls  in m ock-treated sa m p le s . E ach data point r ep resen ts  the  
m ean and ±SD  o f three experim ents, e a c h  o f w hich w a s  carried out in triplicate.
5.3 Uptake of FMDV by CHO-pG Cells
The work presented in chapter 4 showed, using immunofluorescence microscopy, that 
FMDV is taken up rapidly into early and recycling endosomes in SW480-p6 cells, 
consistent with dependence of infection on a low pH step. However this cell line 
expresses little or no caveolin-1 (see figure 4.36) and as such does not possess 
caveolae. It is possible that FMDV can utilise caveolae-depndent endocytosis to enter 
cells which express caveolin-1. It was therefore decided that the endocytic uptake of 
FMDV by CHO-p6 cells, which do possess caveolae, should be investigated using the 
same methods used for SW480-p6 cells. Virus was allowed to bind to the cell surface 
at 4°C, a temperature which does not allow endocytosis to occur. Internalisation was 
initiated by a shift to 37®C, before paraformaldehyde fixation after a defined period of 
time (between 5 and 30 minutes). Cells were then permeabilised, and virus and 
markers of specific cellular compartments labelled using monoclonal or polyclonal 
primary antibodies, followed by Alexa Fluor conjugated secondary antibodies. The 
data is divided up below by marker protein.
5.3.1 Early Endosomal Antigen 1 (EEA-1)
Early endosomal antigen-1 (EEA-1) is a marker for early endosomes. A timecourse 
of avP6-mediated internalisation of FMDV strain 01Kcad2 by CHO-p6 cells was 
carried out as described above. At each time point CHO-P6 cells were fixed, 
permeabilised and Virus and EEA-1 were labelled using monoclonal antibodies. 
Viral protein (red) was detected using the antibody D9 which recognises a linear 
epitope within the viral protein V Pl, and EEA-1 (gieen) was detected using the
136
monoclonal antibody 14 which was recognises an epitope within human EEA-1, but 
cross-reacts with the hamster version. The data obtained are shown in figures 5.2-5.5. 
At 5 minutes following the initiation of virus internalisation (figure 5.2), a large 
proportion of internalised virus is colocalised with EEA-1. By 10 minutes (figure 5.3) 
the majority of virus has been internalised, and was colocalised with EEA-1. At 15 
and 30 minutes (figures 5.4 and 5.5), FMDV seems to have accumulated in large 
vesicles in the perinuclear area, but still exhibited significant colocalisation with 
EEA-1. The data presented here show that virus is delivered to EEA-1 positive early 
endosomes by 10 minutes after internalisation and a significant proportion seems to 
remain associated with early endosomes right up to 30 minutes after the initiatation of 
internalisation. This contrasts with SW480-P6 cells where virus is delivered to early 
endosomes by 10-15 minutes, but no longer colocalises with EEA-1 by 30 minutes. It 
is possible that this is because traffic of viral protein onwai ds fi om early endosomes is 
either slower in CHO-p6 cells or else it may not occur at all.
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A) EEA-1 D) EEA-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .2 . Dual labelling o f C H 0 -p 6  c e lls  for EEA-1 and FMDV at 5  m in utes after initiation o f virus internalisation. CHO-P6  
cells, prepared on coverslip s  w ere incubated with FMDV strain 0 1 K c a d 2  (Spg/m l) for 4 5  m in utes at 4 “C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 5 m inutes incubation at 37°C  internalisation w a s  
halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, EEA-1 and virus w ere  
d e te c ted  using m on oclon al an tib od ies 14 (m o u se  IgG I-Spg/m l) and D9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by 
A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  antibodies. P a n e ls  A  a n d  D sh o w  EEA-1 labelling  
(green ) and p a n e ls  B a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay of 
p a n els  D and E. DAPI sta ined  nuclei are show n a s  blue.
A) EEA-1 D) EEA-1
B) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .3 . Dual labelling o f CHO-pS ce lls  for EEA-1 and FMDV at 10  m in utes after initiation o f virus internalisation CHO­
PS cells , prepared on coverslip s  w ere incubated  with FMDV strain 0 1  K cad2 (Spg/m l) for 4 5  m in utes at 4 * 0 . Virus 
internalisation w a s  initiated by shifting the tem perature to 3 7 * 0 . Following 10 m inutes incubation at 3 7 * 0  internalisation w a s  
halted by fixation on ice  using 4% paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, EEA-1 and virus w ere  
d e te c ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and D9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by 
A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  seco n d a ry  antibodies. P a n e ls  A a n d  D  sh o w  EEA-1 labelling  
(green ) and p a n e ls  B a n d  E  sh o w  virus (red) P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay of 
p a n els  D and E. DAPI sta ined  nuclei are show n a s  blue.
A) EEA-1 D) EEA-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .4 . Dual labelling o f C H 0-P 6  ce lls  for EEA-1 and FMDV at 15  m in utes after initiation o f virus internalisation CHO­
PS cells , prepared on coverslip s  w ere incubated  with FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in utes at 4*C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 15 m inutes incubation at 37°C  internalisation w a s  
halted by fixation on ice  using 4% paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, EEA-1 and virus w ere  
d e te c ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by 
A lexa fluor conju gated  iso type sp ec if ic  goat-anti m o u se  seco n d a ry  antibod ies. P a n e ls  A  a n d  D  sh o w  EEA-1 labelling  
(green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay of 
p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) EEA-1 D) EEA-1
E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .5 . Dual labelling o f CHO-P6 ce lls  for EEA-1 and FMDV at 30  m in utes after initiation o f virus internalisation CH O ­
PS cells , prepared on coverslip s w ere incubated  with FMDV strain 0 1  K cad2 (Spg/m l) for 4 5  m in utes at 4"C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C  Following 3 0  m inutes incubation at 37°C  internalisation w a s  
halted by fixation on ice  using 4% paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, EEA-1 and virus w ere  
d e tec ted  using m on oclon al an tib od ies 14 (m o u se  IgG I-Spg/m l) and D9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by 
A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  EEA-1 labelling 
(green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B. P a n e l F  s h o w s  an overlay of 
p a n els  D and E. DAP! sta ined  nuclei are show n a s  blue.
5.3.2 Transferrin Receptor
A timecoiirse of av|36-mediated internalisation of FMDV stiain 01Kcad2 by CHO- 
(36 cells was carried out as described above. At each time point CHO-|36 cells were 
fixed, permeabilised and virus and the transferrin receptor (a marker for early and 
recycling endosomes) were labelled using monoclonal antibodies. Viral protein (red) 
was detected using the antibody D9, and the transferrin receptor (gieen) was detected 
using the monoclonal antibody H68.4 which was raised against the human transferrin 
receptor but cross-reacts with the hamster version. The results of these experiments 
are shown in figures 5.6-5.9. At 5 minutes after the initiation of internalisation (figure 
5.6) there is some colocalisation between internalised virus and the transferrin 
receptor. By 10 minutes (figure 5.7), the majority of virus has been internalised and 
there is partial colocalisation between virus and the transferrin receptor was observed. 
At 15 and 30 minutes (figures 5.8 and 5.9 respectively), most virus positive structures 
within the cell also show tiansferrin receptor labelling. The above data suggests that 
FMDV is delivered to early and recycling endosomes by 15 minutes after the 
initiation of internalisation and remains predominantly within these compartments by 
30 minutes.
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A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .6 . Dual labelling o f CHO-pS c e lls  for th e transferrin receptor and FMDV at 5  m inutes after initiation o f virus 
internalisation. CHO-pS cells, prepared on  coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 
4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 5 m in utes incubation at 37°C  
internalisation w a s  halted by fixation on  ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, the  
transferrin receptor and virus w ere  d e tec te d  using m on oclon al an tib od ies H 68.4 (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  antibod ies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red) P a n e l C  s h o w s  an overlay  
of p a n els  A and B, P a n e l F  sh o w s  an overlay o f p a n e ls  D and E. DAP I sta ined  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .7 . Dual labelling o f C H 0 -P 6  ce lls  for th e transferrin receptor and FMDV at 10 m in utes after initiation o f virus 
internalisation. C H 0-P 6  cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (Spg/m l) for 4 5  m in utes at 
4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 3 7 “C. Following 10 m in utes incubation at 3 7 ”C 
internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following perm eabilisation with 0.1%  Triton, the  
transferrin receptor and virus w ere  d e tec ted  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  seco n d a ry  antibod ies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red) P a n e l C  s h o w s  an overlay  
of p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .8 . Dual labelling of CHO-pG ce lls  for th e transferrin receptor and FMDV at 15 m in utes after initiation o f virus 
internalisation. CHO-pS cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 
4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 15 m in utes incubation at 37°C  
internalisation w a s  halted by fixation on  ice  using 4% paraform aldehyde. Following perm eabilisation with 0.1%  Triton, the  
transferrin receptor and virus w ere d e te c ted  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  seco n d a ry  antibod ies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay  
of p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) Transferrin Receptor D) Transferrin Receptor
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .9 . Dual labelling o f C H 0-P 6  c e lls  for th e  transferrin receptor and FMDV at 30  m in utes after initiation o f virus 
internalisation. C H 0-P 6  cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (Spg/m l) for 4 5  m in utes at 
4°C . Virus internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 30  m in utes incubation at 37°C  
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, the  
transferrin receptor and virus w ere  d e tec ted  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  
lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  antibodies. 
P a n e ls  A  a n d  D  sh o w  transferrin receptor labelling (green ) a n d  p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay  
of p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
5.3.3 Lysosomal-associated Membrane Glycoprotein-2 (LAMP-2)
A timecourse of ocvp6-mediated internalisation of FMDV strain 01Kcad2 by CHO- 
p6 cells was carried out as described above. At each time point CHO-p6 cells were 
fixed, permeabilised and vims and LAMP-2 (a marker for late endosomes and 
lysosomes) were labelled using monoclonal antibodies. Viral protein (red) was 
detected using the antibody D9, and LAMP-2 (green) was detected using the 
monoclonal antibody H4B4 which is raised against human LAMP-2 but cross-reacts 
with the hamster version. The results of these experiments are shown in figures 5.10- 
5.12. Little or no colocalisation could be detected between virus and LAMP-2 at 10 
(figure 5.10), 15 (figure 5.11), or 30 minutes (figme 5.12) after the initiation of 
internalisation. This data suggests that infection of CHO-p6 cells by FMDV does not 
require delivery of virus to late endosomes and lysosomes, and is in agreement with 
studies carried out using SW480-P6 cells. However, it is possible that virus is 
delivered to lysosomes but is rapidly degraded and therefore colocalisation is not 
observed. This scenario seems unlikely however since the level of virus labelling 
does not decline over the time period studied, and also viral protein remains 
associated with markers of early and recycling endosomes after 30 minutes.
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A) LAMP-2 D) LAMP-2
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .1 0 . Dual labelling o f CHO-P6 c e lls  for LAMP-2 and FMDV at 10 m inutes after initiation o f virus internalisation. 
C H O -pe cells , prepared on coverslip s w ere incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 4 “C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 10 m inutes incubation at 37°C  internalisation w a s  
halted by fixation on ice  using 4% paraform aldehyde. Following perm eabilisation with 0.1%  Triton, LAMP-2 and virus w ere  
d e tec ted  using m on oclon al an tib od ies H 4B 4 (m o u se  lgG 1-0 .5p g/m l) and D9 (m o u se  lgG 2A -5pg/m l) respectively , followed  
by A lexa fluor conju gated  iso type sp ec ific  goat-anti m o u se  seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling  
(green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  sh o w s  an overlay of 
p a n els  D and E. DAPI sta ined  nuclei are show n a s  blue.
A LAMP-2 D LAMP-2
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .1 1 . Dual labelling o f CHO-pS ce lls  for LAMP-2 and FMDV at 15 m in utes after initiation o f virus internalisation  
CHO-pe ce lls , prepared on coverslip s  w ere incubated with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 4°C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C. Following 15  m inutes incubation at 37°C internalisation w a s  
halted by fixation on ice  using 4% paraform aldehyde Following perm eabilisation  with 0.1%  Triton, IA M P -2 and virus w ere  
d e tec ted  using m on oclon al antibod ies H 4B 4 (m o u se  lgG 1-0 .5p g/m l) and D 9 (m o u se  lgG 2A -5pg/m l) respectively , followed  
by A lexa fluor conju gated  isotype sp ecific  goat-anti m o u se  seco n d a ry  antibod ies. P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling  
(green ) and p a n e ls  B  a n d  E  sh o w  virus (red) P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  sh o w s  an overlay of 
p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue.
D) LAMP-2A) LAMP-2
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .1 2 . Dual labelling o f CHO-pe c e lls  for LAMP-2 and FMDV at 30  m inutes after initiation o f virus internalisation. 
CHO-pe ce lls , prepared on coverslip s  w ere incubated  with FMDV strain 0 1  K cad2 (Spg/m l) for 4 5  m in utes at 4°C . Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C  Following 30  m inutes incubation at 37°C  internalisation w a s  
halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, LAMP-2 and virus w ere  
d etec te d  using m on oclon al an tib od ies H 4B 4 (m o u se  lgG 1-0 .5p g/m l) and D9 (m o u se  lgG 2A -5pg/m l) respectively , followed  
by A lexa fluor conju gated  iso type sp ecific  goat-anti m o u se  seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  LAMP-2 labelling 
(green ) and p a n e ls  B  a n d  E  sh o w  virus (red). P a n e l C  sh o w s  an overlay of p a n els  A and B, P a n e l F  s h o w s  an overlay of 
p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
5.3.4 Caveolîn-1
The data described above suggests that in CHO-p6 cells, FMDV is delivered via 
classical endocytic pathways to early- and recycling-endosomes just as is the case in 
SW480-p6 cells. Caveolin-1 is a major protein constituent of caveolae and acts as a 
marker protein for a non-classical endocytosis pathway, the caveolae-dependent 
uptake pathway (see section 1.5.2.1). Caveosomes and internalised caveolar vesicles 
are negative for classical early endosomal markers such as EEA-1 and ti'ansferrin, 
have a neutral pH, and contain caveolin-1 within their limiting membrane. The 
neutral pH within the caveosome would not be expected to trigger the acid-mediated 
uncoating of FMDV thought to be required for infection.
A timecourse of av(36-mediated internalisation of FMDV strain 01Kcad2 by CHO- 
p6 cells was carried out as described above. At each time point CHO-|36 cells were 
fixed, permeabilised and virus and caveolin-1 (a marker for early and recycling 
endosomes) were labelled using monoclonal antibodies. Viral protein (red) was 
detected using the antibody D9, and caveolin-1 (green) was detected using a rabbit 
polyclonal serum produced using an epitope mapping to the N-terminus of human 
caveolin-1. The results of these experiments are shown in figures 5.13-5.16. At 5 and 
10 minutes (see figures 5.13 and 5.14 respectively) a limited amount of colocalisation 
between virus and caveolin-1 was observed at the cell surface and in intiacellular 
vesicles. This most likely represents vims that is present in early endosomes, since 
caveolin-1 partially colocalises with EEA-1 (334), as trafficking between caveosomes 
and early endosomes has been observed in a number of cell types. At 15 and 30 
minutes (see figures 5.15 and 5.16 respectively) virtually no colocalisation between
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virus and the caveolin-1 protein was seen. This data is not consistent with uptake of 
FMDV via caveolae-dependent endocytosis.
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A) Caveohn-1 D) Caveolin-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .1 3 . Dual labelling o f CHO-P6 ce lls  for C aveolin-1 and FMDV at 5  m inutes after initiation o f virus internalisation. 
CHO-pe cells, prepared on coverslip s  w ere  incubated with FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in utes at 4°C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37"C. Following 5  m in utes incubation at 37°C  internalisation w a s  
halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, Caveolin-1 and virus 
w ere  d e te c ted  using a rabbit polyclonal serum  directed a ga in st th e N-temninus o f hum an Caveolin-1 (1 /2 5 0 ) and the m o u se  
m on oclon al antibody D9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  g o a t anti-rabbit and go a t 
an ti-m ou se  seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  C aveolin-1 labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red) 
P a n e l C  sh o w s  an overlay o f p a n e ls  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are show n  
a s  blue.
D) Caveolin-1A) Caveolin-1
B) virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .1 4 . Dual labelling o f CHO-p6 ce lls  for Caveolin-1 and FMDV at 10 m in utes after initiation o f virus internalisation  
CHO-pe ce lls , prepared on coverslip s w ere  incubated  with FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in utes at 4 “C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 10  m inutes incubation at 37°C  internalisation w a s  
halted by fixation on  ice  using 4% paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, Caveolin-1 and virus 
w ere  d e te c te d  using a rabbit polyclonal serum  directed a g a in st th e N -term inus o f hum an Caveolin-1 (1 /2 5 0 ) and th e m o u se  
m on oclon al antibody D 9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  g o a t anti-rabbit and g o a t  
an ti-m ou se  seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  C aveolin-1 labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). 
P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  
a s  blue.
A) Caveolin-1 D) Caveolin-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .1 5 . Dual labelling o f CHO-P6 ce lls  for C aveolin-1 and FMDV at 15 m in utes after initiation o f virus internalisation. 
C H 0 -p 6  cells, prepared on coverslip s w ere incubated with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 4°C  Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C  Following 15  m inutes incubation at 37"C internalisation w a s  
halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, Caveolin-1 and virus 
w ere  d e te c ted  using a rabbit polyclonal serum  directed a ga in st th e N -term inus o f hum an Caveolin-1 (1 /2 5 0 ) and th e m o u se  
m on oclon al antibody D9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  go a t anti-rabbit and go a t  
an ti-m ou se  seco n d a ry  antibod ies. P a n e ls  A  a n d  D  sh o w  C aveolin-1 labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). 
P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are show n  
a s  blue.
A) Caveolin-1 D) Caveolin-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  5 .1 6 . Dual labelling o f C H 0 -p 6  ce lls  for Caveolin-1 and FMDV at 30  m in utes after initiation o f virus internalisation  
CHO-P6 cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 4 “C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 3 0  m in utes incubation at 37°C  internalisation w a s  
halted by fixation on ice  using 4%  paraform aldehyde Following perm eabilisation with 0.1%  Triton, Caveolin-1 and virus 
w ere d e tec te d  using a rabbit polyclonal serum  directed a ga in st th e N -term inus of hum an Caveolin-1 (1 /2 5 0 ) and the m o u se  
m on oclon al antibody D9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by A lexa fluor conju gated  g o a t anti-rabbit and go a t  
an ti-m ou se  seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  C aveolin-1 labelling (green ) and p a n e ls  B  a n d  E  sh o w  virus (red). 
P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  s h o w s  an overlay of p a n els  D and E. DAPI sta in ed  nuclei are show n  
a s  blue.
5.4 Summary and Discussion
The data presented in chapter 4 shows that virus is rapidly taken up by SW480-p6 
cells and delivered to early/recycling endosomes, consistent with the biochemical data 
presented in chapter 3. However, SW480-P6 cells do not express caveolin-1 and 
therefore do not possess caveolae at their cell surface. It is possible therefore that the 
virus uses different uptake pathways in cell lines which do express caveolin-1. In 
order to investigate this possibility we carried out experiments using CHO-p6 cells, a 
cell line which expresses Caveolin-1 and therefore possesses caveolae.
A key feature of the infection of SW480-P6 cells by FMDV is that it requires a low 
pH step at an early stage (see section 3.2.3). The experiments outlined in section 5.2 
investigate whether the early stages of infection of CHO-p6 cells by FMDV also 
require a low pH step. CHO-P6 cells were treated with concanamycin A, an agent 
which specifically inhibits the vacuolar H+-ATPase, and therefore dissipates the 
acidic pH within endosomes. 100 nM Concanamycin A inhibited infection of CHO- 
p6 cells by an average of 74% when cells were pretreated with the di*ug, indicating 
that infection of CHO-P6 cells by FMDV is dependent on a low pH step. This 
concentration of dr ug was shown to inhibit infection at an early stage since the 
addition of the drug at a later stage (i.e. immediately following removal of the virus 
inoculum) had virtually no effect on infection. These observations indicate that 
raising the endosomal pH inhibits infection at a stage, prior to virus RNA 
tianslation/replication, and post attachment to the cell surface. In contrast to the 
situation seen with SW480-p6 cells, higher concentiations of drug inhibited infection 
(lOpM and l|iM) when added prior to the addition of virus and when added at a later 
stage. This indicates that higher concenti ations of drug inhibit replication of vims as
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well as cell entiy. The data presented in section 5.2 show that infection of CH0-P6 
cells by FMDV requires a low pH step at an early stage, just as is the case for SW480- 
p6 cells.
In chapter 4, FMDV was shown to be delivered to early- and recycling-endosomes in 
SW480-p6 cells by immunofluorescence confocal microscopy. Section 5.3 shows the 
results of similar experiments earned out using CH0-P6 cells. FMDV was allowed to 
enter cells for 5, 10, 15 or 30 minutes and the cells labelled for vims and markers of 
cellular' compartments. The compartment markers used were EEA-1 (a marker of 
early endosomes), the transferrin receptor (a mar ker of early and recycling 
endosomes), LAMP-2 (a marker of lysosomes), and caveolin-1 (a marker of caveolae, 
caveosomes, and caveolae-dependent uptake pathways). At 5 and 10 minutes post­
entry the majority of virus had been internalised into intracellular* vesicle-like 
structures. By 15 and 30 minutes, virtually all virus had been inter*nalised into larger 
intracellular vesicles. At 5 minutes, there was extensive colocalisation of inter*nalised 
virus EEA-1, partial colocalisation with the transferrin receptor, and little or no 
colocalisation with LAMP-2. There was a small amount of colocalisation between 
virus and caveolin-1 at the cell surface and just below the plasma membrane. At 10 
minutes extensive colocalisation between virus and EEA-1, partial colocalisation with 
the transferrin receptor, and little or no colocalisation with LAMP-2, was observed. 
Again at this time point a small amount of colocalisation can be observed between 
virus and caveolin-1 at the cell surface and intracellular vesicles, although the 
majority of virus was not colocalised with caveolin-1. At 15 minutes colocalisation 
can still clearly be seen between virus and EEA-1 but to a lesser extent than seen at 10 
minutes. Extensive colocalisation between virus and the transferrin receptor, and veiy 
little colocalisation between virus and LAMP-2 or caveolin-1, were observed at this
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time point. At 30 minutes virus can still clearly be seen to colocalise with EEA-1, but 
to a lesser extent than observed at the 10 and 15 minute time-points. Extensive 
colocalisation between virus and the ti'ansferrin receptor, and very little colocalisation 
between virus and LAMP-2 or caveolin-1, were again observed at this time point.
The above data shows that the majority of internalised virus is delivered to EEA-1 
positive early-endosomes by 10 minutes after the initiation of virus internalisation. 
The level of colocalisation with transferrin receptor reaches a maximum at the later 
timepoints (15 and 30 minutes) presumably due to delivery of a proportion of virus 
from early to recycling endosomes. Viral protein does not appear to be delivered to 
lysosomes since no colocalisation was observed with LAMP-2 at any time point. A 
small amount of colocalisation of FMDV with caveolin-1 was detected at 5 and 10 
minutes, and little or no colocalisation at 15 and 30 minutes. The small amount of 
colocalisation of vims with caveolin-1 presumably represents virus in early 
endosomes, since caveolin-1 has been shown to colocalise partially with the early 
endosomal marker EEA-1 in a number of cell types (334).
The above observations suggest that FMDV is delivered fr om the surface of CHO- 
P6 cells to early- and recycling-endosomes, but not late endosomes and lysosomes, 
just as is the case in SW480-P6 cells. This entiy pathway is consistent with the low 
pH dependence of infection shown in section 5.2. These data are inconsistent 
however with virus uptake via caveolae-dependent endocytosis.
The virus SV40 is taken up by caveolae-dependent endocytosis and delivered to the 
neutral pH caveosome, and so is not exposed to acidic pH. Caveolae-dependent 
endocytosis is also a relatively slow process in comparison to the clathrin-dependent 
pathway and SV40 has a half time for internalisation of around 60 minutes (251). 
FMDV however is almost completely internalised within 15 minutes, a rapid
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times cale which is not consistent with uptake via caveolae-dependent endocytosis. 
FMDV also displayed very little colocalisation with caveolin-1, a mar ker of caveolae- 
dependent endocytosis, yet colocalised extensively with markers of early and 
recycling endosomes. Again this is not consistent with uptake of virus by caveolae- 
dependent endocytosis.
FMDV is rapidly delivered to early/recycling endosomes in both SW480-p6 and 
CH0-p6 cells. In CHO-p6 cells, virus still colocalises with early and recycling 
endosome markers after 30 minutes, whereas in SW480-p6 cells virus no longer 
colocalised with these markers, or the lysosome marker LAMP-2, at this time point.
It is possible that transfer of viral protein onwards from early and recycling 
endosomes may occur more slowly in CHO-D6 cells or it may not occur at all. It is 
unlikely that this difference between the two cell lines has any bearing on infection 
however, as the extreme sensitivity of the FMDV capsid to low pH makes it highly 
probable that the viral RNA has already been released into the cytoplasm before the 
virus reaches recycling endosomes. Human rhinovirus 2 (HRV-2) undergoes a 
conformational change ti'iggered by pH values less than 5.6 , which are present in late 
endosomal compartments (261) (endosomal carrier vesicles and late endosomes). 
These compartments are the first compartments the virus enters with sufficiently low 
pH to trigger this conformational change. This low pH-tiiggered conformational 
change leads to viral uncoating and delivery of viral RNA to the cytoplasm from late 
endosomes (262). Uncoating of the FMDV capsid occurs at pH values just below 
neutrality, meaning that the first compartment reached with a pH low enough to 
trigger this event is the early endosome. Transfer of viral RNA to the cytoplasm 
across the endosomal membrane would be expected to occur soon afterwards, as is the 
case for HRV-2. Since the transfer of viral RNA to the cytoplasm is all that is
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required to initiate infection of tissue culture cells by FMDV, the fate of internalised 
viral capsid protein after it has left early and recycling endosomes and parted ways 
with viral RNA is unlikely to make a difference to infection.
Taken together, the data presented in chapters 3, 4, and 5 show that infection of both 
SW480-p6 cells and CHO-P6 cells requires an acid pH step at an early stage, and also 
delivery of virus fr om the cell surface to early- and recycling-endosomes. The data is 
inconsistent with a requirement for caveolae-dependent endocytosis for infection, 
since FMDV still infects cells lacking caveolae (SW480-P6), and does not appear to 
utilise this pathway in cells which possess caveolae (CHO-p6). The data presented 
here suggest that FMDV utilises a very similar' entry pathway both in cells which lack 
caveolae and cells which possess caveolae, namely clathrin-dependent delivery of 
virus ft'om the cell surface to acidic early and recycling endosomes.
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Chapter Six: The role of the Integrin avp6 in infection 
of SW480-P6 ceiis by FMDV
6.1 introduction
The integrin avp6 has been shown to act as an attachment receptor for FMDV on the 
surface of SW480-P6 and CH0-p6 cells (145, 147). Virus binding (and infection) on 
these cells is blocked by a function blocking antibody directed against avp6, and by 
peptides containing the ROD integrin-binding motif. The parent cell lines (SW480 
and CHO cells) are not able to bind virus or to support FMDV infection since they do 
not express the P6 integiin subunit and therefore do not express the integi'in avP6 at 
their cell surface. However, despite its role as an attachment receptor, little is known 
of the role of the integi'in avP6 in subsequent virus internalisation and infection. 
Deletion of virtually the entire cytoplasmic domain of the p6 integrin subunit does not 
prevent virus binding to avP6 when this integrin is expressed at the surface of 
SW480-P6 cells, yet virtually abolishes infection (204). This shows that the integrin 
is involved in post-attachment events, but does not provide evidence as to its role. 
Therefore the role of the integi'in in the events following the initiation of virus 
internalisation was investigated using immunofluorescence confocal microscopy.
6.2 The Roie of the integrin av|36 in FMDV infection of 
SW480-P6 ceiis
6.2.1 FMDV Binding to SW480-p6 Cells
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The integrin ocvP6 has been previously shown to act as the major receptor for vims 
attachment to SW480-P6 cells using flow cytometiy (147). To further investigate this 
observation, attachment of vims to the surface of SW480-p6 cells was investigated by 
immunofluorescence microscopy. Virus was allowed to bind to the cell surface for 45 
minutes at 4°C, and excess virus was removed by washing. Cell surface virus and the 
integi'in avp6 were labelled using monoclonal antibodies D9 and E7P6 respectively 
on unpemieabilised cells. Figure 6.1 shows that virus bound to the surface of SW480- 
p6 cells (red -  panels A and D), and cell surface avp6 (green -  panels B and E) both 
adopt a very similar punctate labelling pattern, which is evenly distributed over the 
plasma membrane. When the two channels are overlayed (panels C and F) it can be 
seen that vims almost completely colocalises with integrin at the cell surface, 
consistent with the role of avp6 as the primary attachment receptor for FMDV on 
SW480-P6 cells.
The distribution of the integiins avp6 and avp5 at the surface of SW480-P6 cells 
were also compared. avP5 is an RGD-dependent integrin, but does not act as a 
receptor for FMDV, since wild-type SW480 cells (i.e. not tiansfected with the P6 
subunit and therefore not expressing avP6) express this molecule but do not support 
FMDV binding or infection. Unpeimeabilised SW480-P6 cells were labelled for cell 
surface avp6 (green) and avP5 (red) using the function-blocking monoclonal 
antibodies 10D5 and P1F6 respectively. Figure 6.2 shows this data. Both integiins 
display a punctate labelling pattern, but there is not extensive colocalisation between 
avP6 and avp5 at the cell surface, although the disti ibution of the two integi ins does 
overlap. This experiment shows that av  integiins are not all associated with one 
another in discrete membrane domains, but instead show differing locations at the cell
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surface. Since avp6 and avp5 do not colocalise extensively, it is unlikely that the 
colocalisation observed between FMDV and ovp6 occurs by chance.
Experiments were caiTied out to further explore the FMDV-attachment receptors on 
SW480-P6 cells. FMDV was prebound to SW480-p6 cells and the integrins avp6 
and avps were detected at the cell surface using monoclonal antibodies (MAbs) 10D5 
and P1F6 respectively. These MAbs are fimction blocking antibodies, i.e. they block 
the binding of natural ligands to their integrin receptors. It was reasoned that binding 
of a large multivalent ligand, such as FMDV, to the RGD-binding site on the integi'in 
would be expected to block binding of the MAh. Figure 6.3 shows a number of cells 
which have been labelled for avp6 and avp5 in the absence (Panel A) and presence 
(Panel B) of prebound virus. In the absence of prebound virus (Panel A) cell surface 
labelling for both integiins (avp6 (green) and avp5 (red)) can be seen. However in 
the presence of prebound virus (panel B), the avp6 labelling (green) is reduced, 
whilst the avp5 labelling is similar to that seen in panel A. These observations aie 
consistent with the role of avp6 (but not avp5) as the major attachment receptor for 
FMDV on this cell line.
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A) Virus D) Virus
B) c/v|36
C) Overlay A+B F) Overlay D+E
F ig u re  6 .1 . FMDV c o lo c a lise s  with th e integrin av p S  at th e su rface  o f SW 480-P 6  cells. FMDV strain 0 1  K cad2 (Spg/m l) w a s  
bound to th e  su rface  o f S W 4 8 0 -p 6  ce lls  for 4 5  m in utes at 4°C . C ells w ere  not perm eabilised  and all su b seq u e n t s te p s  w ere  
carried out on ice. Virus and the integrin a v p 6  w ere  d e tec ted  using m on oclon al antibod ies D9 (m o u se  lgG 2A -5pg/m l) and  
E 7P 6  (m o u se  lgG 1-20pg/m l), follow ed by A lexa fluor conju gated  goat-anti m o u se  iso type sp ecific  seco n d a ry  antibodies. 
P a n e ls  A  a n d  D  sh o w  a v p S  at th e cell su rface  (red) and p a n e ls  B  a n d  E  sh ow  FMDV (green ) at th e cell surface. P a n e l C  
s h o w s  an overlay of p a n els  A and B, P a n e l F  s h o w s  an overlay of p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) (/v|)5 D) (/v|)5
B) (/v|^6
C) Overlay A+B F) Overlay D+E
F ig u re  6 .2 . T he integrin a v p 6  and a v p s  partially c o lo c a lise  at th e su rface  o f S W 480-P 6  cells . Integrins a v p 6  and a v p s  
w ere  d e te c ted  using m on oclon al an tib od ies 10D 5 (m o u se  lgG 2A -20p g/m l) and P 1F 6  (m o u se  lgG 1-20pg/m l), follow ed by 
A lexa fluor conju gated  goat-anti m o u se  iso type sp ec if ic  seco n d a ry  antibodies. C ells w ere  not p erm eabilised  and all s te p s  
w ere  carried out on ice. P a n e ls  A  a n d  D  sh o w  a v p s  at th e cell su rface  (red) and p a n e ls  B  a n d  E  sh o w  a v p 6  (green ) at th e  
cell su rface. P a n e l C  sh o w s  an overlay o f p a n e ls  A and B, P a n e l F  s h o w s  an overlay of p a n els  D and E. DAPI sta ined  
nuclei are sh ow n  a s  blue.
A) No Virus B) Virus
F ig u re  6 .3 . FMDV blocks th e binding of a function blocking antibody aga in st th e integrin av p S  but not a v p s  at th e su rface  of 
SW 480-P 6  cells. S W 480  p6 ce lls  w ere  incubated  with FMDV strain 0 1  K cad2 in DMEM (5pg/m l) (P a n e l B) or DMEM alone  
(P a n e l A ) for 4 5  m in utes at 4°C . C ells  w ere  not p erm eabilised  and all su b seq u e n t s te p s  w ere carried out on ice. The  
integrins av p S  (green ) and av p S  (red) at th e cell su rface  w ere  d e te c ted  using function blocking m on oclon al antibod ies 10D 5  
(m o u se  lgG 2A -20ng/m l) and P 1F 6  (m o u se  lgG 1-20pg/m l) respectively , follow ed by A lexa fluor conju gated  goat-anti m o u se  
iso type sp ecific  seco n d a ry  antibodies. DAPI sta in ed  nuclei are sh ow n  a s  blue. Bars = 20pm . In th e a b s e n c e  o f surface  
bound FMDV (P a n e l A )  both a v p S  (green ) and a v p 5  (red) can  b e  d e tec ted  at th e cell surface. In th e p r e se n c e  o f prebound  
FMDV (P a n e l B), only a v p s  labelling is still ob serv ed  but avb6  labelling is virtually a b sen t. T his ind icates that FMDV binds 
a v p s  but not avp S  at th e su rface  of S W 4 8 0 -p 6  cells, s in c e  virus bound to its cell su rface  receptor h a s  b locked th e binding  
of th e an ti-avp s function blocking antibody 10D 5, but not th e  an ti-avp s function blocking antibody P1F 6.
6.2.2 The cell surface distribution of av(36
As shown in figure 6.1, avp6 labelling at the surface of SW480-p6 cells shows a 
punctate distiibution. The plasma membrane also contains cholesterol and 
sphingolipid rich lipid rafts, which are specialised membrane domains that act as 
platforms for cell signalling and endocytic uptake pathways. The experiments 
described in chapters 3, 4, and 5 show that infection by FMDV does not require intact 
lipid-rafts or caveolae-dependent endocytosis. To investigate whether avp6 is 
associated with lipid rafis at the cell surface the B subunit of cholera toxin (CTB) was 
utilised. CTB binds the ganglioside GMl which is located predominantly within lipid 
rafts. Fluorescently conjugated CTB can therefore be used as a marker for lipid rafts 
at the cell surface. CTB was allowed to bind SW480-p6 cells for 45 minutes at 4°C, 
before being crosslinked with a rabbit anti-cholera toxin polyclonal serum. Janes et. 
al. (1999) have utilised this method of lipid raft visualisation previously and showed 
that CTB labelled membrane patches display chaiacteristics consistent with 
biochemically isolated lipid rafts (149). Following paraformaldehyde fixation, avp6 
at the cell surface was labelled using the monoclonal antibody E7P6. Figure 6.4 
shows that avP6 (red) and CTB (green) display minimal colocalisation at the cell 
surface indicating that ocvp6 is predominantly not located within lipid rafts, at least in 
the absence of ligand. A number of cell surface receptors have been shown to only 
partition preferentially to lipid rafts following crosslinking by antibody or multivalent 
ligand. Examples include the folate receptor and the integiin oc6p4 (89). It is 
therefore possible that binding and crosslinking of avP6 by ligand could cause a 
redistribution of avp6 such that it colocalises with lipid raft markers to a greater 
extent. In order to test this hypothesis the experiment shown in figure 6.4 was
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repeated except that FMDV was added to the cells at the same time as fluorescently 
labelled CTB in order to crosslink surface integrin. As shown in figure 6.5, 
crosslinking of avP6 by virus did not increase the degree of colocalisation of avp6 
(red) with cross linked CTB (green) at the surface of SW480-p6 cells. This indicates 
that avp6 does not partition preferentially to lipid raft microdomains at the cell 
surface when crosslinked by ligand.
In order to investigate whether virus bound to the cell surface is associated with 
lipid rafts, CTB and vims were prebound to SW480-p6 cells for 45 minutes at 4°C. 
CTB at the plasma membrane was then crosslinked with a rabbit anti-cholera toxin 
polyclonal serum (in order to visualise lipid rafts). Following paraformaldehyde 
fixation, FMDV bound to the cell surface was visualised using the monoclonal 
antibody D9 and an Alexa-568 conjugated goat anti-mouse IgG2A secondary 
antibody. As shown in figure 6.6, FMDV (red) and lipid rafts (green) did not 
colocalise at the surface of SW480-P6 cells. The degi ee of colocalisation is if 
anything less than that observed between avp6 and crosslinked CTB. These 
experiments show that neither avp6 nor virus at the cell surface is associated with 
lipid rafts, and hence would not be expected to be internalised by lipid raft dependent 
endocytic uptake pathways. These observations are consistent with the insensitivity 
of infection of SW480-P6 cells to the disruption of lipid rafts and lipid raft dependent 
endocytosis by cholesterol depletion (see section 3.2.2.1).
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A) (/v()6 D) (/v()6
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  6 .4 . C olocalisation  o f th e integrin a v p S  with a marker for lipid rafts. A lexa -488  conju gated  cholera  toxin B (CTB- 
0 .2p g/m l) w a s  bound to th e su rface  o f SW 480-P 6  c e lls  for 4 5  m in utes at 4"C. CTB w a s  crosslinked using an anti cholera  
toxin polyclonal rabbit anti serum . Following fixation with 4% paraform aldehyde, the integrin avp S  w a s  d e te c ted  using th e  
m on oclon al antibody E 7P 6  (m o u se  lgG 1-20pg/m l), follow ed by an A lexa  fluor-568 conju gated  goat-anti m o u se  secon d ary  
antibody. P a n e ls  A  a n d  D  sh o w  avp S  at th e cell su rface  (red) and p a n e ls  B  a n d  E  sh o w  crosslinked  CTB (green ) at th e  cell 
su rface. P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei 
are sh ow n  a s  blue. avp S  at th e cell su rface  d o e s  not sh o w  e x te n s iv e  co loca lisa tion  with a marker o f lipid rafts (crosslinked  
CTB).
A) (xv|ib D) (xv|)6
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  6 .5 . C olocalisation  o f th e integrin avp S  with a marker for lipid rafts following binding of virus FMDV strain 0 1  K cad2  
(5ng/m l) and A lexa -488  conju gated  cholera toxin B (C T B -0.2pg/m l) w ere  bound to th e su rface  of SW 480-P 6  ce lls  for 4 5  
m in utes at 4°C . CTB w a s  crosslinked using an anti cholera toxin polyclonal rabbit anti serum . Following fixation with 4%  
paraform aldehyde, the integrin a v p 6  w a s  d e tec ted  using th e m on oclon al antibody E 7P 6 (m o u se  lgG 1-20pg/m l), followed  
by an A lexa fluor-568 conju gated  goat-anti m o u se  seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  a v p 6  at th e cell su rface  (red) 
and p a n e ls  B  a n d  E  sh o w  crosslinked CTB (green ) at th e cell surface. P a n e l C  sh o w s  an overlay o f p a n els  A and B, P a n e l  
F  s h o w s  an overlay of p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue. avp S  at the cell su rface  d o e s  not sh o w  
ex te n s iv e  co loca lisa tion  with a marker o f lipid rafts (crosslinked CTB) following binding of FMDV
A) Virus D) Virus
B) Cholera Toxin B E) Cholera Toxin B
C) Overlay A+B F) Overlay D+E
F ig u re  6 .6 . FMDV d o e s  not co lo ca lise  with a marker for lipid rafts. FMDV strain 0 1  K cad2 (5pg/m l) and A lex a -4 8 8  
conju gated  cholera  toxin B (C T B -0.2pg/m l) w ere  bound to th e  su rface  o f S W 480-P 6  ce lls  for 4 5  m in utes at 4°C . CTB w a s  
crosslinked using an anti cholera toxin polyclonal rabbit anti serum . Following fixation with 4% paraform aldehyde, su rface  
bound virus w a s  d e tec ted  using th e  m on oclon al antibody D 9 (m o u se  lgG 2A -5pg/m l), followed by an A lexa fluor-568  
conju gated  goat-anti m o u se  iso type sp ec ific  seco n d a ry  antibody. P a n e ls  A  a n d  D  sh o w  FMDV at th e cell su rface  (red) and 
p a n e ls  B  a n d  E  sh o w  crosslinked CTB (green ) at th e cell surface. P a n e l C  s h o w s  an overlay of p a n e ls  A and B, P a n e l F  
s h o w s  an overlay of p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue. FMDV at th e cell su rface  d o e s  not co lo c a lise  
with a marker o f lipid rafts (crosslinked CTB), indicating that FMDV e n d o c y to s is  is not d ep en d en t on lipid rafts.
6.2.3 The Role of avp6 in Post Attachment Events
From the data presented above and previous reports, it is clear that avp6 acts as the 
primary attachment receptor on the surface of SW480-P6 cells. The role of this 
integrin in post-attachment events is however less clear. Deletion mutations within 
the cytoplasmic domain of the p6 integr in subunit which eliminate the NPXY putative 
endocytosis motif, produce receptors that still support FMDV binding but no longer 
mediate infection (204), This implies that avp6 has a role in post-attachment events, 
but does not give an indication as to which stage the block in infection occurs. 
Therefore experiments were carried out to determine whether the integrin avp6 can 
mediate virus internalisation as well as binding at the cell surface.
Virus bound to the cell surface at 4°C colocalises with avP6 (see figure 6.1). If 
avP6 acts to internalise virus particles, then virus and avp6 would be expected to 
colocalise with one another inside cells at early times following the initiation of virus 
internalisation. FMDV was allowed to bind SW480-p6 cells at 4°C, and 
internalisation was initiated by shifting the temperature to 37°C. After 5 or 10 
minutes at 37°C internalisation was halted by shifting the temeperature back to 4°C 
and paraformaldehyde fixation. Following Triton permeabilisation, virus and avp6 
were labelled using the monoclonal antibodies D9 and 4B5 respectively (131). At 5 
minutes (figure 6.7) virus (green) and the integiin avp6 (red) were colocalised inside 
the cell. At 10 minutes (figure 6.8) virus was still colocalised with avP6. These 
observations stiongly suggest that avP6 serves not only as an attachment receptor, but 
also to deliver the virus to early endosomes.
If virus internalisation is mediated by avP6, then initiation of vims uptake would be 
expected to cause a change in the distribution of this integiin. Experiments designed
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to examine whether this is the case were therefore carried out. SW480-p6 cells were 
double labelled for avP6 and markers of intr acellular compartments (i.e. EEA-1, the 
transferring receptor and LAMP-2) in the presence or absence of virus internalisation. 
One group of coverslips had no virus added prior to fixation and double labelling.
The other group of coverslips were incubated with virus at 4°C to allow virus binding 
to the cells, before initiation of virus internalisation for 10 minutes at 37°C. The cells 
were then fixed and double labelled for avp6 and cellular compar tment markers as 
above. In this way, the distribution of avp6, and the level of colocalisation of avp6 
with compartment markers at steady state, could be compared with that observed 
fixed after 10 minutes of virus internalisation. In the absence of virus (see figures 6.9, 
6.11, and 6.13 -  panels B and E), the integrin labelling is relatively difhise, and is 
present at the cell surface and in small intracellular- vesicles. Following virus 
internalisation however, the integrin labelling appears more intense, and is 
predominantly found in larger intracellular vesicular structures (see figures 6.10, 6.12, 
and 6.14 -  panels B and E). Intei-nalisation of virus therefore seems to be 
concomitant with an alteration in the distr ibution of avp6. SW480-p6 cells fixed 
after incubation in the absence of vir*us, or after 10 minutes of virus internalisation, 
were double labelled for avp6 and EEA-1 (a marker of early endosomes) and are 
shown in figure 6.9 And 6.10 respectively. In the absence of virus, avp6 (red) 
colocalises little with EEA-1 (green) (see figure 6.9 panels C and F). Following 10 
minutes of virus internalisation, avp6 is found in lar ger intr acellular vesicle-like 
structures and colocalises with EEA-1 to a greater extent (see figure 6.10 panels C 
and F). SW480-p6 cells double labelled for avP6 and the Transfenin Receptor (a 
marker of early and recycling endosomes) in the absence of virus and following 10 
minutes vir*us internalisation are shown in figure 6.12 And 6.11 respectively. In the
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absence of virus the integi in avp6 (red) is found at the cell surface and in small 
inti'acellular vesicles and colocalises little with the tiansferrin receptor (green) (see 
figure 6.11 panels C and F). Following 10 minutes virus internalisation ocvp6 
labelling is more intense, is found in larger inti'acellular vesicle-like structures, and 
colocalises with the transferrin receptor to a much greater extent (see figure 6.12 
panels C and F). When similar experiments were carried out involving the marker 
LAMP-2 (a lysosomal marker protein), the distiibution of integrin changed as 
described above following virus internalisation, but there was little colocalisation of 
avP6 and LAMP-2 either in the absence of virus (figure 6.13 panels C and F) or 
following 10 minutes virus internalisation (figure 6.14 Panels C and F). The above 
data indicates that internalisation of FMDV bound to the surface of SW480-P6 cells 
causes a change in the distiibution of the integrin avp6, and gieater colocalisation 
with markers of early- and recycling-endosomes (the very compartments to which 
virus is delivered). These observations are consistent with a model whereby FMDV 
binding to the cell surface and delivery to early- and recycling-endosomes are both 
mediated by the RGD-dependent integiin avP6.
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A) Virus D) Virus
B) (/v|)6
C) Overlay A+B
F ig u re  6 .7 . FMDV c o lo c a lise s  with th e integrin av^ S  at 5  m in utes after th e  initiation o f virus internalisation. FMDV strain 
0 1 K c a d 2  (5pg/m l) w a s  bound to th e su rface  o f S W 480-P 6  ce lls  for 4 5  m inutes at 4 “C. Internalisation o f bound virus w a s  
initiated by incubation at 37°C . After 5 m in utes at 37°C  virus internalisation w a s  halted by fixation on ice  using 4%  
paraform aldehyde. Following perm eabilisation  using 0.1%  Triton, virus and the integrin avp S  w ere d e te c te d  using  
m on oclon al antibod ies D 9 (m o u se  lgG 2A -5pg/m l) and 4 B 5  (Rabbit IgG), followed by A lexa fluor conju gated  goat-anti m o u se  
and g o a t anti rabbit seco n d a ry  an tib od ies P a n e ls  A  a n d  D  sh o w  avp S  labelling (red) and p a n e ls  B  a n d  E  sh o w  FMDV 
(green ). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei 
are sh ow n  a s  blue.
A) Virus D) Virus
E) (xvB6
C) Overlay A+B F) Overlay D+E
F ig u re  6 .8 . FMDV c o lo c a lise s  with th e integrin a v p 6  at 10  m in utes after th e initiation o f virus internalisation. FMDV strain 
0 1 K c a d 2  (5pg/m l) w a s  bound to th e su rface  o f S W 480-P 6  c e lls  for 4 5  m in utes at 4°C . Internalisation o f bound virus w a s  
initiated by incubation at 37°C . After 10 m in utes at 37°C  virus internalisation w a s  halted by fixation on ice  using 4%  
paraform aldehyde. Following perm eabilisation  using 0.1%  Triton, virus and th e integrin a v p 6  w ere  d e tec ted  using  
m on oclon al antibod ies D9 (m o u se  lgG 2A -5pg/m l) and 4 B 5  (Rabbit IgG), follow ed by A lexa fluor conju gated  goat-anti m o u se  
and g oa t anti rabbit seco n d a ry  antibod ies. P a n e ls  A  a n d  D  sh o w  a v p S  labelling (red) and p a n e ls  B  a n d  E  sh o w  FMDV 
(green ). P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei 
are sh ow n  a s  blue.
A EEA-1
B) (XV116 E) (xvlIB
C) Overlay A+B F) Overlay D+E
F ig u re  6 .9 . T he integrin a v p S  c o lo c a lise s  little with EEA-1 in th e a b s e n c e  o f FMDV. S W 480-P 6  cells, prepared on  
coverslip s  w ere  fixed using 4% paraform aldehyde and perm eabilised  using 0.1%  Triton. A marker o f early e n d o s o m e s  
(E E A -1) and th e integrin a v p 6  w ere d e tec ted  using m on oclon al an tib od ies 14 (m o u se  IgG I-Spg/m l) and 4 B 5  (Rabbit IgG), 
follow ed by A lexa fluor conju gated  goat-anti m o u se  and g o a t anti-rabbit secon d ary  antibodies. P a n e ls  A  a n d  D  sh o w  EEA-1 
(green ) and p a n e ls  B a n d  E  sh o w  integrin a v p 6  labelling (red). P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  
s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
A) EEA-1 D) EEA-1
C) Overlay A+B F) Overlay D+E
F ig u re  6 .1 0 . T he integrin a v p 6  c o lo c a lise s  to  a greater ex ten t with EEA-1 following FMDV internalisation. S W 480-P 6  cells, 
prepared on coverslip s  w ere incubated with FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m inutes at 4°C . Virus internalisation w a s  
initiated by incubation for 10 m in utes at 37  °C. Internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. 
Following perm eabilisation with 0.1%  Triton, a marker o f early e n d o s o m e s  (EEA-1) and th e integrin a v p s  w ere d e tec ted  
using m on oclon al antibod ies 14 (m o u se  lgG 1-5pg/m l) and 4 B 5  (Rabbit IgG -N eat) respectively , follow ed by A lexa fluor 
conju gated  goat-anti m o u se  and go a t anti rabbit seco n d a ry  antibod ies. P a n e ls  A  a n d  D  sh o w  EEA-1 labelling (green ) and  
p a n e ls  B  a n d  E  sh o w  labelling for a v p 6  (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay of 
p a n els  D and E. DAPI sta ined  nuclei are show n a s  blue. C om parison o f p a n els  0  and F with th o se  s a m e  p a n els  in figure 
6 .9  s h o w s  that virus internalisation c a u s e s  a c h a n g e  in th e distribution o f th e integrin a v p 6  and greater co loca lisa tion  of 
virus with E E A -1.
A) Transferrin Receptor D) Transferrin Receptor
B) (/v IId E) (xv|16
C) Overlay A+B F) Overlay D+E
F ig u re  6 .1 1 . T he integrin a v p 6  c o lo c a lise s  little with th e transferrin receptor in th e a b s e n c e  o f FMDV. S W 480-P 6  cells, 
prepared on coverslip s  w ere fixed using 4%  paraform aldehyde and perm eabilised  using 0.1%  Triton. T he transferrin  
receptor and th e integrin a v p 6  w ere  d e te c te d  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and 4 B 5  (Rabbit 
IgG), follow ed by A lexa fluor con ju gated  goat-anti m o u se  and g o a t anti rabbit seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  
th e transferrin receptor (green ) and p a n e ls  B  a n d  E  sh o w  integrin a v p 6  labelling (red). P a n e l C  s h o w s  an overlay o f p a n els  
A and B, P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue
A) Transferrin Receptor D) Transferrin Receptor
B) (/v|16
C) Overlay A+B F) Overlay D+E
F ig u re  6 .1 2 . T h e integrin a v p s  c o lo c a lise s  to  a greater ex ten t with th e  transferrin receptor following FMDV internalisation. 
S W 480-P 6  cells , prepared on c overslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 4 “C. Virus 
internalisation w a s  initiated by incubation for 10 m in utes at 37  °C. Internalisation w a s  halted by fixation on ice  using 4%  
paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, th e  transferrin receptor and th e integrin a v p 6  w ere  
d e te c ted  using m on oclon al an tib od ies H 68.4  (m o u se  lgG 1-5pg/m l) and 4 B 5  (Rabbit IgG -N eat) respectively , follow ed by 
A lexa fluor con ju gated  goat-anti m o u se  and g o a t anti rabbit seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  transferrin 
receptor labelling (green ) and p a n e ls  B  a n d  E  sh o w  labelling for a v p 6  (red). P a n e l C  sh o w s  an overlay o f p a n els  A and B, 
P a n e l F  s h o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue. C om parison  of p a n els  C and F with 
th o se  s a m e  p a n els  in figure 6.11 s h o w s  that virus internalisation c a u s e s  a c h a n g e  in the distribution o f th e integrin a v p 6  and  
greater  co loca lisa tion  o f virus with th e transferrin receptor
A) LAMP-2 D LAMP-2
B) (/v|)6 E) (/v|16
C) Overlay A+B F) Overlay D+E
F ig u re  6 .1 3 . T he integrin a v p 6  c o lo c a lise s  little with LAMP-2 in th e a b s e n c e  o f FMDV, S W 480-P 6  ce lls , prepared on  
coverslip s  w ere  fixed using 4% paraform aldehyde and p erm eabilised  using 0.1%  Triton. A marker of ly s o so m e s  (LAMP-2) 
and th e  integrin a v p 6  w ere  d e te c ted  using m on oclon al an tib od ies H 4B4 (m o u se  IgG I-O .Spg/m l) and 4 B 5  (Rabbit IgG), 
follow ed by A lexa  fluor conju gated  go a t an ti-m ou se  and g o a t anti-rabbit seco n d a ry  an tib od ies P a n e ls  A  a n d  D  sh o w  
LAMP-2 (green ) and p a n e ls  B  a n d  E  sh o w  integrin a v p 6  labelling (red). P a n e l C  shovre an overlay of p a n els  A and B, P a n e l  
F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
D) LAMP-2A) LAMP-2
B) av|16 E) (/v|)6
C) Overlay A+B F) Overlay D+E
F ig u re  6 .1 4 . T he integrin avpB  c o lo c a lise s  littile with LAMP-2 following FMDV internalisation. S W 480-P 6  cells , prepared on 
coverslip s  w ere  incubated with FMDV strain 0 1  K cad2 (5p g/m l) for 4 5  m in utes at 4°C . Virus internalisation w a s  initiated by 
incubation for 10 m inutes at 37  °C. Internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. Following 
perm eabilisation with 0.1%  Triton, LAMP-2 and th e integrin a v p 6  w ere  d e tec ted  using m on oclon al an tib od ies H 4B4 (m o u se  
lgG 1-0 .5p g/m l) and 4B 5  (Rabbit IgG) respectively , follow ed by A lexa fluor conjugated  goat-anti m o u se  and g o a t anti rabbit 
seco n d a ry  antibod ies. P a n e ls  A  a n d  D  sh o w  LAMP-2 (green ) and p a n e ls  B  a n d  E  sh o w  labelling for a v p 6  (red). P a n e l C  
sh o w s  an overlay of p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue. 
C om parison of p a n els  C and F with th o se  s a m e  p a n els  in figure 6 .1 3  sh o w s  that virus internalisation c a u s e s  a ch a n g e  in 
th e distribution o f th e integrin a v p 6  but integrin d o e s  not c o lo c a lise  with LAMP-2 in the p r e se n c e  or a b s e n c e  o f virus.
6.2.4 The Trigger for avp6 Internalisation
The evidence presented above suggests that FMDV requires only the integiin avP6 
for binding to and internalisation by SW480-P6 cells. The rate of internalisation of 
FMDV is consistent with uptake of the virus nntegrin complex being tiiggered by the 
virus rather than simply mediated by membrane turnover. If this is the case, the 
trigger could be occupation of the ligand binding site on avp6, avP6 cross linking, or 
a combination of both ligand-binding and integi in cross-linking. In order to 
investigate these possibilities, integiin-binding peptides, a ligand mimetic function- 
blocking anti-avP6 antibody, and a non-ligand mimetic âmction-blocking anti-avp6 
antibody were utilised. The change in avp6 disti'ibution observed when virus 
internalisation is allowed to occur was used to indicate that internalisation of avp6 
had been tr iggered.
The first experiment was designed to assess whether occupation of the RGD- 
binding site of avP6 was sufficient to initiate its internalisation. A 12-mer RGD- 
containing peptide whose sequence corresponds to the GH loop of type O FMDV, and 
the equivalent RGE peptide were utilised. At the concentiations used (10jJ,M) virus 
binding to SW480-p6 cells is completely blocked by the RGD but not the RGE 
peptide (147), indicating that this concentiation of the former peptide results in the 
occupation of virtually all available vims binding sites. The peptides were allowed to 
bind at 4°C, before incubation at 37°C for 10 minutes in order to allow any integrin 
internalisation to occur. One gioup of coverslips had no peptide added prior to 
fixation. The cells were then double labelled for ocvp6 (red) and EEA-1 (green) using 
monoclonal antibodies 4B5 and 14 respectively. The distribution of integrin observed
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was no different when SW480-p6 cells were tieated with the RGD peptide (figure 
6.17), RGE peptide (figure 6.18), or with no peptide at all (figure 6.15). In all cases 
integrin was primarily found at the cell surface and in small inti'acellular vesicles, and 
colocalised little with EEA-1. In contrast, when SW480-P6 cells were treated with 
virus (figure 6.16) in place of peptide, avP6 was found primarily in larger 
inti'acellular vesicles and colocalised with EEA-1 to a gieater extent. This indicates 
that, unlike virus, the RGD-peptide was unable to trigger internalisation of avp6, and 
hence that ligand binding alone is insufficient to trigger internalisation of avp6.
The second experiment was designed to investigate whether ocvp6 crosslinking acts 
as a ti'igger for its internalisation. For these studies two anti-avp6 function blocking 
antibodies were utilised. The antibody 6.8G6 contains the integiin binding RGD- 
motif, and so is classified as a “ligand mimetic” anti-avp6 function-blocking antibody 
(329). The antibody 6.3G9 is an anti-avp6 function-blocking antibody but contains 
no such RGD-like motif and so is classed as non-ligand mimetic (329). Consistent 
with this, binding of 6.8G6 but not 6.3G9 to avp6 is inhibited by an RGD peptide 
(329). Antibody 6.8G6 therefore crosslinks avp6 and occupies the ligand binding 
site, whereas antibody 6.3G9 merely causes avP6 crosslinking. Experiments using 
these antibodies were carried out in the same way as those using RGD and RGE 
peptides. Cells were either not treated with antibody, or were treated with antibodies 
6.8G6 or 6.3G9 (at a concentiation of 10|Xg/ml). The antibodies were bound to the 
cell surface at 4°C followed by a 10 minute incubation at 37°C. Following 
paraformaldehyde fixation, labelling for avp6 was carried out using the rabbit 
monoclonal antibody 4B5. It was not possible to also carry out labelling for EEA-1 
since 6.8G6, 6.3 G9 and the anti-EE A-1 antibody are all mouse isotype IgG l. As
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shown in figure 6.19, the distribution of integiin following ti eatment with the non­
ligand mimetic monoclonal antibody 6.3G9 (Panels C and F) was virtually the same 
as that observed when no antibody was added prior to fixation (Panels A and D). 
However following treatment with the ligand mimetic monoclonal antibody 6.8G6 
(Panels B and E), the distribution of avp6 was altered compared to that observed in 
the absence of crosslinking antibody , and appeared similar to that obseiwed following 
10 minutes of virus internalisation (figure 6.8). It therefore appears that antibody 
6.8G6, but not 6.3G9, is capable of triggering internalisation of (xvp6. This data 
suggests that crosslinking of avp6 alone is insufficient to trigger avp6 internalisation. 
Instead avp6 must be both crosslinked, and the RGD binding site occupied, in order 
to ti'igger avP6 internalisation. This is consistent with a model whereby RGD- 
dependent binding and crosslinking of avp6 by multivalent FMDV particles at the 
cell surface triggers endocytic uptake of the integi in:virion complex.
157
A) EEA-1 D) EEA-1
E) (/v|)6
C) Overlay A+B F) Overlay^ D+E
F ig u re  6 .1 5 . T h e integrin a v p 6  c o lo c a lise s  little with EEA-1 in th e a b s e n c e  o f Peptide. S W 480-p 6  cells, prepared on  
coverslip s  w ere  fixed using 4%  paraform aldehyde and p erm eabilised  using 0.1%  Triton. A marker o f early e n d o s o m e s  
(EEA-1) and th e integrin avp S  w ere  d e tec ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and 4B 5  (Rabbit IgG), 
follow ed by A lexa  fluor conju gated  goa t ant- m o u se  and g o a t anti-rabbit seco n d a ry  antibodies. P a n e ls  A  a n d  D  sh o w  EEA- 
1 (green ) and p a n e ls  B  a n d  E  sh ow  integrin a v p 6  labelling (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  
sh o w s  an overlay o f p a n els  D and E. DAPI sta ined  nuclei are sh ow n  a s  blue.
A) EEA-1 D) EEA-1
B) (xv|16
C) Overlay A+B F) Overlay D+E
F ig u re  6 .1 6 . T he integrin avp S  c o lo c a lise s  to  a greater ex ten t with EEA-1 following FMDV internalisation. S W 480-P 6  cells, 
prepared on coverslip s  w ere incubated with FMDV strain 0 1  K cad2 (5pg/m l) for 4 5  m in utes at 4 ”C. Virus internalisation w a s  
initiated by incubation for 10 m in utes at 37  ”C. Internalisation w a s  halted by fixation on ice using 4%  paraform aldehyde. 
Following perm eabilisation with 0.1%  Triton, a marker o f early e n d o s o m e s  (EEA-1) and th e integrin a v p 6  w ere d etec ted  
using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and 4 B 5  (Rabbit IgG) respectively , follow ed by A lexa fluor conju gated  
g oat an ti-m ou se  and go a t anti-rabbit seco n d a ry  antibod ies. P a n e ls  A  a n d  D  sh ow  EEA-1 labelling (green ) and p a n e ls  B  
a n d  E  sh o w  labelling for a v p 6  (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  sh o w s  an overlay o f p a n els  D 
and E. DAPI sta ined  nuclei are sh ow n  a s  blue. C om parison  of p a n els  0  and F with th o se  s a m e  p a n els  in figure 6 .1 5  s h o w s  
that virus internalisation c a u s e s  a ch a n g e  in th e distribution of th e integrin a v p 6  and greater co loca lisa tion  o f virus with EEA- 
1 .
A) EEA-1 D) EEA-1
B) (XV (16
C) Overlay A+B F) Overlay^ D+E
F ig u re  6 .1 7 . A 17-m er RGD peptide d o e s  not alter th e  distribution of th e integrin avpS . S W 480-P 6  ce lls , prepared on  
coverslip s  wrere incubated with a 17-m er RGD peptide corresp ondin g to th e GH loop of FMDV (lOpM ) for 4 5  m in utes at 4 ”C. 
C overslip s w ere  th en  incubated for 10 m in utes at 37  °C in order to allow  any integrin internalisation to occur. Internalisation  
w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, a marker o f early  
e n d o s o m e s  (EEA-1) and th e integrin a v p 6  w ere  d e te c ted  using m on oclon al antibod ies 14 (m o u se  lgG 1-5pg/m l) and 4B 5  
(Rabbit IgG) respectively , follow ed by A lexa fluor con ju gated  g o a t an ti-m ou se  and g o a t anti-rabbit seco n d a ry  antibodies. 
P a n e ls  A  a n d  D  sh o w  EEA-1 labelling (green ) and p a n e ls  B  a n d  E  sh o w  labelling for a v p 6  (red). P a n e l C  s h o w s  an overlay  
of p a n els  A and B, P a n e l F  s h o w s  an overlay o f p a n e ls  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue. C om parison of 
p a n els  C and F with th o se  s a m e  p a n els  in figure 6 .1 5  s h o w s  that RGD peptide d o e s  not alter th e distribution of th e integrin 
a v p 6 , unlike w h ole  virus particles ( s e e  figure 6 .1 6 ), h e n c e  occu p ation  o f th e RGD binding s ite  o f a v p 6  is insufficient to  
trigger its internalisation.
D) EEA-1A) EEA-1
E) av(16
C) Overlay A+B F) Overlay D+E
F ig u re  6 .1 8 . A 17-m er RGE peptide d o e s  not alter th e distribution of th e integrin av p 6 . S W 480-P 6  ce lls , prepared on  
coverslip s  w ere incubated with a 17-m er RGE peptide corresp ondin g to the GH loop of FMDV (lO pM ) for 4 5  m in utes at 4 “C. 
T his peptide d o e s  not block virus binding. C overslip s w ere  then  incubated for 10 m inutes at 37  °C in order to allow  any  
integrin internalisation to occur. Internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following  
perm eabilisation  with 0.1%  Triton, a marker o f early e n d o s o m e s  (EEA-1) and th e  integrin avp S  w ere  d e tec ted  using  
m on oclon al antibod ies 14 (m o u se  lgG 1-5pg/m l) and 4 B 5  (Rabbit IgG -N eat) respectively , follow ed by A lexa fluor conju gated  
g o a t an ti-m ou se  and g oa t anti-rabbit seco n d a ry  antibod ies. P a n e ls  A  a n d  D  sh o w  EEA-1 labelling (green ) and p a n e ls  B  
a n d  E  sh o w  labelling for a v p 6  (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  sh o w s  an overlay o f p a n els  D 
and E. DAPI sta ined  nuclei are show n a s  blue C om parison  of p a n e ls  C and F with th o se  s a m e  p a n els  in figure 6 .1 5  sh o w s  
that th e RGE peptide d o e s  not alter th e distribution o f th e integrin av p 6 , unlike w hole  virus particles ( s e e  figure 6 .1 6 ), a s  
ex p e c ted  s in c e  th is peptide d o e s  not block virus binding.
A) No Antibody D) No Antibody
B) 6.8G6
C )6 .3G 9 F) 6.3G9
F ig u re  6 .1 9 . T he ligand m im etic function-blocking anti-avp6 antibody 6 .8 G 6  triggers internalisation o f a v p s . S W 480-p 6  
cells , prepared on coverslip s, w ere  incubated with a ligand m im etic function blocking anti avb6  antibody 6 .8 G 6  (P a n e ls  B 
and E), the non-ligand m im etic function-blocking anti-avp6 antibody 6 .3 G 9  (P a n e ls  C and F), or with DMEM (P a n e ls  A and 
D) for 1 hour at 4°C . C overslips w ere th en  incubated  for 10  m inutes at 3 7  ”C in order to allow  any integrin internalisation to 
occur. Internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation  with 0.1%  
Triton, th e integrin a v p 6  w a s  d e tec te d  using th e m on oclon al antibody 4 8 5  (Rabbit IgG), follow ed by an A lexa fluor g o a t anti­
rabbit seco n d a ry  antibody. DAP I sta in ed  nuclei are sh ow n  a s  blue. Incubation with a non-ligand m im etic function blocking  
anti a v p 6  antibody 6 .3 G 9  prior to fixation (P a n e ls  0  and F) did not alter the distribution o f integrin ob serv ed  in th e a b s e n c e  
of antibody (P a n e ls  A and D). In contrast, th e ligand m im etic function-blocking anti-avp6 antibody 6 .8 G 6  (P a n e ls  B and E) 
c a u s e d  a  redistribution o f integrin similar to that o b serv e d  upon FMDV internalisation ( s e e  figures 6 .9 -6 .1 4 ) .
6.3 Summary and Discussion
The RGD-dependent integi'in avP6 has been reported previously to act as the major 
attachment receptor for FMDV on SW480-P6 cells (147). Consistent with this av|36 
colocalises extensively with virus at the surface of SW480-p6 cells (figure 6.1). Also, 
virus binding to the cell surface prevents binding of a fiinction blocking antibody 
against avp6, but not a function blocking antibody against avp5 which does not act 
as a receptor for FMDV. These data confirm previous reports that avp6 is the major 
FMDV attachment receptor in this cell line. avp6 was shown not to colocalise with a 
marker of lipid rafts (crosslinked CTB) at the cell surface in the presence or absence 
of virus. Similarly the virus did not colocalise with lipid rafts. These observations 
are consistent with the insensitivity of infection of SW480-p6 cells by FMDV to the 
disruption of lipid rafts and lipid raft dependent endocytosis by cholesterol depletion 
(see section 3.2.2.1).
The role of avp6 in post-attachment events has been less well defined. Certain 
deletion mutations within the cytoplasmic domain of the p6 integrin subunit prevent 
FMDV infection of, but not binding to, SW480-p6 cells, suggesting that avP6 plays a 
role in post-attachment events. The role of cxvp6 in post-attachment events was 
further investigated as part of this study (section 6.2.2). Internalised vims remained 
colocalised with its integi'in receptor avP6 at early times after the initiation of 
internalisation (5 and 10 minutes). This is consistent with a model whereby virus 
internalisation is also mediated by avp6. Additionally, the distribution of integrin was 
altered following internalisation of virus. In the absence of virus, ocvp6 is primarily 
located at the cell surface and in small intiacellular vesicles. Following virus
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internalisation ocvp6 labelling is less diffuse and is primarily located in larger 
intracellular vesicles. Following virus internalisation the level of colocalisation of 
avp6 with markers of early and recycling endosomes (EEA-1 and the Transferrin 
Receptor) is also increased. The initiation of virus internalisation therefore seems to 
result in a recruitment of (xvp6 to early and recycling endosomes, which are the very 
compartments to which virus is recruited (see chapter 4).
Occupation of the ROD binding site and crosslinking are both required to trigger 
internalisation of avP6, since a reagent capable of achieving both these things 
(monoclonal antibody 6.8G6) was able to trigger avP6 internalisation, whereas 
reagents capable of achieving only one of tliese things (RGD peptide, monoclonal 
antibody 6.3G9) could not. This is consistent with the findings of Weinreb et. al. 
(329), who found that non ligand mimetic anti-avp6 function blocking antibodies 
were not able to induce internalisation of this integrin, whereas ligand mimetic anti- 
avP6 function blocking antibodies were able to do so. Interestingly the 
complementarity determining region of the antibody 6.8G6 contains the integiin- 
binding motif RGDRXXL (in CDR H3), which is also found in the majority of stiain 
SAT-2 isolates of FMDV.
In summaiy, evidence has been presented to show that FMDV is delivered to early 
endosomes whilst still bound to avp6, and therefore that avp6 serves not only as an 
attachment receptor, but also to internalise virus. The data presented here therefore 
support the following model: Virus attaches to avp6 at the cell surface, triggering 
endocytosis of the integrinivirus complex, and its delivery to ear ly- and hence 
recycling-endosomes.
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Chapter Seven: The role of the cytoplasmic domain of 
the p6 integrin subunit in FMDV infection
7.1 Introduction
Many of the functional properties of integrins, including the regulation of binding 
affinity, signal transduction, and integrin-mediated uptake of ligands, are dependent 
on the integr ity of the cytoplasmic domain of the p-subunit. The ability of the 
integrin avp6 to mediate infection of SW480-p6 cells by FMDV has also been shown 
to be dependent on the cytoplasmic domain of the p6 subunit by Miller e t a l (204). 
This study used SW480 cell lines transfected with p6 subunits containing cytoplasmic 
domain deletions, and thus expressing mutant versions of the integrin avp6. These 
cell lines were designated T1-T5 (204). Cell lines T4-T1 express integrin containing 
progressively greater deletions of the P6 subunit cytoplasmic domain, and the T5 cell 
line has an intermal deletion within this domain (residues 746-764). The T1-T5 cell 
lines were all able to support virus binding. However, only those cell lines which still 
possessed an NPXY motif (T4 and T3) were able to support infection, albeit at 
reduced levels. The NPXY motif is highly conserwed among integrin p-subunits and 
has been shown to mediate the clathrin-mediated endocytosis of receptors, such as the 
LDL receptor (49). It was therefore hypothesised that this motif mediates virus 
induced clathrin-dependent uptake of avp6. The block of infection observed in cell 
lines T l, T2, and T5 could therefore be due to a block in avp6-mediated entry of the 
virus. However neither the precise role of the NPXY motif, nor the stage at which 
infection was blocked in the Tl, T4, or T5 cell lines was investigated (204).
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Therefore the role of the cytoplasmic domain of the p6 subunit was further 
investigated, using cell lines containing mutations in the NPXY motif itself.
7.2 The role of tyrosine based motifs within the 
cytopiasmic domain of the p6 integrin sububnit
7.2.1 Mutagenesis of the (36 Cytoplasmic Domain NPXY and NXXY 
Motifs
As outlined above, previous studies have shown that the cytoplasmic domain of the 
p6 integrin subunit is essential for avp6-mediated infection of tissue culture cells by 
FMDV, and point to a potential role for a conserved NPXY motif in this process 
(204). The p6 subunit also contains a similar conserved NXXY motif in its 
cytoplasmic domain. In order to investigate the role of these sequences in FMDV 
infection, cell lines expressing versions of avp6 containing mutations within these 
motifs were utilised. Our collaborating laboratory in the USA (headed by Dean 
Sheppard) had previously made mutations within the p6 NPXY and NXXY motifs to 
study the affect of tyrosine phosphorylation on avP6 activity in the context of its 
“natural” ligands (154). In order to do this the two tyi osine residues found within the 
conserved NPXY and NXXY motifs were mutated to phenylalanine, both individually 
and together, to give the FI, F2 and F1F2 mutant versions of the p6 subunit.
Figure 7.1 shows the sequences of the wild type cytoplasmic domain of the human 
p6 integrin subunit, as well as the mutant versions used. Highlighted in blue are the 
two tyrosine based motifs (NPXY and NXXY) found of the p6 subunit cytoplasmic 
domain, and mutated residues are highlighted in red. The FI p6 subunit contains an
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NPXF sequence instead of the wild type NPXY motif. The F2 p6 subunit contains an 
NXXF sequence instead of the wild type NXXY motif. The F1F2 subunit contains 
both mutations.
Mouse embryonic fibroblasts (MEF) expressing avP6 containing the FI, F2, or 
F1F2 P6 cytoplasmic domains were obtained fiom D.Sheppard and were designated 
MEF-Fl, MEF-F2, and MEF-F1F2 respectively. Mock tiansfected cells were 
designated MEF-MK and cells expressing wild type avP6 were designated MEF-WT.
The level of expression of avp6 and virus binding by the MEF-Fl, MEF-F2, and 
MEF-FlF2 cell lines was investigated using FACS analysis. The integrin (xvp6 or 
virus at the cell surface were labelled using monoclonal antibodies 10D5 and D9 
respectively, followed by a PE-conjugated goat anti-mouse secondary antibody. The 
level of fluorescent labelling at the cell surface represents the degi ee of surface (xvP6 
expression or virus binding and was quantified by flow cytometry counting 6000 cells 
per sample. The resulting data is summarised in figure 7.2. The level of integrin 
expression and virus binding for each cell line aie expressed as a percentage of the 
equivalent value obtained using the MEF-WT cell line (which expresses wild type 
avP6) after coiTection for background. Representative histogiams for this experiment 
are shown in figure 7.3; the figures above each curve represent the geogiaphic mean 
of that curve. The MEF cell lines tiansfected with wild type or a mutant form of p6 
all express avp6 at the cell surface (figure 7.2 - panel B), and bind virus (figure 7.2 - 
panel A), whereas the mock transfected cell line neither expresses av|36 nor binds 
virus. This shows that tiansfection of MEF’s with the |36 integrin subunit greatly 
enhances expression of av|36 and virus binding at the cell surface, consistent with the 
role of (xv(36 as an attachment receptor for FMDV (147, 204). The cell lines
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expressing mutant integrins (MEF-Fl, MEF-F2, MEF-FlF2) all bind virus, although 
less well than the MEF-WT cell line. However the lower level of virus binding can 
be explained by correspondingly lower levels of surface av|36 expression. In 
conclusion mutation of the NPXY motif to NPXF (MEF-Fl, MEF-Fl F2), and the 
NXXY motif to NXXF (MEF-F2, MEF-Fl F2) did not appear to inhibit virus binding 
to avp6.
The ability of each cell line to support FMDV infection was assessed using an 
infectious centie assay. In this assay, 1 million cells in suspension are infected with 
FMDV 01Kcad2 at an m.o.i of ~0.25 for 1 hour at 37°C. After a 2 minute acid wash 
to remove any vims left at the cell surface, the infected cells are serially diluted and 
overlaid on to BHK cells. After two days plaques are visualised by methylene blue 
staining. This data is shown in Table 7.1 and is expressed as the number of infectious 
centres per million cells. Infection is clear ly dependent on the integrin av(36 since 
transfection with the human p6 subunit increases the level of infection ft om less than 
50 infectious centres per million cells (MEF-MK cell line) to over 14000 (MEF-WT 
cell line). When the MEF-WT cell line was incubated at 4°C (rather than 37°C) prior 
to the acid wash step in order to prevent virus internalisation, no infection was 
observed, confirming that the acid wash step is effective in destr oying vims left at the 
cell surface. The cell lines which express mutant integrin are all clearly able to 
support high levels of infection (greater than 13500 infectious centres per million cells 
on average), similar to that supported by the wild type integi'in. In conclusion, 
mutation of the tyr osine residues of the NPXY and NXXY motifs found in the 
cytoplasmic domain to phenyalanine appears to have little or no impact on infection.
The data above show that like SW480 cells, mouse embryonic fibroblasts do not 
bind FMDV or mediate FMDV infection unless transfected with the p6 integrin
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subunit such that ovp6 is expressed at the cell surface. However, mutation of the 
tyi'osine residue within the NPXY and NXXY motifs to phenylalanine did not inhibit 
virus binding or infection mediated by the integi'in avp6. Similarly, mutation of both 
tyrosine residues had no effect. This shows that the tyrosine residues found within the 
cytoplasmic domain of the p6 subunit (as well as any related phosphorylation and 
signalling events) are not essential for infection of P6 transfected MEF cell lines. 
However, these data do not conclusively prove that the NPXY motif is not involved in 
post attachment events in FMDV infection. This is because mutation to 
phenylalanine may not completely inhibit endocytosis of receptor fi'om the cell 
surface. For example CD 18 is internalised by means of a related NPXF motif upon 
ligand binding (265) rather than the NPXY type internalisation motif seen in the LDL 
receptor (49). It has also been shown that the tyi'osine residue of the NPXY motif in 
the LDL receptor can be substituted for phenylalanine without completely abolishing 
receptor uptake (101). In order to define clearly the role of this motif, more severe 
mutations of the NPXY sequence were required.
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IciwjKLLVSFHDRKEVAKFEAERSKAKWQTGNPLYRGSTSTFKNVTYKHREKQKVDLSTDC
Wild Type ^6 Subunit (WT)
NPLF NVTY
FI p6  subunit
NPLY NVTF
F2 P6 subunit
NPLF NVTF
F1F2 p6  subunit
APLA NVTY
APLA p6 subunit
Figure 7.1. Schematic diagram showing the amino acid sequences of the different cytoplasmic domains of the P6 integrin 
subunits used in this study. The sequence of wild type human P6 is shown topmost using the single-letter amino acid code, with 
amino acids thought to make up the cytoplasmic domain capitalised. The last four residues of the transmembrane domain are 
also shown in lower case. The two tyrosine-based motifs (NPXY and NXXY) are picked out in blue type. The sequences of the 
mutant p6 cytoplasmic domains are shown below with residues differing from the wild type picked out in red.
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F ig u re  7.2. FA C S an a ly s is  o f virus binding and  a v p 6  e x p ress io n  by m o u se  em bryonic fibroblast (MEF) cell lin es transfected  with 
wild type or m utant P6 integrin subunits, ctvps integrin and su rface  bound FMDV w ere labelled  using m onoclonal an tib od ies 10D 5  
(10p g/m l) and B2 (lO pg/m l) respectively , fo llow ed by a P E -conjugated  goa t anti m o u se  seco n d a ry  antibody. S u rface flu o rescen ce  
w a s  d e tec te d  by flow  cytom etry counting 6 0 0 0  c e lls  per sa m p le . Integrin ex p ress io n  (P an el B) and virus binding (P anel A) for 
e a ch  cell line are e x p r es s ed  a s  a p er cen ta g e  o f the equ iva len t va lu e obta ined  using th e MEF-WT cell line w hich e x p r e s s e s  the  
wild type hum an p6 integrin subunit. E ach va lu e  rep resen ts  the m ea n  o f  duplicate sa m p le s , ctvpe ex p r ess io n  and virus binding  
w ere  d e te c ted  on  all cell lin es transfected  with th e  P6 integrin subunit (MEF-WT, M EF-F1, M EF-F2, M EF-F1F2) but not on  th e  
m ock transfected  cell line (MEF-MK)
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F igu re  7 .3 . FACS an a ly s is  o f virus binding and a v p s  ex p ress io n  by m o u se  em bryonic fibroblast (MEF) cell lin es transfected  with 
wild type or m utant P6 integrin subunits. For e a c h  cell line av p 6  integrin ex p r essed  at the cell su rface  and su rface  tx)und FMDV 
(20pg/m l) w ere  labelled  using m onoclonal antitx)d ies 10D 5 (10p g/m l) and B2 (10p g/m l) respectively , follow ed by a P E -conjugated  
goat anti m o u se  seco n d a ry  antibody. S u rface  f lu o resce n c e  w a s  d etec ted  by flow cytom etry counting 6 0 0 0  ce lls  per sam p le . 
R ep resen ta tive  h istogram s are sh ow n  depicting virus binding and a v p s  ex p ress io n  by MEF-WT c e lls  (p a n e ls  A and B 
respectively), MEF-MK cells  (p a n e ls  C and D), MEF-F1 ce lls  (P a n e ls  E and F), MEF-F2 (P a n e ls  G and H), and M EF-F1F2 c e lls  
(P a n e ls  I and J). In e a c h  c a s e  the blue filled curve rep resen ts  background flu o rescen ce  a s s e s s e d  in the a b s e n c e  o f virus or the  
primary integrin detection  antibody. The unfilled curve r ep resen ts  th e  level o f virus binding or integrin ex p ress io n . T he figure  
a b o v e  e a c h  curve rep resen ts  th e m ean  flu orescen t intensity o f the curve, o v p s  ex p ress io n  and virus binding w ere d e te c ted  on all 
cell lin es  transfected  with th e pS Integrin subunit (MEF-WT, M EF-F1, MEF-F2, M EF-Fl F2) but not on  the m ock transfected  ceil line 
(MEF-MK).
Cell Line No. Infectious Centres Per Million CeilsExperiment 1 Experiment 2 Experiment 3 Experiment 4 Average
MEF- p6 28500 12000 2250 15000 14437.5
MEF- p6 @4‘*C 7.5 - - - 7.5
MEF-MK 48 31.5 36 13 32
MEF- FI - - 11250 18000 14625
MEF- F2 - - 9600 27000 18300
MEF- F1F2 - 14250 13500 13875
Table 7.1. A table detailing the ability of virus(type 01KCad2) to infect MEF cell lines expressing wild type and mutant P6 
integi'in subunits by means of an infectious centre assay. The figines represent the number of infectious centres obtained per 
million cells, infected at an MOI o f -0.25. Each experiment was carried out in duplicate.
7.2.2 Alanine substitution within the |36 Cytopiasmic Domain NPXY 
motif
In order to dismpt the NPXY motif of the p6 cytoplasmic domain more severely, I 
consti'ucted a mutant form of the P6 subunit in which both the asparagine (N) and 
tyrosine (Y) residues of the NPXY motif were changed to alanine. This mutant 
subunit was termed the APLA subunit, and the sequence of its cytoplasmic domain is 
shown in figure 7.1. The work described in the following paragiaph was carried out 
by a research assistant (Sarah Gold)
The APLA mutant subunit was transfected in to SW480 cells to produce the 
SW480-APLA cell line. This cell line was found to bind virus to a similar extent to 
the cell line expressing wild type p6 (SW480-P6 cells). To determine whether the 
integrin was correctly assembled at the cell surface the ectodomain of the mutant 
avP6 integrin was subjected to epitope mapping using a number of monoclonal 
antibodies to avp6 or the P6 subunit. These studies showed that no epitopes were lost 
due to the mutations within the cytoplasmic domain. In further experiments this cell 
line was shown not to be infected by FMDV stiain 01Kcad2. Mutation of the NPXY 
motif to APLA therefore did not prevent virus binding or alter the gross conformation 
of the P6 ectodomain, but did abolish the ability of avp6 to mediate infection of P6- 
transfected SW480 cells. This strongly suggests that the NPXY motif is required for 
a post-attachment stage of infection of SW480 cells by FMDV.
Internalisation of the LDL receptor is blocked by mutation of the NPXY motif 
within its cytoplasmic domain to APLA. I therefore investigated whether mutation of 
the NPXY motif within the cytoplasmic domain of the |36-integrin subunit prevents 
internalisation of av[36 (and therefore virus), using immunofluorescence microscopy.
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Virus was allowed to bind to the cell surface at 4°C, a temperature which does not 
allow endocytosis to occur. Internalisation was initiated by a shift to 37°C, before 
being halted by paraformaldehyde fixation. Virus was detected using the monoclonal 
antibody D9. Figure 7.4 shows SW480-P6 cells (Panels A) and SW480-APLA cells 
(Panel B) labelled for virus at 15 minutes after the initiation of virus internalisation. It 
appears that virus has been internalised in both cell lines. However, the pattern of 
virus labelling differs between the two cell lines. In SW480-APLA cells, virus 
appears to be present in vesicle like structures around the periphery of the cell, 
whereas virus appears to have migr ated further towards the centre of the cell in 
SW480-P6 cells.
Further experiments were carried out in which virus was allowed to enter both cell 
lines for 15 minutes, before fixation and labelling for virus and the early endosome 
marker EEA-1. This data shows that virus colocalises with EEA-1 at this time point 
both in SW480-P6 cells (figure 7.5) and SW480-APLA cells (figure 7.6), despite the 
fact that virus is more restricted to the periphery in SW480-APLA cells.
The above data shows that virus is intermalised and delivered to EEA-1 positive 
early endosomes in both SW480-P6 and SW480-APLA cells. This data would appear 
to suggest that mutation of the NPXY motif of the p6 integrin subunit to APLA 
abolishes infection, but not avp6-mediated delivery of virus to early endosomes.
This was unexpected since one would hypothesise that mutation of the NPXY 
putative endocytosis motif would inhibit infection by preventing avp6-mediated virus 
internalisation.
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A) SW 480-|’>6 B) SW480-APLA
F ig u re  7 .4 . U ptake of FMDV by S W 480-p 6  and SW 480-A P L A  cells. S W 480-p 6  (P anel A) and SW 480-A P L A  (P anel B) cells, 
prepared on coverslip s  w ere  incubated with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m inutes at 4"C. Virus internalisation w a s  
allow ed to p roceed  for 15  m in utes at 3 7 ”C. Internalisation w a s  halted by fixation on ice  using 4% paraform aldehyde. 
Following perm eabilisation  with 0.1%  Triton, virus (red) w a s  d e tec ted  using th e m onoclonal antibody D 9 (m o u se  lgG 2A - 
5pg/m l), follow ed by an A lexa fluor conju gated  iso typ e  sp ec if ic  goat-anti m o u se  secon d ary  antibody. B ars = lO^m. Both 
S W 480-P 6  (P an el A) and SW 480-A P L A  ce lls  (P an el B) h ave  internalised virus at this tim e point. H ow ever s o m e  virus 
rem ained at th e su rface  o f th e SW 480-A P L A  cells.
D EEA-1A) EEA-1
B) Virus E) Virus
C) Overlay A+B F) Overlay D+E
F ig u re  7 .5 . Dual labelling o f S W 480-p 6  ce lls  for EEA-1 and FMDV at 15 m in utes after initiation o f virus internalisation. 
S W 4 8 0 -p 6  cells, prepared on coverslip s  w ere incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 4®C. Virus 
internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 15 m in utes incubation at 37°C  internalisation w a s  
halted by fixation on ice  using 4% paraform aldehyde. Following perm eabilisation  with 0.1%  Triton, EEA-1 and virus w ere  
d e tec ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5 |ig /m l) and D 9 (m o u se  lgG 2A -5pg/m l) respectively , follow ed by 
A lexa fluor conju gated  iso typ e  sp ec if ic  goat-anti m o u se  seco n d a ry  antibod ies. P a n e ls  A  a n d  D sh o w  EEA-1 labelling  
(green ) and p a n e ls  B a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay o f p a n els  A and B, P a n e l F  s h o w s  an overlay of 
p a n els  D and E. DAPI sta in ed  nuclei are show n a s  blue.
A EEA-1
B) Virus E) Virus
C) Overlay A+B
F ig u re  7 .6 . Dual labelling o f SW 480-A P L A  ce lls  for EEA-1 and FMDV at 15 m in utes after initiation o f virus internalisation. 
SW 480-A P L A  cells, prepared on coverslip s  w ere  incubated  with FMDV strain 0 1 K c a d 2  (5pg/m l) for 4 5  m in utes at 4°C .
Virus internalisation w a s  initiated by shifting th e tem perature to 37°C . Following 15 m in utes incubation at 37°C  
internalisation w a s  halted by fixation on ice  using 4%  paraform aldehyde. Following perm eabilisation with 0.1%  Triton, EEA- 
1 and virus w ere  d e te c ted  using m on oclon al an tib od ies 14 (m o u se  lgG 1-5pg/m l) and D 9 (m o u se  lgG 2A -5pg/m l) 
respectively , followed by A lexa fluor conju gated  iso typ e  sp ec if ic  goat-anti m o u se  secon d ary  antibod ies. P a n e ls  A  a n d  D  
sh o w  EEA-1 labelling (green ) and p a n e ls  B a n d  E  sh o w  virus (red). P a n e l C  s h o w s  an overlay o f p a n e ls  A and B, P a n e l F  
sh o w s  an overlay o f p a n els  D and E. DAPI sta in ed  nuclei are sh ow n  a s  blue.
7.3 Summary and Discussion
Previous studies have shown that the cytoplasmic domain of the p6 integi'in subunit is 
required for avP6-mediated infection of tissue culture cells by FMDV, and point to a 
potential role for a conserved NPXY motif in this process (204). In order to explore 
this possibility we utilised cell lines transfected with P6 subunits carrying mutations 
within the NPXY (and related NXXY) motif of the cytoplasmic domain (see figure 
7.1).
The P6 cytoplasmic domain contains two tyi'osine residues, one of which forms part 
of the conserved NPXY motif, and one of which forms part of a similai' conserved 
NXXY motif. We obtained mouse embryonic fibroblasts cell lines tiansfected with 
the wild type p6 integrin subunit (MEF-WT), a subunit in which the NPXY motif was 
mutated to NPXF (MEF-Fl), a subunit in which the NXXY motif was mutated to 
NXXF (MEF-F2), and a subunit containing both mutations (MEF-FlF2). We also 
obtained a MEF cell line transfected with the expression plasmid alone containing no 
insert (MEF-MK). Infection of MEF’s was found to be dependent on the P6 integi'in 
subimit since MEF’s tiansfected with the wild type p6 integi'in subunit were able to 
bind virus and support FMDV infection, whereas mock transfected MEF’s were 
unable to support virus binding or infection. The cell lines expressing mutant ocvp6 
(MEF-Fl, MEF-F2, MEF-FlF2) were still able to support virus binding and infection. 
Since the F1F2 mutant does not contain any tyr osine residues in its cytoplasmic 
domain, this indicates that tyrosine phosphorylation and/or tyrosine mediated 
signalling mediated by the p6 cytoplasmic domain are not essential for infection of 
MEF’s by FMDV. However these data do not clearly prove that the NPXY motif is 
not involved in post attachment events in FMDV infection. This is because mutation
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of tyi’osine to phenylalanine may not completely inhibit uptake of receptor from the 
cell surface. For example GDI 8 is internalised by means of an NPXF motif upon 
ligand binding (265) rather than the NPXY type internalisation motif seen in the LDL 
receptor (49). It has also been shown that the tyrosine residue of the NPXY motif in 
the LDL receptor can be substituted for phenylalanine without completely abolishing 
receptor uptake (101).
In order to investigate the role of the NPXY motif further, a cell line expressing 
avp6 containing the sequence APLA in place of the p6 cytoplasmic domain NPXY 
motif integrin subunit was generated. Replacement with alanine of either the 
asparagine (N) residue or tyr osine residue (Y) of the NPXY motif found in the 
cytoplasmic domain of the LDL receptor reduces its clathrin-dependent internalisation 
to around 10% of contr ol values (49). If internalisation of avP6 is mediated by the 
NPXY motif found in the p6 cytoplasmic domain, this double mutation would be 
expected to block uptake of this integrin and therefore FMDV uptake and infection.
In our laboratory, SW480-APLA cells were found to bind FMDV to a similar extent 
to the cell line expressing wild type p6 (SW480-p6), and in an RGD-dependent 
fashion. Epitope mapping of the avp6 ectodomain using monoclonal antibodies 
revealed that no epitopes were lost due to the mutations within the cytoplasmic 
domain, indicating correct assembly of avP6 at the cell surface. However, infection 
of SW480-APLA cells was greatly reduced in comparison to SW480-|36 cells. This 
strongly suggests that mutation of the NPLY motif to APLA inhibits avp6-mediated 
infection of P6 transfected SW480 cells at a post attachment stage.
In order to try to identify the stage at which infection of SW480-APLA cells is 
blocked, uptake of virus was studied by immunofluorescence microscopy. The data is 
shown in figures 7.4-7.6. Contrary to expectations, virus was found to have entered
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both SW480-P6 and SW480-APLA at 15 minutes after the initiation of 
internalisation, and also to colocalise with EEA-1 in both cell lines at this time point. 
This data would appear to show that the inhibition of infection observed in SW480- 
APLA cells is not due to inhibition of clathrin-dependent delivery of virus to early 
endosomes, but at a different stage. However, these studies use saturating quantities 
of virus and may not reveal differences in the rate of virus uptake by the wild type and 
mutant forms of avp6. Although not conclusive, the studies shown in figures 7.4-T.6 
suggest that: 1) less virus may have entered the cells expressing the APLA mutant 
compared with the cells expressing the wild type integi'in, and 2) the internalised virus 
had a more peripheral location in the cells expressing the APLA mutant.
One possible explanation is that mutation of the NPXY motif within the p6 
cytoplasmic domain causes subtle changes within the p6-ectodomain which result in a 
reduced affinity of avP6 for FMDV. It has been reported previously that changes 
made within the cytoplasmic domain of the p6 subunit can result in 1) changes in the 
conformation of the ectodomain of the integrin avp6, 2) altered specificity for RGD 
peptides, and 3) a reduction in the concentration of RGD peptide required to prevent 
FMDV binding (142). These observations imply that such alterations result in a 
reduced affinity of FMDV for avP6. Such a reduction in affinity would not 
necessarily be detected using the FACS virus-binding assay since this assay uses 
saturating concentrations of virus.
Why should a reduced affinity of av|36 for FMDV result in a slower rate of virus 
internalisation? The work described in chapter 6 suggests that internalisation of 
integrin :FMDV complexes at the cell surface requires both occupation of the integrin 
RGD-binding site and cross-linking of av|36. It may be that a lower affinity of av(36
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for virus results in less receptor cross linking, and therefore reduced infection as a 
result of a slower rate or lesser extent of FMDV internalisation.
A reduced affinity of FMDV for avP6 could also inhibit infection by reducing the 
delivery of viral KNA to the host cell cytoplasm. Poliovirus undergoes a 
conformational change upon binding its receptor, resulting in the externalisation of 
VP4 and the N-terminus of V P l. This altered conformation of poliovirus (the A- 
particle) is able to interact directly with host cell membranes, an interaction which is 
thought to involve both the N-terminus of VPl and VP4 (63). FMDV however does 
not possess the N-terminal hydrophobic extension of VPl which is thought to mediate 
attachment of poliovirus to host cell membranes. Instead, FMDV most likely remains 
close to the cell membrane by prolonged interaction with its receptor, until uncoating 
occurs within acidic endosomal compartments. A reduction in affinity of avp6 for 
FMDV could mean the virus dissociates from its receptor at the cell surface or within 
endosomes before acid dependent capsid uncoating takes place. As a result the viral 
RNA would no longer be locally concentrated in the vicinity of the target membrane, 
inhibiting its tiansfer across the endosomal membrane to the cytoplasm. In order to 
test this hypothesis, a biochemical analysis of the affinity and kinetics of binding of 
FMDV to both wild type and mutant avP6 would need to be carried out. Analysis of 
ion channel formation triggered by FMDV in liposomes containing either wild type or 
mutant avP6 could also be carried out.
Another possible explanation for the data presented in this chapter is that the 
cytoplasmic domain of the P6 integrin subunit is required for translocation of the viral 
RNA in to the cytoplasm, and that this process is prevented by mutation of the NPLY 
motif to APLA. This is not without precedent since otvp5-mediated tianslocation of 
adenovirus 2 particles across endosomal membranes has been shown to be dependent
170
upon the cytoplasmic domain of the P5 integrin subunit (328, 330). However, this 
scenario is unlikely for FMDV as virus has been shown to be able to use a variety of 
non-integi'in receptors in tissue culture, including heperan sulphate 
proteoglycans( 143), the Fc receptor (when virus is coated with antibodies) (189, 192), 
and a single chain antibody fused to intercellular adhesion molecule-1 (269). Also, 
the mechanisms of host membrane peraieabilisation utilised by adenoviruses and 
picornaviruses are thought to differ. Adenovirus is thought to penetiate host cell 
membranes by causing local membrane disruption (262), whereas human rhinovirus-2 
(262) and poliovirus (63) are thought to form pores in the host membrane through 
which the viral RNA is extruded. Since FMDV can utilise non-integrin receptors in 
tissue culture and picornaviruses are thought to permeabilise host membrane by a 
different mechanism to adenovirus, it would seem unlikely that the cytoplasmic 
domain of the P6 integrin subunit (or specifically the NPXY motif) is essential for 
release of viral RNA to the cytosol.
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Chapter Eight: The role of VP4 in FMDV Ceil Entry
8.1 introduction
FMDV particles are formed when twelve 14S pentameric intermediates associate to 
form either 140S RNA containing viral particles, or 75S empty capsids. Each 
pentamer is formed from five protomers, each of which contains a single copy of 
VPO, VPl, and VP3. The final step in the assembly process occurs when VPO in the 
provirion is cleaved into VP2 and VP4, in a process known as maturation cleavage, 
VP4 is effectively an N-terminal extension of VP2, which, when released by 
maturation cleavage, foiins a small relatively disordered protein chain, which is 
located on the inner surface of the capsid (2).
The precise role of VP4 in the infectious process is not well understood. However, 
for many picornaviruses, cleavage of VPO is required for infectivity. This has been 
shown for poliovirus (53), rhinovirus-14 (170), and hepatitis A virus (34), and more 
recently for FMDV (160). It should be noted that VPO cleavage is not necessary for 
all picornaviruses because VPO of some of the kobu- and parechoviruses remains 
uncleaved in the mature virion. Recombinant FMDV particles carrying uncleavable 
VPO are able to assemble and bind to cells normally, and have a similar degree of acid 
sensitivity to wild-type virions (160). The only major difference obseiwed was that 
the acid breakdown products of tlie VPO-containing particles were considerably more 
hydrophobic than the wild type virus, presumably due to a failure to release 
myristoylated VP4. This evidence shows that VPO cleavage is not needed for normal 
RNA replication, viral protein expression, virus assembly, receptor-binding, or acid- 
mediated capsid dissociation. These data appear to indicate that the maturation 
cleavage is required for the ti anslocation of the viral RNA in to the cytoplasm. It is
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unclear from this evidence whether VP4 itself is involved in this process directly, or 
whether the cleavage and subsequent release of VP4 simply allows the viral 
pentamers to perform this task in some way.
Evidence fr om studies with poliovirus suggests that VP4 could be involved in RNA 
tianslocation into the cytosol. Poliovirus undergoes a conformational change upon 
receptor binding resulting in the externalisation of both VP4 and the N-terminus of 
V P l. This altered form of the poliovims particle (or “A-particle”) has been shown to 
be capable of forming ion channels within the ar tificial lipid bilayers (312, 313). It 
has been hypothesised that these channels serve to deliver the viral RNA across host 
cell membranes to the cytoplasm. Mutation of threonine-28 of VP4 (which abolishes 
a threonine-myi'istate hydrogen bond but does not prevent VPO cleavage) abolishes 
the infectivity of the viral particle, without affecting receptor binding characteristics 
(214). Furthermore, mutations at this position have been shown to alter both the 
characteristics of the ion channels formed by poliovirus following receptor binding, 
and the rate of delivery of viral RNA to the cytoplasm (63, 313). Taken together 
these observations indicate that VP4 plays a role in ion channel formation and RNA 
escape in poliovirus.
FMDV differs fr om poliovirus in that it does not form A-particles or possess the 
hydrophobic N-terminal extension of VPl thought to be partly responsible for binding 
of poliovirus to the host cell membrane (63, 86). Instead FMDV is uncoated in 
response to the low pH within endosomes rather than by receptor binding. In FMDV 
the role of VP4 in infection is less clear, altliough as mentioned above, it is thought 
that the maturation cleavage is necessary to allow RNA to enter the cytoplasm (160). 
The aim of the work described in this chapter was to shed further light on the role of 
VP4 in FMDV infection. To determine the regions and sequences of VP4 that are
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essential for infection, recombinant viruses were constructed in which all or part of 
VP4 were swapped for the equivalent sequences from equine rhinitis A virus (the 
other member of the genus aphthovirus). The results obtained from this work are 
described below.
8.2 The Role of VP4 in FMDV cell entry
8.2.1 Creation of Recombinant Viruses containing mutations in 
VP4.
In our laboratory we possess a reverse genetics system enabling the manipulation of 
the FMDV genome. This consists of a plasmid containing a full-length infectious 
cDNA clone of the OlKaufbeuren strain of FMDV (pT7S3) downstream of a T7 
polymerase promoter site (78). RNA copies of the FMDV cDNA can be synthesised 
in vitro using T7 polymerase. Since FMDV RNA is infectious, virus particles can be 
produced by tiansfection of the viral RNA in to susceptible cells. This system was 
utilised to investigate the role of VP4 in FMDV infection.
The mutations made to VP4 are described in figure 8.1 panel A. The amino acid 
sequence of the mutant forms of VP4 are aligned with that of the wild type virus in 
panel B. The plasmids pT7S3-ER-VP4, pT7S3-F/E-VP4 and pT7S3-E/F-VP4 all 
contain copies of VP4 in which all or pai't of the FMDV sequence has been replaced 
by the equivalent sequence fr om Equine Rhinitis A Virus (ERAV).
In order to construct these plasmids it was first necessary to inti'oduce restriction 
enzyme sites at either end of the region coding for VP4 in the FMDV infectious copy 
plasmid. The stiategy for achieving this is shown in figure 8.3. First, a Kpnl 
subclone of the plasmid pT7S3 was cloned in to pGEM7Zf and used as a template for
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overlap PCR. To inti'oduce a Hindlll site at the 5’ end of VP4, primer PI and the 
mutagenic primer P3 (for primer sequences see figure 8.2) were used to create PCR 
product PCRl, and primer P2 and the mutagenic primer P4 were used to give PCR 
product PCR2. PCR product PCRl contains the Hindlll site intioduced by primer P3 
at its 3 ’ end, and PCR product PCR2 contains the Hindlll site introduced by primer 
P4 at its 5’ end. The two PCR products (PCRl and PCR2) contain a region of overlap 
corresponding to the junction between L and VP4 and containing the introduced 
Hindlll site. PCR products 1 and 2 were mixed and amplified using the outside 
primers PI and P2 to give PCR product 3. PCR product 3 consists of a 600bp region 
of the infectious copy plasmid covering the whole of VP4 and parts of the L pro tease 
and VP2, in which a Hindlll site has been introduced at the 5’ end of VP4 by means 
of a silent mutation (aagctc to aagctt). The final PCR step was carried out using Tag 
polymerase, thus allowing the PCR product to be cloned in to pGemT for sequencing. 
This constr uct was then used as a template for a further round of overlap PCR as 
shown in figure 8.3, in order to introduce an Nhel site at the 3’ end of VP4 by means 
of a silent mutation (tctcgc to gctacg). The resulting constr uct was cloned in to 
pGemT and sequenced to confirm that the Nhel site had been introduced and that no 
unforeseen changes had been introduced by PCR. The resulting construct (pGeinT- 
HVP4N) contains a 600bp region of the infectious copy plasmid encompassing all of 
VP4 and parts of L and VP2, with a Hindlll site and an Nhel site at the 5’ and 3’ ends 
of VP4 respectively. The location of the introduced restriction sites, as well as the 
sequence data confirming that both sites had been successfiilly introduced, are shown 
in figure 8.4. DNA sequencing showed that no other changes had been introduced by 
the PCR reactions.
175
The introduced Hindlll and Nhel sites were subsequently utilised to swap FMDV 
VP4 for altered forms containing all or part of VP4 fi*om ERAV. Figure 8.5 shows 
the process by which non-chimeric and chimeric forms of VP4 bounded by Hindlll 
and Nhel sites were produced. Wild type ERAV VP4 was amplified fi'om ERAV 
cDNA by PCR with Hindlll and Nhel sites being introduced at either end by the PCR 
primers. As a control wild type FMDV was amplified fiom pT7S3 and Hindlll and 
Nhel sites were added in the same way. In order to form F/E VP4 (N-terminus fiom 
FMDV, C-terminus fiom ERAV) and E/F VP4 (N-terminus fiom ERAV, C-tenninus 
fiom FMDV) overlap PCR was required. Figure 8.5 shows the primers and strategy 
utilised to achieve this. All final PCR products were cloned in to pGemT and 
sequenced (see figure 8.6). The process by which these altered forms of VP4 were 
incorporated in to the infectious copy plasmid is shown in figure 8.7. Firstly the wild 
type form of VP4 found in the pGemT-HVP4N construct was replaced by the mutant 
forms utilising the introduced Hindlll and Nhel sites. Unique SunI and Sail sites 
were then utilised to reconstitute this altered form of VP4 and surrounding sequences 
into the Kpnl subclone of pT7S3. The Kpnl firagment of pT7S3 was then replaced by 
the Kpnl fiagements containing the altered forms of VP4 to give fiill length pT7S3 in 
which FMDV VP4 had either been wholly or partially replaced by the equivalent 
sequences fiom ERAV. The resulting plasmids were pT7S3-ER-VP4, pT7S3-F/E- 
VP4 and pT7S3-E/F-VP4.
A previous study has shown that mutations at the boundary between VP4 and VP2 
(AD to FK) results in the production of a non-infectious virus in which cleavage of 
VPO does not occur (160). These mutations were recreated in our system using 
overlap PCR as shown in figure 8.8. The initial template used for overlap PCR was 
PCR3 fi'om figure 8.1. This constiuct contains a 600bp region of the infectious copy
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plasmid spanning all of VP4, and parts of L and VP2, and contains a Hindlll site at 
the 5 ’ end of VP4. The mutagenic primers P9 and PIO were used in the first step of 
overlap PCR in order to alter the sequence at the VP4-VP2 boundary fiom gccgac 
(codes for the amino acid sequence AD) to ttcaaa (equivalent to the sequence FK at 
the amino acid level). Two bases were altered within each codon in order to minimise 
the possibility of reversion to the wild type sequence. The final PCR product was 
cloned in to pGemT and sequenced in order to confirm the presence of the desired 
mutation and to check for any errors introduced by PCR. The location of the 
mutations made, together with the sequence data confirming that the desired mutation 
had indeed been introduced are shown in figure 8.9. The sequence coding for the 
mutated VP4-VP2 boundary was reconstituted in to the full-length infectious copy 
plasmid as shown in figure 8.7 (fiom the second stage onwards) to give the plasmid 
pT7S3-VP0*.
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(A)
Name of 
Virus Changes Made
WT None
rWT Hindlll and Nhel sites introduced at 5 ’ and 3 ’ end of VP4 bysilent mutation
ERVP4 VP4 swapped for that from Equine Rhinitis A Virus
F/E VP4 C-terminus of VP4 swapped for that from ERAV
E/F VP4 N-terminus of VP4 swapped for that from ERAV
VPO* Junction of VP4 and VP2 made uncieavabie by mutation from AD to KF
(B)
WT a n d  rWT 
VPO*
ER VP4 
F \ E  VP4 
E \ F  VP4
WT a n d  rWT 
VPO*
ER VP4 
F \ E  VP4 
E \ F  VP4
WT a n d  rWT 
VPO*
ER VP4 
F \ E  VP4 
E \ F  VP4
*  20  *
GAGQ S S PATG S QNQ S GNTG S I I N N YYMQQY
. . . T . T . T . . N . . M . . . S . . . V Q . F ............
. . . T . T . T . . N . . M . . . S . . . V Q . F ............
4 0  * 60
q n s m d t q l g d n a i IsIg g s n e g s t d t t s t h t t
I . AD . . . . V
I  .A D V
PEGQGSN.SSSTSSSQ
PEGQGSN.SSSTSSSQ
* 8 0 VP4 VP2
NTQNNDWFSKLASSAFSGLFGALLAD
................................................................... FK
 . GTK. . .
 . GTK. . .
S S G L G G . . . S . LN-  
S S G L G G . . . S . LN-
Figure 8.1. VP4 mutant viruses constructed and utilised in tliis study. Panel A shows a list of mutant viruses utilised, together 
with a description o f the changes made relative to wild type FMDV expressed from the pT7S3 infectious copy plasmid. Panel B 
shows a lineup of the amino acid sequences o f VP4 (plus the first amino acid of VP2) from wild type and each of the mutant 
vimses using the single letter amino acid code. Residues which are identical to wild type FMDV (top row) are identified by a 
dot (.) Gaps are represented by a dash(-) The boundary between VP4 and VP2 is denoted by a black vertical line. The central 
serine residue which represents the boundary of the N-terminal and C-terminal domains o f VP4 is boxed
Primer Name Sequence (5’ to 3')
P1 gat ttc cat get ggc att tt
P2 gaa gtg ttc ggt ccg etc ac
P3 tcc age ccc ttt aag ctt gcg ttg aa
P4 ttc aac gca age tta aag ggg ctg ga
P5 ctt ctt gtc ggc tag cag age gcc gaa a
P6 ttt egg cgc tct get age eg a caa gaa
P7 aaa age tta aag gag ctg gta cat cga etc
P8 gga gcc etc gtt aga gcc tcc act aat tac att gtc tcc
P9 ggt gac aac gca ate agt cet gaa ggc caa ggg 
age
P10 gca get age age ttt gtc cca agg tt
P11 get ccc ttg gcc ttc agg act gat tgc gtt gtc acc
P12 gga gac aat gta att agt gga ggc tct aac gag ggc
tcc
P13 gtg gtc tcc tct gtc ttc ttt ttg aag aga aga gcg ccg 
aaa aga ccg c
P14 gcg gtc ttt teg gcg etc ttc tct tea aaa aga aga 
cag agg aga cca c
Figure 8.2. A figure showing the sequences o f the primers utilised in VP4 mutagenesis.
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* Kpnl SunI
P4-
Hindlll
P6-
Nhel
. " P2
: Sail
Kpnl subclone o f  Infectious Copy Plasmid in pGEM  7ZF
P3-
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P5-
INhei Kpnl •
Kpnl Subclone used as initial template for two rounds of overlap PCR in order 
to introduce Hindlll and Nhel sites at boundaries of VP4
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PCR 1 and 2 mixed and used as template for PCR 3
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Final Product
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Figure 8.3. A schematic diagram showing the strategy for the introduction of Hindlll and Nhel sites at the 5’ and 3’ ends of 
FMDV VP4 respectively. PCR primers are depicted as unbroken arrows lying alongside DNA sequence. Non-mutagenic 
primers are depicted as straight arrows, whereas mutagenic primers are depicted as kinked arrows. See figure 8.2 for the 
sequences of the primers depicted in this diagram. The labels in orange (P1-P6) at either end of each PCR product represent the 
primers used to produce that PCR product. Naturally occurring restriction sites are highlighted by black broken arrows, and 
those introduced by PCR are highlighted by blue arrows. Hindlll and Nhel sites were introduced at the indicated locations by 
two rounds of overlap PCR as shown.
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Figure 8.4. Sequence data for the introduction of Hindlll and Nhel sites at the 5’ and 3’ ends o f FMDV VP4 respectively.
Panels A and B show sequence data for the 5’ and 3’ ends respectively of VP4 from the wild type infectious copy plasmid. 
Panels C and D  show sequence data for the 5’ and 3’ ends respectively of VP4 following the introduction of silent mutations by 
overlap PCR as shown in figure 8.3. In each case the equivalent amino acid sequence is written below the nucleotide sequence, 
with each amino acid being placed beneath the first residue of the codon which encoded it. The junction between VP4 and the L 
protease (panels A and C) or VP4 and VP2 (panels B and D) are shown by a vertical line. Residues mutated by overlap PCR are 
boxed and the introduced restriction enzyme sites highlighted. All sequencing shown is of the coding strand sequenced in the 5’ 
to 3' direction using primer PI (see figure 8.2) and a Beckman automatic sequencer.
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Figure 8.5. A schematic diagram showing the strategy for production of altered forms of VP4. Wild-type ERAV VP4 and 
FMDV VP4 were amplified by a single round o f PCR using primers containing Hindlll or Nhel sites. The VP4 chimeras F/E- 
VP4 and E/F-VP4 were produced by overlap PCR as shown utilising primers complementary to the join between the N- and C- 
terminal domains of the final product. Regions of nucleotide sequence derived from ERAV VP4 are coloured blue and sequence 
derived from FMDV VP4 are coloured red. PCR primers are depicted as arrows lying alongside DNA sequence, and are also 
colour coded according to whether they are complementary to ERAV VP4 (blue) or FMDV VP4 (red). See figure 8.2 for the 
sequences of the primers depicted in this diagram. The labels in green at either end of each PCR product represent the names of 
the primers used to produce that PCR product. Restriction enzyme sites introduced by PCR are highlighted by blue arrows.
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F ig u re  8.6. Sequence data for the production of VP4 chimeras. Panels A and B show sequence data for the boundary between 
the N- an C-terminal domains of VP4 from wild type FMDV VP4 and ERAV VP4 respectively (PCR 14 and 13 from figure 
8.5). Panels C and D show sequence data for the same region of the F/E and E/F chimeric versions of VP4 respectively (PCR 
12 and 9 from figure 8.5). In each case the equivalent amino acid sequence is written below the nucleotide sequence, with each 
amino acid being placed beneath the first residue of the codon which encoded it. The serine residue (and the codon which 
encodes it) common to both FMDV and ERAV VP4 which marks the boundary between the N- an C-terminal domains is boxed 
(see figure 8.1). All sequencing shown is of the coding strand sequenced in the 5’ to 3’ direction using primer PI (see figure 
8.2) and a Beckman automatic sequencer.
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Figure 8.7. A schematic diagram showing the strategy for the reconstitution of VP4 mutants produced by PCR into the FMDV 
full length infectious copy plasmid (pT7S3). Mutant forms o f VP4 produced as shown in figure 8.5 were introduced in to pT7S3 
as shown above using the E/F VP4 chimera as an example. Sequence derived from ERAV VP4 is coloured blue and that derived 
from FMDV VP4 is coloured red. VP2 is shaded purple, L protease pale green, and the remainder of the coding region of the 
FMDV genome is shaded a darker green. Naturally occurring restriction sites are highlighted by black broken arrows, and those 
introduced by PCR are highlighted by blue arrows.
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Figure 8.8. A schematic diagram showing the strategy for the creation of the VPO* Mutant. The Junction between VP4 and VP2 
was altered by overlap PCR in order to prevent VPO cleavage (see figure 8.9 for the specific mutations made) as reported 
previously for type A viruses. PCR primers are depicted as arrows lying alongside DNA sequence. Non-mutagenic primers are 
depicted as straight arrows, whereas mutagenic primers are depicted as kinked arrows. See figure 8.1 for the sequences of the 
primers depicted in this diagram. The labels in green at either end of each PCR product represent the names of the primers used 
to produce that PCR product. Naturally occurring restriction sites are highlighted by black broken arrows, and sequences 
introduced by PCR are highlighted by blue arrows.
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Figure 8.9. Sequence data for the creation of the VPO* mutant. Panel A shows sequence data for the junction between VP4 and 
VP2 from the wild type infectious copy plasmid. Panel B shows sequence data for the same region following overlap PCR as 
shown in figure 8.8. The amino acid sequence at the VP4-VP2 boundary was changed from AD to FK as shown by mutation of 
the boxed residues in panel A to the boxed residues shown in panel B by overlap PCR. In each case the equivalent amino acid 
sequence is written below the nucleotide sequence, with each amino acid being placed beneath the first residue of the codon 
which encoded it. The junction between VP4 and VP2 is shown using a vertical line. All sequencing shown is of the coding 
strand sequenced in the 5’ to 3’ direction using primer PI (see figure 8.2) and a Beckman automatic sequencer.
8.2.2 Infectivîty of VP4 Mutant Viruses
Described above is the construction of infectious copy plasmids containing mutant 
versions of VP4. The names of the mutant plasmids along with a description of the 
mutations made, as well as the amino acid sequence of VP4 coded by each plasmid 
are shown in figure 8.1, Next, T7 polymerase was used to produce full length 
genomic RNA fiom each plasmid, which was processed using the RNAeasy kit from 
AMBION. The viral RNA was electioporated into BHK cells using two charges of 
750V at a capacitance of 25jLiFD, the cells were then incubated for 2 days at 37°C. A 
lysate (derived by fieeze-thawing the cells) prepared fiom the electroporated cells was 
subsequently passed four times on BHK cells, A control sample of cells was 
electi oporated in the absence of viral RNA and handled as above. At each passage 
the development of cytopathic effect, was observed over a period of 2 days.
The results of these observations are set out in figure 8.10. At passage 1, samples 
derived fiom both the original infectious copy plasmid (pT7S3-WT) and the 
infectious copy plasmid with Hindlll and Nhel sites inti oduced at either end of VP4 
(pT7S3-rWT), rapidly exhibited signs of cytopathic effect. This shows that the 
introduction of Hindlll and Nhel sites does not appear to inhibit virus infectivity. All 
other mutants including the “No RNA” control displayed no cytopathic effect at 
passage 1. This indicates that mutation of the VP4-VP2 junction to prevent VPO 
cleavage (pT7S3-VP0*), as well as replacement of all of VP4 (pT7S3-ER-VP4), the 
N-terminus of VP4 (pT7S3-E/F-VP4) or the C-terminus of VP4 (pT7S3-F/E-VP4) 
with the equivalent sequence from ERAV does not result in the production of viable 
virus.
It is possible that some of the mutant viruses which displayed no cytopathic effect 
after the first passage underwent limited replication, due to the inti oduction of
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compensatory mutations. These mutations may enhance virus replication on a second 
passage and provide information on the residues witliin VP4 which are essential for 
its function. On subsequent passage in BHK cells the samples derived from plasmids 
pT7S3-F/E-VP4, pT7S3-E/F-VP4, and pT7S3-ER-VP4 continued to display no 
detectable cytopathic effect. However, the VPO* mutant, which did not cause 
cytopathic effect at passages 1 and 2, caused extensive cytopathic effect after 
passages 3 and 4. In order to establish the sequence changes that caused this 
transition, viral RNA extracted fr om passage 4 was reverse tianscribed and 
sequenced. For comparison pui'poses, passage 4 of the WT and rWT virus was also 
sequenced. Figure 8.11 shows an alignment of the nucleotide sequence of VP4 and 
10 codons either side derived from pT7S3-WT prior to electioporation and passage 
(FMDV WT PO), with the sequence derived from vims after 4 passages (FMDV WT 
P4). These sequences are identical showing that there is minimal selection pressure 
against the wild type sequence in this region during tissue culture passage. Figure 
8.12 shows an alignment of the same region derived from pT7S3-rWT before 
electioporation (FMDV-rWT PO), and after 4 passages (FMDV-rWT P4), with the 
wild type sequence. Both sequences only differ fi'om wild type at the sites where 
Hindlll and Nhel sites were introduced by silent mutation. After 4 passages the 
sequences coiTesponding to these two restiiction sites are still present indicating that 
there is no selection pressure against these sequences. Figure 8.13 shows an 
alignment of the nucleotide sequences of VP4 and 10 codons either side derived fr om 
pT7S3-VP0* prior to electroporation (VPO* PO), and after 4 passages (VPO* P4), with 
the wild type sequence. VPO* PO differs from the wild type sequence at both the 
junction between VP4 and VP2, due to mutations designed to prevent VPO cleavage, 
and at the 5’ end of VP4, due to the presence o f the same Hindlll sequence introduced
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in to the pT7S3-rWT sequence. This site was included to act as a marker both during 
cloning and passage. After 4 passages of the VPO* virus, the sequence of VP4 is 
identical to the wild type version, having lost the introduced mutations at the 
VP4/VP2 boundary and also the Hindlll site at the 5’ end of VP4. It is possible that 
the cytopathic effect that appeared at passage 3 occurred due to the reversion to the 
wild type sequence following limited replication. This is unlikely however, since the 
aagctt “Hindlll” sequence was maintained during passage of the rWT virus, indicating 
that there is little or no selection pressure against this sequence. Also the fact that the 
two codons either side of the VP2-VP4 junction each contain two nucleotide changes 
rather than one makes reversion unlikely. Unfortunately it is more likely that the 
appearance of cytopathic effect two passages downsti eam of electi oporation with 
RNA derived from the pT7S3-VP0* plasmid is simply due to cross contamination 
with wild type virus.
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Cytopathic Effect
Passage 1 Passage 2 Passage 3 Passage 4
WT + + + +
rWT + + + +
VPO* - - + +
ER - - - -
F/E - - - -
E/F - - - -
No RNA - - - -
Figure 8.10. Infectivity of VP4 mutant viruses as judged by the development of cytopathic effect. BHK cells were 
electroporated with RNA derived from infectious copy plasmids carrying mutant versions of VP4 (see figure 8.1 to see the 
amino acid sequence of each mutant). Any virus produced was passaged onto fiesh BHK cells four times. After each passage 
the development of cytopathic effect, characterised by cell rounding and detachment, was observed for 48 hours at 37°C. A plus 
sign (+) indicates that cytopathic effect was observed, whilst a minus sign (-) indicates that no cytopathic effect was observed.
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Figure 8.11. Sequence alignment o f FMDV rWT VP4 before and after tissue culture passage, with the wild type sequence. T7 
polymerase was used to create full genome length RNA from the wild type infectious copy plasmid pT7S3 WT. The RNA was 
then electroporated in to BHK cells and the mutant virus formed passaged four times in tissue culture.
The above figure shows an alignment of the nucleotide sequences o f VP4 derived from the infectious copy plasmid (FMDV WT 
PO), with that obtained from viral RNA following four passages in BHK cells (FMDV WT P4). 10 codons either side of VP4 
are also shown. Residues which are identical to the wild type sequence are identified by a dot (.) The boundaries between VP4 
and VP2, and between VP4 and the L protease are each denoted by a black vertical line.
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Figure 8.12. Sequence alignment of FMDV rWT VP4 before and after tissue culture passage, with the wild type sequence. T7 
polymerase was used to create full genome length RNA from the mutant infectious copy plasmid pT7S3 rWT. The RNA 
produced carries sequences conesponding to Hindlll and Nhel sites introduced at either end of VP4 by silent mutation. The 
RNA was then electroporated in to BHK cells and the mutant virus formed passaged four times in tissue culture.
The above figure shows an alignment of the nucleotide sequences o f VP4 derived from the mutant infectious copy plasmid 
(FMDV rWT PO), and from viral RNA following four passages in BHK cells (FMDV rWT P4) with the wild type sequence 
(FMDV WT). 10 codons either side of VP4 are also shown. Residues which are identical to the wild type sequence are 
identified by a dot (.) The boundaries between VP4 and VP2, and between VP4 and the L protease are each denoted by a black 
vertical line. The Hindlll and Nhel sequences introduced by silent mutation are boxed and remained present after passage 
through BHK cells.
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Figure 8.13. Sequence alignment o f FMDV VPO* before and after tissue culture passage, with the wild type sequence. T7 
polymerase was used to create full genome length RNA from the mutant infectious copy plasmid pT7S3 VPO*. The RNA 
produced carries mutations at the boundary of VP4 and VP2 which prevent the maturation cleavage o f VPO. The RNA was then 
electroporated in to BHK cells and the mutant virus formed passaged foui- times in tissue culture.
The above figure shows an alignment o f the nucleotide sequences of VP4 derived from the mutant infectious copy plasmid 
(VPO* PO), and from viral RNA following four passages (VPO* P4) with the wild type sequence (FMDV WT). 10 codons either 
side of VP4 are also shown. Residues which are identical to the wild type sequence are identified by a dot (.) The boundaries 
between VP4 and VP2, and between VP4 and the L protease are each denoted by a black vertical line. The mutated codons at 
the VP4/VP2 boundary and the Hindlll sequence are boxed. The sequence of VPO* P4 at the Hindlll site and the VP4/VP2 
boundary are the same as the wild type virus.
8.3 Summary and Discussion
The above work forms the starting point for further study of the role of VP4 in 
infection of tissue culture cells by FMDV. Section 8.2.1 covers the process by which 
a system for the creation of VP4 mutant viruses was set up, and infectious copy 
plasmids containing mutant versions of VP4 in place of the wild type sequence 
created. Infectious copy plasmids were constiucted in which the N-terminal domain 
(E/F VP4), the C-terminal domain (F/E VP4), or all of VP4 (ER VP4) were replaced 
by the same region from ERAV. Each plasmid also has Hindlll and Nhel sites at 
either end of VP4 inti oduced by silent mutation, since these sites were required during 
plasmid construction. As a contiol an infectious copy plasmid was also constmcted in 
which wild type FMDV VP4 is bounded by the same Hindlll and Nhel sites (rWT 
VP4). Finally an infectious copy plasmid was constructed in which the boundary 
between VP4 and VP2 was mutated such that the maturation cleavage cannot occur 
(VPO*).
T7 polymerase was used to create full-length positive-sense RNA genome copies 
fr om each of the wild type and mutant infectious copy plasmids. The RNA produced 
was electroporated in to BHK cells and virus produced passaged four times in tissue 
culture. At each tissue culture passage the development of cytopathic effect was 
obseiwed (figure 8.10). Virus derived from the plasmids pT7S3-WT and pT7S3-rWT 
caused cytopathic effect at each passage. This indicates that the introduction of 
Hindlll and Nhel sites in to the infectious copy plasmid does not inhibit the infectivity 
of FMDV. No infectious vims was produced following electroporation of BHK cells 
with RNA derived from the pT7S3-ER-VP4, F/E-VP4, or E/F-VP4 infectious copy
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plasmids. However, from this work it is not possible to tell whether the introduced 
mutations prevent particle assembly.
Following electroporation of BHK cells with RNA derived fr'om infectious copy 
plasmid pT7S3-VP0*, no cytopathic effect was observed after passage 1 or 2, but 
cytopathic effect was observed at passage 3 and 4. One possible explanation for the 
increased virulence in BKH cells is that during passage 1 and 2 low level replication 
occurs, which is insufficient to produce cytopathic effect, but leads to the introduction 
of mutations which increase virulence resulting in the production of cytopathic effect 
on subsequent passage. In order to investigate this possibility, vims derived fr om the 
pT7S3-VP0* infectious copy plasmid was sequenced after four passages, and the 
sequence aligned with the equivalent sequence prior to passage and with the wild type 
sequence. The sequence of the VP4 region of the virus produced after four passages 
was identical to the wild type sequence, i.e. the Hindlll site had been lost and the 
sequence at the VP4A/^P2 boundary restored to wild type. One possible explanation is 
that the mutant virus reverted to to the wild type sequence. However, passage of the 
rWT vims shows that the sequence corresponding to the Hindlll site is maintained 
during passage, and is not selected against. Also, the codons either side of the VP4- 
VP2 boundary were each mutated at two positions making reversion less likely. 
Unfortunately the most likely explanation for the observed cytopathic effect at 
passages 3 and 4of the VPO vims is contamination by the wild type virus.
All of the changes made to VP4 (other than the introduction of Hindlll and Nhel 
sites) prevented the production of infectious virus. It is uncleai' whether 
electioporation of cells with RNA containing mutations within VP4 results in the 
production of virus particles which are nonviable, or whether tliese mutations prevent 
the assembly of vims particles. It is possible that VP4 tolerates little sequence
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variation, either because this region is important for particle assembly, or because 
conserved sequences within VP4 are required for an important aspect of FMDV 
infection
From this work, the next step would be to investigate whether electroporation of 
susceptible cells with RNA from each mutant infectious copy plasmid results in the 
assembly of virus particles. This could be achieved by monitoring the presence or 
absence of 140S particles (virions) using sucrose density gradient analysis following 
electroporation. If non-infectious particles are produced, these particles could be 
purified and chai acterised in terms of their ability to bind and enter cells, to uncoat in 
response to acid, and to deliver the viral RNA genome to the cell cytoplasm.
Three infectious copy plasmids were produced in which particular regions of VP4 
were swapped for the equivalent sequence from ERAV. No infectious virus was 
obtained using any of these mutant infectious copy plasmids. These constructs could 
be utilised as a starting point for more targeted mutagenesis of VP4. ERAV VP4 
shows 48% identity and 65% similarity to FMDV VP4. As shown in figure 8.1, the 
N-terminal domain of ERAV VP4 is more similar in sequence to that of FMDV than 
the C-terminal domain. Consequently E/F VP4 shows gieater sequence identity and 
similarity to FMDV VP4 than F/E VP4. E/F VP4 contains 85 residues, 72 of which 
are identical and 6 similar to the equivalent residue in wild type FMDV VP4. This 
means that there are only 7 positions at which the amino acid residue found in E/F 
VP4 is significantly different fr om that found in wild type FMDV VP4. These 
sequence differences would appear to be sufficient to render infectious copy plasmids 
carrying E/F VP4 rather than wild type FMDV VP4 unable to produce infectious 
virus. Production and characterisation of seven mutant viruses in which each of these
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seven residue changes are infroduced individually in future could prove very 
beneficial in the investigation of the function of FMDV VP4.
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Chapter Nine: Summary and Future
The work presented in this thesis sheds light on the early events in av(36-mediated 
entry to, and infection of, tissue culture cells by FMDV. However, avp6 is just one 
of several RGD-dependent integrins reported to act as receptors for FMDV. A 
number of lines of evidence would suggest that avP6 is the most important receptor 
in the natural hosts of foot-and-mouth disease virus. In particular, the expression 
pattern of the integrins reported to act as receptors for FMDV supports this 
conclusion. FMDV shows a strong ti'opism for epithelial cells and, following a 
natural infection, initial virus uptake and replication is thought to take place in the 
pharynx and soft palate (5). Subsequently, the virus becomes widely disseminated 
and infectious lesions develop on the feet and mouth of the infected animal (5). Work 
published during the preparation of this thesis compared the expression of avp6 and 
avps in tissue sections taken from uninfected and infected cattle (209). These studies 
showed that (xvP6, but not avp3, is expressed on the surface of epithelial cells in the 
tongue and interdigital skin of uninfected cattle, both of which are sites where FMDV 
replicates to high levels and lesions normally form. In addition, avp6 was also 
detected on the surface of epithelial cells within the coronary band and vential soft 
palate. In these tissues av^3 expression was low and was limited to the vasculature.
In infected cattle, avp6 (but not avp3) was detected on the surface of infected cells in 
tissue sections taken fr om early stage lesions located on the interdigital skin. The 
expression of av p i and avps have not been assessed in a natural host of FMDV, 
however p i integrins are ubiquitously expressed in mammalian cells, and although 
avpS has been detected in human airway epithelia it is largely associated with the 
basal cells rather than the spinosum layer targeted by FMDV (46). Therefore the
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expression pattern of avp6 within a natural host animal (the cow) matches the cells 
infected by FMDV much more closely than the expression of avp3, or that of avp l 
and avpS inferred from other mammalian species. In this context, the insights in to 
the process by which avp6-mediated uptake of FMDV occurs described in this thesis 
are of key physiological relevance.
The data presented in this thesis are consistent with a model for FMDV cell-entry 
involving virus-induced, clathrin-dependent endocytosis of a FMDV-avP6 complex 
into early- and recycling-endosomes, where the prevailing low pH h iggers capsid 
disassembly and the franslocation of the vRNA into the cytosol. The microtubule 
network and actin cytoskeleton also did not appear to play an essential role in avp6- 
mediated infection by FMDV. Experiments with p6-transfected SW480 and CHO 
cells showed that lipid raft dependent endocytosis pathways, including the caveolae- 
dependent uptake pathway, are not essential for FMDV infection.
Although avP6 has been shown previously to act as an attachment receptor for 
FMDV, it was not known whether this receptor also mediated virus internalisation. 
This question was addressed using immunofluorescence microscopy. The studies 
presented here show that FMDV colocalises with avP6 both at the cell surface and 
also inside the cell at early times after the initiation of virus internalisation. In 
addition, ocvp6 was shown to be delivered to the same compartments as FMDV and 
accumulated in early- and recycling-endosomes on virus internalisation. These 
observations strongly suggest that av(36 serves to mediate both the attachment and 
uptake of FMDV. Internalisation of av(36 appears to be ti iggered by a combination of 
the occupation of the integrins’ ROD-binding site, and receptor cross-linking by a 
multivalent ligand (e.g. FMDV).
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The cytoplasmic domain of the p6-integrin subunit contains a conserved NPXY 
putative endocytosis motif. Alanine substitutions within this motif led to the 
production of receptors that were able to mediate virus binding but not infection, and 
virus internalisation appeared to be slowed by these mutations. The stage at which 
infection is blocked however remains unclear, and this issue requires further study.
The precise compartment in which FMDV uncoating and RNA transfer to the 
cytosol occur, remains to be detennined. Given the extr eme acid lability of the 
FMDV capsid, it would be assumed that particle uncoating and RNA delivery would 
be triggered in early endosomes, since this is the first acidic compartment to which 
FMDV is delivered. One possible approach to address this issue would be to 
investigate the effect of dominant negative Rab proteins on FMDV endocytosis. 
Transport steps inside cells are co-ordinated by Rab GTPases, and each Rab protein is 
thought to act at different stages in the endocytosis pathway (297). Rab5 GTPase for 
example controls clathrin-dependent delivery to early endosomes, Rab 7 controls 
traffic fi'om early to late endosomes, and rab 4 and 11 control traffic fiom early to 
recycling endosomes. It should therefore be possible, using dominant negative 
versions of these proteins, to establish whether transport of viral particles to early 
endosomes is sufficient to initiate infection by FMDV, or whether transport beyond 
this compartment is necessary. This question could also be addressed by attempting 
to investigate uncoating more directly. For example, the structural protein VP4 could 
be used as a marker for uncoating, since this protein is not surface exposed until the 
virus particle dissociates in to its constituent pentarners. It may also be possible to 
label the viral RNA with fluorescent intercalating dyes, since FMDV par ticles are 
permeant to such molecules.
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During the preparation of this thesis, O’Donnell et. al. (Plum Island, USA) 
published work examining FMDV internalisation in cultured cells (232), This work 
was published back-to-back with my own publication (30) in the journal of virology. 
The studies by O’Donnell et. al. concentrated primarily on the use of confocal 
microscopy to study virus internalisation by MCF-lOA cells (a human breast cancer 
line), with only limited biochemical data. Nonetheless, the authors of this work 
concluded that FMDV was internalised by clathrin-dependent endocytosis in to early 
endosomes, before passing to a transferrin receptor positive compartment. 
Immunofluorescence experiments involving early endosome markers were carried out 
in av|36 transfected COS cells rather than MCF-lOA cells, since surprisingly no EEA- 
1 labelling could be detected within the latter. They also concluded that virus was not 
transported to late endosomes, since no colocalisation was detected with the mannose- 
6-phosphate receptor (a late endosome marker). These conclusions are in line with 
my own findings as outlined above. The authors identified clathrin-dependent 
endocytosis as the uptake pathway for FMDV because of apparent colocalisation 
between FMDV and the clathrin light chain, and also the inhibition of infection by 
chlorpromazine, a drug reported to inhibit this endocytosis pathway. These 
techniques are different to those used in my own study, and therefore serve to 
reinforce the findings presented here, namely that the virus is taken up by the clathrin- 
dependent endocytosis pathway.
The results presented in this thesis will pave the way for future studies to identify 
the compartment in which FMDV uncoating occurs, and to elucidate the mechanism 
of viral RNA ti ansfer to the cytosol.
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